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 ABSTRACT 
 
This thesis concerns the synthesis and biological evaluation of bifunctional inhibitors of the 
type [NRTI]-spacer-[HI-236] as well as development of HI-236 derivatives as NNRTI’s. 
 
Following a comprehensive review on RT and HIV double drugs, in the first part of the 
Results and Discussion section (Chapter 2) of the thesis, a library of derivatives of the 
NNRTI HI-236 substituted at the C-2 oxygen of the phenyl ring is described and evaluated for 
their inhibitory activity against HIV (IIIB) replication in MT-2 cell culture. The compounds were 
synthesized in order to fine-tune the activity of HI-236 as well as to gain insight into spatial 
characteristics in the pocket pertaining to the positional choice of the tether in the design of 
[NRTI]-spacer-[HI-236] bifunctional inhibitors. Two of the thiourea derivatives bearing a 
butynyl (77c) or hydroxyethyl tether (77m) were endowed with improved anti-HIV activity 
compared to HI-236. NNRTI activity was confirmed by a cell-free RT assay on six of the 
derivatives in which (77c) returned an IC50 of 3.8 nM compared to 28 nM for HI-236, 
establishing it as an improved lead for HI-236. 
 
The second part (Chapter 3) involves the synthesis and biological evaluation of four 
bifunctional inhibitors of the type [d4U]-spacer-[HI-236] varying the spacer length. This was 
accomplished using a divergent synthesis starting with uridine to furnish each bifunctional in 
between 13 and 19 steps respectively using a Sonogashira coupling as a key step in each 
case. Each bifunctional derivative was fully characterised using NMR, IR and MS techniques. 
Similarly, a phosphoramidate as a mono-phosphorylated pro-drug of the 4-PEG bifunctional 
was prepared, except in this case the Sonogashira coupling proceeded via coupling of an 
amine version of the NNRTI followed by condensation post-coupling to install the HI-236 
thiourea grouping. All bifunctional compounds were tested against HIV-1 replication in MT-2 
cell culture as well as in an vitro RT enzyme assay. The results (EC50 and IC50) indicated 
good inhibitory activity likely due to an elongated NNRTI with some binding outside the 
pocket. However, there was no evidence for conversion to the bifunctional triphosphate for 
possible full “mixed-site” inhibition. 
 
In the final part (Chapter 4) two bifunctionals incorporating an ANP (acyclic nucleotide 
phosphonate) prototype instead of d4U were prepared and tested in cell-culture. The EC50 
results indicated a similarity to those for the d4U bifunctional, hence leading support for the 
conclusions from Chapter 3.      
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Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
                                                                                                             ABBREVIATIONS 
 
 vi 
δ    Chemical shift in ppm 
d    Doublet 
dd    Doublet of doublets 
dt    Doublet of triplets 
d2U    2',3'-Dideoxyuridine 
d4T    2',3'-Didehydro-2',3'-dideoxythymidine 
d4U    2',3'-Didehydro-2',3'-dideoxyuridine 
DABO    Dihydroalkoxybenzyloxopyrimidine 
DAPY    Diarylpyrimidine 
DATA    Diaryltriazine 
DBU    1,8-Diazabicyclo[5.4.0]undec-7-ene 
DCC    1,3-Dicyclohexylcarbodiimide 
DCM    Dichloromethane / Methylene chloride 
dCMP                                     deoxyribonucleoside monophosphates kinase  
dCTP    Deoxycytidine triphosphate 
dCyd                                       Deoxycytidine kinase 
ddC    2',3'-Dideoxycytidine 
ddI    2',3'-Dideoxyinosine 
Delavirdine   1-(5-Methanesulfonamido-1H-indol-2-yl-carbonyl)-4-[3-(1- 
methylethyl-amino)pyridinyl]piperazine monomethane sulfonate 
DIA    (Diisopropylamino)phosphine 
DIAD    Diisopropylazodicarboxylate 
DIEA    Diisopropylethylamine 
DMA    N,N-Dimethylacetamide 
DMAP    N,N-Dimethylaminopyridine 
DME    1,2-Dimethoxyethane 
DMP    2,2-Dimethoxypropane 
DMSO    Dimethylsulfoxide 
DNA    Deoxyribonucleic acid 
dGTP    Deoxyguanidine triphosphate 
dNMP    Deoxyribonucleotide monophosphate 
dNTP    Deoxyribonucleotide triphosphate 
dsDNA    Double-stranded deoxyribonucleic acid 
dTTP    Deoxythymidine triphosphate 
EDC    Ethylene dichloride 
Efavirenz   (-)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-
2H- 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
                                                                                                             ABBREVIATIONS 
 
 vii 
3,1-benzoxazin-2-one 
E1    Unimolecular elimination 
E2    Bimolecular elimination 
EDTA    Ethylenediaminetetraacetate monosodium 
EI    Electron impact 
Enfuvirtide   36-amino acid peptide 
ES    Electron spray 
Et3N    Triethylamine 
Et2O    Diethyl ether 
EtOAc    Ethyl acetate 
EtOH    Ethanol 
eq.    Equivalent 
FAB    Fast atom bombardment 
FDA    US Food and Drug Administration 
FDU    5-Fluoro-2'-deoxyuridine 
(-)-FTC   (-)-β-L-3'-thia-2',3'-dideoxy-5-fluorocytidine 
(+)-FTC   (+)-β-D-3'-thia-2',3'-dideoxy-5-fluorocytidine 
g    Grams 
GALT    Gastrointestinal associated lymphoid tissue 
gp    Glycoprotein 
GR    Glutathion reductase 
HAART   Highly active anti-retroviral therapy 
HBY 097   (S)-4-Isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4- 
dihydroquinoxaline-2(1H)-thione 
HCl    Hydrochloric acid 
HCMV    Cytomegalovirus 
HEPT    1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)thymine 
HI-236    N'-(5-bromo-2-pyridyl)-N-[2-(2,5-
dimethoxyphenyl)ethyl]thiourea 
HIV-1    Human Immunodeficiency Virus type 1 
HOPT    1-Hydroxybenzotriazole 
HPLC    High-pressure liquid chromatography 
hr.    Hour 
HRMS    High-resolution mass spectrometry 
Hz    Hertz 
IDU    5-Iodo-2'-deoxyuridine (Idoxuridine) 
IN    Integrase 
Un
ive
r i
ty 
of 
Ca
pe
 To
wn
                                                                                                             ABBREVIATIONS 
 
 viii 
IR    Infrared spectrometry 
ITU    Imidoylthiourea 
J    Coupling constant  
LAH    Lithium aluminium hydride 
Lit.     Literature 
LTR    Long terminal repeat 
m    Meta 
m    Multiplet 
M+    Molecular ion 
MA    HIV-1 matrix protein 
MeOH    Methanol 
mg    Milligram(s) 
MHz    Mega hertz 
MKC-442   6-Benzyl-1-(ethoxymethyl)-5-isopropyluracil 
ml    Millilitre(s) 
mmol    Millimole(s) 
Mp    Melting point 
mRNA    Messenger ribonucleic acid 
MsCl    Methanesulfonyl chloride 
m/z    Mass to charge ratio 
NBS    N-Bromosuccinamide 
NCp    Nucleocapsid protein 
NDP                                        Nucleoside-diphosphate kinase 
NEM    Nucleotide excision mechanism 
Nevirapine   11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-f) 
(1,4)diazepin-6-one 
NMM    N-Methylmorpholine 
NMR    Nuclear magnetic resonance 
NNIBP    Non-nucleoside inhibitor binding pocket 
NNIBS    Non-nucleoside inhibitor binding site 
NNRTI    Non-nucleoside reverse transcriptase inhibitor 
NNRTI-BP      Non-nucleoside reverse transcriptase inhibitor binding pocket 
NRTI    Nucleoside reverse transcriptase inhibitor 
o    Ortho 
p    Para 
 
PBS    Primer binding site 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
                                                                                                             ABBREVIATIONS 
 
 ix 
PG    Protecting group 
P(OEt)3   Triethyl phosphite 
Pd/C    Palladium-on-carbon 
Pet ether   Petroleum ether 
PETT    Phenylethylthiazolylthiourea 
PFA    Phosphonoformate 
Phospho   Phosphonate 
PI    Protease inhibitor 
PLM (II)   Plasmepsin (II) 
PMBCl    p-Methoxybenzyl chloride 
PMEA    9-(2-phosphonylmethoxyethyl)adenine 
PMPA    (R)-9-(2-Phosphonylmethoxypropyl)adenine 
PPh3    Triphenylphosphine 
(PPh3)4P   Tetrakis(triphenylphosphine)palladium (0) 
PQ    Primaquine 
PR    Protease 
PT                                           Proton transfer 
RDDP    RNA-dependent DNA polymerase 
Ribavirin   1-β-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide 
RNA    Ribonucleic acid 
RNase H   Ribonuclease H 
RT    Reverse transcriptase 
rt    Room temperature 
s    Singlet 
SATE    S-Acyl-2-thioethyl 
SN1    Unimolecular nucleophilic substitution 
SN2    Bimolecular nucleophilic substitution 
ssRNA    Single-stranded ribonucleic acid 
t    Triplet 
TBDMSCl   tert-Butyldimethylsilyl chloride 
TBDPS   tert-Butyldiphenylsilyl chloride 
3TC    (-)-β-L-3'-Thia-2',3'-dideoxycytidine 
td    Triplet of doublets 
TFA    Trifluoroacetic acid 
TFT    5-Trifluoromethyl-2'-deoxyuridine (Trifluorothymidine or  
Trifluridine) 
THF    Tetrahydrofuran 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
                                                                                                             ABBREVIATIONS 
 
 x 
THP    Tetrahydropyran 
TIBO    (+)-(S)-4,5,6,7-Tetrahydro-8-chloro-5-methyl-6-(3-methyl-2- 
                                          butenyl)imidazo[4,5,1jk][1,4]benzodiazepine-2(1H)-thione 
TIPS    Triisopropylsilyl 
TLC    Thin layer chromatography 
TMSCl    Trimethylsilyl chloride 
TSAO    2',5'-bis-O-(tert-Butyldimethylsilyl)-3'-spiro-5'-(4''-amino-1'',2''- 
oxathiole-2'',2''-dioxide)pyrimidine 
p-TsOH   para-Toluenesulfonic acid  
q    Quartet 
UV    Ultra violet 
w/v    Weight by volume 
v/v    Volume by volume 
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
_                                                                                                     TABLE OF CONTENT 
 
 xi 
CONTENTS 
                          
CHAPTER 1:  INTRODUCTION……………... …………………………………………………..1                                                                                                                                                                                                                                                                                                                                                                                
1.1  Human Immunodeficiency Virus (HIV)……………………………………………………….1  
1.2  The Structure of the HIV-1 Virion …………………………………………………………....1 
1.3  Epidemiology of HIV/AIDS…………………………………………………………………….2 
1.4  The HIV Life-Cycle……………………………………………………………………………..3 
1.5  HIV Pathogenesis……………………………………………………………………………...5 
1.6  The Reverse Transcriptase Enzyme (RT)…………………………………………………..6 
1.7  Developments in Anti-HIV Chemotherapy…………………………………………………..8 
1.8  Nucleoside Reverse Transcriptase Inhibitors (NRTIs)……………………………………..9 
1.9  The Structure of HIV-1 RT in Complex with Nucleoside Inhibitors………………………12 
1.10  Nucleotide Reverse Transcriptase Inhibitors (NtRTIs)…………………………………..14 
          1.10.1  The Prodrug Approach (The Pronucleotide Approach)………………………..15 
          1.10.2  The Acyclic Nucleotide Phosphonates (ANPs)………………………………....18 
1.11  NRTI Resistance...........................................................................................................21 
1.12  Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)…………………………...23 
          1.12.1  The NNRTI-Binding Pocket……………………………………………………….26 
          1.12.2  The mechanism for NNRTI Inhibition of RT……………………………………..27 
          1.12.3  First-and Second-Generation NNRTIs: Differences in the Mode of Binding to  
                     HIV-1 RT……………………………………………………………………………..29 
1.13  Phenethylthiazolythioureas (PETT) Derivatives……………………………………….....32  
1.14.  NNRTI Resistance…………………………………………………………………………..35 
1.15.  The Double-Drugs Strategy………………………………………………………………..38  
            1.15.1  Double-Drugs in Cancer and Malaria…………………………………………...38 
            1.15.2  Double-Drugs in HIV……………………………………………………………...40 
 1.16  Objective of the Study……………………………………………………………………....56 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
_                                                                                                     TABLE OF CONTENT 
 
 xii 
CHAPTER 2: C-2-ARYL O-SUBSTITUTED HI-236 DERIVATIVES AS  
                        NON-NUCLEOSIDE HIV-1 RT INHIBITORS…………………………………59 
 2.1  Modeling of HI-236…………………………………………………………………………..60 
 2.2  Overview on Synthesis of the PETT Derivatives…………………………………………62 
 2.3  Retrosynthetic Analysis of HI-236 Derivatives 77………………………………………..64 
 2.4  Biological Results, Modeling and Discussion……………………………………………..81 
 
CHAPTER 3:  SYNTHESIS OF [d4U]-SPACER-[HI-236] DOUBLE-DRUGS……………..89 
3.1  Introduction……………………………………………………………………………………89 
3.2  Overview on the Synthesis of d4T………………………………………………………….90 
       3.2.1 Synthesis of d4T from 5-Methyluridine………………………………………………91 
3.3  Strategies for the Synthesis of [d4U]-spacer-[HI-236]……………………………………93 
3.4  Overview on Sonogashira Coupling………………………………………………………..95 
3.5  Route (A): Synthesis of Target Compounds 51, 78 and 79……………………………...99 
       3.5.1  Synthesis of [d4U]-butyne-[HI-236] 51………………………………………………99 
                 3.5.1.1  Synthesis of 5’-O-Benzoyl iodo-d4U……………………………………….99 
                 3.5.1.2  Sonogashira Coupling, Deprotection and Condensation……………….101 
                 3.5.2.3  The End-Game……………………………………………………………...103 
       3.5.2  Synthesis of [d4U]-monpPEG-propyne-[HI-236] 78………………………………103 
       3.5.3  Synthesis of [d4U]-diPEG-propyne-[HI-236] 79…………………………………...106 
3.6  Route (B):  Synthesis of Target Compounds 80 and 81...............................................110 
       3.6.1  Synthesis of [d4U]-tetraPEG-propyne-[HI-236] 80………………………………..110 
       3.6.2  Synthesis of [d4U-phosphoramidate]-teraPEG-propyne-[HI-236] 81…………...113 
                 3.6.2.1  Synthesis of Iodo-d4U-Phosphoramidate………………………………...113 
 3.7  Biological Results and Rationale……………………………………………....................119 
 
CHAPTER 4:  SYNTHESIS OF [ANP]-SPACER-[HI-236]…………………………………...123 
4.1  Synthesis of [ANP]-n-PEG-propyne-[HI-236]: (n = 4 and 6)……………………………..124 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
_                                                                                                     TABLE OF CONTENT 
 
 xiii 
        4.1.1  Retrosynthetic analysis of [ANP]-n-PEG-propyne-[HI-236]……………………..125 
        4.1.2  Synthesis of the ANP moiety……………………………………………………….126 
        4.1.3  Synthesis of [ANP]-tetraPEG-propyne-[HI-236] 134……………………………..131 
        4.1.4  Synthesis of [ANP]-hexaPEG-propyne-[HI-236] 135…………………………….132 
4.2  Biological results and rationale……………………………………………………………..134 
 
CHAPTER 5:  EXPERIMENTAL SECTION…………………………………………………....137 
 
REFFERANCES…………………………………………………………………………………...199 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
CHAPTER_1________________________________________________   INTRODUCTION 
 1 
CHAPTER 1: INTRODUCTION 
 
1.1 HUMAN IMMUNODEFICIENCY VIRUS (HIV)    
 
The Human Immunodeficiency Virus (HIV) is an intracellular parasite, belonging to a class 
viruses called retroviruses (viral family Retroviridae), and is the causative agent of Acquired 
Immunodeficiency Syndrome (AIDS). Retroviruses are ribonucleic acid (RNA) viruses, and in 
order to replicate they must make a deoxyribonucleic acid (DNA) copy of their RNA. It is DNA 
genes that allow the virus to replicate. HIV exists as two distinct viruses: type-1 (HIV-1) and 
type-2 (HIV-2), which both have a similar molecular structure in that they contain a single-
stranded RNA genome but which differ in origin and gene sequence. The difference between 
them is that HIV-1 carries a vpu gene whereas HIV-2 carries the vpx gene, and HIV-2 is 
more geographically restricted to West Africa compared to HIV-1. HIV-2 also tends to have 
slower rates of disease progression to AIDS than HIV-1, although when this occurs the 
symptoms are almost indistinguishable between the two types.1,2 
 
1.2 THE STRUCTURE OF THE HIV-1 VIRION 
 
The HIV-1 structure involves outer and inner cores. The outer core consists of a lipid bilayer 
acquired from the host cell, while the inner core contains two proteins, p24 and p17, as 
matrix proteins surrounding the nucleocapsid containing the genetic material. A single virion 
has an icosahedral shape with a knobby-looking envelope. The knobs are comprised of the 
envelope glycoproteins gp-120 and gp-41.3,4 Beneath the envelope are the viral matrix 
proteins p17 and p24, which, aside from structural maintenance, houses the nucleocapsid 
containing the viral genome for be transmission to the host nucleus. The HIV genome 
transcribes nine genes: gag, pol, env, tat, rev, nef, vif, vpu and vpr, which carry all the 
information needed to make new viruses (Fig. 1.1).5a Copies of reverse transcriptase (RT), 
integrase (IN) and protease (PR) necessary for replication purposes are also housed 
together with the HIV viral RNA. 
 
 
 
 
 
       
                                                 
                                            Figure 1.1 Structure of an HIV-1 virion.5b 
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1.3 EPIDEMIOLOGY OF HIV/AIDS 
 
According to statistics released by UNAIDS and WHO for July 2008, everyday, over 6800 
people become infected with HIV and over 5700 people die from AIDS. The estimated 
number of people having died from HIV/AIDS-related illnesses is around 2.1 million per 
annum for 2007. The annual number of new HIV infections (for 2008) stands at around 2.5 
million, while the total number of people estimated to be living with HIV/AIDS is 
approximately 33.2 million [30.6-36.1 million]. Sub-Saharan Africa presents itself as the 
region most heavily affected by HIV with 22.0 million people living with HIV (Fig. 1.2), 
accounting for 67% of all people living with HIV and 75% of global AIDS deaths. Of these an 
estimated 5.7 million of these people live in South Africa.6 
 
 
 
 
 
 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Estimated number of people living with HIV and adult HIV prevalence. Global HIV   
epidemic, 1990-2007, and HIV epidemic in Sub-Saharan Africa, 1990-2007 (2008 report on the global 
AIDS Eipdemic).6 
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1.4 THE HIV LIFE-CYCLE 
 
Like all viruses, HIV-1 needs a host-cell to proliferate itself, which it uses for replication, 
Figure 1.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                            Figure 1.3 The Life-cycle of the HIV-1 virus.7 
 
However, what differentiates HIV from other viruses and what makes it so lethal, is that HIV 
mostly infects cells of the immune system. HIV-1 will only infect a human cell that bears a 
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CD4 surface marker.8 Such cells include macrophages, some dendritic cells, and most 
importantly, CD4+ T-lymphocytes, also referred to as “T-helper cells”, which play an 
important role in the body‟s immune-defence when foreign entities invade the body. HIV-1 
entry into CD4+ cells involves several sequential steps (Fig. 1.4) that involve firstly the 
interaction of gp-120 with the host CD4 receptor. This gp-120/CD4 complex leads to a loss of 
entropy (i.e. ordering) in the HIV receptor gp-120, which counteracted by a large enthalpy of 
formation (∆H < 0). This interaction leads to conformational changes in gp-120, and to extent 
CD4, that enable the interaction of gp-120 with the CCR5 or CXCR4 co-receptor. The 
subsequently formation of a CD4-gp-120-CCR5/CXCR4 complex triggers conformational 
changes in the gp-41 that eventually allows fusion between the cellular and viral membranes 
leading the viral core into the cytoplasm.9,10,11,12  
 
                                       Figure 1.4 HIV-1 attachment and fusion to CD4+ cell.12 
 
Viral entry thus involves the following three distinct steps: CD4 binding, chemokine receptor 
engagement and the structural changes in the viral envelope required for fusion between 
viral and cellular membranes. HIV-1 entry inhibitors thus encompass three mechanistically 
distinct classes of agents known as attachment inhibitors (PRO-452, PRO-2000), co-receptor 
inhibitors such as MaravirocTM (Met-RANTES, T-22, T-134), and the fusion inhibitor 
FuzeonTM (Enfuvirtide, T-20).13 Once the HIV nucleocapsid enters the cell (Fig. 1.3), partial 
uncoating of the viral core occurs to release the genetic material of the virus into the host cell 
cytoplasm, where the viral enzyme reverse transcriptase (RT) transforms the ssRNA genome 
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to a dsDNA form.14 RT promotes (catalyst) three types of reactions: RNA-directed DNA 
synthesis, DNA-directed DNA synthesis both of which carried out by the polymerase moiety 
of RT, and RNA hydrolysis directed by ribonuclease (RNase H). The dsDNA is subsequently 
transported into the cell nucleus, where another virion-associated enzyme, HIV integrase, 
catalyses the integration of the viral DNA into the host-cell genome. Importantly though, the 
viral DNA lies dormant until called upon to transcribe, when transcription of the integrated 
viral DNA leads to the production of genomic messenger RNA (mRNA) molecules that are 
transported back to the cell cytoplasm, where translation takes place leading to the 
production of Gag and Gag-Pol proteins. Immature Gag and fused Gag-Pol precursor are 
transported to the cell membrane, where viral progeny begin assembling and “budding” from 
the infected cells. Viral particles released following budding, however, do not contain the 
characteristic HIV condensed core and are not infectious. Virus infectivity is acquired after 
particle maturation, which is mediated by the virion-associated HIV aspartyl protease. This 
enzyme cleaves the immature Gag and Gag-Pol precursors into functional polypeptides.15  
 
1.5 HIV PATHOGENESIS 
 
AIDS results from selective depletion of CD4+ helper T-lymphocytes.16a,b Progressive CD4 
cell depletion has been identified as the fundamental basis of AIDS, but the specific 
mechanism by which this cell death occurs is still not well understood. It is well accepted that 
in chronic disease less than 15% of all CD4 cells are infected. The proportional loss of CD4 
cells in AIDS far exceeds this prevalence of cell infection, implying that a direct cytopathic 
effect of the virus cannot be the sole explanation of CD4 cell depletion. In recent years, it has 
been shown that during acute infection there is massive depletion of CD4 cells in the 
gastrointestinal associated lymphoid tissue (GALT) and other mucosal tissues. Importantly, 
CD4 cell depletion in these tissues appears to be significantly greater than that observed in 
peripheral blood.16b  
The function of CD4 cells is to help CD8+ cytotoxic T-lymphocytes to destroy other cells that 
express foreign antigens and also to enhance antibody production by B-lymphocytes. Thus, 
CD4 cells represent a key component of the immune system. In a healthy individual, about 
1200 CD4 cells circulate per µL blood; when CD4 counts drop below 400 µL, opportunistic 
infections start to occur.2  HIV eventually kills the helper T-cell that are vital for the immune 
system, and the decline in CD4+ T-cells eventually has a great effect on humoral response 
functions, specifically the functioning of the B-cells. Helper T-cell depletion inhibits the B-cells 
from differentiating into plasma cells and memory cells, thus impairing the immune system‟s 
ability to fight against foreign antigens that have entered the body.17 A person with a CD4 
level below 200/ µL defines a state of AIDS. 
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1.6 THE REVERSE TRANSCRIPTASE ENZYME (RT) 
 
HIV reverse transcriptase (RT) is a multifunctional enzyme (Fig. 1.5) responsible for catalytic 
transformation of single-stranded viral RNA into double-stranded DNA (dsDNA) that in turn 
gets integrated into host cell chromosomes by integrase.18 In summary again, HIV-1 RT 
carries out reverse transcription by the following catalytic activities:  
(i) RNA-dependent DNA polymerization to form an RNA-DNA hybrid. 
(ii) RNase H degradation of the RNA strand from RNA-DNA hybrid. 
(iii) DNA-dependent DNA polymerization to form a dsDNA.     
 
 
Figure 1.5 (a) Structure of the HIV-1 reverse transcriptase enzyme adapted from Pata et al.19 (b) 
RNA-directed followed by DNA-directed synthesis. 
 
From a structural point of view, HIV-1 RT is a heterodimer consisting of two subunits: a 66 
kDa one and a 51 kDa one (p66 and p51). The p66 subunit contains an N-terminal 
polymerase domain and a C-terminal RNase H domain. The p51 subunit is derived either 
from p66 or from a large gag-pol precursor by proteolytic cleavage with HIV-1 protease, and 
has the same amino acid sequence as the polymerase domain of p66. Crystal structures of 
RT have revealed the part of the p66 subunit responsible for transcription to resemble a right 
hand with fingers, palm, thumb, and connection subdomains. The p66 palm contains the 
polymerase active site that is defined by Asp110, Asp185, and Asp186 residues located in 
the β9-β10 sheet. These amino acids bind the divalent magnesium cations required for 
catalysis (more details later).20,21,22 
 
The primary function of reverse transcriptase is to build a DNA strand from an RNA template, 
which is performed at the polymerase active site of the p66 subunit. This process is complex 
and requires the concerted function of two enzyme active sites in RT (Fig.1.6).  
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Figure 1.6 a) HIV reverse transcription mediated by the DNA polymerase, RNase H and the transfer 
activities of the viral RT.22 b) simplification of the transcription process. 
 
Reverse transcription is initiated at the 3‟-end of a cellular lysyl-tRNALys,3, hybridized to the 
primer binding site (PBS) of the HIV RNA genome, by the RNA-primed RNA-dependent DNA 
polymerase activity (RDDP) of the RT. This elongates to produce viral DNA until the 5‟-end of 
the HIV-1 RNA is reached (Fig. 1.6, Step 1). The product formed from this reaction is termed 
the minus-strand strong-stop DNA. RT ribonuclease H (RNase H) activity then hydrolyzes 
the HIV genomic RNA (Fig. 1.6, Step 2) to allow the nascent DNA to hybridize with the 
repeat sequence (R) at the 3‟-end of the HIV genomic RNA (Fig. 1.6, Step 3). After this 
strand transfer, the nascent DNA strand is further elongated by RT DNA-primed RDDP 
activity (Fig. 1.6, Step 4). RNase H activity is again required to hydrolyze the rest of genome 
RNA except for the a purine rich sequence, termed the polypurine tract (PPT), which serves 
as a primer for the initiation of second strand DNA synthesis (Fig. 1.6, Step 5). RNA-primed 
DNA-dependent DNA polymerase activity (DDDP) then elongates the PPT primer (Fig. 1.6, 
Step 6). Removal of the PPT and tRNA primers by RT RNase H activity (Fig. 1.6, Step 7) 
then allows second strand transfer to take place by interaction of the complementary PBS 
a) b) 
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sequences (Fig. 1.6, Step 8). HIV-1 RT DNA-primed DDDP activity including strand-
displacement activity completes the synthesis of the double-strand proviral DNA precursor. 
The final product of the complete reaction carries U3-R-U5 long terminal repeats (LTR) at 
both ends (Fig 1.6, Step 9).22 
 As a result, the reverse transcriptase enzyme has played a key role in the HIV-1 life-cyle, 
making it a primary target for development of new anti-HIV drugs used in the treatment of 
HIV/AIDS.14,23 
 
 1.7 DEVELOPMENTS IN ANTI-HIV CHEMOTHERAPY 
 
With the onslaught of drug-resistant mutations, combination therapy comprising of at least 
three anti-HIV drugs, has become the standard treatment of HIV-infected patients.23 Drugs 
used in Highly Active Anti-retroviral Therapy (HAART) fall into one of three categories: (i) 
nucleoside/nucleotide RT inhibitors (NRTIs) that following two phosphorylation steps (for 
nucleotides) or three phosphorylation (for the nucleosides) steps act as chain terminators at 
the substrate binding site (Fig. 1.7) of RT; (ii) non-nucleoside RT inhibitors (NNRTIs) that are 
able to interact with reverse transcriptase at an allosteric, non-substrate binding site; and (iii) 
protease inhibitors (PIs) that inhibit the virus-associated protease.23 Generally, drug 
combinations involve two NRTI‟s plus one NNRTI, or two NRTI‟s plus one PI. Entry inhibitors, 
Integrase inhibitors and Protease inhibitors will not be dealt with in any further detail. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7 Ribbon representation of HIV-1 RT in complex with efavirenz. The p66 and p51 domains of 
RT is highlighted in red in blue respectively. The DNA active site and the RNase H active site is 
higglighted with yellow spheres.22 
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Recent studies have shown that the combination therapy of NRTIs, NNRTIs and PIs are able 
to significantly reduce the viral load, increase CD4 count, decrease mortality and delay 
disease progression.23 This type of therapy has been shown to work particularly well in AIDS 
patients with advanced immune suppression.24 In addition, there has been found to be a 
significant benefit in early aggressive anti-HIV chemotherapy, especially in patients showing 
no symptoms of the disease (asymptotic stage).25 HAART is able to partially restore the 
immune system in patients with advanced HIV infection, but also exacerbates cryptococcal 
meningitis.26 Thus, HAART has profound repercussions on various AIDS-associated 
diseases. 
Therefore, almost all current HIV-drug candidates, either in preclinical or advanced clinical 
development, target well-defined steps in the HIV replicative life cycle. These drugs fall into 
categories associated with the life cycle such as (i) viral adsorption (gp-120) inhibitors; (ii) 
viral co-receptor antagonists; (iii) viral fusion (gp-41) inhibitors; (iv) nucleocapsid protein 
(NCp7) Zn finger-targeted agents; (v) HIV integrase inhibitors; (vi) transcription 
(transactivation) inhibitors and (vii) HIV protease inhibitors.23 
The inhibitors that lie at the core of this project are the reverse transcriptase inhibitors. 
 
1.8 NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIs) 
 
The substrate (dNTP) binding site of HIV-1 reverse transcriptase is the obvious target for a 
large variety of NRTI analogues,23 and the HIV-1 binding site has been targeted for many 
years now as an efficient way of combatting HIV. In 1987, zidovudine (AZT), a nucleoside RT 
inhibitor (NRTI), was approved in USA as the first chemotherapeutic agent against HIV/AIDS. 
However, resistance to anti-HIV compounds develops rapidly, sometimes within a few days 
of initiating treatment. Errors made by the viral enzyme RT and cellular RNA polymerase II 
result in about one mutation per viral replication cycle (1 base change in 10 000 RNA 
nucleotides), which together with the rapid replication of the virus, is responsible for rapid 
emergence of drug-resistant mutants. This problem led many in pursuit of developing other 
NRTIs, and over 21 years of research has culminated in seven US Food and Drug 
Administration (FDA) approved NRTIs Examples of such NRTIs are zidovudine27 (AZT, 
1987), didanosine28 (ddI, 1991), zalcitabine29 (ddC, 1992), stavudine30 (d4T, 1994), 
lamivudine31 (3TC, 1995), abacavir32 (ABC, 1998) and emtricitabine33 (racemic FTC, 2000) 
all of which are FDA-clinically approved drugs (Fig. 1.8).  
These NRTIs are pro-drugs and need to firstly be phosphorylated by cell-derived kinases to 
their 5‟-triphosphate forms, before they can halt the chain propagation step at the reverse 
transcriptase level as illustrated in Figure 1.9. The active metabolites then act as competitive 
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inhibitors (alternative substrates) with respect to the normal substrates (dATP, dGTP, dCTP 
or dTTP), and lead to the termination of chain elongation.23 
 
 
 
 
                Figure 1.8 Nucleoside reverse transcriptase inhibitors and Tenofovir (PMPA). 
 
D4T shows selective anti-HIV activity comparable to that of AZT in vitro. However, d4T is 
more toxic than AZT,34a and is thought to be the worst culprit for lipodistrophy and other body 
composition changes associated with antiretroviral therapy. However, there is some 
evidence that reducing or stopping the drug can slow or halt the changes in body 
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composition and metabolism. Lowering the dose of d4T has also been shown to help to 
alleviate peripheral neuropathy, another side effect of the drug. The World Health 
Organization recommended in 2007 that d4T dosing should be reduced to 30mg twice a day 
in order to counter toxicity.34b  
It has also been shown, though, that under physiological conditions, RT can remove these 
chain-terminators, thus unblocking the primer terminus with great efficiency and thus 
restoring DNA synthesis.35 
In contrast to the nucleoside analogues, the nucleotide analogues (NtRTIs), e.g. PMPA are 
mono-phosphorylated pro-drugs in the form of phosphonates, and thus only require a further 
two phosphorylation steps by cellular kinases in order to be transformed into the active 
metabolite. NtRTIs can therefore by-pass the nucleoside-kinase reaction, the later well 
documented to be the rate-determining step en route to the active triphosphate, and which 
can limit the activity of the dideoxynucleoside analogues.7 An included bonus is that the 
phosphonate, unlike the phosphate, cannot be cleaved by esterases that would normally 
convert nucleoside monophosphates back to their parent nucleoside. 
 
 
 
Figure 1.9 Mechanism of anti-HIV action of 2‟, 3‟-deoxynucleoside analogues- shown for 2,3‟-               
                dideoxycytidine.7    
                   
 
Tenofovir36, which is FDA clinically approved, has proven to be antivirally active and has 
showed favourable activity/resistance profiles. It is currently the only approved NtRTI for 
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treatment in HIV chemotherapy. It is scarcely affected by HIV-1 RT mutations while at the 
same time retains its full potency as an antiretroviral. 
 
At present, the existing drugs still find it remarkably difficult to comply with the ever- 
increasing demands of higher activity (potency), lower toxicity (side-effects) and favorable 
resistance profiles required for anti-HIV drugs. As a result, several new NRTIs are in clinical 
development.37 Racivir, also know as (±) FTC, is one such inhibitor. Its mechanism of action 
is precisely the same as that of zidovudine38, in that after successful phosphorylation to the 
active metabolite, the ddNTP competes with the normal substrates. Upon expulsion of the β, 
γ-diphosphate, following nucleophilic substitution by the HIV DNA 3‟-hydroxyl with an 
incoming ddNTP, ddNMP is incorporated in the 3‟-end of the DNA chain, leading to chain 
termination since the decoy inhibitor does not possess the necessary 3‟-hydroxyl functionality 
for further elongation (Fig. 1.9). Racivir comprises of a 50:50 racemic mixture of the two 
enantiomers39a and is thus considered a form of combination therapy. (-) FTC is moderately 
more potent than (+) FTC. Pharmacokinetic studies carried out by Anderson and co-workers 
revealed that compared to the (+)-isomer, (-)-FTC is more efficiently taken up into the cell 
and phosphorylated to its active triphosphate form. Also, by serving as a much poorer 
substrate of cytidine deaminase than the (+)-isomer, (-)-FTC is not degraded back to its 
parent nucleoside. FTC has also shown diminished resistance profiles.39b 
Further successes have come in the form of NtRTI prodrugs.40,41,42 Attempts have been 
made to synthesize 2‟, 3‟-dideoxynucleotide (ddNMP) prodrugs, as well as other forms of 
prodrugs that are taken up into the cell immediately in the nucleotide form. Successes have 
been achieved using this approach for a number of NRTIs such as d4T (more later). 
  
1.9 THE STRUCTURE OF HIV-1 RT IN COMPLEX WITH NUCLEOSIDE 
INHIBITORS 
 
Nucleotide analogues bind at the dNTP-binding site (Fig. 1.10), adjacent to the 3' terminus of 
the primer strand that is located in the palm subdomain of the p66 subunit.43 The catalytic 
triad of aspartic acids, (Asp110, Asp185 and Asp186), which are conserved in most 
polymerases are also located at this site. The nucleotide analogue binding site is composed 
of both protein and nucleic acid. The nucleic acid part of the binding site is made up of the 3'-
primer terminus, which possesses the 3'-OH group that is the site for the covalent attachment 
of the incoming substrate. The base of the 3'-primer terminal nucleotide also helps to bind 
incoming substrate via base-stacking interactions. The first base in the template overhang 
contributes base-specific H-bond donor and acceptor groups that guide dNTP selection 
based on Watson-Crick base pairing rules. Based on modelling experiments, residues 
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Asp185 and Asp186 of the conserved Tyr-Met-Asp-Asp motif and Asp110 are believed to 
bind the triphosphate moiety of the incoming dNTP via two chelated Mg2+ ions (Fig. 1.11).43 
Once again, substitution with expulsion of the diphosphate (as described before) leads to 
incorporation of the resulting dNMP at the 3‟-end of DNA chain. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10 Superposition of HIV-1 RT in complex with an inhibitor and in ternary complex with primer 
template DNA and incoming dNTP. Displacement of TRP-229 and concomitant displacement of the 
primer grip are indicated with arrows. Nonspecific contacts between the primer grip and the primer 
strand DNA are indicated with parallel lines.19 
 
  
 Figure 1.11 Proposed transition state of DNA polymerase-catalyzed nucleotide insertion.44 
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1.10 NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS (NtRTIs) 
 
The ultimate bottleneck in the metabolic pathway leading from 2‟,3‟-dideoxynucleoside (ddN) 
analogues to their active 5‟-triphosphate form is the first phosphorylation step.23 Unlike 
adefovir dipivoxil [9-(2-phosphonylmethoxyethyl)adenine (PMEA)] and tenofovir disoproxil 
[(R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA)] (Fig. 1.12) which are already equipped 
with a phosphonate group and therefore only require two more phosphorylations to be 
converted to their active metabolites (PMEApp and PMPApp, respectively), nucleoside 
analogues lack this advantage. (Fig.1.12) depicts various known versions of mono-
phosphorylated nucleotide pro-drugs, which will be discussed.   
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Figure 1.12 Acyclic nucleotides phosphonates: PMEA and PMPA in their prodrug forms. Prodrugs of 
ddNMPs.23 
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Many research groups have focused their attention on constructing 2‟,3‟-dideoxynucleotide 
(ddNMP) prodrugs as esters or amides that once taken up by the cells, deliver the nucleotide 
(ddNMP) form. This so-called pronucleotide or prodrug approach (discussed in detail later) 
has proven successful for a number of NRTIs such as 2‟,3‟-dideoxyadenosine (ddA) and d4T 
(Fig. 1.12). The bis(S-acetyl-2-thioethyl)phosphotriester of ddA [bis(SATE)ddAMP] was 
synthesized by Imbach  and co-workers45 and found to be 1000-fold more potent than the 
parent nucleoside. This increase in potency can be attributed to direct delivery of 
bis(SATE)ddAMP into the cells, which circumvents adenosine deaminase enzymes rapidly 
degrading ddA to ddI.45  
Similarly, McGuigan and co-workers46,47,48 have over a number of years synthesized and 
evaluated the highly potent arylphosphoramidate derivatives of d4T, AZT and ddU as pro-
drugs (Fig. 1.12).  This prodrug comprises a phosphate derivative bearing aryloxy and 
alaninyl (methyl ester) O- and N-based groups respectively as a phosphoramidate 
derivatives. Direct intake of aryloxyphosphoramidate derivatives of d4T, d4A and ddA 
intracellularly (via the alaninyl nucleoside-MP intermediate49) have provided anti-HIV 
activities that are 25- to 625-fold greater than the parent nucleosides.50 
Similarly, Meier and co-workers51,52 having introduced the cyclic saligenyl group (Fig. 1.12), 
which by-passes the rate-determining, thymidine kinase (in the case of d4T) and adenosine 
deaminase (in the case of ddA) enzymatic step. CycloSaligenyl pronucleotides deliver the 
monophosphate nucleotides of d4T and ddA exclusively under intracellular conditions of 
pH.53,54 To fully understand how this works, the „the Prodrug Approach‟ will now be discussed 
in detail. 
 
1.10.1 THE PRODRUG APPROACH (The Pronucleotide Approach) 
 
The first introduction of prodrugs to the field of medicinal chemistry is kindly attributed to 
Albert55 in 1951 who wrote: “A prodrug is a molecule which does not have any intrinsic 
biological activity but which is capable during the different phases of its metabolism to 
generate a biologically active drug”. Furthermore, a potent suitable prodrug should overcome 
the crucial paradox: to be lipophilic enough to by-pass a membrane or metabolic barrier and 
to be hydrophilic enough to fulfill solubility, bioavailability or transport criteria.56 The 
systematic enzymatic cleavage of the chemical bond allowing efficient prodrug-to-drug 
conversion is of particular interest since it depends on the type of cleavable linkage: -
carbonate, -ester, -amide, carbamate, -phosphate, -phosphonate, -phosphoramidate, or –
amidine.56 The enzymatic stability of the resulting prodrug is characterized by its half-life, 
which can vary from a few minutes to several weeks.  
All of the above is schematically depicted in Figure 1.13 for d4T. 
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Figure 1.13 Metabolic transformation of d4T into active ddNTPP, after controlled selective delivery,        
i.e. the prodrug approach.57 
 
In contrast to d4T, the fate of the majority of nucleoside analogues has not yet been studied 
in detail. After being tested, many parent nucleosides are discarded after not displaying any 
biological activity. Thus, it is likely that such a lack of understanding of the metabolic 
blockade has prevented the successful development of certain nucleosides into active 
nucleotide prodrugs.57 
 
Nucleotides are very polar molecules that do not easily pass through cellular membranes 
and are dephosphorylated in the serum by non-specific phosphorylases.57 However, this 
problem can be overcome by masking the phosphate or phosphonate moiety of the 
nucleotide with degradable lipophilic carrier groups as illustrated in Figure 1.13. This leads to 
neutral, membrane-permeable nucleotide delivery systems, which is known as the 
pronucleotide approach. Under physiological conditions nucleotides are charged species 
(phosphate monoester pKa values are about 1.6 and ca. 6.6). Therefore, as reported by 
Meier, one requires two masking groups to obtain a neutral lipophilic phosphate triester.57 
Several methods with corresponding mechanisms for achieving this have been employed. 
Strategies involving pure chemical hydrolysis of dialkyl, dibenzyl and diphenyl phosphate 
triesters have proven to be successful in in vitro and in vivo studies.58 However, recent 
pronucleotide approaches are based on enzymatic or chemical activation of the masking 
groups. These approaches use carboxyesterase activity and specific pH conditions.58,59 
 
An example of this is the neutral lipophilic phosphotriesters using pivaloyloxymethyl (POM) 
phosphate-masking groups (Fig. 1.14), which can penetrate into cells via passive diffusion.60 
Cleavage of one of the POM groups by non-specific cellular carboxylate esterases yields the 
hydroxymethyl analogue which is inherently chemically labile and spontaneously dissociates 
with elimination of formaldehyde to give the phosphodiester.60 
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Figure 1.14 Metabolic transformation of d4T into active ddNTPP, after controlled selective delivery, 
i.e. the prodrug approach.60 
 
 
Cleavage of the second POM group by cellular phoshodiesterases regenerates the desired 
parent nucleoside 5‟-monophosphate.  These enzyme-triggered approaches on POC and 
POM phosphate-masking groups have proven very successful in in vitro intracellular delivery 
systems.60 
However, thus far, the only successful intracellular pH-driven nucleotide delivery strategy is 
the cycloSal approach.61,62 This designed chemically induced coupling, follows a cascade 
mechanism61,62, and gives as follows (Fig. 1.15): following nucleophilic attack of hydroxide at 
the phosphorus atom of cycloSal triester 1, the phenolate is displaced preferentially in an 
SNP reaction, since it is the best leaving group of the three OR groups. This leads to 2-
hydroxybenzylphosphate diester 2 via proton transfer. The resulting ortho substituent of the 
benzyl ether is changed from a very weak electron-donating group (phosphate) to a strong 
electron-donating group (hydroxy). This electronic change activates the remaining masking 
group and induces a spontaneous rupture of diester 2 to yield the nucleotide and salicyl 
alcohol 8 (cascade reaction; steps b1 and b2). The bond cleavage proceeds after 
intramolecular proton transfer (intermediate 4) via zwitterion 5 or 2-quinone methide 6.57  
The disfavoured pathway involves cleavage of the benzyl ester bond (step c), in which cation 
3 is rapidly trapped by water to yield phenyl phosphate diester 7. However, no further 
chemical hydrolysis of the phosphate diester takes place at physiological pH and 7 comes to 
a dead end. Thus, the pathway via step c does not occur.57 
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Figure 1.15 Two possible mechanisms for the hydrolysis of cycloSal-d4TMP triester 1.57a,b 
 
 
In summary, the cycloSal strategy requires one bifunctional masking group per equivalent 
nucleotide and is chemically triggered intracellularly at physiological pH to render the desired 
parent nucleotide-MP. 
 
1.10.2 THE ACYCLIC NUCLEOTIDE PHOSPHONATES (ANPs) 
 
The acyclic nucleotide phosphonates (ANPs) represent a new dimension for the treatment of 
DNA virus and retrovirus infections.63 These ANPs encompass three compounds that have 
been formally licensed for the treatment of (i) HCMV (human cytomegalovirus) infections (i.e. 
HCMV retinitis) in AIDS patients (cidofovir, Vistide ®) (Fig. 1.16), (ii) chronic HBV (hepatitis B 
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virus) infections (adefovir dipivoxil, Hepsera ®), and (iii) HIV (human immunodeficiency virus) 
infections (AIDS) [tenofovir disoproxil fumarate (TDF), Viread ®].40 
ANPs have therefore proved to be the cornerstone of anti-viral therapy. The question would 
therefore be: What is the significance of an acyclic nucleoside „phosphonate‟? In regular 
nucleotides (or nucleoside phosphates), the phosphate group is attached, to the 5‟-oxygen 
as an ester sugar.  
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 Figure 1.16 a) Broad spectrum of acyclic nucleotide phosphonates (ANPs); b) Mechanism of action  
 of cidofovir.40 
 
bound to the nucleoside.40 In the ANPs, the phosphate group, is attached to the nucleoside 
via of a phosphonomethyl ether phosphonate grouping, which, unlike the phosphate ester 
linkage, should resist any attack from esterases, or any catabolic enzymes at large, by virtue 
of it having a more P-C bond over a P-O bond. 
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The concept of ANPs  was born in 1986 with the discovery of the ANP prototype, (S)-9-(3-
hydroxyl-2-phosphonylmethoxypropyl)adenine (HPMPA) (Fig. 1.16), as a broad spectrum 
anti-DNA virus agent.64 HPMPA itself could be envisaged as a kind of construct resulting 
from the replacement of the carboxylate group of phosphonoacetic acid [PAA, the 
predecessor of the antiviral agent phosphonoformic acid (foscarnet, Foscavir ®] by the 
acyclic nucleoside analogue DHPA [(S)-9-(2,3-dihydroxypropyl)adenine], which was 
described in 1978 as an acyclic nucleoside analogue with broad spectrum antiviral activity.65 
Cidofovir, adefovir, tenofovir and several others show high potential as therapeutic agents. 
According to their activity spectrum, the ANPs can be classified into two categories: (i) the 
„HPMP‟ derivatives, represented by HPMPC (cidofovir), which are active against a broad 
variety of DNA viruses (polyoma-, papilloma-, adeno-, herpes- and poxvirus, and (ii) the 
„PME‟ and „PMP‟ derivatives, represented by PMEA (adefovir) and PMPA (tenofovir) (Fig. 
1.12, pg. 14), which are primarily active against hepadna- and retroviruses. Their clinical 
usages, approved and potential are represented in Table 1.1. 
 
Table 1.1 Clinical applications of acyclic nucleotide phosphonates.40 
Compound 
Commercially available 
Dosage and route  
of administration 
Approved clinical  
           use 
Off-label (potential) 
clinical use 
Cidofovir 
(Vistide®) 
 
Intravenous 
(5 mg/kg weekly or 
two-weekly) 
CMV retinitis in AIDS 
patients         
- Severe polyoma-, 
papilloma-, adeno-, 
herpes- and pox-virus 
infectious 
 
 
 
Topical 
(gel/cream) 1% 
 
 - HPV-, HSV-1-, HSV-
2-, MCV-, and poxvirus 
Adefovir dipivoxil 
(Hepsera ®) 
Oral 
(10 mg daily) 
Chronic hepatitis B 
(HBV infection) 
 
 
Tenofovir disoproxil 
fumarate (TDF) 
(Viread ®) 
 
Oral 
(300 mg daily) 
AIDS (HIV infection) Chronic hepatitis B 
(HBV infection) 
TDF in fix-dose 
combinations with 
emtricitabine 
(Truvada ®) 
 
Oral 
(300 mg TDF daily) 
(200 mg emtricitabine 
daily) 
AIDS (HIV infection) Chronic hepatitis B 
(HBV infection) 
TDF in fix-dose 
combinations with 
emtricitabine and 
efavirenz 
(Atripla ®) 
 
Oral 
(300 mg TDF daily) 
(200 mg emtricitabine 
daily) 
(600 mg efavirenz 
daily) 
AIDS (HIV infection)  
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1.11 NRTI RESISTANCE 
 
HIV-1 RT is very tolerant to non-standard base pairs and modified sugars which has 
advantages for chemotherapy. However, one drawback are the resultant mutations (no 
proof-reader), due to misincorporation ranging from 1/1700 to 1/4000 nucleotides.  One 
estimate suggests about 10 base changes in the HIV genome per replication cycle, and the 
resultant mutant strains can exhibit NRTI resistance. There are two currently known 
biochemical mechanisms of NRTI drug resistance. The first is mediated mutations in the RT 
enzyme that allow it to discriminate against NRTIs during DNA synthesis, thereby preventing 
their addition to the growing DNA chain. The second mechanism “nucleotide excision 
mechanism” “NEM” involves an increase in nucleotide excision rate in the mutant strain, 
resulting in continued DNA synthesis.66,67 In the second mechanism, the oxygen anion of a 
nucleoside diphosphate or triphosphate is used as a pyrophosphate nucleophile to attack 
and cleave the 3'/5'-phosphate bond of the primer, producing an unblocked primer and a 
dinucleoside tri- or tetraphosphate containing the dideoxynucleoside monophosphate from 
the primer terminus linked through its phosphate group to the distal phosphate of the free 
nucleoside di- or triphosphate  (Fig. 1.17).67 
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Figure 1.17 Removal of NRTI from the primer terminus through dinucleoside polyphosphate synthesis 
  
Biochemical and modelling studies suggest that incorporation of AZT results in steric strain 
between the azido group and Asp185 of the mutant, resulting in an enhanced excision rate 
(Fig. 1.18). This explains why NEMs cause the highest levels of phenotypic resistance to 
AZT.  
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Figure 1.18 Steric hindrance when an AZT-terminated primer is bound to RT at the P site. The figure, 
based on the structure of the ternary RT-DNA-dNTP complex, shows that the distance between the 
azido of AZT and D185 (mutant) would cause steric conflict; the distance between D185 and the first 
and second azido nitrogens is less than the sum of the van der Waals radii.  
 
The M184V mutation causes the high-level of lamivudine resistance observed and emerges 
rapidly in patients receiving lamivudine monotherapy. This mutation (M184V) and other NRTI 
resistance mutations interfere with the effects of the NEMs. The mutational antagonism 
between the NEMs and several of the mutations that act by allowing RT to discriminate 
against NRTIs explains the clinical synergism observed with dual NRTI combinations such as 
Zidovudine/Lamivudine, Stavudine/Lamivudine, Zidovudine/didanosine and 
Stavudine/didanosine.66 
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1.12 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIs) 
 
More than 30 structurally different classes of NNRTIs (Fig. 1.19) have been synthesized,68,69a-
c since the well known TIBO derivatives70 were first discovered by the Janssen group in 
1987. More than 29 NNRTIs have been approved by the FDA, with the most recent one 
being Etravirine.69b  NNRTIs are a chemically diverse set of compounds, largely specific for 
HIV-1 RT, although some examples of NNRTI inhibition of HIV-2 RT have reported, including 
certain members of the PETT series.14a,b And unlike the NRTIs, they do not require 
intracellular metabolism for activity.  
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                              Figure 1.19 Non-nucleoside reverse transcriptase inhibitors.69 
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In general, NNRTIs are a group of small (< 600 Da) hydrophobic compounds with diverse 
structures, as can be seen in Figure 1.19. They specifically inhibit HIV-1, but not HIV-2 RT, 
which is unable to form the required pocket for binding. 
 
By far and the chief pioneer for nearly 17 years in NNRTI development is the late Dr. Paul 
Janssen. Beginning in 1987, Janssen and his co-collaborators (Das, Clark, Arnold, De Corte, 
De Clercq, Pauwels, Lewi, Kukla and others) engineered the field of non-nucleoside reverse 
transcriptase inhibition of HIV-1 RT. Figure 1.20 provides crucial insight in the form of a 
historical synopsis of the developments that ultimately led to the discovery of TMC278.70 
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                      Figure 1.20 Chemical evolution from TIBO to TMC278, starting in 1987.71 
 
TIBO (tetrahydroimadazobenzodiazepinone) analogues were discovered by screening a 
subset of a Janssen compound library in a cell-based anti-HIV test at the Rega Institute.70 
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Subsequent screening of the Janssen compounds led to the discovery (2nd lead series) of 
the α-APA (α-anilinophenylacetamide) class of NNRTIs.72 Further chemical modification led 
to the class of potent ITU (iminothiourea) NNRTIs.73 In an attempt to synthesize the 
corresponding imino-N-cyanoguanidine derivatives of ITU, an unexpected ring closure 
occurred, producing the first compound of the DATA (diaryltriazine) class of NNRTIs.74 
Molecular modeling studies suggested in 1996 that replacing the central aminotriazine ring of 
DATA with a pyrimidine ring would lead to greater activity. This was the birth of the DAPY 
(diarylpyrimidine) NNRTIs, of which TMC120 (R147681) is the prototype. TMC120 and 
TMC125  have subsequently proved to be highly active in reducing viral loads.75  
Further collaborative work among medicinal chemists, crystallographers, and molecular 
modelers led in 2001 to the discovery of the cyanovinyl DAPY compounds, of which the E-
isomer TMC278 (R278474) is the prototype. The potency of TMC278 against wild-type and 
mutant HIV-1 RTs are compared in Table 1.2 below with those of two other DAPY 
compounds (TMC120 and TMC125) as well as with three approved NNRTI drugs. 76 
 
Table 1.2 Potency studies of DAPY compounds and the three approved NNRTIs.76 
               EC50 (μM) {fold resistance}** 
Compound Wild-type K103N Y181C K103N/Y181C L100l L100l/K103N 
TMC278 
 
0.0004 0.0003 0.0001 0.0008 0.0005 0.008 
TMC125 
 
0.002 0.001 0.006 0.005 0.003 0.01 
TMC120 
 
0.001 0.004 0.008 0.044 0.016 >10 
Efavirenz 
 
0.001 0.039 0.002 0.04 0.038 >10 
Delavirdine 
 
0.016 >1 >1 >10 >1 N/A 
Nevirapine 0.085 >1 >1 >100 0.6 N/A 
** EC50 is defined as the concentration of compound required to inhibit syncytia formation in HIV-1    
        infected cells. The fold resistance is the ratio of mutant/wild type EC50s for each compound. Table 1 is   
        adapted from reference 2. 
 
 
Table 1.2 reveals how first-generation NNRTIs (Nevirapine and Delavirdine) are effective in 
inhibiting wild-type HIV-1 RT, but are poor at over coming single and double point mutations 
because of their rigidity. Efavirenz, often referred to a second-generation NNRTI is very good 
(1 nM range) at inhibiting HIV-1 RT, as well as being capable of inhibiting single point 
mutations. The flexible third-generation DAPY compounds, especially TMC125 and TMC278, 
display an outstanding anti-HIV profile for inhibition against all single point mutations as well 
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as a remarkable 8 nM activity for TMC278 against the double point mutation of L100/K103N. 
The mechanism by which this works will be discussed later.  
 
1.12.1 THE NNRTI-BINDING POCKET 
 
All NNRTIs bind to a single site on the p66 subunit of the HIV-1 RT p66/p51 heterodimer 
termed the NNRTI binding pocket (NNRTI-BP) (see Fig. 1.7 again), despite being a 
heterogeneous class of inhibitors with diverse chemical structures. The NNRTI-BP is situated 
between the β6-β10-β9 and β12-β13-β14 sheets in the palm subdomain of the p66 subunit. 
This is also approximately. 10Ǻ away from the RT DNA polymerase aspartic acid catalytic 
triad.20 The NNRTI-BP is predominantly hydrophobic in nature with substantial aromatic 
character (Y181, Y188, F227, W229 and Y232), but also contains hydrophilic residues 
(K101, K103, S105, D192, and E224 of the p66 subunit and E138 of the β7-β8 loop of the 
p51 subunit). A likely entrance to the NNRTI-BP is located at the p66/p51 interface, ringed by 
residues L100, K101, K103, V179, and Y181 (p66 subunit) and E138 (p51 subunit).77 In the 
absence of ligand, the side chains of Y181 and Y188 of p66 point into the hydrophobic core, 
and thus, the NNRTI-BP does not exist in the free „apo‟-enzyme (Fig. 1.21).77,78 NNRTI-
binding to HIV-1 RT causes the Y181 and Y188 to rotate away from their positions in the 
hydrophobic core thereby creating space for ligand accommodation.77 Effectively, this 
equates to an approx. 30o twisting of the β12-β13-β14 sheet, which leads to an expansion of 
the NNRTI-BP.69 
 
Figure 1.21 Close-up of the future binding pocket area in unliganded RT. Amino acid residue 100 
(shown in blue) makes contact with residues Y181 and Y188 (shown in red) which undergo major 
structural rearrangement prior to non-nucleoside inhibitor binding. L100 also makes contact with K101 
and K103 (purple) in the uncomplexed state.79 
 
In NNRTI-bound RT, the p66 fingers and RNase H domain fluctuate in opposite directions 
(anti-correlated motions), giving rise to open and close conformations (Fig. 1.22).69 The p66 
palm and connection serve as a rigid support for the flexible regions. The p66 thumb, on the 
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other hand, is subject to orthogonal, but cooperative motions, with respect to the p66 fingers 
and RNase H. Thus, the net effect of NNRTI-binding to RT is to change the direction of 
domain movements.80 To understand this, the mechanism of NNRTI-RT inhibition will be 
discussed in details.  
 
 
Figure 1.22 Residue fluctuations along the x-, y- and z-directions for unliganded (black line) and 
nevirapine-bound (blue line) RT. The X axis coincides with the out-of-plane direction; the Y and Z axis 
lie along the in-plane directions. The ribbon diagrams on the right represent the p66 fingers, thumb, 
RNase H, and the p51 thumb are coloured blue, red, pink and magenta, respectively.69 
 
1.12.2 THE MECHANISM FOR NNRTI INHIBITION OF RT 
 
A number of different mechanisms for NNRTI inhibition of RT have been proposed. 1992, 
Kohlstaedt and co-workers20 suggested that binding of nevirapine induces so-called 
„molecular arthritis‟ whereby relative domain movements, similar to Figure 1.22 above, 
though to be necessary for the catalytic cycle of the enzyme, are inhibited.20 Crystal 
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structures of RT with bound NNRTIs generally have the p66 thumb subdomain in an 
extended position. For unliganded RT, the thumb subdomain can either be folded down into 
the DNA-RNA binding cleft81 or can adopt a more extended position.82 Examination of 
various crystal forms of RT with different NNRTIs bound showed significant variations in 
relative domain positioning.83 Thus, there is no clear evidence that NNRTI binding induces a 
single positioning of the p66 thumb subdomain. Comparing the NNRTI bound and free forms 
of RT indicated a significant and consistent movement of the strands β2-β3 containing the 
critical Asp110, Asp185 and Asp186 active site triad,81 which ultimately explains the inhibition 
of RT by the NNRTIs (Fig. 1.23). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.23 Diagram comparing the NNRTI site and polymerase active site in RT for the apo enzyme 
(in green) and for the inhibitor-bound form (I051U91, shown in grey as ball and stick representation) in 
brown. The three key aspartic acid residues in the polymerase active site (110, 85 and 186) are shown 
as small spheres which mark their Cα atoms. The three-stranded β-sheet (strands β4, β7 and β8) 
moves as a rigid body on binding an NNRTI, thereby causing inhibition of the enzyme. The direction of 
movement is indicated by the arrow; the Cα atom of Asp186 is displaced by 1.9 Ǻ.82,84  
 
Parallel rapid reaction kinetic experiments showed that the rate limiting step inhibiting was 
the chemical bond formation, in line with the proposed structural mechanism.85 An alternative 
to the active site displacement mechanism was proposed by Das and co-worker in 2007, in 
which the NNRTI distorts the catalytic triad position into in a conformation incompatible with 
the binding of divalent cations Mn2+/Mg2+.86 This idea was build on the back of an RT crystal 
structure determined in the absence of NNRTI and with ATP bound but in a mode 
significantly different to dNTP binding in the complex.88 The loss of the Mn2+ or Mg2+ counter 
ion would be expected to significantly weaken the binding of dNTPs, since charge repulsion 
between the nucleotide phosphate groups and the catalytic aspartates would result. In fact, 
the opposite is the case as kinetic data shows that the presence of an NNRTI in fact 
significantly strengthens the binding of the deoxynucleoside triphosphate in the intial collision 
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complex for the quaternary complex.85,88 Additionally, there is a metal-ion dependency of 
dTTP binding in the complexes with nevirapine/delavirdine or efavirenz present, giving 
further evidence that the cations remain in place after an NNRTI is bound.88 These data 
hence argue against the proposal of the NNRTI-shifted aspartates being unable to bind 
divalent cations. 
An alternative mechanism of NNRTI inhibition has been described which relates to 
movement of residues in the region of the primer grip.89 This region, containing residue 
Pro236, is however extremely flexible taking up very variable conformations which are 
unrelated to NNRTI potency.90 Interference of the catalytic step of the polymerase would thus 
be via an indirect route involving perturbation of the primer position. The effects of NNRTIs 
on the stability of RT heterodimer formation do not appear to significantly contribute to the 
mechanism of inhibition of the enzyme.22 The status quo in 2009, on the NNRTI mechanism 
of RT inhibition is that any of the above mechanisms are acceptable and that the precise 
mechanism is still not known.  
 
1.12.3 FIRST-AND SECOND-GENERATION NNRTIs: DIFFERENCES IN THE 
MODE OF BINDING TO HIV-1 RT 
 
NNRTIs can be broadly categorized into first- and third-generation compounds. Efavirenz 
appears to be the odd one out as a bridging second-generation type. First generation 
NNRTIs such as nevirapine, delavirdine, TIBO and loviride were mainly discovered by 
random screening but are associated with rapid development of mutations due to their inherit 
rigidity. By comparison, third-generation NNRTIs, such as DAPY compounds in view of 
flexibility and hydrogen bonding ability to K101 were developed with „rational drug-design‟ 
strategies in mind. These strategies include molecular modeling, rational-based drug 
synthesis and biological and pharmacokinetic evaluations. In general, third-generation 
NNRTIs tend to be more potent than first generation counterparts and are more active 
against a broader spectrum of drug-resistant strain of HIV-1.91 
The common pharmacophores92,93 that are crucial for tight and specific binding to the RT 
NNRTI-BP include an aromatic ring capable of π-stacking interactions at the back of the 
pocket, NH-C=O or NH-C=S groups able to participate in hydrogen-bonding, and a few more 
hydrocarbon-rich regions for hydrophobic contacts.69 The X-ray crystal structure analysis of 
HIV-1 RT has demonstrated similarities in the geometry of the binding modes both 
generation types.94 Generally, the binding of first-generation NNRTIs in the pocket resembles 
a „butterfly‟ (Fig. 1.24) resting on the β6-β10-β9 sheet. 
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Figure 1.24 Stereoview of a) nevirapine and b) delavirdine in a clear butterfly binding mode in the  
NNRTI-BP.69 
 
This butterfly-like mode is defined by Wing I, Wing II and the body/linker modular segments 
to which specific pharmacophores bind. The Wing II region is lined with aromatic amino acid 
residues Y181, Y188 and W229 at the back of the pocket that have favorable π-π 
interactions. Wing I has fewer hydrophobic interactions compared to Wing II and involves the 
side chains of K101, K103, V106, V179 and Y318. The body of the „butterfly‟ has interactions 
with the main chain atoms of Y188, Y189 and G190, and with the side chains of V106 and 
V179. The back of the „butterfly‟ is flanked with residues L100 and L234, which interact with 
both wings.69 
 
The crystal structures of second-generation NNRTIs (ITU, DATA and DAPY compounds) 
bound to HIV-1 RT show a different, unique „horseshoe‟ or „U‟ mode95 compared to the 
butterfly-like nevirapine above. The torsional flexibility of the DAPY structure permits access 
to numerous conformational variants, and their compact structure permits repositioning and 
reorientation (Fig. 1.25) when mutations are present in the NNRTI-BP.96,97 The ability of 
etravirine (TMC125) to bind the RT enzyme in more than one conformationally distinct mode 
explains the exceptional spectrum of activity observed for this compound (Table 1.2 above).96 
 
Depicted in Figure 1.26, the proposed docking of TMC125 and X-ray structure of TMC120, 
sees the pyrimidine-unit firmly embedded into the Wing I compartment of RT, together with 
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the less-substituted phenyl ring (attached to C-2 of the pyrimidine) into the hydrophobic Wing 
II (interacting with Lys101, Tyr188 and Tyr181). However, the more substituted phenyl ring 
(attached to C-4 of the pyrimidine) clearly exits the hydrophobic pocket and leads off towards 
Glu188 and the p66 subunit of RT. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.25 Schematic representation depicting how flexibility of an inhibitor can assist in overcoming 
resistant mutations.97 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.26 a) Proposed docking site for TMC125 at the entrance of NNRTI binding pocket of HIV-1 
RT,98 b) X-ray crystallographic structure of TMC120 in the NNRTI-BP.72   
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1.13 PHENETHYLTHIAZOLYTHIOUREAS (PETT) DERIVATIVES 
 
Recent studies including crystallographic analysis and computational modeling have made it 
possible to develop drugs based on a deeper understanding of the structural features 
required for anti-HIV activity as well as conformational changes that may help in minimizing 
the drug resistance. Trovirdine (LY 300046.HCl) represents a second-generation NNRTI 
developed by Eli Lilly and Medivir in 1995.99,100,101 This NNRTI was generated through a 
multidisciplinary approach involving synthesis, molecular modelling and biological assaying 
starting form LY 73497, a lead compound prototypic of the PETT series of antiviral agents 
(Fig. 1.27).72 
 
 
 
                         Figure 1.27 Structures of LY 73497 (PETT), Trovirdine and HI-236.  
 
From the structural point of view, PETT NNRTIs have two chemical moieties joined together 
by a thiourea group. The one end of the compound is either a thiazole ring (PETT) or a 5-
bromopyridine ring (Trovirdine) in which the rings are capable of forming an intramolecular 
hydrogen-bond between the thiourea and the heterocyclic ring.102,103,104 The other end of the 
molecule is a pyridine or phenyl ring separated from the thiocarbonyl group by an ethyl linker 
(Fig. 1.27). 
 
A comparison of PETT inhibitors, revealed that PETT-1 (Fig. 1.28) inhibits HIV-1 RT with an 
IC50 of 6 nM but showed only weak inhibition of HIV-2, whereas PETT-2 retains similar 
potency against HIV-1 RT (IC50 of 5 nM) and also inhibits HIV-2 RT (IC50 of 2.2 μM). These 
inhibitors adopt conformations that occupy similar volumes of the space within the drug 
pocket despite their diverse structures.105 
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Figure 1.28 Simulated annealing omit electron density maps showing the bound inhibitors at the 
NNRTI pocket of HIV-1 RT. a, PETT-1; b, PETT-2.105 
 
 
Uckun and co-workers in their modelling studies reported that trovirdine and other PETT 
molecules docked into the composite binding site, had a greater binding score than the 
parent compound (PETT) based on a “butterfly”-shaped binding with one residue in Wing I 
and the other in Wing II. The composite binding pocket showed space around the pyridine 
ring in the Wing II (ring B) region of the binding site. The 5-bromopyridyl group binds tightly in 
Wing I,105 with an intramolecular hydrogen bond between the ring B pyridyl nitrogen atoms 
and one of the nitrogen atoms of the thiourea group (Fig. 1.29 and Fig. 1.30). Ring A is 
positioned at the back of the NNRTI pocket in Wing II, and thus forms ring stacking 
interactions with the side chains of both Tyr188 and Tyr 181. The sulphur atom makes a 
number of van der Waals contacts with the backbone of Lys101, while there is a single 
hydrogen bond to the main chain from one of the thiourea nitrogens to the carbonyl of 
Lys101 (Fig. 1. 29).101 
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Figure 1.29 Stereo view showing PETT-1 and PETT-2 positioned in the NNRTI binding pocket of HIV-
1 RT. RT side chains that form the NNRTI binding site are marked. The inhibitors are in atom colours 
with PETT-2 shown in a darker hue. The protein for the PETT-1 complex is shown in light gray, 
whereas that for the PETT-2 complex is shown in dark gray. The positions of hydrogen bonds are 
marked in broken yellow lines.105 
 
 
 
 
 
Figure 1.30 Schematic diagrams showing the intermolecular interactions between PETT 
inhibitors (in red) and the surrounding residues of HIV-1 RT for (a) PETT-1 and (b) PETT-2. 
Residues that contact the NNRTI with a minimum inter-atomic distance of 3.6 Å are shown in green, 
whereas other residues lining the binding pocket are shown in blue. The individual distances between 
the NNRTI and the protein atoms are shown as dashed lines (distances 3.3 Å in pink and 3.6 Å in light 
blue). Hydrogen bonds together with their distances are shown in black.105 
 
Once again, docking studies with PETT and trovirdine revealed that the Wing II space of both 
had a substantial molecular volume (~160 Ǻ) surrounding the pyridine or phenyl ring that 
could be more efficiently occupied by a larger functional group to achieve a high binding 
affinity even against the problematic Y181C and Y188C RT mutants. When Y181 and Y188 
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are mutated to a cysteine residue, the volume change for NNRTI binding is larger and the 
ability of the NNRTI to inhibit the RT mutant would be attenuated. Uckun and co-workers 
concluded that a larger NNRTI would perform better against mutants such as the Y181C and 
Y188C mutants. In accordance this composite binding pocket, a series of thiourea NNRTIs or 
(PETT) derivatives were synthesized to generate more potent thiourea compounds, by 
substituting the phenyl ring with various functional groups. Replacement of the pyridylethyl 
ring of trovirdine with a 2,5-dimethoxy-substituted phenyl ring led to the discovery of N-[2-
(2,5-dimethoxyphenylethyl)]-N'-[2(5-bromopyridyl)]-thiourea as HI-236 (Fig. 1.26), which was 
designed to optimize occupancy at the Wing II of the binding pocket in order to have an 
advantage against Wing II mutants such as the Y181C and Y188C mutants Table 1.3. 106,107  
 
 
 
Table 1.3 Resistance of the Y181C and the Y181C + K103N strains HIV RT inhibition by   NNI, 
relative to wild-type (WT) RT107 
                                          rRT*          WT/RT                        Y181C mutant  (A17)                   Y181C +K103N mutant  (A17 variant) 
RT  inhibitors                  IC50 (μM)    IC50 (μM)             IC50 p24(μM)      Resistance relative     IC50 p24               Resistance relative  
                                                                                                                  to WT RT (fold)        (μM)                  to WT RT (fold)                         
HI- 236 0.1 < 0.001 0.1 > 100 11 11,000 
HI-240 0.1 < 0.001 0.2 > 200 41 41,000 
HI-241 0.7 < 0.001 ND† ND ND ND 
HI-253 0.7 < 0.001 ND ND ND ND 
HI-280 5.6 < 0.001 > 100 > 100,000 > 100 > 100,000 
HI-281 7.0 0.02 38 1,850 55 2,750 
HI-443 0.8 0.030 0.048 1.5 3.3 110 
Delavirdine 2.3 0.009 50 5,556 38 4,222 
Nevirapine 19.8 0.034 > 100 > 2,941 > 100 > 2,941 
AZT ND 0.004 0.006‡ 1.5 0.005‡ 1.2 
* rRT, recombinant RT assay 
† ND, not determined  
‡AZT binds to a different site on RT than NNI; therefore it would be as affected by NNI binding site mutations. 
 
1.14 NNRTI RESISTANCE 
 
Resistance mutations associated with NNRTI treatment failure occur primarily in and around 
the NNRTI-BP. The most common NNRTI-resistance mutations (Fig. 1.31) include 
Leu100Ile, Lys103Asn, Tyr181Cys, Tyr 188Leu, and Gly190Ala.108,109 Structural and 
molecular modeling studies of drug-resistant HIV-1 mutants110, both in the presence and in 
the absence of bound NNRTIs, have suggested possible mechanisms by which key 
mutations confer resistance to NNRTIs. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
CHAPTER_1________________________________________________   INTRODUCTION 
 36 
The Gly190Ala mutation, which causes high-level resistance to loviride and HBY-097, has no 
significant effect on the ITU, DATA, and the DAPY inhibitors. The resistance was proposed 
to be caused by filling the area of the binding pocket that would otherwise be occupied by the 
linker/body portion of the butterfly-shaped NNRTIs like loviride or by the quinoxaline ring of 
HBY-097.111 The ITU, DATA, and DAPY inhibitors are not affected by the mutation. Since a 
Cβ atom introduced by the Gly190Ala mutation would point toward the central part of the 
inhibitors (a thiourea, triazine or pyrimidine group). A minimum distance of 6.0 Ǻ between the 
Cα atom of Gly190 and the central part of these inhibitors suggests that there would be no 
serious steric conflict between the alanine at position 190 and the bound NNRTI.97 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.31 Diagram showing the NNRTI site with the principle drug-resistance mutation sites 
coloured either in green (crystal structures known) or red (structures not reported as yet). Residues 
where no mutations have been reported are coloured in blue. The NNRTI shown is nevirapine.112 
 
 
Leu100,113 Tyr181,114 and Tyr188115 amino acid residues form a portion of the hydrophobic 
core of the binding pocket that interacts with Wing I of the ITU, DATA, and DAPY NNRTIs. 
Mutations of one or more of these amino acids can affect inhibitor-protein interactions and 
the size, shape, and chemical environment of the binding pocket.107 Previous studies have 
shown that the Tyr181Cys115 and Tyr188Leu111 mutation affect the binding of an NNRTI by 
loss of favorable aromatic ring interactions. The Lys103Asn mutation possibly affects the 
kinetics of inhibitor-binding by stabilizing the unbound state of RT via the generation of an 
additional hydrogen bond between the Tyr188 phenoxyl group and the Asn103 side chain.111 
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A connection of the NNRTI binding pocket and the NRTI substrate site through the use of a 
double-drug was previously suggested by both Arnold et al.116 and Anderson et al.85 The first 
suggestion came from Arnold et al.116 in 1993 who wrote: “An interesting approach that would 
take optimal advantage of the currently available structural information would be to design 
and synthesize inhibitors that would incorporate structural features from both nucleoside 
analog and non-nucleoside inhibitors……Synthesis of these agents could be challenging but 
there are a number of substituent positions that could be used for the linkage. Site of 
attachment for the linkers to nucleoside analogs include sugar ring positions (e.g. 2‟, 3‟ and 
5‟ substitutions), extensions of mono-, di- and tri-phosphate esters, and positions on the 
nucleoside base (e.g., the 5-position of a pyrimidine ring). Selection of sites of attachment on 
the non-nucleoside moieties would vary according to the inhibitor type.” 
This was followed by a Science article in 1995 in which Anderson86 wrote: “We have 
established the mechanism of inhibition of RT by the three (clinically approved) NNRTIs. 
Although the long-term inhibition of RT is limited by the high frequency of mutations of the 
enzyme, this detailed understanding of the action taken by RT when presented with these 
inhibitors (i.e that binding of a NNRTI does not stop the binding process of a NRTI) should 
assist in the search for effective drugs to attenuate the AIDS virus. In particular, the 
interaction between the nucleotide binding site may provide a means to increase the 
effectiveness of drugs used in combination therapy. A single drug combining the 
functionalities of nucleotide analog and a non-nucleoside inhibitor would bind much more 
tightly because of the cooperative interaction between the sites.” These two research 
contributions gave birth to the field of HIV bifunctional double-drugs. 
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1.15 THE DOUBLE-DRUG STRATEGY 
 
The double-drug strategy involves a chemotherapeutic approach combining two different 
inhibitors into a single chemical entity via a linker, with the aim of improving the 
physicochemical characteristics of the individual compounds.  
 
1.15.1 DOUBLE-DRUGS IN CANCER AND MALARIA 
 
5-Fluoro-2‟-deoxyuridine (FDU) either as its 5‟-O-butanoate or its 5'-O-butanoate-3'-O-
retinoate (from retinoic acid) diester (FDU) (Fig. 1.32) have been synthesized to act as 
anticancer double prodrugs that would serve as a mean of releasing at least two active drugs 
that act through different mechanisms. The FDU once released could act as a competitive 
inhibitor for thymidylate synthase whereas retinoic acid and butyric acid once released were 
expected to induce cell differentiation. The ester derivatives exhibited comparable activity to 
FDU.117  
 
  
 Figure 1.32 Example of 5-fluoro-2‟-deoxyuridine (FDU) either as its 5‟-O-butanoate or its 5'- 
 O-butanoate-3'-O-retinoate. 
 
Retinoids have been reported to induce differentiation and arrest proliferation in a wide 
spectrum of cancer cells and are currently used for treatment of promyelocytic leukaemia. 
Butyric acid is an effective inhibitor of cell proliferation and inducer of cytodifferentiation. In 
the case of 5'-O-Butanoate-3'-O-retinoate, a mutual prodrug combining butyric acid and all-
trans-retinoic acid into FDU, it was evaluated for anticancer activity and was found to be 
more potent than the parent drugs.118 Furthermore, the differentiation activity elicited by the 
double-drug was greater than that of the combined parent acids. The large increase in 
activity was attributed to two factors: 
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(i) The all-trans-retinoic acid fragment imparted lipophilicity and facilitated the 
penetration of butyric acid to the cellular target site. 
(ii) The intracellularly released all-trans-retinoic acid and butyric acid affected the cells 
synergistically. 
 
Similarly, the statine-based inhibitor of Plasmepsin (II) (PLM II) was linked to the antimalarial 
drug Primaquine (PQ) using a dicarboxylic acid linker (Fig. 1.33).  PLM II is one of the 
aspartic proteases involved in the degradation of haemoglobin during the intraerythrocytic 
cycle of Plasmodium falciparum. Primaquine is highly active against all malaria species 
infecting humans. Its toxicity levels can be minimised and its activity increased by converting 
it into a peptide prodrug. The PQ-Statine double-drugs showed remarkable improvement in 
the inhibition of both PLM II and P. falciparum growth in vitro. The double drugs kill the 
parasites mainly by inhibiting PLM II together with digestion of haemoglobin that is essential 
for the survival of the parasite.119  
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                       Figure 1.33 Structure of [Primaquine]-4,4‟-oxy-bis(benzoic acid)-[PLM II]. 
 
 
Biot et al.120,121 synthesized double-headed antimalarial prodrugs that target two essential 
functions of the malarial parasite, namely glutathione regeneration and heme detoxification, 
with the aim of exploring their synergistic or additive effects. The double drugs combined a 
glutathione reductase (GR) inhibitor to a 4-aminoquinoline moiety with a bioreversible linker. 
However, these double-drugs exhibited poor inhibition activity (Fig. 1.34). 
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                             Figure 1.34 Structure of [4-aminoquinoline]-[GR Inhibitor]. 
 
1.15.2 DOUBLE-DRUGS IN HIV 
 
Several strategies have been employed in the chemotherapy and chemoprophylaxis of HIV 
infections. The most effective current strategies involve the following targets: (i) CD4 as 
primary cell receptor for viral entry into the cell; (ii) gp120 as the viral glycoprotein involved in 
virus adsorption to the cells; (iii) CXCR4 and CCR5 as co-receptors for viral entry; (iv) gp41 
as viral glycoprotein required for virus-cell fusion; (iv) NRTI binding site of the HIV reverse 
transcriptase (RT) enzyme; (vi) NNRT binding site of RT; (vii) integration of the proviral DNA 
into the host genome by the HIV integrase; (viii) proviral DNA expression (ix) HIV protease. 
As mentioned in Section 1.7. Based on a combination of inhibition for these targets, the 
double-drug inhibitors of HIV can be divided into the following classes: 
(A) Fused: Two drugs fused together, to create a single entity that is active on two different 
drug-targets corresponding to the individual drugs. 
(B) Cleavable: Two drugs joined by a cleavable (via hydrolysis) linker (spacer) that can target 
either the same or different drug-target. The cleavable linkers are stable outside the target 
cell, but are cleaved to individual drugs once in the cell cytoplasm. 
(C) Non-cleavable: Stable (to hydrolytic cleavage) bifunctional entity (“mixed-site inhibitors”) 
whose rationale is to interact the drug entities simultaneously at distinct sites that are in close 
proximity on the same drug target.122  
 
(A) Fused double-drug inhibitor for RT and IN 
 
Vince and co-workers123 synthesized fused double-drug inhibitors, also referred to as 
“portemanteau inhibitors” based on the fusion of a non-nucleoside reverse transcriptase (RT) 
inhibitor (NNRIs) with a diketoacid (DKA) integrase (IN) inhibitor pharmacophore (Fig. 1.35). 
(IN) is the third virally encoded enzyme that lacks a mammalian counterpart and represents a 
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validated target for anti-HIV chemotherapeutic. Intriguingly, active sites for RT and IN require 
one or two Mg+2 ions. Further more, catalytic cooperation and even physical interaction 
between RT and IN, certain peptide fragments from RT inhibit IN activity in vitro. The double-
drug had a low cytotoxicity (EC50: 24 nM against RT; 4.4 µM against IN; 10 nM against HIV-1 
in a cell-based assay; CC50 >10 µM SI=>1000). 
 
 
 
 
 
 
 
 
 
       Figure 1.35 Structure of a portemanteou inhibitor combining an RT inhibitor with an IN inhibitor. 
 
(B) CLEAVABLE DOUBLE-DRUG INHIBITORS  
These have been by far the most common type studied with the emphasis on the synergistic 
effects of the two drugs released in combination.  
The cleavable double-drug inhibitors can be divided into two categories:  
 
(1) Cleavable double-drugs on different targets: 
  
A combination of an HIV protease inhibitor and AZT into a single molecule has also been 
successfully used to improve poor membrane permeation. The protease inhibitor KNI-727, 
unable to penetrate the cell membrane was linked to AZT by a cleavable linker (Fig. 1.36) 
resulting in a considerable boost in potency according to a MTT-cell assay by virtue of the 
parent components being released intracellularly (EC50 = 5.3 nM for the double drug, 
compared to 92.0 nM for KNI-727 and 6.2 nM for AZT).124 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                            Figure 1.36 Structure of [AZT]-succinic-[KNI-727] conjugate  
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Similarly, Tamamura et al.125 employed the double-drug strategy to synthesize a bifunctional 
drug that incorporated a CXCR4 inhibitor (T140) as a co-receptor antagonist with an NRTI 
(AZT) linked by succinate (Fig. 1.37). T140 is a 14-amino acid peptide which inhibits infection 
of target cells by T cell-line-tropic strains of HIV through specific binding to its chemokine 
receptor, CXCR4. An equimolar mixture of AZT and T140 caused a remarkable increase in 
anti-HIV activity compared to the single compounds. This result led to the synthesis of 
conjugated compounds which combined each entity into a single molecule. The conjugated 
drug exhibited a synergistic effect for anti-HIV in vitro (EC50 = 4.6 nM in MT-4 cells with HIV-
1, SI= > 4300; AZT = 20 nM; T140-succinic acid = 310 nM). The mechanism of action is 
based on the hydrolysis of the enzymatically labile ester 5'-O-bond between the NRTI and 
the spacer.  
 
 
 
 
 
 
 
 
 
 
 
 
                                             Figure 1.37 Structure of [AZT]-succinate-[T140] 
 
Daoudi et al.126 synthesized bifunctional compounds combining bicyclam AMD3100 and a 
galactosylceramide (GalCer) analogue into a single molecule with the aim of inhibiting 
several steps of the complex virus/cell cascade interactions (virus-cell adsorption/fusion 
processes). The double-drug [Gal]-[AMD3100] conjugate (Fig. 1.38) exhibited superior 
potency to that of AMD3100 (EC50 = 65 nM in MT-4 cells with HIV-1; AMD = 2.9 μM; GalCer 
>100 μM). AMD3100 is a CXCR4 antagonist and interferes with viral binding to the cellular 
co-receptors, whereas GalCer provides an attachment platform (alternative receptor in CD4- 
cells) for the virus (through its gp120 and/or gp41) onto the cell. When compared to the 
activity of GalSer, the bipharmacophore conjugate moderately increased its anti-HIV activity.  
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                                     Figure 1.38 Structures of Gal-AMD3100 Conjugates. 
 
Similarly, AZT coupled onto -carrageenan using a succinate diester spacer was synthesized 
with the aim of enhancing AZT intracellular uptake as well as to test the synergism of the 
prodrug.127 Carrageenans are naturally occurring sulphated polysaccharides extracted from 
different species of red seaweed that have a common structural backbone of D-galactose 
residues. The -form is characterised by a repeating unit of 4-sulfate- -D-galactopyranose 
linked 1 3 and 3,6-anhydro- -D-galactopyranose linked 1 4.  The -carrageenan was 
expected to act not only as a drug-delivery carrier for AZT, but also as an anti-HIV agent 
which would act synergistically with AZT. Carrageenans possess anti-HIV activity and inhibit 
the binding of the virions to the cell as gp-120 adsorption inhibitors, as well as cell-to-cell 
fusion inhibition. The [ -carrageenan]-succinate diester-[AZT] (Fig.1.39) conjugate inhibited 
the binding of the virions to the MT-4 cells and concomitantly delivered AZT to these cells to 
further inhibit the RT (EC50 = 6.8 nM, SI = 3000; AZT = 25 nM). 
 
 
 
 
 
 
 
 
 
 
                        
                        Figure 1.39 Structure of [AZT] -succinate diester-[ -carrageenan]. 
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The Ladurée  group has reported the synthesis of a NRTI/NNRTI heterodimer of the formula 
[NRTI]-Glycyl-Succinyl-[Trovirdine].128 Nucleosides d4U, d2U and d4T were varied as the 
NRTI and spacer linking was achieved via the C-5' hydroxyl group of the NRTI with the N-
piperazine of a modified trovirdine. A succinyl-glycine moiety was chosen as a spontaneously 
cleavable linker, and introduced via coupling of the NRTIs with Boc-gly-OH using DCC in the 
presence of DMAP in DMF to give the 5'-esters 9. Deprotection of Boc using 4M HCl/dioxane 
afforded the amine hydrochlorides 10 which were condensed with modified trovirdine 
analogue 11 using BOP/HOBt in the presence of triethylamine in DMF to afford the 
heterodimers 12 a-c in 35-45% yield. The heterodimers were unfortunately devoid of antiviral 
activity at non-toxic concentrations (Scheme 1.1).  
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Scheme 1.1 Reagents and Conditions: (i) HOOC–CH2–NHBoc, DCC, DMAP, DMF; 78%. (ii) 4M 
HCl/Dioxane; 87%. (iii) succinic anhydride, CH2Cl2; 64%. (iv) Et3N, HOBt, BOP, DMF; 35-45%. 
 
The synthesis of an analogous system using C-5/NRTI as the attachment point129,130 
(Scheme 1.2) was accomplished employing a Sonogashira reaction. Pd(0)-mediated 
Sonogashira coupling at C-5 of 14 with a C-3 propynyloxy spacer protected as its THP ether 
produced 15. Deprotection of THP using CF3COOH in CH2Cl2 followed by condensation of 
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the resultant alcohol with Boc-Gly-OH using DCC in the presence of DMAP and subsequent 
deprotection of the Boc group using 4M HCl in dioxane afforded the amine hydrochloride 16. 
Condensation of amine 16 with modified trovirdine derivative 11 followed by deprotection of 
the acetate group with cyanide ion gave the heterodimer 18 in 35-45% yield for the last step. 
The heterodimers displayed inferior anti-HIV activity (compound 18 displayed an IC50  20 
M) compared to the parent compounds. The lack of activity was attributed to the wrong 
positioning of the linker to either NRTI or NNRTI with respect to their active sites in the 
enzyme. 
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Scheme 1.2 Reagents and Conditions: (i) alkyne, (PPh3)4Pd, CuI, Et3N, DMF; 67%. (ii) CF3COOH, 
CH2Cl2, CH3OH (iii) HOOC–CH2–NHBoc, DCC, DMAP, DMF (iv) 4M HCl/Dioxane (v) 11, Et3N, HOBt, 
BOP, DMF; 48%. (vi) NaCN, MeOH; 38%. 
 
(2) Cleavable double-drugs on the same target site 
 
Several NRTI homo- and heterodimers targeting the HIV reverse transcriptase enzyme have 
been synthesized by attaching the linker at the 5', 5 or N-3 positions of the nucleosides. Ijichi 
et al.131 have reported the synthesis of nucleotide heterodimers of AZT, ddI and Ribavirin. 
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The dimers were formulated as a mixed phosphate diester via the 5'-hydroxyl groups of the 
nucleoside, with the aim of releasing two nucleosides at the active site. Thus, 5'-O-
phosphorylation of AZT gave AZT cyanoethyl phosphate 19, which condensed with ddI 20 in 
the presence of p-toluenesulfonyl chloride to afford heterodimer [AZT]-cyanoethylphosphate-
[ddI] 21. Deprotection of the cyanoethyl group with 1N NaOH led to the heterodimer 22 
(Scheme 1.3). Similarly, [ddI-phospho-Ribavirin] 23 (EC50  17.5 M) and [AZT-phospho-
Ribavirin] 24 (EC50 = 0.004 M) heterodimers (Fig. 1.40) were synthesized using the same 
procedure. The heterodimers 22 and 24 showed enhanced anti-HIV activity relative to their 
monomers. Furthermore, AZT-P-ddI 22 (EC50 = 0.002 M, CC50 = 18.2 M) was ~2-fold 
times less toxic than AZT to human granulocytes macrophage progenitor cells (EC50 = 0.002 
μM, CC50 = 10.7 M for AZT; EC50 = 13.3 μM, CC50 = 226 μM for ddI). 
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Scheme 1.3 Reagents and Conditions: (i) p-TsCl, CH2Cl2 (ii) NaOH. 
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Figure 1.40 Structures of AZT, ddI, Ribavirin and HEPU heterodimers 
 
In a similar fashion, homo- and heterodimers of ddI, AZT and d4T have been synthesized by 
Mohamed et al.132 with the aim of enhancing the antiviral activity of their components 
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(Scheme 1.4). An ester linkage was used to link to a glutaric acid spacer. The synthetic 
strategy involved converting d4T 13 into half ester 25 by treatment with glutaric anhydride in 
methylene chloride, followed by an EDC-promoted esterification of the glutarate with ddI to 
form the heterodimer 26 in good yield (Scheme 1.4). AZT-ddI and ddI-ddI heterodimers 
bearing an ester linkage were also synthesized using this methodology. Other spacers used 
in this class of compounds were carbonate and carbamate based to form AZT and d4T 
homo- and heterodimer carbonates 27 and carbamates 28, respectively (Fig. 1.41). 
Following intracellular hydrolysis of the carbonate or carbamate, the two nucleosides would 
be regenerated in the cytoplasm. The carbonates displayed anti-HIV activity comparable to 
AZT, while the carbamates displayed low anti-HIV activities. No synergistic effects on the 
inhibition of HIV replication was detected for either the carbonates 27 a-c and carbamates 
28a-c. 
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Scheme 1.4 Reagents and Conditions: (i) Glutaric anhydride, Et3N, CH2Cl2; 85%. (ii) ddI/DMAP/EDC, 
HCl, CH2Cl2/DMF; 80%. 
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Figure 1.41 Structure of AZT/d4T homo- and heterodimer linked by a carbonate or carbamate spacer. 
 
Pederson et al.133 has been recently reported the synthesis and antiviral activities of 
cleavable [NRTI/ NNRTI] double-prodrugs against HIV based on the mixed S-acyl-2-thioethyl 
(SATE) prodrug approach. The SATE prodrugs were first introduced in 1993 by Imbach. et 
al.117a,b as a carboxyesterase-labile protecting group for the ddU nucleotide. The double pro-
drug in question incorporated d4T as a 5‟-phosphate and as a SATE ester linking through the 
phosphate to N-3 of MKC-442 (a HEPT derivatives) via a cleavable p-hydroxybenzoyl linker. 
The double-prodrug (Fig. 1.42) had good activities against HIV-1 (EC50 = 0.03 µM) and the 
Y181C mutant strain (EC50 = 2.7 µM). Most probably, the activity of the SATE prodrug given 
in Figure 1.42 is due to the activity of the separate compounds, in which MKC442 strongly 
loses activity against the Y181C mutant.The activity was thus mainly attributed to the NNRTI 
(MKC-442) part of the molecule (Fig. 1.42). 
 
 
 
                                
 
 
 
 
 
Figure 1.42 SATE pro-drug                                                      
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(C) NON-CLEAVABLE DOUBLE-DRUG (“MIXED-SITE INHIBITORS”) 
       
The combination of a nucleoside and a non-nucleoside RTI into a single molecular entity was 
advocated by Arnold et al in 1993.116 This was supported by structural18,116 and 
biochemical85,134 studies which indicated that linking the compounds with an appropriate 
spacer might result in an improved inhibitory capacity. The first heterodimers incorporating 
an NRTI with an NNRTI were synthesized by the Camarasa group in 1995.135 They reported 
the synthesis of a family of anti-HIV heterodimers based on combining AZT with either 
TSAO-T or HEPT via a polymethylene spacer between the N-3 of the thymine base of both 
compounds (Scheme 1.5). TSAO derivatives were first synthesized in 1992 and represent a 
unique structural class of NNRTI as they specifically interact at the interface between the p51 
and p66 subunits of HIV-1 RT. The prototype compound of this family is the thymine 
derivative designated TSAO-T and the most active compound is its 3-N-methyl substituted 
derivative TSAO-m3T.  The synthetic strategy for formation of 30a and 30b involved selective 
N-3 alkylation of AZT with a dibromoalkyl reagent followed by N-alkylation of the N-3-
bromoalkyl AZT intermediate with TSAO-T or HEPT. The polymethylene spacer was varied 
in length from n = 4->7. Thus, treatment of AZT with 2 equiv of 1,3-dibromopropane in dry 
acetone: DMF (1:1) in the presence of K2CO3 gave the N-3 substituted derivative 29. 
Subsequent reaction of 29 with TSAO-T or HEPT under basic conditions gave heterodimers 
30a and 30b in 50-60% yield. 
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Scheme 1.5 Reagents and Conditions: (i) (CH2)nBr2 (n = 3-9), K2CO3, acetone, DMF (1:1); (ii) K2CO3, 
acetone, DMF (1:1). 
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The most active compound in the series was [TSAO-T]-(CH2)3-[AZT] 30a (EC50 = 0.10 M; 
TSAO-T = 0.06 μM) incorporating a short spacer. Heterodimers bearing polymethylene 
linkers [-(CH2)n-] with n = 4-6 showed good antiviral activity, while longer spacers with n > 7 
showed diminished activity. The precursors to the dimers were also tested. Specifically, AZT 
derivatives such as 29 proved inactive irrespective of the chain length of the methylene 
spacer. The activity of the TSAO-T-spacer derivatives 31c decreased with increasing length 
of the spacer. Replacement of AZT with d4T resulted in improved anti-HIV activity. No 
marked differences in activity were observed when the spacer consisted of 1-butynyl, 1-
butenyl or ethoxyethyl moieties. Similarly, heterodimers 31a,c were synthesized using the C-
5 of the NRTI for attachment, and these showed comparable activities to that of 30a, 
whereas the corresponding d4T analogue of 31b led to a 5-fold decrease in anti-HIV 
potency.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.43    [TSAO-T]-spacer-[AZT] 
 
Spacer rigidity in the C-5 series did not markedly influence the antiviral potency since the 
heterodimer 31b bearing a flexible propyl group as spacer was endowed with anti-HIV-1 
activity comparable to that of the corresponding propynyl analogue 31a (Fig. 1.43). 
Converting AZT, d4T and thymidine heterodimers to phenoxyphosphoramidate136 
heterodimers had no improved activity over the corresponding non-phosphorylated 
analogues. Overall, the d4T heterodimers had better inhibitory efficacy than the AZT ones. 
 
By comparison, combinations of TSAO-m3T and foscarnet (PFA) (Fig. 1.44), also 
synthesized by the Camarasa group as individual entities, at a variety of concentrations 
revealed that these compounds displayed additive antiviral activity.137 These results inspired 
the synthesis of a single molecule combining a TSAO derivative with foscarnet through a 
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labile phosphate ester bond, hence making it a cleavable double-drug. PFA is an effective 
antiviral agent approved for intravenous treatment of Human Cytomegalovirus (HCMV) 
Retinitis in patients with AIDS.138 It is also effective against HIV replication and inhibits HIV-1 
RT by blocking the pyrophosphate binding site.139 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.44 Structure of TSAO-m3T and Foscarnet 
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Scheme 1.6 Reagents and Conditions: (i) (a) 33, Et3N, CH2Cl2, -20 °C (b) H2O; 54%. (ii) H2, Pd/C, 
MeOH; 60%. 
 
Thus, treatment of TSAO derivative 32 with the foscarnet-based phosphorylating reagent 33 
in the presence of triethylamine led to the formation of the PFA diester 34 in moderate yield. 
Catalytic hydrogenolysis of 34 yielded the [TSAO-T]-[PFA] conjugate 35 in 60% yield 
(Scheme 1.6). Unfortunately, conjugate 35 was less active than the parent compound 32, 
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displaying no additive or synergistic anti-HIV activity and thus indicating the activity to be due 
to the TSAO part of the molecule and not the PFA part. 
The design, synthesis and anti-HIV-1 evaluation of several non-cleavable heterodimers of 
the general formula [d4T]-NH(CH2)n–NH-[imidazo[1,5-b]pyridazine] (n = 6-12) involving a C-5 
linkage to d4T was reported by Ladurée et al.140 in 1998. Imidazo[1,5-b]pyridazine was 
chosen as the NNRTI due to its exceptional potency. The synthetic strategy involved 
synthesis of the NNRTI linked to a 1,n-diaminoalkyl spacer followed by substitution onto d4T 
via a C-5 chloromethyl group. The synthesis of the d4T coupling derivative (Scheme 1.7) 
involved C-5 hydroxymethylation of protected uridine 37 to give 38 in good yield followed by 
C-2'/3' double-bond introduction to afford 39 and selective chlorination of the hydroxymethyl 
group in the presence of the C-5' hydroxyl group of 39 to give 40.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1.7 Reagents and Conditions: (i) 2,2-DMP, APTS, MeCOMe. (ii) CH2O, Et3N, 60 °C; 93%. (iii) 
TMSCl, 1,4-dioxane, 60 °C. 
 
Imidazo[1,5-b]pyridazine 41 was synthesized in seven steps from alanine, and was heated 
with a 1,n-diaminoalkane at 120 °C to give monomers 42 a-d via aromatic nucleophilic 
substitution. Condensation of 42 a-d with 40 in DMF gave heterodimers 43 a-d in 72-85% 
yield (Scheme 1.8). The anti-HIV activity of the NNRTI linked to its spacer 43 a-d was 
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evaluated independently and the results revealed a decrease in activity compared to the 
unsubstituted NNRTI. The activity of the heterodimers 43 a-d was comparable to that of d4T 
and thus mainly due to the nucleoside part of the molecule. 
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Scheme 1.8 Reagents and Conditions: (i) H2N–(CH2)n–NH2; a: n=6, b: n=8, c: n=10, d: n=12. (ii) 
d4ClMUrd 40, DIEA, DMF. 
 
 
Similarly in 2000, Monneret141 and co-workers synthesized a variety of (N-3 and C-5)AZT -
HEPT bifunctional conjugates displaying anti-HIV activity ranging between 2-5 μM. In the 
same report, a non-cleavable ddC-HEPT conjugate was found to exhibit an anti-HIV potency 
of 0.45 μM against HIV-1 (wild-type and the Y181C nevirapine-resistant strain) and HIV-2 in 
cell culture. The ddC component in the mixed inhibitor 46 (Scheme 1.9) was prepared in a 
one-pot procedure (33% yield), involving reaction of 5‟-O-acetyl-2‟,3‟-dideoxyuridine 46 with 
triisopropylbenzenesulfonyl (TPS) chloride, followed by treatment with 1,12-
diaminododecane. Coupling of amino derivative 45 with 45a using N-methylmorpholine 
(NMM) and 2-chloro-4,6-dimethoxy-1,3,5-triazine (CMDT) provided 46 in good yield.  
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Scheme 1.9 Reagents and Conditions: (i) TPSCl, Et3N, DMAP, DCM, then NH2(CH2)12NH2 (33%); (ii) 
CDMT, NMM, DMF, then 45a (69%). 
 
No synergistic effects were observed, and 38 appeared to inhibit RT through interaction of 
only one component (NNRTI) in its bis-substrate structure. A plausible reason offered by the 
authors is that the tethering arm is poorly adapted to permit the nucleoside and the NNRTI 
motifs to communicate simultaneously with their respective sites. 
 
Recently ongoing research at University of Cape Town by Hunter et al.142 has reported the 
synthesis of a non-cleavable [d4U]-butyne-[HI-236] bifunctional using a Sonogashira strategy 
similar to that used by Ladurée (Scheme 1.10). These compounds are the subject of this 
thesis. Thus, coupling of 5‟-benzoyl-5-iodo-d4U 47 with an N-Boc-protected alkyne that was 
prepared in a number of steps from 2-hydroxy-5-methoxybenzaldehyde furnished nucleoside 
48. The latter underwent Boc-deprotection with trifluoroacetic acid followed by condensation 
with thiourea 49 to furnish benzoylated bifunctional 50. Methoxide deprotection of 50 gave 
the target bifunctional [d4U]-butyne-[HI-236] 51, which showed an impressive inhibitory 
activity (EC50 = 0.25 μM; HI-26 = 0.048 μM; d4T = 1 μM) against HIV-1 (IIIB) replication in 
MT-2 cell cultures using an MTT assy. The biological results suggest that the prototype 
compound behaves as an extended NNRTI.   
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Scheme 1.10 Reagents and Conditions: (i) alkyne 70c, (PPh3)4Pd(10%), CuI (50%) Et3N (2 eq), DMF: 
THF (1: 2),  rt, 4h, 69%; (ii) CF3COOH, CH2Cl2, 0 oC; (iii) EtN(i-Pr)2 followed by 49, THF, rt/ over night, 
60% for 2 steps; (iv) NaOMe (cat), MeOH, 0 oC, 20 min, 51%.  
 
 In conclusion, most approaches have pursued the easier synthetic option of connecting the 
tether via the C-5' OH or N-3 of the nucleoside base. For the C-5 heterodimers, linker 
attachment has been achieved via a Pd(0) Sonogashira coupling (compounds 18 and 51) or 
hydroxymethylation of uridine (compound 43a-d). Most of the heterodimers have been 
designed as prodrugs linked with a cleavable tether, with the aim of regenerating the parent 
drugs once in the cell cytoplasm. Non-cleavable systems have as yet not suggested 
connection between the two sites to fulfil the conceptual objective of “mixed-site” inhibition, 
probably mainly as a result of poor choice of the spacer attachment. 
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1.16 OBJECTIVE OF THE STUDY 
 
The use of combinations of different drugs as in HAART is designed to prevent resistant HIV 
strains by effectively suppressing viral replication, thus denying HIV the opportunity to 
produce new mutations. This principle holds provided that there is minimised cross-
resistance between the drugs. NNRTIs act by slowing down the chemical step catalyzed by 
RT, and this retardation allows the two-step binding of NRTI to come to equilibrium leading to 
tighter binding of the nucleotide. The objective of this study was thus to join these concepts 
by synthesizing and evaluating HIV bifunctional non-cleavable double-drugs of the type 
NRTI-spacer-HI-236 in order to probe the possibility of “mixed-site” inhibition.  
 
HI-236 was selected owing to its potency against wild-type and NNRTI resistant HIV-1 
strains (carrying the NNRTI resistant mutations K103N, V106A and Y181C). Furthermore, 
the relative simplicity of its structure, ease of its synthesis and options for spacer attachment 
also made HI-236 an attractive NNRTI choice. The NRTI‟s chosen were d4T, which is 
currently used to treat HIV, as well as an acyclic nucleotide phosphonate based on the 
Tenofovir concept.      
  
The site of attachment of the linker on the d4U (NRTI) was chosen as an alkynyl linker at the 
C-5 position on the pyrimidine ring of the base, since this was considered to exit the 
substrate binding site with anticipated low interference with base-pairing in DNA in 
accordance with the study by Ruth and Chen.143 Also, linking at the C-5 position with a 
flexible linking chain of about 10Ǻ has been reported by Arnold116 to permit the triphosphate 
to be generated and be incorporated into the nucleic acid.  
 
 
 
 
                        
   
 
 
                                
 
 
 
  
                                Figure 1.45 HI-236 docked into the HIV pocket.107       
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On the HI-236 side, it was decided to extend at the C-2 phenolic oxygen for synthetic 
reasons as well as because of studies conducted by Uckun and co-workers107,144 regarding 
the binding mode of HI-236 in the RT pocket, which showed that the C-5-methoxy group 
forges cooperative C-Hπ interactions with the highly conserved W229, while the phenyl ring 
interacts with Y188. The C-2 methoxy group (labelled in Fig. 1.45) is positioned underneath 
the phenyl ring, pointing into available space near Y188 in Wing 2. Thus a tether connected 
to the C-2 methoxy position might plausibly point downwards and exit the front of the pocket 
making its way towards the substrate binding site as shown in Fig. 1.45. Note that the view in 
Fig. 1.45 is from the “back” of the pocket. A tether exiting the “front” would have to find its 
way to the substrate binding site shown in Fig. 1.45 to the “right” as one looks at the Figure. 
In reality, the DNA site is “behind” W229 shown at the “back” of the NNRTI pocket in Fig. 
1.45. Varying the spacer lengths would be needed to probe the length needed to join the two 
sites. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.46 Shows a d4U-spacer-TMC-120 bifunctional exiting from the “back” of the NNRTI pocket. 
 
Figure 1.46 also assists this visualisation and was generated in conjunction with a different 
system based on TMC-120 as the NNRTI from a sister project at University of Cape Town. It 
shows the tether exiting from the “back” of the pocket. In the HI-236 case, such an exit was 
not possible because of the way the tether was attached to HI-236. Thus the hope was that 
the tether might exit out of the “front” and make its way to the “right” towards the DNA site for 
NRTI. 
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Thus, the overall objectives of the project were the following: 
 
(i) Synthesize HI-236 derivatives substituted at the C-2 oxygen of the phenyl ring 
and evaluate them for their inhibitory activity against HIV-1 (IIIB) replication in MT-
2 cell culture in order to fine-tune the activity of HI-236 as well as to establish a 
structure-relationship (SAR) between the spacer and activity.  
(ii) Synthesize and test a library of bifunctional [d4U]-spacer-[HI-236] derivatives 
varying the spacer length in order to establish a structure-activity relationship in 
the search for evidence of synergism between the two drugs and hence sites.  
(iii) Synthesize a phoshoramidate pro-drug of one of the bifunctionals in order to 
apply a pronucleotide strategy to this class of compound.  
(iv) To synthesize and study the influence of changing d4U as the NRTI component of 
the double-drug to an acyclic phosphonate modeled on the Tenofovir concept.  
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CHAPTER 2: C-2-ARYL O-SUBSTITUTED HI-236 DERIVATIVES 
                       AS NON-NUCLEOSIDE HIV-1 RT INHIBITORS 
 
This thesis concerns the synthesis and biological evaluation of bifunctional inhibitors of the 
type [d4U]-spacer-[HI-236] shown in Figure 2.1.  
 
OHO
N
N
O
O
H
O
OMe
N NH
N
Br
S
H[spacer]
d4U HI-236                             
                                        Figure 2.1 General formula [d4U]-spacer-[HI-236] 
 
The main difference between this target and the others previously studied by other workers 
in the field was the choice of NNRTI as HI-236. This was made on the basis that HI-236 had 
emerged in the late 1990’s as a potent inhibitor with a solid profile against resistant strains. 
Furthermore, HI-236 offered relatively attractive synthetic connection points, and the 
modeling data of it in the NNRTI pocket had been reported by Uckun144 giving crucial insight 
into the all important question of where to attach the tether on the NNRTI so as to lead out of 
the pocket to the NRTI substrate binding site. The story of HI-236, though, is predated by 
that of the Phenethylthiazolylthiourea (PETT) derivatives, which were first synthesized by 
Bell and co-workers at the Eli Lilly Company and reported in 1995.101 Changing the thiazole 
ring to pyridine ring as N-(5-bromo-2-pyridinyl)-N’-(2-pyridylethyl)-thiourea (Trovirdine) 
resulted in enhanced activity and a detailed structural analysis of it carried out by the Uckun 
group in 1999 revealed abundant sterically usable space surrounding the pyridyl group as 
well as the ethyl linker.102,107 They postulated that an efficient use of this space would lead to 
more potent anti-HIV agents with higher affinity for the NNRTI binding pocket, and this 
resulted in several more potent derivatives including the highly potent HI-236,107,144 with a 
much superior inhibition profile in which the pyridyl ring of Trovirdine was replaced by a 2,5-
dimethoxyphenyl group (Fig. 2.2a and Fig. 2.2b). 
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                                     Figure 2.2a Structures of PETT, Trovirdine and HI-236. 
 
 
 
Figure 2.2b Design of PETT compounds from PETT to Trovirdine as lead to HI-236. The IC50 values 
against HIV-1 replication of these compounds are shown below each compound. The surface of the 
composite binding pocket is color-coded for chemical preference: gray for hydrophobic regions, blue 
for polar regions, and red for hydrogen bonding regions.107 
 
 
 
2.1 Modeling of HI-236 
 
Structural studies around HI-236 revealed, as with other PETT derivatives, that the thiourea 
portion interacts in Wing 1 toward the front of the pocket via H-bonding with K101.144,107 
Conversely, the C-5-methoxy group forges cooperative C-Hπ interactions with the highly 
conserved W229, while the phenyl ring interacts with Y188. The methoxy group at C-2 was 
found to lie underneath the ethyl linker and was considered to occupy some of the vacant 
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spacer near Y188 in wing 2, an issue which assumes a greater weight of importance for the 
drug-resistant strains where there is an increase in the pocket size due to mutated residues 
of smaller size such as Y181C and Y188L. Figure 2.3 depicts HI-236 docked into the NNRTI 
pocket with the C-2 methoxy group positioned underneath the ring and pointing into available 
space.  
 
                                                                                                                                                                                                                                               
                                                                  
                
                                                              Figure 2.3 HI-236 docked into the HIV pocket.107   
 
 
It was thus conjectured whether extending from this position might allow a tether to exit the 
pocket as already discussed in the objective. Thus, the first part of the study, it was decided 
to synthesize and evaluate the biological activity of a small library of C-2 tethered HI-236 
derivatives, the objective being not only to shed light on NNRTI attachment at the C-2 
oxygen for the bifunctional design, but also to probe the possibility of further binding in the 
region of the pocket just mentioned in an attempt to improve the activity of HI-236 even 
further. Tethers (R) attached to the C-2 phenolic oxygen were chosen to probe length, 
functionality and polarity (Table 2.1). 
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                     Table 2.1 HI-236 derivatives synthesized with different tethers (R).5 
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2.2 Overview on synthesis of the PETT derivatives 
 
Phenethylthiazolylthiourea (PETT) compounds were first synthesized in 1995 by Bell et al.101 
as lead inhibitors of HIV-1 RT, resulting in a structure-activity relationship profile involving 
various substituents in their structure. The PETT derivatives were synthesized according to 
two general methods. In the first route, thiourea analogue 54 (as a representative example) 
was prepared by condensation of the amine 52 with the thiocarbonyl reagent 53 derived from 
2-aminothiazole and thiocarbonyldiimidazole (Scheme 2.1).  
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52 53 54  
                        
                            Scheme 2.1 Synthesis of PETT compounds from thiourea 53. 
 
The second method, exemplified by synthesis of thiourea analogue 57, involved reacting an 
isothiocyanate such as phenethyl isothiocyanate 55 with a heterocyclic amine (2-
aminothiazole) 56 (Scheme 2.2). 
 
N C S +
DMF
100oC NH
N
H
N
SS
55 56 57
N
S
H2N
   
                             Scheme 2.2 Synthesis of PETT compounds from phenethyl isothiocyanate. 
                                                                                                                                                                        
In Uckun’s study,102 HI-236 60 was synthesized according to the first method by high-
temperature condensation of amine 59 with thiocarbonyl reagent 49 derived from 1,1'-
thiocarbonyldiimidazole and 2-amino-5-bromopyridine 58 (Scheme 2.3).145 
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Scheme 2.3 Reagents and Conditions: (i) 1,1'-thiocarbonyldiimidazole, acetonitrile, rt, 12-15h. (ii) 
DMF, 100 °C, 16h. 
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2.3 Retrosynthetic analysis of HI-236 derivatives 77 
 
The retrosynthetic analysis of the generic structure 77 (Fig. 2.4) in this project involved a 
similar  set of disconnections to those for Uckun’s HI-236 synthesis, and identified phenolic 
amine 66 as a key intermediate, which was readily available in multigram quantities using 
chemistry reported by Glennon146a via a three-step sequence from commercially available 2-
hydroxy-5-methoxybenzaldehyde 61. In this project, amine 66 was isolated as its N-Boc 
carbamate 68. Catalytic hydrogenolysis of 68 would furnish 69, which was considered to be a 
key intermediate in the synthesis of the target molecules (77a-q) via alkylation.   
     
    
                                    Figure 2.4 Retrosynthetic analysis of HI-236 derivatives.  
 
Thus, for the actual synthesis, the phenolic hydroxyl group of aldehyde 61 was first protected 
so as to avoid complications with the phenolic hydroxyl group later in the synthesis. A benzyl 
ether protecting group was chosen in view of facile chemoselective removal, and conversion 
of 61 under standard phenolic benzylation conditions furnished 62 in excellent yield (Scheme 
2.4). Its 1H NMR spectrum displayed diagnostic peaks at H 7.43 (5H, m) for the aromatic 
protons and a methylene singlet at H 5.16 for the benzyl group, while its 13C NMR spectrum 
displayed corresponding signals at C 136.3, C 128.7, C 128.3 and C 127.4 for the aromatic 
carbons and C 71.4 for the benzylic carbon. The melting point (44-46 oC) of the 
recrystallised sample was in agreement with the literature value of (47-48 oC),146b and the 
sample returned an acceptable combustion microanalysis. 
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Scheme 2.4 Reagents and conditions: (i) BnBr, K2CO3, EtOH, reflux, 16 h; 94%; (ii) CH3NO2, 
NH4OAc, 70 oC, 14 h; 80%.  
 
In the next step, the benzylated aldehyde 62 was condensed with nitromethane as both 
solvent and reagent in a Henry reaction147 at 70 oC using ammonium acetate as promoter to 
give nitrostyrene derivative 65 in 80 % yield as a bright-yellow solid after recrystallization 
from EtOH. The temperature of the reaction was carefully monitored to minimize by-product 
67 formation as a result of subsequent Michael addition onto 65. 
Mechanistically, the ammonium acetate provides both a proton source to activate the 
carbonyl oxygen as well as a base to abstract the acidic proton on the nitromethane. The 
nitromethane anion formed then attacks the electrophilic carbonyl carbon generating 
intermediate 63. Following proton transfer, an E1CB elimination of water, which proceeds via 
a conformation in which NO2 and the aromatic ring are anti-periplanar subsequently results in 
the formation of β-nitrostyrene 65 (Fig. 2.5) exclusively as an E-isomer. At higher 
temperatures, the nitrostyrene 65 acts as a Michael acceptor and undergoes a conjugate 
addition with a second nitromethane anion to form by-product 67, which was not observed 
due to controlling the reaction temperature at 70 oC. 
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Figure 2.5 Mechanism of formation of nitrostyrene 65. 
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The spectroscopic and analytical data for 65 was in agreement with the assigned structure. 
Its 1H NMR spectrum displayed two doublets at H 8.17 and H 7.83 for the nitroethenyl group 
with a large coupling constant J1,2 of 13.6 Hz for an E-configuration, while its 13C NMR 
spectrum displayed diagnostic signals at C 136.1 for C-1 and C 135.1 for C-2. The melting 
point of this compound was in agreement with the literature value.147 The absence of formyl 
signals for both the 1H (at H 10.53) and 13C (at C 189.5) in the NMR spectra of 65 confirmed 
the assigned structure. The large coupling constant between H-1 and H-2 indicated a trans-
configuration. If the protons had been cis, the coupling constant Jcis would have been around 
10 Hz. Reduction of nitrostyrene 65 by lithium aluminum hydride (LAH) in refluxing THF 
yielded the amine 66 in good yield (Scheme 2.5).  
 
 
 
                                         
 
 
 
                              Scheme 2.5 Reagents and conditions: (i) LiAH4, THF, reflux, 4 h; 91% 
 
The reaction could be followed by tlc towards the formation of a polar spot assigned as the 
amine. Conventional extractive work-up could not be pursued in view of the amine’s water 
solubility. Thus, the work-up involved adding a saturated aq. Na2CO3 solution dropwise at 0 
oC. The precipitate formed was filtered and the filter-cake washed with large volumes of 
methanol, followed by complete evaporation of all solvent. As expected, the amine was very 
polar towards tlc, running with an Rf = 0.3 in an EtOAc/ MeOH (9:1) system. Thus it was not 
purified but used directly in the next step. 
 
Protection of the amine 66 as a N-Boc carbamate 68 was considered to provide a more 
workable route to the desired thioureas in terms of the polarity of 68. Also the protecting 
group would serve appropriately in subsequent steps including the Sonogashira coupling 
reaction. The Boc group is relatively stable under basic conditions since the carbonyl group 
is relatively hindered and its electrophilicity diminished due to mesomeric stabilization by 
oxygen and nitrogen. To this end, amine 66 was protected as its Boc-carbamate by reaction 
with di-tert-butyldicarbonate (1.2 equiv.) in acetonitrile at room temperature to give 68 in an 
overall 88% yield after purification by column chromatography (Scheme 2.6).  
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Scheme 2.6 Reaction condition and mechanism of formation of N-Boc carbamate 68. (i) (Boc)2O, 
CH3CN, rt, 20 h, 88%.  
 
The 1H NMR spectrum of 68 revealed the presence of a methyl singlet at H 1.44 for 9H, and 
a downfield shift in the methylene protons adjacent to nitrogen at H 3.40. The 13C NMR 
spectrum of 68 revealed the presence of a carbamate carbonyl carbon at C 155.9 and a 
methyl carbon (t-butyl) at C 28.4. The presence of a carbonyl group was also confirmed by a 
stretch at 1703 cm-1 in the IR spectrum.  
 
Hydrogenolytic debenzylation of 68 in the presence of palladium-on-carbon in ethanol at 
room temperature led to phenol 69 in good yield (Scheme 2.7). The 1H NMR spectrum of 69 
revealed the absence of a benzylic methylene singlet at H 5.04. The debenzylation was also 
confirmed by its 13C NMR spectrum, which showed only six aromatic carbons and no 
benzylic methylene carbons at C 70.8. The IR spectrum of 69 displayed a diagnostic broad 
peak between 3457-3326 cm-1 for the hydroxyl stretch. 
 
 
 
 
 
 
 
                        Scheme 2.7 Reagents and conditions: (i) H2, Pd/C, EtOH, rt, 5 h; 74%. 
 
Initially, a range of short chains as tethers were selected to probe steric and electronic 
effects in the hydrophobic NNRTI pocket and the various groups are shown in Table 2.1 
(77a-i) and Fig. 2.6 for the N-Boc derivatives (70a-i). Of particular interest was the 
incorporation of a triple bond in the chain not only to address the Sonogashira chemistry but 
also to probe the possibility of π- π stacking with aromatic residues in the pocket. Other 
functionalities included cyano and ester as groups as well as hydroxyl for probing hydrogen 
bonding interactions (77g-n). 
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For 70a-i, the derivatives could be synthesized under standard alkylation conditions (Scheme 
2.8) using a simple electrophile, which was readily available either commercially or via a one-
step derivatisation (Fig. 2.6). 
 
 
 
 
 
 
 
       Scheme 2.8 Reagents and Conditions: (i) K2CO3, CH3CN, reflux, 20 h, with ROTs or RBr. 
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                         Figure 2.6 A library of oxy-alkylated N-Boc derivatives 70 (simple chain).148 
 
Thus, 69 was reacted with the appropriate tosylate or bromide (2.0 equiv.) electrophile using 
K2CO3 (4.0 equiv.) in acetonitrile at reflux for around 20 h. The reaction was monitored by tlc, 
and was easily chromatographed to give the desired product in excellent yield (Fig. 2.6). 
A full spectroscopic analysis using 1H and 13C NMR spectroscopy was carried out on each 
compound (70a-i) to return acceptable data as well as microanalytical and IR data. The 1H 
NMR spectra for compounds 70b-d displayed a signal for the alkyne proton at around H 2.03 
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which appeared as a triplet with a small coupling constant of J = 2.7 Hz, due to allylic 
coupling with the propargylic methylene protons. The 13C NMR spectra of 70b-d as well as 
their IR spectra similarly gave diagnostic signals for the triple bond around 80 and 70 ppm 
and 3300 (≡CH) and 2120 (C≡C) respectively. Similarly, the other side chains could be earily 
identified in their 1H and 13C NMR spectra in terms of normal resonances for the allyl group 
and the methyl ester. The nitriles 70h and 70i could be identified from their IR C≡N stretching 
frequencies at 2240 cm-1 as well as relaxed 13C NMR resonances for the cyano carbon at 
around 110 ppm. Table 2.2 summarizes NMR data for H-1” and C-1” as the first carbon of 
the alkylated chain of the various derivatives. 
 
                    Table 2.2 1H and 13C NMR chemical shifts for H-1” and C-1” for compounds 70a-i 
 
                 R 
H 
 H-1” 
C 
C-1” 
                  
R 
H 
 H-1” 
C 
C-1” 
          CH2  70a       
 
3.88 
 
70.2 
 
CH2   70f  
 
4.50 
 
69.5 
 
CH2   70b  
 
4.65 
 
56.7 
      MeO CH2   70g
O
 
 
3.40 
 
66.0 
 
CH2CH2   70c  
 
4.05 
 
66.8 
 
N CH2   70h  
 
4.73 
 
54.9 
   
CH2CH2CH2  70d  
 
4.02 
 
66.9 
 
N CH2CH2CH2   70i  
 
4.03 
 
66.3 
        
       CH2   70e  
 
4.60 
 
57.3 
   
 
Finally, microanalytical data for the compounds that were isolated as solids, confirmed a 
correct molecular formula, Table 2.3.  
 
Table 2.3 Elemental analysis results for compounds 70f, 70g and 70i. 
Atom 
 
CH2   70f        
MeO CH2   70g
O
 
 
N CH2CH2CH2   70i  
 
Calculated 
 
Experimental 
 
Calculated 
 
Experimental 
 
Calculated 
 
 Experimental 
C 66.43% 66.41% 60.16% 60.37% 64.65% 63.62% 
H 8.20% 8.21% 7.16% 7.36% 7.84% 7.82% 
N 4.56% 4.40%       4.13%          3.91%       8.38% 8.06% 
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In the second set of derivatives, the electrophile needed to be prepared (77j-q) from the 
commercially available diol. For 70j, which could be used to prepare 70k and 70m, the 
synthesis began with mono-protection of ethylene glycol 71 via alkylation with benzyl 
bromide in tetrahydrofuran using NaH as base at room temperature, following the method 
described by Marshall et. al.149 to afford 72 in 49% yield (Scheme 2.9). The product was 
easily isolated by distillation (bp: 98-103 oC/0.7 mm Hg), and although obtained in only a 
moderate yield, the mono-benzylation could be carried out on a large scale. The presence of 
a benzyl group in the product was confirmed by the 1H NMR spectrum, which revealed 
aromatic protons integrating for 5 protons resonating at H 7.36 as well as methylene protons 
resonating at H 4.56. The 13C NMR spectrum displayed a methylene carbon at C 73.3 as 
well as the appearance of four aromatic singlets.  
 
 
 
 
                       Scheme 2.9 Reagents and Conditions: (i) BnBr, NaH, THF, reflux, 20 h; 49%   
 
Treatment of alcohol 72 with carbon tetrabromide and triphenylphosphine in methylene 
chloride smoothly yielded the bromide 73 in 92% yield (Scheme 2.10). Isolation involved 
evaporating the solvent and purifying the crude product directly by column chromatography. 
Mechanistically, the reaction of triphenylphosphine with carbon tetrabromide generates a 
bromophosphonium ion in situ which then reacts with the alcohol to give an 
alkoxyphosphonium ion (Fig. 2.7). The phosphonium ion intermediate then undergoes 
nucleophilic attack by the bromide ion, displacing triphenylphosphine oxide. The driving force 
for the cleavage of the C-O bond is the formation of the strong phosphine oxide bond (P=O). 
The 1H NMR spectrum of compound 73 revealed the disappearance of the hydroxyl proton at 
H 2.58 in 72, while its 13C NMR spectrum revealed an upfield shift of the carbon at C-1 from 
61.8 for 72 to C 30.4 in 73, thus confirming that substitution by bromine had taken place. 
 
 
 
 
                  
                 Scheme 2.10 Reagents and Conditions: (i) PPh3, CBr4, CH2Cl2, 0 oC, 30 min; 92%. 
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                                             Figure 2.7 Mechanism for formation of bromide 73.  
                    
With electrophile 73180 in hand, nucleophilic substitution of it by phenol 69 in the presence of 
K2CO3 as a base  in acetonitrile was carried out to afford the desired compound 70j  
smoothly in a good isolated yield (85%) (Scheme 2.11). 
 
 
 
 
 
 
 
                     Scheme 2.11 Reagents and Conditions: (i) K2CO3, CH3CN, reflux, 20 h; 85%. 
 
The 1H NMR spectrum of alkylated carbamate 70j revealed a downfield shift of the proton α 
to bromine at H 3.51 for the bromide 73 to H 4.01 as well as the presence of signals for the 
phenolic moiety. The 13C NMR for 70j displayed a downfield shift of the carbon α to bromine 
at c 30.4 for the bromide 73 to c 68.7, thus confirming that the alkylation had taken place. 
 
After the C-2 phenolic alkylation reaction, compound 70j was submitted to hydrogenolytic 
debenzylation using 10% palladium-on-carbon catalyst in ethanol under hydrogen gas at rt 
for 18 h. Column chromatography gave the desired alcohol 70m in an excellent yield (93%) 
(Scheme 2.12). 
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                            Scheme 2.12 Reagents and Conditions: (i) H2, Pd/C, EtOH, rt, 18 h; 93%      
 
The 1H NMR spectrum of 70m revealed the disappearance of five aromatic protons and the 
singlet benzylic methylene peak. In addition, there was the appearance of a hydroxyl proton 
as a broad singlet resonating at H 1.25, while the 13C NMR spectrum of 70m revealed the 
disappearance of four aromatic singlets and the methylene singlets at C 73.2. The presence 
of the hydroxyl group of 70m was also confirmed by the IR spectrum, which revealed a 
stretch around 3681-3449 cm-1.   
 
With alcohol 70m in hand, three possible reactions were considered for the conversion of 
alcohol 70m to alkyne 70k. The first involved direct alkylation with propargyl bromide to 
furnish alkyne 70k in a single step. The second strategy relied on Mitsunobu coupling of 
propargyl alcohol with 70m. The last strategy was conversion of the hydroxyl group to a good 
leaving group, in this case a tosylate, followed by substitution with propargyloxide anion. The 
second method was attempted first and resulted in the desired target in low yield. Of the 
other two methods, it turned out to be more efficient to substitute with propargyloxy anion, 
rather than alkylate with propargyl bromide, probably due to the softness of propargyloxide 
anion. Thus, the hydroxyl group on 70m was converted to its tosylate 74 in a good yield 
(77%) by reacting it with p-toluenesulfonyl chloride in the presence of triethylamine and a 
catalytic amount of DMAP in methylene chloride for 16 h at room temperature (Scheme 
2.13).   
 
 
 
 
                    
  
             
             Scheme 2.13 Reagents and Conditions: TsCl, Et3N, DMAP, CH2Cl2, 0 oC-rt, 16 h; 77%. 
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Evidence for the formation of the tosylate 74 was obtained from the 1H and 13C NMR spectra 
which confirmed the appearance of four aromatic protons as an AB doublet pair (JAB 8.2 Hz) 
resonating at H 7.80 and H 7.34 as well as a methyl singlet at H 2.43. The presence of 
additional aromatic signals in the 13C NMR spectrum further confirmed the presence of a 
tosylate group. The appearance of a sulfonate (O-SO2-) group was also confirmed by a 
stretch in the IR spectrum at 1176 cm-1.    
 
Alkylation of tosylate 74 then processed successfully in the presence of NaH and a large 
excess of propargyl alcohol in THF at reflux. An aqueous work-up followed by column 
chromatography furnished the alkyne 70k in a good yield (77%) (Scheme 2.14).  
 
 
 
 
 
 
 
              Scheme 2.14 Reagents and Conditions: (i) Propargyl bromide, NaH, reflux, 20 h; 77%.  
         
The 1H NMR spectrum of  compound 70k revealed an upfield shift for the H-2” protons in 
tosylate 74 at H 4.35 to H 3.88  in the alkyne 70k as well as the disappearance of aromatic 
peaks for the tosylate and the methyl singlet. The 13C NMR of 70k displayed diagnostic 
signals around C 79.5 and C 74.7 for the alkyne carbons, thus confirming that alkylation had 
taken place. The presence of an alkyne was further confirmed by the IR spectrum, which 
displayed a weak signal around 3304 cm-1 for the ≡CH stretch as well as a weak signal 
around 2123 cm-1 for the alkyne C≡C stretch. 
 
Similarly, for 70n, the same methodology was used to elongate the chain by one more 
carbon in order to investigate the H-bonding effect. Thus mono-benzylation of propane-1,3-
diol 71a using the standard procedure above gave the desired product 72a in 37% after 
column chromatography (Scheme 2.15). The product structure was confirmed using 1H and 
13C NMR spectroscopy, which revealed a new benzyl group. 
 
The mono-benzylated glycol 72a was then converted to its bromide 73a using carbon 
tetrabromide in methylene chloride as before to give the desired product in 91% yield 
(Scheme 2.15). Once again, the 1H NMR spectrum of compound 73a revealed the 
disapperance of the hydroxyl proton at H 2.56, while its 13C NMR spectrum revealed an 
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upfield shift of the carbon at C-1 from C 61.4 to 72a to C 33.0 in 73a, supporting the 
structure 73a. 
 
 
 
 
 
Scheme 2.15 Reagents and Conditions: (i) BnBr, NaH, THF, reflux, 20 h; 37% (i) PPh3, CBr4, CH2Cl2,  
 0 oC, 30 min; 91%. 
 
Using the standard alkylation conditions (K2CO3 as a base in acetonitrile at reflux) for 
nucleophilic substitution of 73a by phenol 69 afforded the desired product 75 in an excellent 
yield (100%) after column chromatography (Scheme 2.16). All the expected resonances 
were observed in much the same positions as for compound 70j (Scheme 2.11). Its 1H NMR 
spectrum revealed a downfield shift of the protons α to bromine at H 3.55 for the bromide 
73a to H 4.04 as well as the presence of signals for the phenolic moiety. The 13C NMR 
spectrum of 75 displayed a downfield shift of the carbon α to bromine at c 33.0 for the 
bromide 73a to c 66.9, thus confirming that alkylation to 75 had taken place. 
 
Scheme 2.16 Reagents and Conditions: (i) 73a, K2CO3, CH3CN, reflux, 20 h; 100%. (ii) H2, Pd/C, 
EtOH, rt,18 h; 93%.     
 
75 was subjected to hydrogenolytic debenzylation using 10% palladium-on-carbon catalyst in 
ethanol under hydrogen gas to give the alcohol 70n as the desired product in 93% (Scheme 
2.16). Similar trends in the 1H and 13C NMR spectra of 70n were noted as 70m containing 
the shorter tether.  
 
The methodological procedures just described were used to prepare the remaining elongated 
derivatives 77l, 77o, 77p and 77q. Once again, the mono-protection of diols 71b-d, were 
carried out using the benzylation to give the desired products 72b-d (Scheme 2.17). 1H and 
13C NMR spectroscopy data for each compound 72b-d confirmed benzylation had occurred. 
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Subsequently, alcohols 72b-d were converted into their bromides using carbon tetrabromide 
and triphenylphosphine as described before to give the desired products 73b-d, whose 
spectroscopic data were consistent with previous trends.  
  
Scheme 2.17 Reagents and Conditions: (i) BnBr, NaH, THF, reflux, 20 h; (n = 0, 44%), (n = 3, 39%), 
(n = 5, 38%); (ii) PPh3, CBr4, CH2Cl2, 0 oC, 30 min; (n = 0, 91%), (n = 3, 88%), (n = 5, 77%). 
 
Once again, C-2 O-alkylation of 69 with bromides 73b-d employing K2CO3 in refluxing 
CH3CN as described before afforded the alkylation products 75a-c in a good yield as shown 
in Scheme 2.18. A full spectroscopic analysis using 1H and 13C NMR spectroscopy was 
carried out on each compound to return acceptable data. Mass spectrometry and IR were 
also used.  
 
 
 
 
 
 
 
                  Scheme 2.18 Reagents and Conditions: (i) 73b-d, K2CO3, CH3CN, reflux, 20 h.  
 
Carbamates 75a-c were then debenzylated using 10% palladium-on-carbon catalyst in 
ethanol under hydrogen gas as before to afford desired alcohols 70o-q as shown in Scheme 
2.19 in an overall yield of about 90%.  
                           
 
 
 
 
 
                                                 
 
                            Scheme 2.19 Reagents and Conditions: (i) H2, Pd/C, EtOH, rt, 18 h.  
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Similar trends for 70o-q as for 70m,n in the 1H and 13C NMR spectra were noted which, 
provided sufficient evidence that debenzylation had taken place. 
 
For the Sonogashira coupling reaction which will be discussed later, alcohols 70o-q were 
tosylated and then converted to the desired alkynes 70i, r, s (Scheme 2.20 and Scheme 
2.21) as described before in Scheme 2.13 and Scheme 2.14.  
 
 
 
 
 
 
 
 
                         Scheme 2.20 Reagents and Conditions: TsCl, Et3N, DMAP, CH2Cl2, 0 oC-rt, 16 h. 
 
The 1H and 13C NMR for 74a-c returned the correct number of the resonances in each case, 
while HRMS (ES/I) as shown in Table 2.4 for 74a-c was used to confirm correct molecular 
formula to four decimal places. 
 
Table 2.4 High resolution mass spectrum HRMS(ES/I) observed for 74a-c. 
Compound 
 
Mass 
(experimental) 
 
Mass 
(calculated) 
  74a (n = 1)              509.2067 (M+) 509.2083 (M+) 
  74b (n = 3)     598.2673 (M+ + H)        598.2686 (M+ + H) 
  74c (n = 5)     686.3192 (M+ + H)        686.3210 (M+ + H) 
 
                   Scheme 2.21 Reagents and Conditions: (i) Propargyl alcohol, NaH, THF, reflux, 20 h. 
 
These compounds 70l, 70r and 70s were fully characterised by NMR, IR and high resolution 
mass spectrometry. The IR spectra of these compounds indicated characterization peak for 
OMe
O
NHBoc
O
HO
n
i
70o, n = 1 
70p, n = 3 
70q, n = 5 
OMe
O
NHBoc
O
TsO
n
74a, n = 1 (80%
74b, n = 3 (84%)
74c, n = 5 (93%)
)
OMe
O
NHBoc
O
OH n
i
OMe
O
NHBoc
O
TsO n
70l, n = 1 (80%
70r, n = 3 (84%)
70s, n = 5 (93%)
)74a, n = 1 
74b, n = 3 
74c, n = 5 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
CHAPTER 2___________________________________________      HI-236 DERIVATIVES 
 77 
(C≡C) around Vmax 3309-3304 cm-1 and for ≡CH around Vmax 2123-2116 cm-1. The 1H and 13C 
NMR spectra data for 70l, 70r and 70s revealed the disappearance of the aromatic peaks as 
well as the appearance of the alkyne signals, thus, confirming that alkylation had taken 
place. 
 
The end-game of HI-236 derivatives 77 
 
To complete the synthesis of the targets 77 required Boc deprotection to the amine and 
condensation with thiourea reagent 49. As described by the Eli Lilly group,101 49 was 
synthesized by condensation of 2-amino-5-bromopyridine with 1,1’-thiocarbonyl diimidazole 
in CH3CN at room temperature for 20 h (Scheme 2.22). The precipitate formed was filtered to 
give 49 in good yield, which was recrystallized from methanol/CH3CN. This treatment 
resulted in substitution of the imidazole group by methoxy to form 49a as evidenced by 1H 
NMR. Therefore, the material was used directly without further purification. 
 
 
  
            Scheme 2.22 Reagents and Conditions: (i) 1,1’-Thiocarbonyldiidaazole, CH3CN, rt, 20 h; 92%.  
 
The 1H NMR spectrum of compound 49 displayed the following diagnostic peaks: a singlet at 
H 7.79 for H-2 of the imidazole ring and a broad singlet at H 10.19 for the NH proton. The 
presence of a carbamate carbonyl was indicated by the 13C NMR spectrum, which revealed a 
downfield peak at C 176.8 (C=S).  
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Strategy for deprotection and condensation of N-Boc derivatives 70  
 
                            Table 2.5 N-Boc derivatives synthesized with different tethers (R).5 
 
 
 
 
                        
              R                R         R 
 
CH2   70a  
 
CH2  70b  
 
CH2CH2   70c  
CH2CH2CH2   70d              CH2   70e  CH2   70f  
 
MeO CH2   70g
O
 
 
              N CH2   70h  
 
N CH2CH2CH2   70i  
BnO CH2   70j
 CH2O
CH2
70k
 
CH2O O
CH2
70l
 
HO CH2   70m
 
HO
CH2   70n
 
OHO CH2 70o
 
OO CH2 70pOHO
 
O CH2   70qOO
3
HO
 
 
                      
Deprotection of N-Boc derivatives 70 show in Table 2.5 were accomplished with 
trifluoroacetic acid in methylene chloride at 0 oC for 1-3 h to provide the desired amines 76 
(scheme 2.23).  
 
 
 
 
 
 
                      Scheme 2.23 Reagents and Conditions: (i) CF3COOH, DCM, 0 oC, 1-3 h. 
 
The tlc revealed complete deprotection to a polar amine spot, and in view of the amine’s 
anticipated water solubility, the final step was conducted without using an aqueous work-up. 
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Thus, following complete removal of all volatiles including any excess trifluoroacetic acid, 
Hünig’s base (EtN(i-Pr)2) was added to liberate the free amine. 
 
The mechanism for deprotection of the Boc group involves protonation of the carbonyl 
oxygen to form intermediate I (Fig. 2.8), which fragments with elimination of a stable tert-
butyl carbocation III via an E1 mechanism to give carbamic acid II, which undergoes 
decarboxylation to give the desired amine. The reaction is driven by the relative stability of 
the tert-butyl cation III.  
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                   Figure 2.8 Mechanism for the deprotection of the Boc protecting group. 
 
Subsequently, condensation between the amine and thiourea reagent 49 could be realized in 
DMF at 100 oC as described by Bell and co-workers101 to afford the targets 77 in an overall 
yield of around 30% for the two steps (Scheme 2.24). However, later on, it was discovered 
that condensation could be carried out under much milder conditions in THF or DMF at room 
temperature to increase the two-step yield to around 60% as shown in Table 2.6. Some of 
the targets were isolated by silica-gel column chromatography as crystalline solids that were 
crystallized to a constant, sharp melting point to return acceptable combustion analysis data. 
 
 
 
 
 
 
 
Scheme 2.24 Reagents and Conditions: (i) CF3COOH, DCM, 0 oC, 1-3 h; (ii) (EtN(i-Pr)2), 0 oC, 10 min, 
followed by thiourea 49, DMF at 100 oC (77b, 77c) and THF at rt, 20 h. 
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                                    Table 2.6 Two-step yield for Compound 77 from 70.148  
 
                     R 
 
Yield% 
        
R 
 
  Yield% 
 
              CH2   77a  
 
65 
  
BnO CH2   77j   
 
58 
         
             CH2   77b  
 
17a             CH2O
CH2
77k  
 
62 
        
          CH2CH2   77c  
 
25a       CH2O O
CH2
77l             
 
60 
  
     CH2CH2CH2   77d  
 
69 
                 
                 HO CH2   77m  
 
65 
     
          CH2   77e  
 
60 
 
     HO
CH2   77n
 
 
51 
           
            CH2   77f  
 
67 
 
OHO CH2 77o  
 
62 
         MeO CH2   77g
O
 
 
50 
   
  OO CH2 77pOHO  
 
63 
     
N CH2   77h  
 
68 
 
O CH2   77qOO
3
HO
 
 
52 
      
       N CH2CH2CH2   77i  
 
53 
  
          a DMF at 100 oC; others involved THF at rt. 
 
 
A full spectroscopic analysis using 1H and 13C NMR spectroscopy was carried out on each 
derivative to return acceptable data. Notably, the aromatic region in the 1H NMR spectra 
provided convenient markers for the aromatic and heteroaromatic rings to demonstrate that 
condensation had take place. The thiourea N-H’s could be discerned downfield as two 
separate resonances. The C=S carbon resonated at around 179 ppm in the 13C NMR. The 
retention of bromine in the pyridine ring was confirmed by 13C NMR ( C-Br ~ 112.6 ppm), and 
microanalytical data confirmed the correct molecular formulae, Table 2.7. Finally, IR data 
confirmed the disappearance of the carbonyl group of the Boc and the appearance of a 
thiocarbonyl group (C=S) at around 1475-1464 cm-1.  
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Table 2.7 Elemental analysis results for solids 77m, 77g, 77d, 77l, 77k, and 77h.148 
Atom             
HO CH2   77m  BnO CH2   77j  CH2CH2CH2   77d  
 
Calculated 
 
Experimental 
 
Calculated 
 
Experimental 
 
Calculated 
 
Experimental 
C 47.89% 47.96% 55.82% 56.07% 53.58% 53.54% 
H 4.86% 4.61% 5.07% 4.86% 4.95% 4.78% 
N 9.86% 9.77% 8.14% 7.37% 9.37% 7.81% 
S 7.52% 7.01% 6.21% 5.80% 7.15% 5.62% 
Atom 
N CH2CH2CH2   77i  N CH2   77h  CH2O
CH2
77k  
 
Calculated 
 
Experimental 
 
Calculated 
 
Experimental 
 
Calculated 
 
Experimental 
C 50.78% 50.61% 48.38% 48.38% 51.73% 51.76% 
H 4.71% 4.78% 4.07% 4.04% 4.78% 4.72% 
N 12.47% 12.37% 13.30% 12.38% 9.05% 8.66% 
S 7.135 6.92% 7.61% 6.76% 6.91% 6.86% 
 
 
 
 
2.4 Biological results, modeling and discussion 
 
The biological activities of the compounds synthesized in this part of the project were 
determined by project collaborators at the Division of Pharmacology, Yale University, USA, in 
the laboratories of Professor Karen Anderson. The inhibitory activities of compounds 77 were 
measured against HIV-1 (IIIB) replication in MT-2 cell culture using an MTT assay150 (see 
Appendix). HI-236 was included as a reference compound. The results are shown in Table 
2.8.  
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Table 2.8 Inhibition and cytotoxicity assaya results for 77a –77q against HIV -1 (IIIB) in MT-2 cell  
culture.148  
 
R EC50b 
(μM) 
CC50c 
(μM) 
T.Id R EC50b 
(μM) 
CC50c 
(μM) 
T.Id 
CH3   HI-236  0.048 1.0 21          N CH2CH2CH2   77i  0.050 3.8 76 
CH2   77a  
0.095 0.1 1 
  
BnO CH2   77j   
2.0 5.8 3 
CH2   77b  0.052 0.1 2             CH2O
CH2
77k  0.095 9.5 100 
 
CH2CH2   77c  
0.026 1 38       CH2O O
CH2
77l             0.39 6.8 17 
 
CH2CH2CH2   77d  
0.25 10.0 40 
                 
                 HO CH2   77m  
0.012 1.0 83 
 
CH2   77e  
0.27 20.0 74 
 
     HO
CH2   77n
 
0.098 8.5 94 
 
CH2   77f  
0.20 11.0 55 
 
OHO CH2 77o  
0.80 9.5 12 
MeO CH2   77g
O
 
12 48 4 
   
 OO CH2 77pOHO  
0.32 8.5 27 
 
N CH2   77h  
0.12 5.5 46 
 
O CH2   77qOO
3
HO
 
1.20 53 44 
a Reference 16; MOI was 0.1 
b Effective concentration that inhibits viral-mediated T-cell death by 50% and as an average of three 
measurements.  
cConcentration that kills 50% of the T-cells and as an average of three results. 
d In vitro therapeutic index (IC50 /EC50). 
 
 
Regarding a general comparison of all derivatives, the results from the cell culture shown in 
Table 2.8 were taken to reveal important trends within classes of different tether (polar vs 
lipophilic). Four of the compounds returned activities equal to HI-236 (77b and 77i) or greater 
(77c, twofold increase; 77m, fourfold increase). In order to assist with interpretation of the 
results, docking studies were carried out in the laboratories of Professor Kevin J. Naidoo  
(University of Cape Town) using Auto-Dock 3.05151 based on the recently published HIV-1 
RT protein crystal structure of N-(5-chloro-2-pyridinyl)-N'-[2-(4-ethoxy-3-fluoro-2-
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pyridinyl)ethyl]-thiourea as template.105 The conformation of the PETT derivatives studied 
was set to accommodate the well-documented102,105,152 intramolecular hydrogen bond 
between the hydrogen of the thiourea nitrogen attached to the alkyl side and the nitrogen of 
the pyridinyl ring to form a flat six-membered pseudo-ring (Fig. 2.9). 
 
 
 
 
 
 
 
 
                         Figure 2.9 Structure of HI-236 showing the intramolecualr hydrogen bond. 
 
This protocol resulted in a strong preference for one low energy conformation that dominated 
153 of the 250 possible conformations.  HI-236 was docked first, and we were able to 
establish parity of result with that obtained by Uckun.102,105,107,152 The two structures are 
shown in Figure 2.10.     
 
 
 
 
 
 
 
 
 
 
 
 Uckun’s HI-236 docked into the HIV pocket.                       Our HI-236 docked by AutoDock 3.05.148 
     Figure 2.10 HI-236 docked into the HIV pocket. 
Thus, as established by Uckun, the inhibitor adopts the characteristic butterfly-shaped 
orientation with the thiourea moiety embedded in Wing 1 in which hydrogen bonding between 
the thiourea hydrogen on the N-pyridyl side and the carbonyl oxygen of K101 is clearly 
visible.  Wing 2 accommodates the phenyl ring of HI-236 close to the Y181 and Y188 region 
with the 5-methoxy group interacting with W229.  The 2-alkoxy substituent positions into a 
well containing residues Y181, Y188, F227, V106 and V179. This feature had significance for 
Wing 1 
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the aims of this study. The only difference between our structure and that of Uckun’s was the 
orientation of W229 relative to Y181. In Uckun’s model, the six-membered ring of the indole 
of W229 overlapped Tyr181, whereas the model obtained from our calculations had the five-
membered ring of the indole overlapping Tyr181. This could have been due to differences in 
the static protein structure used in our docking calculations as compared with the structure of 
the HIV-1 RT binding pocket used in the studies by Uckun. 
 
 
 
 
  
 
 
 
 
 
 
       
   
 Figure 2.11 The similarities in orientation between the AutoDock models of HI-236 and 77g.148 
 
Attention was then focused on docking two of the derivatives, chosen as the ester 77g and 
the alcohol 77n. The parity of 77g and 77n with our docked HI-236 in terms of overall 
topology in the pocket was first investigated, as illustrated in Figure 2.11 for 77g.  The 
elongation of the 2-alkoxy substituent can be seen but the positioning of the rest of the PETT 
structure essentially stayed the same, revealing that EC50 differences are likely to be based 
on interactions in the Wing 2 region as postulated. 77n gave a similar result. 
 
Examination of the way in which the 2-alkoxy substituents of 77g and 77n positioned 
themselves in the hydrophobic region of Wing 2 gave insights into the possible interactions 
responsible for fluctuation of biological activity as shown in Figures 2.12 and 2.13 taken from 
each end of the pocket for both cases.    
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Figure 2.12 Docking of Ester 77g.148  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13 Docking of Alcohol 77n.148 
 
Both structures suggest the possibility of interaction with V106 or, to a lesser extent V179, 
towards the floor of the pocket.  A possible explanation of their vastly different activities may 
be that while alcohol 77n might forge a hydrogen bond with a backbone valine carbonyl 
group, the ester moiety of 77g presumably promotes unfavourable carbonyl-carbonyl group 
repulsion exacerbated by steric interactions between the ester methyl (methoxy) group and 
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the valine methyl groups. Furthermore, other conformations for 77g involving swinging the 
ester group of 77g away from the valine region, only result in promoting repulsive 
electrostatic interactions between the carbonyl group and the aromatic faces of Y181, Y188 
and F227. A cooperative hydrogen bond for 77n would nicely explain the much enhanced 
activity of alcohol 77m (EC50 = 0.012 μM) with a shorter (two-carbon) chain, in which 
presumably the distance between hydrogen-bond donor and acceptor is optimal. 77m 
returned an activity four times higher than HI-236 in our system, and presents as an 
interesting candidate for the problematic V106A mutation if the hydrogen bonding postulate 
is correct. 
 
Similarly, for the alkyl and alkynyl compounds 77a-77f, the results show that the hydrophobic 
pocket is accommodating but with the only significant cooperative interaction being with the 
triple bond. In this regard, the butynyl chain of 77c, rather than the propargyl 77b or pentynyl 
substituents 77d appears to be optimal, with 77c indicating a twofold increase in activity 
compared to HI-236.  Although this classical force field does not include an explicit π-π term, 
the charge distribution on the aromatic rings mimics this fundamentally quantum effect 
surprisingly well.  Therefore we suggest that the increased activity of 77c is an optimal 
cooperative π-π face-to-face interaction between the aromatic residues of Y181, Y188 and 
the triple bond.  It was thus interesting to test this derivative against the Y181C mutant. The 
PEG derivatives 77n-q predictably returned lower activities, but not overly so given their bulk. 
Thus 77l, with 10 atoms in the substituent, returned an activity of 0.39 μM as only eightfold 
less potent than HI-236.  By comparison, the benzyl derivative 77j is too apparently bulky to 
be satisfactorily accommodated IC50 = 2 μM). Finally, the nitrile derivative 77i indicated some 
level of cooperation in the pocket being as active as HI-236, in spite of its five-atom 
substituent.  Once again, π-π and/or hydrogen bonding possibilities appear to be likely 
explanations.  
 
 
In order to lend support that these HI-236 derivatives indeed act as NNRTIs, six of the 
derivatives (77c, 77d, 77k, 77g, 77m and 77n) as the most (77m) to the least active (77g) 
were subjected to an in vitro steady-state RT inhibition assay (details given in Chapter 3), the 
results of which are shown in Table 2.9. 
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Table 2.9 Comparison of cell-culture versus in vitro RT inhibition (nM) for selected derivatives of 77.148 
 
 
 
 
 
 
R 
Cell-culture EC50 
(nM) 
RT assay IC50     
(nM) 
Cell-culture 
Y181C EC50 
(nM) 
Cell-culture 
Y181C IC50 (TI) 
(nM) 
Me (HI-236) 48 28 1200 18000        (15) 
 
CH2CH2   77c  
             26 3.8  <200   4000         
(>20) 
   
CH2CH2CH2   77d  
            250 27   
CH2O
CH2
77k  
95 41   
MeO CH2   77g
O
 
12000 100 
  
 
HO CH2   77m  
            
             12 
 
19 
  
 
  HO
CH2   77n
 
 
              98 
 
   24 
  
 
The RT assay results present strong support for all the derivatives in this study to be acting 
as NNRTIs since the derivatives have no possibility of being phoshorylated for NRTI activity 
against RT. This is also in keeping with published findings on HI-236. The activities ranged 
from 3.8 to 100 nM, and as expected were superior to those from the cell-culture results 
except for 77m, which was slightly poor. Such improvements likely reflects the lipophilicity of 
the derivatives and their poor solubility in the aqueous cell-culture medium.153 Notably, the 
ester 77g, which was effectively inactive in cell culture (12 μΜ), revealed a 120-fold 
improvement to 100 nM in the RT assay, possibly due to ester hydrolysis in the cell-culture 
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medium. Importantly, the alkyne 77c returned a value of 3.8 nM in the RT assay, which was 
more active compared to that of alcohol 77m (19 nM), in spite of the reverse being true in cell 
culture (26 nM vs 12 nM, respectively). The most active derivative 77c was then evaluated in 
cell culture against the Y181C resistant strain and this retained activity much better than HI-
236 (8-fold decrease against 25 for HI-236). 
 
In summary, it is important to note that of the 17 compounds tested in cell-culture, two (77c, 
77m) were more active than HI-236 and two (77b, 77i) were as active, while this picture 
improved in the RT assay in which of the six derivatives tested, two (77c, 77m) were more 
active and two were as active as HI-236 (77d, 77n). Such results endorse the conclusions 
drawn from the study by Uckun107 that the PETT derivatives have unused available pocket 
volume with good potential for drug-development. Furthermore, they have identified tethered 
butynyl derivative 77c as an advanced lead. Further fine-tuning is worthwhile pursuing on 
developing side chains that can cope with mutated residues contained in resistant strains,154 
and the modelling results suggest that this might be pursued by substituting at the C-3 
position of the aromatic ring ortho to the C-2 O-tether. In addition, in view of the tethered 
PEGed derivatives (e.g 77l) retaining appreciable activities, the study has generated support 
regarding the choice of the C-2 oxygen as the attachment point for the tether in the 
bifunctional compounds, and the likelihood of a tether at this position providing a route from 
the pocket to the NRTI binding site. This part of the Ph.D study just described effectively 
paved the way for a comprehensive study of elongated alkynylated bifunctional double-drugs 
to be carried out, which is the topic of the next Chapter.  
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CHAPTER 3: SYNTHESIS OF [d4U]-SPACER-[HI-236] DOUBLE-DRUGS 
 
3.1 Introduction 
 
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) act allosterically by slowing down 
the chemical step catalysed by the HIV reverse transcriptase (RT) enzyme, and Anderson85 
has shown that this retardation still allows the two-step binding of the nucleoside analogues 
(NRTI) to come to equilibrium leading to a tighter binding of the nucleotide triphosphate.  
Thus, in such a case there is communication between the two sites, and the close proximity 
(10-15 Ǻ) of the NRTI/NNRTI binding sites has inspired several groups to synthesize 
bifunctional heterodimers containing one of each class of drug separated by a spacer 
following an original suggestion by Arnold.116 In principle, such a bifunctional inhibitor might 
utilize the additive binding energies from the interactions at each site, translating into very 
tight binding. Based on results in Chapter 2, as well as the reasons given in the objectives 
regarding the attachment points of the drugs to the spacer, a family of flexible non-cleavable 
bifunctional systems [d4U]-spacer-[HI-236] 51, 78, 79, 80 and the pro-drug 81 were initially 
identified as shown in Figure 3.1 to explore their ability to interact and thus (shut down) HIV-
RT.  
  
 
 
 
 
 
 
 
 
 
  
                                                 
                                    Figure 3.1 Structure of bifunctional target molecules.   
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Attachment of the linker to the C-5 position of the nucleoside was thought to be achievable 
via a palladium cross-coupling Sonogashira reaction of a terminal alkyne with a 5-iodo 
nucleoside. C-5 tethered heterodimers have been developed extensively by the Ladurée 
group129,130 in which a Sonogashira coupling155 strategy has been demonstrated. 
Furthermore, C-5 substituted pyrimidine nucleosides constitute a class of biologically 
significant molecule in which the C-5 alkenyl and alkynyl substituted molecules have shown 
various antiviral activities. For example, (E)-5-(bromovinyl)-2’-deoxyuridine (BVDU) shown in 
Figure 3.2 is a highly potent and selective anti-Herpes agent that inhibits Herpes Simplex 
Virus type 1 (HSV-1) and which is currently in clinical use. Other C-5 substituted nucleosides 
in clinical use156 include 5-iodo-2’-deoxyuridine (IDU) and 5-trifluoromethyl-2’-deoxyuridine 
(TFT) which are both administered as eye drops or ophthalmic cream in the treatment of 
herpes virus infection.157    
 
   
 
 
 
 
 
 
 
 
 
 
                                    Figure 3.2 C-2 substituted nucleoside in clinical use. 
  
 
3.2 Overview on the synthesis of d4T 
 
Horwitz et al.158 reported the first synthesis of d4T 13 in 1964 as a potentially novel anti-
cancer drug. The strategy used involved conversion of 3',5'-anhydrothymidine 83 to d4T by a 
base-mediated elimination reaction. Thus, 2'-deoxythymidine 82 was readily converted into 
1-(3',5'-anhydro-2-deoxy- -D-threo-pentofuranosyl)-thymine 83 by converting it first into its 
3',5'-di-O-mesyl derivative, and then by heating the crude product under reflux with an 
excess of aq. sodium hydroxide. Oxetane formation from the dimesylate of 82 proceeded via 
intermediacy of the pyrimidine base with the ring closing step as shown. Elimination of 
oxetane 83 to afford d4T 13 was achieved via treatment with t-BuOK in DMSO (Scheme 3.1).  
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Scheme 3.1 Reagents and Conditions: (i) MeSO2Cl (3eq), C6H5N; (ii) aq. NaOH, reflux; (iii) t-BuOK, 
DMSO; 57%. 
 
Prolonged exposure of d4T to strong base at high temperatures led to its decomposition to 
give thymine as an undesired product thereby decreasing the overall yield. 
 
3.2.1 Synthesis of d4T from 5-methyluridine 
 
Chen et al.159 (Scheme 3.2) from the Bristol-Myers Squibb group minimized extensive 
nucleoside bond cleavage by inverting the 2’,3’-stereochemistry to proceed via a trans 
haloacetate. This was achieved by base-mediated conversion of the trimesylate of 84 into 
epoxide 86 via intermediate 85. 86 opened with acetyl bromide to afford a regioisomeric 
mixture of trans-bromoacetates 87a,b. -Elimination with a Zn/Cu couple as before afforded 
5'-mesyl d4T 87 under mild reductive elimination conditions, without significant nucleoside 
bond cleavage as a result of superior trans stereoelectronic alignment in the elimination step. 
87 could then be transformed into d4T 13.  
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Scheme 3.2 Reagents and Conditions: (i) (1) MsCl (3.0 eq), NMM, acetone; (2) 1N NaOH/H2O, 82%; 
(ii) AcBr (5.0 eq), MeOH, 92%; (iii) Zn/Cu, MeOH, 88%; (iv) PhCO2Na, ∆, DMF, 91%; (v) BuNH2, 90%. 
 
 
Alternatively, Bristol-Myers-Squibb also made use of a sulfonyl group at the 3'-position of 5-
methyluridine instead of an acetyl group in the syn-bromomesylate 90 to completely avoid 
the undesired cleavage of the thymine base (Scheme 3.3). D4T was prepared employing this 
methodology in 75% overall yield starting from the readily available ribonucleoside 5-
methyluridine.160 The key step in the synthesis was the zinc-induced reductive elimination of 
bromomesylate 90, which afforded d4T without nucleoside bond cleavage. Sodium benzoate 
acted as a base to form anhydro sugar 89 as well as acting as a nucleophile to displace the 
5'-mesyl group, preparing the way for the final facile deprotection with butylamine.  
      
 
Apart from the Bristol–Myers-Squibb synthesis, most of the other d4T syntheses are only 
amenable to producing research quantities of d4T and not for production purposes, owing to 
the involvement of protecting groups or convergent coupling of a silylated thymine to a 
suitably primed ribosugar. 
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Scheme 3.3 Reagents and Conditions: (i) MsCl, NMM, acetone, 97%; (ii) PhCO2Na, CH3CONH2, 
90%;  (iii) AcBr, MeOH, EtOAc, 98%; (iv) Zn, EtOAc/MeOH, cat. AcOH, 97%; (v) BuNH2, 70 °C, 90%. 
   
3.3 Strategies for the synthesis of [d4U]-spacer-[HI-236] 
 
Two divergent routes were envisioned for the synthesis of the target molecules 51, 78-80, 
with appropriate synthetic analysis using forward arrows depicted in Figure 3.3 starting from 
the useful synthon 69 explored at length in Chapter 2. These routes were developed in view 
of the failure initially to develop a convergent synthesis based on Pd (0) cross-coupling of the 
two drugs intact, in view of thiourea interference with cross-coupling. Later appraisal 
revealed this to be actually possible, albeit in low yield. The following points for the strategies 
used apply:  
 
(1) Route (A) was used in the synthesis of compounds 51, 78 and 79 involving a divergent 
approach via palladium cross-coupling reaction of an alkyne a with iodo-d4U 47 followed by 
deprotection of the Boc group and condensation of the resultant amine with thiourea 
derivative 49. Subsequent deprotection of the benzoyl group furnished the target compounds 
51, 78 and 79.   
(2) Route (B), which involved deprotection of the alkyne a to amine b. Palladium cross-
coupling reaction of amine b with iodo-d4U 47 followed by condensation with thiourea 
derivative 49 and deprotection would furnish 80. 
(3) Strategies for phosphoramidate 81 will be discussed in the text.  
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                 Figure 3.3 Synthetic analysis of target molecules 51, 78-80 using forward arrows.                                      
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The steps envisaged to present potential challenges in these syntheses were the Boc and 
benzoate deprotection steps in view of the unknown chemical stability of the nucleoside part 
of the molecule. Fortunately, protocols for these could be developed. 
  
3.4 Overview on Sonogashira coupling 
 
The Sonogashira coupling of 5-iodouridine with terminal alkynes has been extensively 
studied.161 The mechanism of this reaction involves firstly oxidative insertion of Pd(0) into the 
aryl-halide bond. CuI activates the alkyne by forming a copper acetylide, which undergoes 
transmetallation with the palladium complex to form an alkynyl-Pd-R intermediate. Reductive 
elimination of the Pd(0) leads to the coupled product (Fig. 3.4), with regeneration of the 
coordinatively unsaturated Pd(PPh3)2 (d14) catalyst.   
 
                
   
                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                     General equation for Sonogashira coupling reaction 
 
                          Figure 3.4: General equation and mechanism of Sonogashira coupling. 
 
Regarding literature precedent for our approach on nucleosides, Crisp and Flynn162 have 
demonstrated that the C-5 alkynyl derivatives 94 could be obtained in high yield (70-90%) by 
cross-coupling of acetylated uridine triflate 92 with a range of terminal alkynes 93 (Scheme 
3.4) using tetrakis(triphenylphosphine)palladium(0) as a catalyst. A slight elevation of 
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reaction temperature increased the rate of coupling. In this case, furanopyrimidine by-product 
95163 was isolated in low yield (7%) to trace amounts. 
 
Scheme 3.4 
 
Similarly, Robins et al.163 applied the Sonogashira reaction to couple protected 2’-
deoxythymidine derivatives 96 with several alkynes 97 in triethylamine at 50 oC in the 
presence of bis(triphenylphosphine)palladium (II) chloride and copper (I) iodide (Scheme 
3.5). 
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 Scheme 3.5 Sonogashira reaction to couple protected 2’-deoxythymidine derivatives. 
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others, under the same conditions gave the cyclized furanopyrimidine compound 99 as the 
major product. Conversely, coupling reactions with the same range of alkynes but using the 
nucleoside protected as its p-toluyl ester proceeded smoothly with minimal formation of 
deiodinated and furanopyrimidine by-products. 
 
Hobbs164 (Scheme 3.6) attempted to use the conditions optimized by Robins et al.165 to 
couple propargylamine 101 with unprotected 5-iodouridine 100 but failed owing to the 
nucleoside’s insolubility in triethylamine. Successful coupling was achieved to form the 
products 102 in good yields (70-90%) by using DMF as a solvent and 
tetrakis(triphenylphosphine)palladium as a catalyst instead of the Pd(II) used by Robins. He 
concluded that the successful coupling was a result of using Pd(0) instead of Pd(II). A review 
of these conditions by Robins revealed that the use of DMF significantly improved the rate of 
coupling and not the Pd(0).  
 
 
Scheme 3.6 
 
Sonogashira coupling of protected propargylamine 101a with 2’-deoxynucleoside 102 by the 
Robins group in the presence of triethylamine as a base furnished the target nucleoside 103 
together with triethylammonium salts that were difficult to separate. To improve the 
purification of these nucleosides, Garg et al.166 developed a heterogeneous protocol that 
employed a palladium-on-carbon catalyst and a resin-bound tertiary amine (Amberlite IR-67) 
as a base. These conditions furnished the coupled product 103 in good yield (Scheme 3.7). 
The study involved a cross-coupling reaction of the nucleoside 102 in the presence of 
Amberilte IR-67 and Pd(0) (10 mol%) which resulted in the coupled compound 103 in 79% 
yield after filtration of the reaction media and purification by column chromatography. The 
authors then substituted Pd(0) with a heterogeneous transition-metal catalyst (Pd/C) to 
further simplify the purification process. 
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Scheme 3.7 
 
C-5 alkynylated d4U analogues 105 and 107 have been synthesized via the smooth and 
efficient coupling of alkynes 104 and 106 with 5’-O-acetyl-5-iodo d4U 14 in DMF under co-
catalysis with Pd and Cul (Scheme 3.8). Reaction with unprotected alkynes 106 gave the 
coupling compounds 107 after 22-24 h in low yields (35-45%), whereas the protected 
alkynes 104 gave the target compounds in good yields (70-76%). 
                                                                                                                                                                                                                                                    
 
Scheme 3.8 
 
In summary, the use of Cul as a co-catalyst has been shown to give better results. A mole 
ratio of 2:1 copper to palladium has been shown to offer the best coupling conditions for 
alkynes, as the production of side products (cyclic furanopyrimidine) is minimized. It is 
noteworthy that performing the reaction in the presence of CuI has also reported to increase 
the conversion rate of by-products. The solvent employed has been reported to be an 
important determinant for successful coupling of terminal alkynes with iodonucleosides, with 
the use of DMF as a solvent having been shown to reduce the percentage of cyclic by-
product formed.165 A considerable percentage of this cyclized by-product was isolated when 
longer reaction times were employed or when an electron-withdrawing group on the 
nucleoside was present. Optimal conditions have been found to be 2.0-2.5 equiv of terminal 
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alkyne, 10% Pd(PPh3)4, 20% CuI and 1.2 equiv Et3N in DMF. Pd(0) has been reported to give 
better results than Pd(II).161 
 
 3.5 Route (A): Synthesis of target compounds 51, 78 and 79  
 
3.5.1 Synthesis of [d4U]-butyne-[HI-236] 51 
 
3.5.1.1 Synthesis of 5’-O-benzoyl iodo-d4U 
 
The 5’-O-benzoyl d4U derivative 112158c was synthesized in four steps as outlined in Scheme 
3.9 according to the Bristol-Mayers Squibb procedure for d4T.160 Thus, reaction of uridine 
with methanesulfonyl chloride (4.5 eq.) in pyridine furnished trimesylate 109181 in good yield. 
The product was isolated by adding the reaction mixture into ice-cold water, followed by 
filtration of the precipitate formed and washing the filter cake. Following extensive drying on 
the pump, the 1H NMR spectrum of 109 revealed the presence of the three mesylate methyl 
singlets resonating at H 3.35, H 3.33 and H 3.22, while its 13C NMR spectrum displayed 
resonances at C 38.0, C 37.9 and C 36.9 for the methyl carbons. 
 
The next step involved chemoselective transformation of the C-5’ centre as well as 
preparation of C-2’ for bromide substitution. Thus, the 2,2’-anhydrouridine 110181 was 
synthesized by treatment of 109 with sodium benzoate in acetamide at 132 oC. After 2 h, the 
product was poured into ice-cold water, stirred at 0 oC for 15 min and the solid filtered to give 
the target compound as a very insoluble paste in 77% yield. The 1H NMR spectrum of 110 
displayed the absence of an NH singlet at H 11.51 from 109 as well as the presence of 
additional resonances in the downfield region for the aromatic protons of the benzoyl group. 
Its 13C NMR spectrum displayed the appearance of a different carbonyl carbon at C 170.5 as 
well as aromatic carbons, confirming the presence of a benzoyl group, which could be 
assigned to the C-5’ position in view of the relative deshielding of the diastereotopic H-5’ 
protons. There was also a significant downfield shift in the C-2’ carbon from C 76.0 in 109 to 
C 86.0, thus suggesting that displacement of the mesylate and formation of the anhydro ring 
had taken place at this carbon. C-2’ over C-3’ attack by the pyrimidine base occurs in view of 
5-exo-tet cyclization being faster than the 6-exo-tet process as well as the C-3’ substitution 
forming a bridged compound.  
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Scheme 3.9 Reagents and Conditions: (i) MsCl (4.5 eq), pyridine, 0 oC, 5 h, 80%; (ii) PhCO2Na (3.5 
eq) CH3CONH2, 132 oC, 2 h, 77%; (iii) AcBr (4.0 eq), MeOH/EtOAc (1:10), reflux, 1 h, 86%; (iv) Zn 
(3.0 eq) MeOH, cat. (conc) H2SO4, rt, 15 min, 91%; (v) I2 (0.6 eq), CAN (0.5 eq), CH3CN, 35 oC, 4 h, 
82%. 
 
Acid-catalysed ring opening of 110 with nucleophilic attack by bromide ion at the 2’-position 
using acetyl bromide in MeOH/EtOAc (1:10) gave cis-bromomesylate 111182 in 86% yield. 
Introduction of the bromine atom was evident in the 1H NMR spectrum by virtue of an upfield 
shift in the H-2’ protons from H 5.69 in 110 to H 4.77 in 111. Similarly, the 13C NMR 
spectrum of 103 displayed an upfield shift of the C-2’ resonance from C 86.0 in 110 to C 
47.5 consistent with substitution by bromine. The mechanism of this reaction involves SN2 
displacement by bromide at C-2’ with a protonated pyrimidine ring as a leaving group. The 
net result is inversion of configuration to afford the syn stereochemistry shown in 111.  
 
For the reductive elimination of bromomesylate 111, zinc metal was employed in methanol. It 
was found that the reaction was accelerated by the addition of 2% (v/v) conc. HCl (15 min) 
compared to using acetic acid (3.5 h). This afforded the 5’-O-benzoate ester of d4U 112 in an 
excellent yield (91%) after chromatography, with no detectable cleavage of the nucleoside. 
The downfield shift of the C-2’ and C-3’ carbons in the 13C NMR spectrum of 112 from C 
47.5 and C 75.7 in 111 to C 127.1 and C 133.5 respectively, confirmed the introduction of 
the double bond via elimination of bromine and mesylate groups. Elimination of the mesylate 
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was further confirmed by the absence of the mesylate methyl carbon at C 38.7. Although 
syn-elimination is energetically more demanding than anti, undoubtedly the potent leaving 
ability of the sulfonyl group assisted the elimination over the alternative involving uracil.  
 
The CAN-mediated C-5 halogenation of uracil derivatives was first reported by Asakura et 
al.167 in 1990, in which molecular iodine as well as NaI and LiI were used as the iodine 
source. Ultimately in this work, iodination of 112 to its 5-iodo d4U 47142 was effected using 
elemental iodine and CAN at 35 oC to afford the product in 82% yield. This reaction was 
found to be heavily dependent on time and temperature. Thus, higher temperature and long 
reaction times led to isolation of a by-product due to migration of the benzoyl group from the 
C-5’-hydroxyl to the pyrimidine nitrogen. Iodination was confirmed by the 1H NMR spectrum 
which revealed the absence of a doublet at H 5.32 for H-5 as well as a downfield shift in H-6 
from H 7.33 in 112 to H 7.73. H-6 also appeared as a singlet in the 1H NMR spectrum of 47. 
The 13C NMR spectrum of 47 revealed that C-5 had shifted upfield from C 102.6 in 112 to C 
69.6, consistent with the presence of iodine at C-5. The double bond resonances were still 
intact, confirming that iodination of the double bond had not taken place.  
 
3.5.1.2 Sonogashira coupling, deprotection and condensation  
 
Sonogashira coupling of 5-iodo-5’-O-benzoyl d4U 47 with alkyne 70c, which had been 
successfully synthesized and already discussed (Figure 2.6, Chapter 2) yielded the desired 
coupled product 48 in 69% within 4 h at room temperature (Scheme 3.10). The conditions of 
using Pd(0) catalyst (10%), CuI (20%) and NEt3 (2 eq) in DMF as already described were 
used throughout the project. The 1H NMR spectral data for 48 revealed signals for both the 
alkynyl and d4U moieties in a ratio of 1:1. A successful coupling was further supported by the 
absence of an alkyne proton at around H 2.04. The 13C NMR spectrum of 48 displayed 
diagnostic resonances at 141.6 (C-6), 150.5 (C-1”), 100.7 (C-2’”), 91.3 (C-1’”), C 90.1 (C-1’), 
72.4 (C-5), 40.6 (C-2””’) and 1.40 (OC(CH3)3 confirmed by 2D NMR. The HMBC spectrum 
revealed a correlation between the methylene protons at H 2.68 (H-3”’) with the carbons at 
C 100.7 (C-2”’), 91.3 (C-1”’), 72.4 (C-5), 66.6 (C-4”’) and 28.4 (OC(CH3)3. The mass 
spectroscopy data also confirmed that the coupling had taken place. 
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Scheme 3.10 Reagents and Conditions: (i) alkyne 70c, (PPh3)4Pd (10%), CuI (50%), Et3N (2 eq), 
DMF: THF (1: 2),  rt, 4h, 69%; (ii) TFA, CH2Cl2, 0 oC; (iii) EtN(i-Pr)2 followed by 49, THF, rt, 18 h, (60% 
for 2 steps); (iv) NaOMe (cat), MeOH, 0 oC, 20 min, 51%.  
 
With 48 in hand, the key condensation/deprotection steps required extensive optimization 
and the isolation conditions proved critical to ensure a reproducible result. Eventually, it was 
found that using trifluoroacetic acid in methylene chloride at 0 oC furnished the crude amine 
as a triflate salt. The reaction could be monitored by tlc to form a very polar primary amine 
spot (Rf = 0.3 in 5% MeOH in CH2Cl2). Since the product could not be extracted from water 
into an organic solvent, work-up involved adding Hünig’s base to liberate the amine. The 
solvent was evaporated and dried on a vacuum pump. The crude amine was then 
condensed directly with thiocarbonyl derivative 49 in THF at rt for 20 h to afford the desired 
product 50 in 60% yield for the two steps. Interestingly, these conditions contrast with the 
much harsher ones reported by Bell101 of heating at 100 oC for 1 h in DMF. The 1H NMR 
spectrum of 50 displayed  diagnostic signals for two thiourea NH signals at H 10.92 and H 
9.75, the H-3”’ propargylic methylene diastereotopic protons at H 3.03, H 2.88 and the 
aromatic methoxy at H 3.79. Its 13C NMR spectrum showed the presence of a thiocarbonyl 
carbon at C 179.1 as well as  C-Br at C 111.1, C-6 at C 141.2, OCH3 at C 55.5 and C-1”’” at 
C 20.9. The IR spectrum also revealed the presence of a C=S stretch at 1461 cm-1 and a 
C≡C  stretch at 2254 cm-1. High resolution mass spectrometry data also confirmed the 
molecular ion of 50.  
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3.5.2.3 The end-game 
 
The final step of the synthesis was deprotection of the benzoyl group to afford the target 
molecule 51142. Considerable optimization of conditions was needed and the reaction was 
clearly sensitive to cleavage of the sugar residue. This could be monitored by 1H NMR and 
integration of the two drug moieties. Unfortunately, the cleaved product eluted with 50. 
However, eventually, efficient debenzoylation could be achieved in a satisfactory manner 
with sodium methoxide (cat) in methanol at 0 oC. The reaction was monitored carefully by tlc 
to reveal the formation of a polar spot (Rf = 0.4 in 10% MeOH in CH2Cl2). The reaction was 
quenched using a few drops of acetic acid, followed by solvent removal and direct flash 
chromatography in view of the nucleoside’s solubility in water. Ultimately, this gave the 
deprotected compound 51 in 51% yield. The 1H NMR resonance for 51 exhibited an 
expected upfield shift for the H-5’ methylene protons to H 3.80 as a result of a loss in the 
deshielding effect of the carbonyl group. Similarly, the 13C NMR spectrum of 51 displayed the 
absence of the carbonyl carbon at C 166.3 and an upfield shift of C-5’ from C 65.3 in 50 to 
C 62.9 in 51. Otherwise, all of the other resonances were present in similar places to 50, and 
the product structure was also confirmed by mass spectrometry.  
 
3.5.2 Synthesis of [d4U]-monoPEG-propyne-[HI-236] 78 
 
For structure-activity purposes, It was decided to turn towards synthesizing a family of 
flexible bifunctional systems with longer spacers. A polyethylene (PEG) unit was chosen as 
the repeating unit in view of its synthetic accessibility as well as its promotion of water 
solubility.  
Synthesis of [d4U]-monoPEG-propyne-[HI-236] 78 was accomplished using the methodology 
described for 51. Specifically, palladium (0) cross-coupling of alkyne 70k (described in 
Scheme 2.14, Chapter 2), with 47 afforded the coupled compound 113 in 76% yield after 
column chromatography (Scheme 3.11).  
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Scheme 3.11 Reagents and Conditions: (i) alkyne 70k, (PPh3)4Pd (10%), CuI (50%), Et3N (2 eq), 
DMF: THF (1: 2), rt, 4h; 76%; (ii) TFA, CH2Cl2, 0 oC; (iii) EtN(i-Pr)2 followed by 49, THF, rt, 18 h 60% 
(for 2 steps); (iv) NaOMe (cat), MeOH, 0 oC, 20 min, 69%.  
 
The 1H NMR spectrum of 113 revealed (see Figure 3.5) the disappearance of the alkyne 
proton at H 2.45 in 70k. Some of the resonances for 113 derived from 47 and 70k included a 
singlet at H 7.68 (1H, H-6), a multiplet for the anomeric sugar proton (1H, H-1’) at H 6.92, a 
singlet at H 4.27 (2H, H-3”’), a singlet at H 3.73 (3H, OCH3) and a multiplet at H 3.33 (2H, H-
2””’). The 13C NMR spectrum displayed diagnostic signals for the alkyne carbons at C 90.0 
for C-1”’, C 99.9 for C-2”’, C 55.6 for OCH3, C 30.8 for C-1””’ and the anomeric carbon of the 
sugar (C-1’) at C 90.8. 
 
 
 
                                Figure 3.5 A portion of 1H NMR (CDCl3) spectrum of compound 113.  
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The Boc group of 113 was deprotected employing trifluoroacetic acid in methylene chloride 
as before and the resultant amine condensed with thiourea derivative 49 in THF at rt to 
furnish 114 in 60% yield after chromatography for the two steps. The 1H and 13C NMR 
spectra of compound 114 revealed the absence of resonances for the Boc group. The 1H 
NMR spectrum revealed the three desired NH peaks at H 10.82, H 9.00, and H 8.84, the H-
3”’ at H 4.25, OCH3 at H 3.75, H-6””” at H 8.03 and H 7.70 for H-6. The 13C NMR spectrum 
confirmed the presence of a thiocarbonyl carbon at C 179.2, C-Br at C 112.5, C-6 at C 
142.6, OCH3 at C 55.6 and C-1”’” at C 30.8. The parent ion was found to be 776.1379 (M+ + 
H) correlating to a correct molecular formula of C36H35N5O8SBr, thus confirming the formation 
of 114.  
 
The benzoyl group on 114 was once again successfully deprotected using the standard 
established conditions of NaOMe (cat) in MeOH to give the target molecule 78 in 69% yield 
after purification by column chromatography. The structure of compound 78 was 
unequivocally assigned on the basis of its spectroscopic data, using a combination of both 
1D and 2D 1H and 13C NMR as well as IR techniques and high-resolution mass spectrometry. 
The 1H and 13C NMR spectra of 78 revealed the absence of resonances for the benzoyl 
group. Interestingly H-6 shifted downfield in the free nucleoside suggesting shielding of it in 
benzoate 114 by the phenyl group. In addition, the 1H NMR spectrum (see Figure 3.6) in 
CDCl3 revealed that H-5’ had moved upfield from H 4.68 and H 4.54 in 114 to between H 
4.06-3.78 in 78, indicating that debenzoylation had taken place. The three NH resonances for 
the thiourea and imide were discernible downfield between 9 and 11 ppm. The appearance 
of a broad singlet at H 3.36 corresponding to a hydroxyl group, supported the absence of a 
benzoate ester. Importantly, 78 showed a correct integration for the two drug fragments with 
no loss of sugar. Generally, the longer the spacer, the more stable the bifunctional became. 
Further evidence was given in the 13C NMR spectrum, which displayed an upfield shift in the 
resonance of C-5’ from C 65.1 in 114 to C 62.8 as well as the absence of the carbonyl 
carbon at C 166.3. Overall, the carbon spectrum returned the correct number of resonances 
29. Furthermore, the mass spectrometry data correlated with the molecular formula (HRMS 
(ES): m/z found 672.1139 (M+ + H), C29H31N5O7SBr requires (M+ + H) 672.1128).  
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                                         Figure 3.6 1H NMR (CDCl3) spectrum for compound 78. 
 
 
3.5.3 Synthesis of [d4U]-diPEG-propyne-[HI-236] 79 
 
The synthesis of the next homologue as bifunctional [d4U]-diPEG-propyne-[HI-236] 79 was 
carried out using a similar procedure as described above (Scheme 3.11) for 78. The 
Sonogashira coupling of 47 with alkyne 70l, which was successfully synthesized before 
(Scheme 2.21, Chapter 2) yielded the desired coupling product 115 within 4 h at room 
temperature in 72% yield (Scheme 3.12). Tlc showed the product to be more polar than the 
previous product 113, but the similar profile as before helped to follow the reaction.    
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Scheme 3.12 Reagents and Conditions: (i) alkyne 70l, (PPh3)4Pd (10%), CuI (50%), Et3N (2 eq), 
DMF: THF (1: 2), rt, 4h, 72%; (ii) TFA, CH2Cl2, 0 oC; (iii) EtN(i-Pr)2 followed by thiourea 49, THF, rt, 18 
h, 63% (for 2 steps); (iv) NaOMe (cat), MeOH, 0 oC, 20 min, 54%.  
 
The 1H NMR spectral data for 115 (Fig. 3.7) as expected showed the lack of an alkyne proton 
at around H 2.40. Some important resonances in the 1H NMR spectrum of 115 included the 
peaks at H 6.92 for H-1’, H 7.68 for H-6, H 4.25 for H-3”’, H 3.75 for OCH3 and H 2.80 for H-
1””’. A highfield singlet for the Boc t-butyl group could be clearly seen at H 1.43. Similarly, its 
13C NMR spectrum displayed corresponding resonances at C 90.7 for (C-1’), C 142.2 for C-
6, C 58.9 for C-3”’, C 55.6 for OCH3 and C 31.0 for C-1””’. Importantly, no cleavage of the 
sugar moiety was observed in that the double bond protons H-2’ and H-3’ integrated 
relatively for one proton each. 
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                                       Figure 3.7 A full 1H NMR (CDCl3) spectrum for compound 115.  
 
Deprotection of the Boc group and condensation with thiourea derivative 49 (Scheme 3.12) 
was carried out for compound 115 using the standard procedure that was described before, 
to  afford the desired product 116 in 63% yield over the two steps after column 
chromatography. Once again, the 1H and 13C NMR spectra of 116 were consistent with 
desired changes. The 1H NMR spectrum (Fig. 3.8) showed resonances for the two new NH 
protons at H 11.01 and H 9.29 as well as H 6.91 for H-1’, H 4.21 for H-3”’, H 3.74 for OCH3 
and H 3.98 for H-2””’, with correct relative integrations. The individual six protons of both the 
pyridine and aromatic ring could be discerned. The pyrimidine proton H-6 appeared, as 
expected, relatively shielded by the benzoate phenyl group at H 7.67 consistent with other 
cases.  
 
 
 
 
                                  Figure 3.8 A full 1H NMR (CDCl3) spectrum for compound 116. 
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The 13C NMR spectrum for compound 116 revealed the presence of a thiocarbonyl carbon at 
C 179.2, C 112.5 for C-5”””, C 55.5 for OCH3, C 90.8 for C-1’ and C 90.1 for C-1”’ as well as  
four OCH2 carbons as shown in Figure 3.9.     
                                            
 
 
 
 
 
 
                            Figure 3.9 A portion of 13C NMR (CDCl3) spectrum for compound 116. 
 
With 116 in hand, only benzoyl deprotection remained for synthesis of the target molecule 
79, which was carried out using the same conditions as above (NaOMe (cat) in MeOH at 0 
oC), to afford the target 79 with retention of the sugar moiety in 54% after column 
chromatography, as revealed by relative integration. The 1H and 13C NMR spectra of 79 
revealed the disappearance of the benzoyl group, (Fig. 3.10) as well as an upfield shift for 
the diastereotopic protons H-5’ from H 4.67 and H 4.50 in 116 to between H 3.66-3.56 in 
79. The appearance of a triplet at H 4.94 corresponding to a hydroxyl group confirmed the 
absence of a benzoate ester. H-6 of the pyrimidine ring now appeared downfield at H 8.10 
consistent with the benzoyl group shielding mentioned previously. As with the shorter pegged 
bifunctional 78, the three NH resonances could be clearly discerned but even more downfield 
than before. The 13C NMR spectrum displayed the absence of a carbonyl carbon at C166.2 
as well as an upfield shift of the C-5’ resonance from C 65.1 in 116 to C 61.7. Four 
methylene singlets 69.5 (OCH2), 68.9 (OCH2), 68.5 (OCH2), 68.2 (OCH2), could be seen for 
the peg. Further evidence was given by mass spectrometry data, HRMS (ES): 716.1389 (M+ 
+ H), which correlated with the molecular formula of C31H35N5O8SBr. 
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                              Figure 3.10 A portion of 1H NMR (CDCl3) spectrum of compound 79. 
 
3.6 Route (B): Synthesis of target compounds 80 and 81 
 
 3.6.1 Synthesis of [d4U]-tetraPEG-propyne-[HI-236] 80 
 
Extending the sequence to the 4-PEG tether give the first signs of breakdown. Thus, the 
Sonogashira coupling of iodo-d4U 47 with alkyne 70r, which had already been synthesized 
(Scheme 2.21, Chapter 2) gave the coupling product 117 in 70% yield (Scheme 3.13). Its 
structure was confirmed by 1H NMR spectroscopy, which showed all the expected 
resonances in much the same position as the mono-and 2-PEG derivatives (113 and 115) 
except with the appearance of the additional signals for the extra PEG groups. The coupling 
product 117 was then subjected to the standard deprotection conditions of TFA in DCM 
followed by condensation with thiourea derivative 49 using the standard procedure. However, 
following product isolation, the 1H NMR spectrum of the reaction product revealed the 
absence of the sugar moiety, indicating that cleavage of the sugar had taken place and that 
the product was not 119. This step was extensively optimized in different way by minimizing 
trifluoroacetic acid equivalents and carrying out the reaction at various (lower) temperatures, 
but the cleavage persisted.  
A plausible explanation for the cleavage relates to the leaving ability of a protonated 
pyrimidine base being favoured by the allylic bond resonance in the sugar ring helping to 
stabilize the resultant oxocarbenium ion as shown in Scheme 3.14. The cleavage was only 
observed for the 4-PEG derivative for reasons unknown. 
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Scheme 3.13 Reagents and Conditions: (i) alkyne 70r, (PPh3)4Pd (10%) CuI (50%), Et3N (2 eq), DMF: 
THF (1: 2), rt, 4h, 70%; (ii) TFA, CH2Cl2, 0 oC; (iii) EtN(i-Pr)2 followed by thiourea 49, THF, rt, 18 h.  
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                                  Scheme 3.14 Plausible mechanism for degradation of 117. 
 
Since Sonogashira coupling reactions are documented to proceed in the presence of 
unprotected hydroxyl and amino groups,165,168 It was decided to deprotect the Boc group of 
70r to the amine first, and then react under Sonogashira coupling conditions. Condensation 
with thiourea derivative 49 followed by benzoyl deprotection would then afford the target 
product. To this end, deprotection of alkyne 70r using trifluoroacetic acid in DCM at 0 oC 
gave a very polar primary amine spot (Rf = 0.9 in 10% MeOH in CH2Cl2). Since the product 
could not be extracted from water into an organic solvent, work-up involved adding 
anhydrous K2CO3 in MeOH, filtering  and evaporating to liberate the crude amine 118, which 
was used in the next step without further purification. Sonogashira coupling of iodo-d4U 47 
with amine 118 carried out using the same conditions above yielded a coupling product 
according to tlc, which was subjected to column chromatography employing EtOAc / MeOH / 
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Et3N (5 / 4 / 1). The amine product was then condensed with thiourea derivative 49 in THF at 
room temperature for 20 h. Following evaporation of solvent, the residue was subjected 
directly to column chromatography to afford the desired product 119 in 40% over the three 
steps (Scheme 3.15). 
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Scheme 3.15 Reagents and Conditions: (i) TFA, DCM, 0 oC, 2 h, K2CO3; (ii) 47, (PPh3)4Pd (10%), CuI 
(50%) Et3N (2 eq), DMF: THF (1: 2), rt, 4h; (iii) followed by thiourea 49, THF, rt, 18 h, 40% (for the 3 
steps); (iv) NaOMe (cat), MeOH, 0 oC, 20 min, 52%. 
  
Given the spectral information on the other adducts already available, it was reasonably 
straightforward to confidently conclude that the desired product 119 had been formed. The 
1H and 13C spectra of 119 are shown in Figures 3.11 and 3.12, and pleasingly they reveal a 
very pure sample. 
 
With 119 in hand, deprotection of the benzoyl group using the same conditions as described 
before (NaOMe (cat) in MeOH at 0 oC) was carried out to give the target molecule 80 in 52% 
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yield, with spectral data consistent with previous assignments. The structure of compound 80 
was unequivocally assigned on the basis of its spectroscopic data using a combination of 
both 1D and 2D 1H and 13C NMR as well as IR techniques and high-resolution mass 
spectrometry. The 1H and 13C NMR spectra of 80 revealed the absence of resonances for the 
benzoyl group. The 1H NMR spectrum in d6 DMSO (Fig. 3.13) revealed an upfield shift for the 
H-5’ protons from H 4.70 and H 4.52 in 119 to between H 3.60-3.47, indicated that 
debenzoylation had taken place. The appearance of a triplet at H 5.02 corresponding to the 
hydroxyl group supported the absence of a benzoate ester. As expected, the three pyridine 
ring signal were downfield to those for the aromatic ring. Integration of sugar signals to those 
for HI-236 confirmed a 1:1 ratio. The 13C NMR spectrum (Fig. 3.14) displayed the absence of 
a carbonyl carbon at C166.2 as well as an upfield shift in the C-5’ resonance from C 65.0 in 
119 to C 61.7. For HRMS (ES), the parent ion was found to be 804.1932 (M+ + H) correlating 
to the correct molecular formula of C35H43N5O10SBr (requires (M+ + H) 804.1914), thus 
confirming the formation of 80.  
 
 
3.6.2 Synthesis of [d4U-phoshoramidate]-tetraPEG-propyne-[HI-236] 81 
 
3.6.2.1 Sythesis of iodo-d4U-phosphoramidate. 
 
It was decided to convert the [d4U]-tetraPEG-propyne-[HI-236] bifunctional molecule 80 into 
a phosphoramidate prodrug 81 in an attempt to improve inhibitory activity. The main idea as 
discussed in Chapter 1 was to bypass the rate-determining first step by virtue of having one 
phosphate in place, thus facilitating formation of the triphosphate in vitro.169 A McGuigan-type 
phosphoramidate170,171 was chosen initially in view of its proven biological track-record as well 
as the prospect of realising it in a one-pot reaction in a straightforward manner via conditions 
compatible with the bifunctional. The 4-PEG derivative was the one chosen in view of its 
length being perceived as optimal for reaching the DNA site.   
 
The first approach, therefore, involved attempting to directly phosphorylate bifunctional 
nucleoside 80 with phosphorochloridate 121172, itself readily prepared from p-methylphenol 
and phosphorous oxychloride followed by substitution with L-alanine methyl hydrochloride 
ester according to McGuigan’s original protocol.172,173 However, reaction of 121 with 80 failed 
to give the desired product 81 (Scheme 3.16) and only degradation of the starting material 
was observed on the tlc.     
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     Scheme 3.16 Reagents and Conditions: (i) N-Methylimidazole, THF, rt, 24 h.  
 
Thus, it was decided to pursue a synthesis involving a convergent Sonogashira coupling of 
an iodo-nucleotide as its phosphoramidate with an alkynylated version of HI-236. Given the 
problems of coupling with the thiourea moiety intact as well as a lack of confidence of Boc 
removal with TFA in the presence of the phosphoramidate, it was decided to use amine 118 
in the strategy just described in Scheme 3.15.  
 
For the synthesis of the nucleotide coupling partner, deprotection of the benzoyl group of 5’-
O-benzoyl iodo-d4U 47 using NaOMe (1.0 eq.) in MeOH was carried out to give the desired 
product 122183 in a good yield and as a more polar product on tlc Scheme 3.17. The 1H and 
13C NMR spectra of 122 displayed the absence of resonances for the benzoyl group, while its 
1H NMR spectrum displayed an upfield shift of H-5’ from H 4.52 in 47 to H 3.62, indicating 
that debenzoylation had taken place. The appearance of a triplet at H 5.01 corresponding to 
the hydroxyl group, supported the presence of a primary alcohol. Further evidence was given 
in the 13C NMR spectrum which displayed an upfield shift in the C-5’ resonance from C 65.3 
in 47 to C 61.5 as well as the disappearance of the ester carbonyl carbon at C 165.5. 
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Scheme 3.17 Reagents and Conditions: (i) NaOMe (1.0 eq), MeOH, 0 oC-rt, 2 h, 74%. 
 
Following the method described by McGuigan et. al.,172,173 p-methylphenol was reacted with 
phosphoryl chloride in diethyl ether and triethylamine to afford the aryl phosphorodichloridate 
120172 in 81% after vacuum istillation (bp 85-90 oC, 0.1 mmHg), (lit. bp 80-85 oC, 0.1 mmHg) 
as shown in Scheme 3.18. The product was also confirmed using 1H and 31P NMR 
spectroscopy data which corresponded to that of the literature.172   
p-Methylphenyl phosphorodichloridate 120 was allowed to react with alanine methyl ester 
hydrochloride in dichloromethane in presence of triethylamine to give p-methylphenyl 
methoxyalaninyl phosphorochloridate 121 as a colourless oil in 100%, which was used in the 
next step without further purification (Scheme 3.18).  
 
Scheme 3.18 Reagents and Conditions: (i) Et3N (1 eq), Et2O, 0 oC-rt, 17 h, 81%; (ii) DCM, Et3N (2 eq), 
 -78 oC–rt , 14 h, 100%. 
 
Chloride 121 was then reacted with iodo-d4U 122 in THF in the presence of N-
methylimidazole to give the desired compound 123 as a (1:1) mixture of diastereoisomers in 
a 54% yield after purification by column chromatography (Scheme 3.19). The 1H NMR 
spectrum of 121 revealed split peaks at H 6.38, 6.32 for (dt, H-3’), between H 4.46-3.82 for 
(m, H-5’), at H 3.72, 3.71 for (s, OCH3) and at H 1.41, 1.36 for (d, Ala-CH3) due to 
diastereoisomers at the phosphoramidate centre.  The additional aromatic resonance at H 
7.11 for the new phenyl ring also confirmed substitution. The 13C NMR spectrum also 
revealed split peaks due to diastereoisomers (starred) for (CO2Me) 173.9*, (C-3”, C-5”) 
133.0*, (C-5’) 66.6*, (Ala-OCH3) 52.4* and (ArCH3) 20.8* (given as an average). Further 
evidence of substitution to 121 was provided by the 13P NMR spectrum which displayed two 
closely-spaced singlets at δP 3.7, 3.5 (1:1).  
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                Scheme 3.19 Reagents and Conditions: (i) N-Methylimidazole, THF, rt, 24 h, 54%. 
 
Finally, the phosphoramidate bifunctional 81 was achieved by Sonogashira coupling of 
amine 118, which was obtained via Boc deprotection of alkyne 70r (Chapter 2, Scheme 2.21) 
with iodo-d4U-phosphoramidate 123. The work-up of the product involved extracting with the 
polar solvent system of MeOH: CHCl3 (1: 4), which was washed with 5% aq. disodium EDTA 
and water to remove copper (II) salts. The crude product was flashed through a silica-gel 
column to afford the coupled amine product, which was reacted with thiourea derivative 49 at 
room temperature for 20 h. The solvent was evaporated and the residue was subjected 
directly to column chromatography to give the target compound 81 as a mixture of 
diastereoisomers (1:1) in 20% yield over the three steps (Scheme 3.20). 
 
N
OO
N
O
O
H I
P
NH
O
CO2Me
O
123
OMe
OOOOO
H NHBoc
OMe
OOOOO
H NH2
1'4'
5'
2
4
6
2""3""
1'" 2
'" 3'" 6'"
1"
1""'
2"""
4"""
9"'
i
ii
N
H
NH
N
Br
S
O
OMe
OOOON
OO
N
O
O
H
P
NH
O
CO2Me
O
70r
118
81
N N
Br
N
N
S
H
49
iii
 
Scheme 3.20 Reagents and Conditions: (i) TFA, CH2Cl2, 0 oC, K2CO3, 2h, rt; (ii)123, (PPh3)4Pd (10%) 
CuI (50%), Et3N (2.0 eq), DMF: THF (1: 2), rt, 4h; (iii) K2CO3 followed by thiourea 49, THF, rt, 18 h, 
(40% over the 3 steps). 
 
A combination of both 1D and 2D 1H, 13C and 31P NMR techniques were used to assign the 
structure of compound 81 as well as IR spectroscopy and high-resolution mass 
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spectrometry. The 1H and 13C NMR spectra for compound 81 revealed that some peaks were 
split due to diastereoisomers as a result of stereogenicity at phosphorus as expected. 
Notably, some important 1H NMR chemical shifts are shown in Table 3.1 and Figure 3.15. 
The 13C NMR spectrum displayed resonances at 179.2 for C=S, 173.9* for CO2Me, 66.7 for 
(d, Jcp = 4.5 Hz, C-5’), 99.9 for C-2”’, 91.3* for C-1’, 58.9 for C-3”’, 55.6 for OCH3, 52.5 for 
CO2CH3, 50.3* for Ala-CH, 29.8 C-1””’ and 20.7 Ph-CH3 with starred peaks as an average for 
the diastereoisomers. The 31P NMR spectrum revealed two closely-spaced singlets at δP 3.63 
and 3.56 in 1:1 ratio (Fig. 3.16). The IR spectrum of 81 indicated a characteristic peak for 
C=S at 1462 cm-1, for C=O at 1707 cm-1 and for P=O at 1259 cm-1.  Finally, a correct HRMS 
evaluation established in structure of 81 (m/z HRMS (ES) found 1059.2548 (M+ + H), 
C46H57N6O14SBrP requires (M+ + H) 1059.2574). 81 is the second reported phosphoramidate 
of a bifunctional HIV inhibitor following those of Camarasa.135  
 
 
                        Table 3.1 Some Important split resonances in the1H NMR spectrum of 81 
 
    
      H 
     
 Multiplicity and Assignment  
 
      H 
 
 Multiplicity and Assignment   
 
 
   
   7.79, 7.78 
 
             
            1H, s, H-6 
 
 
5.91, 5.81 
 
 
               1H, dq, H-2’ 
 
   
   7.66, 7.63 
 
 
1H, dd, H-4””” 
 
 
3.68, 3.67 
 
 
 3H, s, CO2CH3 
 
 
6.96, 6.94 
 
 
            1H, m, H-1’ 
 
 
1.37, 1.33 
 
 
3H, d, Ala-CH3 
 
 
6.37, 6.27 
 
 
            1H, dt, H-3’ 
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                           Figure 3.15 A portion 1H NMR (CDCl3) spectrum of compound 81. 
 
 
 
 
 
                                   Figure 3.16 31P NMR (CDCl3) spectrum of compound 81. 
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3.7 Biological results and rationale 
 
The following experimental applies for biological work carried out at Yale University. dTTP 
and dGTP were purchased from GE Biosciences.  Oligonucleotide primers and template 
were synthesized at the Keck Facility at Yale University and were purified using 20% 
denaturing gel-electrophoresis.  Primers and template used in this study are as follows: D23 
(5’-TCA GGT CCC TGT TCG GGC GCC AC -3’), D24 (5’-TCA GGT CCC TGT TCG GGC 
GCC ACT-3’), and D36 (5’-TCT CTA GCA GTG GCG CCC GAA CAG GGA CCT GAA AGC-
3’).  Labeling and annealing of primer/templates were performed as described.174 
  
Expression and Purification of HIV-1 RT.  C-terminal histidine tagged heterodimeric 
p66/p51 wild-type HIV-1 RT was expressed and purified as described previously175 using a 
clone generously provided by Stephen Hughes, Paul Boyer, and Andrea Ferris (Fredrick 
Cancer Research and Development Center, Fredrick, MD).   
 
IC50 determination. 8 nM RT (active sites based on pre-steady state active site 
determination) was pre-incubated for at least 15 minutes with 1 μM 5'-labeled 
primer/template prior to mixing with appropriate concentrations of inhibitor and allowed to 
incubate for a minimum of 15 additional minutes on ice. DMSO concentrations were kept 
constant at less than 2%. DMSO alone was added as a no inhibitor control for each set of 
experiments.  Reactions were initiated with the addition of 5 μM dNTP and 10 mM MgCl2 and 
were quenched after 15 minutes at 37° C with 0.3 M EDTA. All concentrations represent final 
concentrations after mixing.  Reaction products were subjected to 20% denaturing 
polyacrylamide gel-electrophoresis and quantitated on a Bio-Rad Molecular Imager FX.  
Product formation was plotted as a function of inhibitor concentration and fitted to a 
hyperbola to generate IC50 curves.  IC50 values are defined as the concentration of inhibitor 
that inhibits steady-state single nucleotide incorporation by 50%. 
 
 
The inhibitory activity of the bifunctional compounds 51, 78, 79, 80 and 81 was explored 
against HIV-1 (IIIB) replication in MT-2 cell culture using an MTT assay. The results are 
shown in Table 3.2. HI-236 and d4T were also evaluated for comparison purposes. The 
bifunctional [d4U]-butyne-[HI-236] 51 showed a good inhibitory activity of EC50 = 250 nM, 
which is eight times greater than d4T (EC50 = 2 μM), five times less active than HI-236 and 
thus between those of the two component drugs.  
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Table 3.2 Comparison of cell-culture versus in vivo RT inhibition (nM) for bifunctional compunds.  
                                                                                                               Cell culture   RT Enzyme assay    
 HI-236 
  
 0.058 μM      38 ±  7 nM 
    51 
  
 
 
 
   0.25 μM     61 ± 15 nM 
     78 
 
   1.3 μM 
  940 ± 580 nM  
  575 ± 137 nM 
     79 
  
   950 nM  850 ± 140 nM 
    80 
  
   3.1 μM 
  1.4 ± 0.9 μM 
  1.4 ± 0.5 μM 
    81 
   
    2.9 μM 
  4.7 ± 2.7 μM 
   2.3 ± 0.8 μM 
 
    
    d4T 
 
     2 μM        Not done 
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Lengthening the spacer resulted in a reduction in activity, perhaps as expected, except with 
the 2-PEG derivative 79 being more active than the 1-PEG derivative 78. The 4-PEG 
derivative 80 still retained appreciable activity (3.1 μM), remarkably so for such a large 
molecule. Disappointingly, the phosphoramidate 81 showed no improvement, effectively 
indicating a promotion of triphosphate formation not to be operating, and hence the activity to 
be due to the NNRTI part only. 
 
Similarly, the in vitro RT assay results are shown in Table 3.2. These experiments are based 
on following the inhibition of Th-TP (Thymidine triphosphate) incorporation by the bifunctional 
into a primer strand (D23) of a short dsDNA primer/template (D23/D36) against an A coding 
on the template strand, see Figure 3.17.    
 
 
             Figure 3.17 Schematic representation of correct base-pairing and incorporation experiments. 
 
Certainly, the results in Table 3.2 from the enzyme assay support the expectation that the 
NRTI component of the bifunctional is being recognised as a “T” and getting incorporated in 
order to inhibit the incorporation of Th-TP. The in vitro RT inhibition results followed a similar 
trend, to those of the cell-culture except IC50 values (now directly on the enzyme) were 
generally indicative of greater potency compared to the cell-culture results. Once again, 
though, in spite of a large error factor in the results, phosphoramidate 81 proved to be no 
more active than its unphosphorylated precursor 80. 
 
In conclusion, the retention of activity in the double drugs suggests that one should view 
these inhibitors as substituted NNRTI’s involving NNRTI binding with the tether exiting the 
pocket (maybe 51 can be completely in the pocket), leaving the NRTI in vicinity of the 
substrate binding site or somewhere between the two sites. NNRTI binding seems likely 
since d4T itself is only active at an EC50 of around 2 μM, and such a large “substituted NRTI” 
would be expected to be far less active based on NRTI activity alone. Furthermore, in the 
model study, HI-236 ester derivative 77g was 12 μM as a much poorer but very much 
smaller binder suggesting these bifunctionals must be achieving binding in the NNRTI 
pocket. However, the phosphoramidate result for 81 suggests conversion to a triphosphate is 
not operating via a pronucleotide involvement and thus, no mixed-site inhibition is being 
realised. The NNRTI of such bifunctionals cannot go through the “back” of the pocket 
5’-TCTCTAGCAGTGGCGCCCGAACAGGGACCTGAAAGC-3’ 
* 3’- CACCGCGGGCTTGTCCCTGGACT-5’ 
Th-TP / Bif-TP 
D23/D36 
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because the molecules are not configured correctly, thus NNRTI binding must occur in the 
normal way through the “front” end.  
However, bifunctional 51, 78 and 78 compounds are much superior to the d4U dimers (with 
Trovirdine) by Ladurée and co-workers,128 which were inactive. Their results indicated an 
incorrect choice of attachment point of the NNRTI to the tether, and lend some credibility to 
our hypothesis that our HI-236 system can exit the pocket and still retain activity.  
In view of the lack of success with the phosphoramidate 81, at this point it was decided to 
change the NRTI to an acyclic nucleotide phosphonate, which is the topic of the final 
Chapter.        
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CHAPTER 4: SYNTHESIS OF [ANP]-SPACER-[HI-236] 
 
Results from the bifunctional [d4U]-spacer-[HI-236] inhibitors described in Chapter 3 
indicated that the d4U was not converted to its triphosphate in cell-culture and thus it was 
decided to change it to an acyclic nucleotide phosphonate (ANP) for two reasons. Thus, 
although a more flexible system would have a greater entropy penalty on binding, the hope 
was that this would be offset by the bifunctional finding a more favorable binding enthalpy in 
view of greater conformational freedom. Secondly, a phosphonate would qualify as a 
pronucleotide and have the advantage of by-passing the rate-determining first 
phosphorylation step.   
It was decided to synthesize double-drugs of the general formula [ANP]-spacer-[HI-236] as 
shown in Figure 4.1.  
 
 
 
 
                                              
 
 
 
 
                                               Figure 4.1 General formula [ANP]-spacer-[HI-236] 
 
The choice of a model prototype for the ANP in (Fig. 4.1) was made for simplicity sake as 
well as the possibility of using the uracil chemistry developed in the project. Thus, the ANP 
base was chosen as uracil rather than cytosine (Cidofovir) or adenine (Tenofovir) as shown 
in Figure 4.2. 
 
 
 
 
 
 
 
 
 
                                         Figure 4.2 Structures of Cidofovir and Tenofovir 
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Similarly, the chiral centre in the side chain was omitted. Finally, a phosphate ester was 
chosen as the simplest option for a pro-drug,176 but we were well aware of the possible need 
for better (cleavable) groups such as POM or POC. As before, a peg spacer was chosen for 
connection of the two drugs. Long spacers were chosen to probe flexibility.   
 
4.1 Synthesis of [ANP]-n-PEG-propyne-[HI-236]: (n = 4 and 6) 
4.1.1 Retrosynthetic analysis of [ANP]-n-PEG-propyne-[HI-236]  
 
The synthesis of the ANP-incorporated bifunctionals 134 and 135 with medium-length (n = 4) 
and long spacers (n = 6) respectively was envisaged as being achievable via a condensation 
reaction between thiourea 49 and a convergently-derived Sonogashira coupling product from 
tethered amine 118 (or 133) and pyrimidine-tethered phosphonate 132 as shown in Fig. 4.3.  
N N
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                   Figure 4.3 Retrosynthetic analysis of ANP incorporated bifunctionals 134 and 135. 
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An amine-based Sonogashira coupling was preferred because the favored N-Boc-based 
coupling presented a potential problem with TFA deprotection regarding the phosphonate 
protecting groups.  Phosphonate 132 would be generated from CAN iodination of 131, which 
in turn would be prepared from 1N-alkylation of unprotected uracil 130 by a modified two-
carbon tethered phosphonate of type C. The latter was envisaged as available via alkylation 
of protected alcohol 73 by phosphonate 126. Known chemistry in the form of the Pudovik 
reaction would be employed for the synthesis of 126. 
 
4.1.2 Synthesis of the ANP moiety 
 
The synthesis towards 5-iodo-ANP 132 began with esterification of phosphorus trichloride 
with three equivalents of isopropanol (IPA) using two equivalents of sodium hydride in THF 
as outlined in a publication in 2004 by Fakhraian and co-workers177 (Scheme 4.1). 
Diisopropyl hydrogen phosphonate 124177 was isolated in 98% yield after an aqueous work-
up using ammonium chloride and evaporation of solvent, without the need for any column 
chromatography. The mechanism of the reaction (Fig. 4.4) reveals the importance of only 
adding two equivalents of base. Three equivalents of HCl are produced during the course of 
the reaction (step 1), of which only two equivalents can be neutralised up by the base. The 
remaining equivalent of HCl is used in the protonation of the phosphorus of the 
trialkylphosphite, which rearranges to a more stable pentavalent phosphorus in the form of 
the desired dialkyl hydrogen phosphonate (DAHP) via an Arbuzov-type dealkylation. In the 
case of adding three equivalents of base, no DAHP is produced. The reaction can also be 
performed under base-free conditions, but this means having to neutralize large quantities of 
HCl in the work-up. The 1H NMR spectrum of 124 revealed the characteristically large P-H 
coupling for the hydrogen attached to phosphorus at δH 6.77 (1H, d, JHP = 687.0 Hz), thus 
confirming an H-phosphonate structure rather than a hydroxyphosphite one.  
 
 
 
 
 
 
 
 
                     Scheme 4.1 Reagents and conditions: (i) IPA (3eq), NaH (2eq), THF, r.t, 98%. 
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                                Figure 4.4 Mechanistic pathway proposed for production of DAHP.177  
 
Diisopropyl α-hydroxymethylphosphonate 125 was synthesized next by reacting 124 with 
paraformaldehyde and anhydrous potassium carbonate as a catalyst in IPA at 60 oC, 
(Scheme. 4.2) in a transformation better known as the Pudovik reaction178a (Fig. 4.5).178b  
O P
H
O
O
P CH2
O
O
O
OH
i
124
125
 
 
                       Scheme 4.2 Reagents and conditions: (i) (H2CO)n, K2CO3, IPA, 60 oC, 98%. 
 
 
 
 
 
 
 
 
 
 
           Figure 4.5 Proposed mechanism of the Pudovik reaction under heterogeneous conditions.178 
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Carbonates are commonly used in heterogeneous phase as a non-nucleophilic solid ‘soft’ 
base because they are easy to handle, and to eliminate by filtration at the end of the 
reaction. Therefore, the α-hydroxymethylphosphonate 125 was isolated in 98% yield without 
the need for silica-gel chromatography. 
The 1H NMR spectrum of 125 revealed a diagnostic OH singlet at δH 2.15, as well as a 
methylene doublet at δH 3.82 (2H, d, JHP  = 6.6 Hz, CH2P). Its 31P NMR spectrum displayed a 
characteristic signal at δP 22.9, exactly as reported in the literature.178 
 
Subsequent tosylation of alcohol 125 using p-toluenesulfonyl chloride in the presence of 
triethylamine and a catalytic amount of DMAP in dichloromethane returned the desired 
tosylate 126 uneventfully in 92% yield after column chromatography as shown in Scheme 
4.3.  
 
P CH2
O
O
O
OH P CH2
O
O
O
OTs
i
125
126
 
     
              Scheme 4.3 Reagents and conditions (iii) p-TsCl, NEt3, CH2Cl2, DMAP (cat), r.t, 92%. 
 
The 1H NMR spectrum of 126 displayed a new set of aromatic protons as an AB pair (JAB = 
8.0 Hz) resonating at δH 7.36 and δH 7.80 as well as a methyl singlet at δH 2.46. The presence 
of additional aromatic signals in the 13C NMR spectrum of 126 further confirmed the presence 
of a tosylate group. 
 
With 126 now in hand, the next phase involved coupling of it to obtain 5-iodo-ANP 132, which 
in the first strategy tried out began with nucleophilic substitution of bromide 73, whose 
synthesis was mentioned previously (Scheme 2.10, Chapter 2). Thus uracil 130 was reacted 
with 73 in the presence of NaH as a base in DMF at 100 oC. The desired product 136 was 
obtained as the major product but in only 30% isolated yield after column chromatography 
(Scheme 4.4). The product was fully characterized using 1H and 13C NMR spectroscopy. 
Thus, apart from the correct integration of the two molecular fragments, 1N-alkylation over 
3N-alkylation was supported by the disappearance of the 1NH proton in the 1H NMR spectrum 
as well as the retention of the 3NH proton at around δH 9.07. HMBC connectivities were also 
used to reveal H-6 coupling to H-1’. This chemoselective alkylation is consistent with a 
literature report176 describing the greater reactivity of the 1N anion over the more stable 3N 
anion. Thereafter, compound 136 was committed to hydrogenolytic debenzylation using a 
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10% palladium-on-carbon catalyst in MeOH:THF (1:1) under hydrogen gas at rt for 6 h to 
afford alcohol 137 in 80%. The 1H NMR of 137 confirmed the disappearance of aromatic 
protons as well as the benzyl methylene singlet. Under varying conditions of temperature, 
solvent and base (see Table 4.1), alcohol 137 was subjected to alkylation with 
tosyloxyphosphonate 126, however the reaction failed to give the desired product 131, as 
shown in Table 4.1. The tlc of the reaction showed only starting material and no conversion.  
 
   Table 4.1 Different reaction conditions for alkylation of alcohol 137 with tosyloxyphosphonate 126.  
Reaction     Solvent Base   Time Temperature Observation 
1 THF NaH 18 h 70 oC No product 
2 CH3CN K2CO3 20 h 80 oC No product 
3 DME Cs2CO3 24 h 100 oC No product 
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Scheme 4.4 Reagents and conditions: (i) 130, NaH, DMF, 100 0C, 30%; (ii) H2, Pd/C, MeOH:THF 
(1:1), r.t, 6 h, 80%; (iii) 126, various see Table 4.1.  
 
The second strategy pursued was based on a more convergent approach involving 
substitution of a tethered phosphonate (Scheme 4.5). This was accomplished through 
alkylation of mono-benzyl ether 72 by tosylated phosphonate 126 using sodium hydride as 
base in THF at reflux, to obtain protected tethered phosphonate 124 in 72% yield after 
column purification. The 1H NMR spectrum of 124 revealed an upfield shift of methylene 
protons α to phosphorus at δH 4.12 (d, JHP  = 10.0 Hz, CH2P) for the tosylate 126 to δH 3.82 in 
127, as well as the presence of a new benzylic methylene singlet at δH 4.54.  Its 31P NMR 
spectrum returned a single peak at δH 19.7. Finally, a correct HRMS evaluation (m/z HRMS 
(ES) 331.16681 [M+H]+, C16H28O5P requires m/z 331.1674 [M+H]+), confirmed the structure 
of 127. 
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Scheme 4.5 Reagents and conditions: (i) 72, NaH, THF, ∆, 72%; (ii) H2, Pd/C, MeOH: THF (1:1), r.t 
77%; (iii) p-TsCl, NEt3, CH2Cl2, DMAP (cat), r.t, 90%. 
 
Catalytic hydrogenation of 127 to a more polar, non-uv active spot on tlc using a palladium-
on-carbon catalyst in methanol/THF (1:1) furnished 128 in 77% yield (Scheme 4.5). The 
appearance of a hydroxyl proton as a broad singlet resonating at δH 2.52 and the absence of 
the characteristic benzylic methylene singlet at δH 4.54 for 128 provided evidence that 
debenzylation had taken place. 
 
The hydroxyl group of 128 was subsequently converted to tosylate 129 in 90% yield by 
reacting it with p-toluenesulfonyl chloride in the presence of triethylamine and a catalytic 
amount of DMAP in dichloromethane (Scheme 4.5). The 1H NMR spectrum of 129 displayed 
aromatic protons with AB coupling (JAB = 8.3 Hz) resonating at δH 7.33 and δH 7.78 as well as 
a methyl singlet at δH 2.43. The presence of additional aromatic signals in the 13C NMR 
spectrum further confirmed the presence of a tosylate group. The 31P NMR spectrum 
returned a singlet peak at δP 18.6 for the phosphonate. 
 
The final part in the synthesis of the ANP involved coupling of the modified tethered 
phosphonate 129 (Scheme 4.6) via 1N-alkylation of uracil 130 and was carried out using 
cesium carbonate in DMF at 100 oC. ANP 131 was isolated following aqueous work-up and 
purification by column chromatography in a modest 35% yield. Once again 1N-
chemoselectivity was observed based on alkylation of the the more reactive anion. The 1H 
NMR spectrum of 131 (Fig. 4.6) displayed two doublets at δH 5.64 (d, J = 7.9 Hz) and δH 7.36 
(d, J = 7.9 Hz) for the H-5 and H-6 protons respectively. An upfield shift of the H-1’ signal in 
the 1H NMR spectrum from δH 4.14 in tosylate 129 to δH 3.94 in 131 supported the 
displacement of the tosylate. The 13C NMR spectrum of compound 131 displayed signals for 
the ANP at δC 66.2 (d, JC-P = 166.9 Hz, H-4’), δC 48.3 (C-1'), δC 101.5 (C-5) and δC 145.8 (C-
6). The diastereotopic methyl groups were observed as two sets of doublets (isopropoxy 
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groups enantiotopic). Its 31P NMR spectrum displayed a diagnostic phosphonate singlet at δP 
18.8. 
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Scheme 4.6 Reagents and conditions: (i) uracil 130, Cs2CO3, DMF, 100 oC, 35%; (ii) I2, CAN, CH3CN, 
40 oC, 4 hrs, 62%. 
 
 
                                          Figure 4.6 1H NMR (CDCl3) spectrum of ANP 131. 
 
 
Finally, compound 131176 was iodinated (Scheme 4.6) using elemental iodine and cerium 
ammonium nitrate (IV) at 40 oC. Tlc confirmed reaction completion after 4 hrs and 132 was 
obtained in 62% yield after column chromatography. The 1H NMR spectrum of 132 supported 
iodination based on the change from an AB doublet pair in 131 to a singlet at δH 7.78 for H-6 
in 132. Its 13C NMR spectrum also displayed a large upfield shift for C-5 from δC 101.5 in 131 
to δC 67.2 in 132 consistent with the introduction of iodine. The 31P NMR spectrum of 132 
revealed a singlet at δP 18.7. The parent ion was found to be 461.0341 (M+ + H) correlating to 
a correct molecular formula of C13H23N5O6PI, thus confirming that iodination had taken place.  
 
N 
N 
O P O 
O 
O O 
O 
H 
1 
3 5 
1 ' 
2 ' 
3 ' 
4 ' 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
CHAPTER 4______________________________ SYNTHESIS OF [ANP]-SPACER-[HI-236] 
 131 
4.1.3 Synthesis of [ANP]-tetraPEG-propyne-[HI-236] 134 
 
The target compound 134 was achieved by Sonogashira coupling of 5-iodo-ANP derivative 
132 to 4-PEG amine 118 as the key step, following the same methodology as described 
before in Chapter 3. Thus the Boc group of alkyne 70r was deprotected to amine 118 as 
described before using TFA (Chapter 3, Scheme 3.15). The amine was then coupled with 
phosphonate 132 without complications using the standard reaction conditions of 
Sonogashira coupling to afford the intermediate coupled amine, which was condensed 
directly with thiourea 49 in THF for 20 h at rt to afford the desired product 134 in 20% yield 
over the three steps after column chromatography Scheme 4.7.    
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Scheme 4.7 Reagents and conditions: (i) 70r, TFA, DCM, 0 oC, 2 h, K2CO3; (ii) (PPh3)4Pd (10%), CuI    
(50%), Et3N (2 eq), DMF:THF (1: 2), rt, 2 h; (iii) Thiourea 49, THF, rt, 20 h, (20% over the 3 steps).  
 
Key spectroscopic indicators in the 1H NMR spectrum (Fig. 4.7) of 134 were the ANP uracil 
proton singlet (H-6) at δH 7.58, the absence of an alkyne signal at δH 2.40 as well as the 
characteristic aromatic signals for the HI-236 moiety. The two thiourea NH signals could be 
discerned downfield as usual, but the ANP imide proton was more upfield compared to the 
d4U series. The 13C NMR spectrum of 134 returned the correct number of resonances of 43. 
Its 31P NMR spectrum displayed the definitive phosphonate resonance at δP 18.7. Finally, a 
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correct HRMS evaluation (m/z HRMS (ES) 1016.3100 [M+H]+, C43H64N5O14PSBr requires 
m/z 1016.3091 [M+H]+), confirmed the structure of 134. 
 
 
 
 
 
 
    
                                 Figure 4.7 
1H NMR (CDCl3) spectrum of compound 134. 
 
 
4.1.4 Synthesis of [ANP]-hexaPEG-propyne-[HI-236] 135 
 
As an elongated variant of the prototype, the 6-PEG bifunctional 135 was synthesized using 
an identical sequence to that just described, except using alkyne 70s from Chapter 3, 
Scheme 2.21 to afford the desired bifunctional 135 in a 15% yield over three steps after 
column chromatography as shown in Scheme 4.8. 
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Scheme 4.8 Reagents and conditions: (i) 70r, TFA, DCM, 0 oC, 2 h, K2CO3; (ii) (PPh3)4Pd (10%), CuI   
(50%), Et3N (2 eq), DMF: THF (1: 2), rt, 2 h; (iii) Thiourea 49, THF, rt, 20 h, (15% over the 3 steps).  
 
  
The 1H NMR spectral data for 135 was very similar to that of the 4-PEG derivative 134 and 
revealed signals for both the HI-236 and 5-iodo-ANP moieties in a ratio of 1:1 (Fig. 4.8). The 
13C NMR spectrum of 135 displayed diagnostic resonances at δC 66.2 (d, JCP = 166.7 Hz, C-
4’), δC77.1 (C-5), δC 55.6 (OCH3), and δC 179.3 (C=S), thus confirming the presence of both 
the nucleotide and the alkyne. The structure was further confirmed by 2D NMR. The IR 
spectrum of 135 indicated a characteristion peak for C=S at Vmax1469 cm-1 , for C≡C at Vmax 
2239 cm-1 and for P=O at Vmax 1230  cm-1. The parent ion was found to be 1016.3100 (M+ + 
H) correlating to a correct molecular formula of C43H64N5O14PSBr, thus confirming the 
formation of 135. The two bifunctionals were both oils, hence the use of High resolution mass 
spectrometry (HRMS).  
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                                        Figure 4.8 
1H NMR (CDCl3) spectrum of compound 135. 
 
 
 
4.2 Biological results and rationale  
 
The inhibition of viral replication in HIV-infected cells by the bifunctional targets 134 and 135 
was measured for HIV-1 (IIIB) replication in MT-2 cell culture using an MTT assay (see 
Appendix). The results are summarized in Table 4.2, which includes the results for the 4-
PEG d4U bifunctional 80 for comparison purpose. EC50 represents the inhibitory potency, 
while CC50 reflects cytotoxicity of the compounds towards untreated cells.   
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      Table 4.2 In vitro anti-HIV and activity cytotoxicity of bifunctionals 134, 135 and 80.in MT-4 cells. 
 
Compound 
 
EC50
a (μM) 
 
CC50
b(μM) 
 
     T.Ic 
 
                              
MeO
N N
N
Br
OMe
S
H
H
HI-236
 
 
 
0.012 
 
 
> 0.1 
 
 
   > 10 
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H
N
N
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OOO
N
O
N
O
O
H
HO
OMe
3
80
 
 
 
 
3.1 
 
 
 
18 
 
 
 
     6 
            
OOON
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O
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O
O O
N N
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134
 
 
 
               
     3.1 
 
 
 
      16   
 
 
      
       5 
 
OOON
N
O
OP
H
O
O
O O
N N
N
Br
OMe
S
H
H
5
135
 
              
 
 
 
8.9 
 
 
 
 
27 
 
 
 
 
3 
 
a Effective concentration that inhibits viral-mediated T-cell death by 50% and as an average of three 
measurements.  
bConcentration that kills 50% of the T-cells and as an average of three results. 
c In vitro therapeutic index (IC50 /EC50). 
  
The results in Table 4.2 reveal that the 4-PEG ANP prototype heterodimer 134 was 3-fold 
more potent than the 6-PEG analogue 135. Furthermore, no evidence of an enhancement 
due to the phoshophonate was provided as judged by comparing the d4U bifunctional 80 
with the ANP one. This of course, could have also been due to changing from d4U to the 
ANP prototype chosen here. Given that the ANP in 134 is not based on a proven drug by 
comparison to the d4U bifunctional 80 result, the value for 134 is highly encouraging. 
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Together with results from the other bifunctional series, the following conclusions can be 
drawn:  
 
(i) The activity in both series likely involves NNRTI pocket binding rather than just NRTI 
binding. The similarity of the results between the two different series (4-PEG) bears this out 
since changing d4U to ANP is quiet a significant change and the ANP chosen here has no 
guarantee of binding by itself even if phosphorylated. Thus, to retain the same activity of 3.1 
μM (80 to 134) should reflect the constancy due to the NNRTI component being the same in 
each case.   
 
(ii) The tether-ANP or tether-d4U would then protrude from the cavity since these moieties 
are far too large to be accommodated completely in the cavity. The relatively high potencies 
(high nM range for the d4U series or low μM for the ANP) observed suggest a significant 
degree of cooperative binding outside the pocket, probably via H-bonding. Thus, these 
derivatives should be considered as elongated NNRTI’s with some cooperative binding to 
residues outside the pocket, since the molecules are far too large to fit into the pocket 
completely. The degree to which the NRTI binding site is involved is unknown. Possibly there 
is none in which case the NRTI must have found a significant binding zone somewhere else.  
 
(iii) No evidence exits for phosphorylation to an activated bifunctional in either series. This 
must be due to poor recognition by the kinases appropriate to each series.  
 
(iv) A case exists for changing the presence ANP to a known one such as found in Cidofovir 
or Tenofovir, in order to fully evaluate the influence of changing from one proven NRTI to 
another (NtRTI).  
 
Future work could be carried out on more established ANP’s like Tenofovir, and to vary the 
pro-drug groups as Cyclo-Sal, POC or POM, or a phoshoramidate. However, the issue of 
converting to a bifunctional triphosphate in vitro continues to be limiting. Finally, based on the 
possibility of exiting the back of the NNRTI pocket, it would be interesting to explore the C-5 
oxygen of HI-236 as the tether attachment point on the NNRT. 
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CHAPTER 5: EXPERIMENTAL SECTION 
 
5.1 General procedures 
 
All reactions were performed in oven-dried glassware under an inert atmosphere of dry 
nitrogen. All starting materials were purchased from Sigma-Aldrich, South Africa except the 
solvents, acids and common salts. The following reaction solvents were distilled from the 
indicated drying agents: methylene chloride (P2O5), N,N-dimethylaniline (CaH2), diethyl ether 
(P2O5), tetrahydrofuran (Na, benzophenone), methanol (Mg), acetonitrile (CaH2), 
triethylamine (CaH2), dimethoxyethane (Na, benzophenone). 
 
1H NMR spectra were recorded on a Varian Mercury Spectrometer at 300 MHz or on a 
Varian Unity Spectrometer at 400 MHz. 13C NMR spectra were recorded at 75 MHz on a 
Varian Mercury Spectrometer or at 100 MHz on a Varian Unity Spectrometer. The spectra 
were recorded in CDCl3, Acetone-d6, CD3OD-d4 or DMSO-d6 with tetramethylsilane as the 
internal standard. Chemical shifts are reported in ppm ( ); multiplicities are indicated by s 
(singlet), d (doublet), t (triplet), q (quartet), m (multiplet) and br (broad). Coupling constants, 
J, are reported in Hertz. High resolution mass spectra were recorded on a VG70 SEQ 
micromass spectrometer. Infrared (IR) absorptions were measured on a Perkin Elmer 
Spectrum One FT-IR spectrometer. Peaks are reported in cm-¹. Melting points were 
determined using a Reichert-Jung Thermovar hot-stage microscope and are uncorrected. 
Elemental analysis for C, H and N were carried out using a Fisons EA 110 CHN Elemental 
Analyser. Optical rotations were obtained using a Perkin Elmer 343 polarimeter at 20 °C. The 
concentration c refers to g/100 mL 
 
The reaction progress was monitored by TLC using Merck silica-gel 60 F254. Visualisation 
was accomplished with UV light or spraying with anisaldehyde and/or cerium ammonium 
sulphate spray reagents and then heating at 150 °C. Column chromatography was performed 
with Merck silica-gel 60 (70-230 mesh). 
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2-Benzyloxy-5-methoxybenzaldehyde (62)
146b
 
                                                     
 
 
 
 
 
2-Hydroxy-5-methoxybenzaldehyde (5.00 mL, 40.10 mmol) was added to a stirring mixture of 
anhydrous potassium carbonate (16.63 g, 120.30 mmol) in ethanol (100 mL). Benzyl bromide 
(7.15 mL, 60.15 mmol) was added to the mixture which was refluxed for 16 h. The potassium 
carbonate was filtered from the mixture through Celite, washed with ethanol (50 mL), and the 
solvent was removed in vacuo. The filtrate was dissolved in diethyl ether (300 mL), washed 
with aqueous sodium chloride (2 × 100 mL), aqueous sodium hydroxide (100 mL) and water 
(2 × 50 mL). The organic layer was dried over MgSO4, and the solvent was removed under 
reduced pressure. Recrystallization of the residue from ethanol gave colorless needles of the 
product 62 (9.10 g, 94%); mp: 44-46 °C; [lit. 47-48 °C]; IR (CHCl3): max 3007, 2870 (C-H), 
1682 (C=O), 1490 (C=C), 1223, 1158 (C-N) cm-1; 1H NMR (400 MHz, CDCl3): δ 10.53 (1H, s, 
CHO), 7.43 (5H, m, ArH), 7.36 (1H, d, J = 3.3 Hz, H-6), 7.12 (1H, dd, J = 3.3, 9.1 Hz, H-4), 
7.02 (1H, d, J = 9.1 Hz, H-3), 5.16 (2H, s, ArOCH2), 3.81 (3H, s, OCH3); 13C NMR (100 MHz, 
CDCl3): δ 189.5 (HC=O), 155.9 (C-2), 154.0 (C-5), 136.3 (C-1’), 128.7 (C-3’, C-5’), 128.3 (C-
4’), 127.4 (C-2’, C-6’), 125.7 (C-1), 123.4 (C-6), 115.2 (C-3), 110.4 (C-4), 71.4 (ArCH2O), 
55.8 (OCH3); HRMS (EI): m/z found 242.09699 (M+). C15H14O3 (M+) requires 242.09429; 
Found C, 74.35; H, 5.81. C15H14O3 requires C, 74.36; H, 5.82 
 
2-(2-Benzyloxy-5-methoxyphenyl)-1-nitroethene (65)
147
 
 
 
 
 
 
2-Benzyloxy-5-methoxybenzaldehyde 62 (6.50 g, 26.85 mmol) dissolved in nitromethane (80 
mL) and ammonium acetate (2.07 g, 26.85 mmol) was heated at 70 °C for 14 h. The solution 
was diluted with dichloromethane (200 mL), washed with sodium chloride (2 Χ 200 mL) and 
water (200 mL). The organic layer was dried over MgSO4 and the solvent removed under 
reduced pressure to give a residue which was recrystallized from hot ethanol to afford yellow 
crystals of 65 (6.10 g, 80%); mp: 112-114 °C, [lit. 114-116 °C]; IR (CHCl3): max 3022, 2949 
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(C-H), 1577, 1498 (C=C), 1498, 1342 (N-O) 1216 (C-N) cm-1; 1H NMR (400 MHz, CDCl3): δ 
8.17 (1H, d, J = 13.6 Hz, H-2), 7.83 (1H, d, J = 13.6 Hz, H-1), 7.43 (5H, m, ArH), 6.99 (3H, m, 
H-3’, H-4’, H-6’), 5.17 (2H, s, ArCH2O), 3.81 (3H, s, OCH3); 13C NMR (100 MHz, CDCl3): δ 
153.8 (C-2’),  153.0 (C-5’), 138.6 (C-1), 136.1 (C-1”), 135.1 (C-2), 128.8 (C-2”, C-6”), 128.4 
(C-4”), 127.4 (C-3”, C-5”), 120.1 (C-1’), 119.2 (C-6’), 116.1 (C-4’), 114.3 (C-3’), 71.4 
(ArCH2O), 55.9 (OCH3); EI HRMS: m/z found 285.09932. C16H15NO4 requires (M+) 
285.10011; Found C, 67.37; H, 5.27; N, 5.00. C16H15NO4 requires C, 67.36; H, 5.30; N 4.91. 
 
2-(2-Benzyloxy-5-methoxyphenyl)-ethanamine (66) 
 
 
                                                  
 
 
A compound of nitroethene 65 (5.00 g, 17.74 mmol), dissolved in THF (50 mL) and was 
added dropwise over 2 h to a stirred and refluxing suspension of lithium aluminium hydride 
(2.66 g, 70.16 mmol) in THF (100 mL). The mixture was refluxed for 4 h, cooled to 0 °C and 
quenched with water (2 mL) and 5% sodium hydroxide solution (2 mL). The mixture was 
stirred for an additional 30 min. The precipitate formed, was filtered through a pad of celite 
and washed with MeOH (3 × 50 mL). The filtrate was reduced under pressure to give crude 
product 66 (4.10 g, 91%). Compound 3 was carried to the next reaction without further 
purification. 
 
N-[2-(2-Benzyloxy-5-methoxyphenyl)ethyl]-tert-butylcarbamate (68) 
 
 
 
 
 
To a solution of crude amine 66 (4.10 g, 15.95 mmol) in acetonitrile (50 mL) and di-tert-
butyldicarbonate (5.22 g, 23.93 mmol) in acetonitrile (6 mL) was added, the reaction mixture 
was stirred at rt for 20 h. The mixture was diluted with EtOAc (100 mL), which was washed 
with aqueous NH4Cl (50 mL), water (50 mL) and dried over MgSO4. The solvent was 
evaporated under reduced pressure and the crude product was subject to column 
chromatography employing EtOAc / petroleum ether (15 / 85) to give product 68 as 
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colourless crystals (5.00 g, 88%); mp: 102-104 °C; IR (CHCl3): max 3449 (NH), 3007, 2935 
(C-H), 1703 (C=O), 1501 (C=C), 1165 (C-N) cm-1; 1H NMR (400 MHz, CDCl3): δ 7.45-7.34 
(5H, m, ArH), 6.85 (1H, d, J = 8.8 Hz, H-3’), 6.76 (1H, d, J = 2.8 Hz, H-6’), 6.72 (1H, dd, J = 
2.8, 8.8 Hz, H-4’), 5.04 (2H, s, ArCH2O), 4.70 (1H, brs, NH), 3.78 (3H, s, OCH3), 3.40 (2H, q, 
J = 6.4 Hz, H-1), 2.85 (2H, t, J = 6.4 Hz, H-2), 1.44 (9H, s, OC(CH3)3); 13C NMR (75 MHz, 
CDCl3): δ 155.9 (C=O), 153.8 (C-5’), 150.9 (C-2’), 137.4 (C-1’’), 129.2 (C-1’), 128.5 (C-3”, C-
5”), 127.8 (C-4’’), 127.2 (C-2’’, C-6”), 116.8 (C-6’), 113.0 (C-4’), 112.0 (C-3’), 79.0 (OC(CH3)3, 
70.8 (ArCH2O), 55.7 (OCH3), 40.8 (C-1), 30.9 (C-2), 28.4 (OC(CH3)3); HRMS (EI): m/z found 
301.13383 [(M+ - t-butyl) + H]. C21H27NO4 requires 301.13409 [(M+ - t-butyl) + H]; Found C, 
70.50; H, 7.62; N, 3.86. C21H27NO4 requires C, 70.56; H, 7.61; N, 3.92. 
 
[2-(2-Hydroxy-5-methoxyphenyl)ethyl]-tert-butylcarbamate (69) 
 
              
 
 
 
 
The carbamate 68 (4.50 g, 12.61 mmol) was added to 10% palladium on carbon (0.22 g, 
1.26 mmol) in ethanol. Hydrogen gas was introduced to the reaction at rt for 5 h. The 
palladium was filtered from the solution through Celite and the precipitate was washed with 
ethanol (3 × 100 mL). The solvent was removed under reduced pressure and the residue 
was subjected to column chromatography using EtOAc / petroleum ether (4 / 6 ) to give a 
white solid 69 (2.50 g, 74%); mp: 115-117 °C; IR (CHCl3): max 3457, 3326 (NH, OH), 1686 
(C=O), 1508 (C=C), 1210, 1166 (C-N) cm-1; 1H NMR (400 MHz, CDCl3): δ 6.99 (1H, brs, OH), 
6.79 (1H, d, J = 8.4 Hz, H-3’), 6.67 (1H, d, J = 2.8 Hz, H-6’), 6.65 (1H, m, H-4’), 5.00 (1H, brs, 
NH), 3.75 (3H, s, OCH3), 3.33 (2H, q, J = 7.1 Hz, H-1), 2.81 (2H, t, J = 7.1 Hz, H-2), 1.46 (9H, 
s, OC(CH3)3; 13C NMR (100 MHz, CDCl3): δ 157.0 (C=O), 153.2 (C-5’), 148.8 (C-2’), 126.0 
(C-1’), 116.5 (C-3’), 116.2 (C-6’), 112.8 (C-4’), 80.0 (OC(CH3)3), 55.8 (OCH3), 41.0 (C-1), 
31.4 (C-2), 28.4 (OC(CH3); HRMS (EI): m/z found 267.14329 (M+) C14H21NO4 (M+) requires 
267.14706; Found C, 62.82; H, 7.92; N, 5.16. C14H21NO4 requires C, 62.94; H, 7.92; N, 5.24. 
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1-Propyl p-toluenesulfonate (138) 
 
                                                         
 
 
 
Triethylamine (5.00 mL, 40.00 mmol) and p-toluenesulfonyl chloride (7.00 g, 40.00 mmol) 
were added to a solution of 1-propanol (2.00 g, 33.30 mmol) in dry CH2Cl2 (30 mL) at 0 oC, 
followed by a catalytic amount of DMAP (20 mg). The reaction mixture was stirred at rt for 16 
h, diluted with aq. NH4Cl (40 mL) and extracted with CH2Cl2 (3 × 30 mL). Following drying 
over MgSO4, filtering and solvent evaporation under reduced pressure, the crude was 
purified by column chromatography using EtOAc / pet ether (15 / 85) to give product 138 as a 
colourless oil (6.50 g, 91%). 1H NMR (400 MHz, CDCl3): δ 7.78 (2H, d, J = 8.1 Hz, H-2’, H-
6’), 7.33 (2H, d, J = 8.1 Hz, H-3’, H-5’), 3.98 (2H, t, J = 7.0 Hz, H-1), 2.43 (3H, s, ArCH3), 1.66 
(2H, sextet, J = 7.0 Hz, H-2), 0.88 (3H, t, J = 7.0 Hz, H-3); 13C NMR (100 MHz, CDCl3): δ 
144.6 (C-1’), 133.3 (C-4’), 129.8 (C-2’, C-6’), 127.8 (C- 3’, C-5’), 72.1 (C-1), 22.3 (ArCH3), 
21.6 (C-2), 9.9 (C-3). 
 
1-But-3-ynyl p-toluenesulfonate (139) 
 
 
 
 
 
 
p-Toluenesulfonyl chloride (4.54 g, 23.80 mmol) in CH2Cl2 (10 mL) was added dropwise to a 
solution of but-3-yn-1-ol (1.50 mL, 19.80 mmol) containing triethylamine (3.14 mL, 23.80 
mmol) and DMAP (20 mg) in CH2Cl2 (20 mL) at 0 oC. The mixture was stirred at rt for 16 h. 
diluted with aq. NH4Cl (30 mL) and extracted with CH2Cl2 (3 × 25 mL). Following drying over 
MgSO4, filtering and solvent evaporation under reduced pressure, the crude was purified by 
column chromatography using ethyl acetate / petroleum ether (15 / 85) to give a colourless 
oil 139 (4.44 g, 100%); 1H NMR (300 MHz, CDCl3):  7.75 (2H, d, J = 7.4 Hz, H-2’, H-6’), 7.31 
(2H, d, J = 7.4 Hz, H-3’, H-5’), 4.06 (2H, t, J = 7.0 Hz, H-4), 2.50 (2H, td, J = 2.7, 7.0 Hz, H-
3), 2.40 (3H, s, CH3), 1.95 (1H, t, J = 2.7 Hz, H-1); 13C NMR (75 MHz, CDCl3):  144.9 (C-1’), 
132.6 (C-4’), 129.7 (C-2’), 127.7 (C-3’), 78.3 (C-2), 70.6 (C-1), 67.3 (C-4), 21.4 (C-3), 19.2 
(CH3). 
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1-Penta-4-ynyl p-toluenesulfonate (140) 
 
 
                                             
 
 
To a solution of pen-4-yn-1-ol (1.11 mL, 11.90 mmol) in dry CH2Cl2 (15 mL), were added 
triethylamine (2.00 mL, 14.30 mmol) and p-toluenesulfonyl chloride (2.72 g, 14.30 mmol) at 0 
°C, followed by a catalytic amount of DMAP (20 mg). The reaction mixture was stirred at rt for 
16 h, diluted with aq. NH4Cl (50 mL) and extracted with CH2Cl2 (100 mL). The organic 
extracts were  dried over MgSO4 and the solvent removed under reduced pressure to give a 
crude product, which was purified by silica-gel column chromatography EtOAc / pet ether (15 
/ 85) to give 140 as a colourless oil (2.70 g, 96%); 1H NMR (400 MHz, CDCl3): δ 7.78 (2H, d, 
J = 8.2 Hz, H-2’, H-6’), 7.33 (2H, d, J = 8.2 Hz, H-3’, H-5’), 4.14 (2H, t, J = 6.2 Hz, H-5), 2.44 
(3H, s, ArCH3), 2.25 (2H, td, J = 2.8 Hz, H-3), 1.87 (1H, t, J = 2.8 Hz, H-1), 1.85 (2H, m, H-4); 
13C NMR (100 MHz, CDCl3): δ 144.7 (C-1’), 133.0 (C-4’), 129.8 (C-2’, C-6’), 127.9 (C-3’, C-
5’), 82.1 (C-2), 69.4 (C-1), 68.7 (C-5), 27.7 (C-3), 21.6 (C-4), 14.6 (ArCH3). 
 
General Procedure for the monobenzylation of the glycol (GP1) 
 
The glycol (1.00 mmol) was added dropwise to a suspension of NaH (60% in mineral oil, 1.00 
mmol) in THF at 0 oC and the mixture was stirred for 30 min. Benzyl bromide (1.00 mmol) 
was added dropwise over 1 h. The reaction mixture refluxed for 20 h. The crude mixture was 
diluted with EtOAc (100 mL), washed with aq NH4Cl (50 mL), water (2 × 50 mL), dried over 
Mg2SO4, filtered and the solvent removed in vacuo. The crude product was purified by 
distillation or column chromatography.  
 
2-Benzyloxyethanol (72)149 
 
 
 
 
According to GP1: Ethylene glycol (4.50 mL, 80.60 mmol), NaH (60% in mineral oil, 3.22 g, 
80.60 mmol) in THF (50 mL) and benzyl bromide (9.58 mL, 80.60 mmol). A distillation of the 
mixture (bp: 98-103 oC/0.7 mm Hg); [lit. 90-95 oC/0.7 mm Hg] afforded 72 as a colourless oil 
(6.00 g, 49%); 1H NMR (300 MHz, CDCl3): δ 7.36 (5H, m, ArH), 4.56 (2H, s, ArCH2O), 3.73 
(2H, t, J = 4.7 Hz, H-2), 3.58 (2H, t, J = 4.7 Hz, H-1), 2.58 (1H, brs, OH); 13C NMR (100 
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CDCl3): δ 138.0 (C-1’), 128.5 (C-2’, C-6’), 127.9 (C-4’), 127.8 (C-3’, C-5’), 73.3 (ArCH2O), 
71.5 (CH2O), 61.8 (C-1). 
 
3-Benzyloxypropan-1-ol (72a) 
 
 
 
 
According to GP1: Propane-1,3-diol (3.00 g, 39.42 mmol), NaH (60% in mineral oil, 1.58 g, 
39.42 mmol) in THF (50 mL) and benzyl bromide (4.69 mL, 39.42 mmol). Purification by 
column chromatography using EtOAc / pet ether (3 / 7) afforded 72a as a colourless oil (2.4 
g, 37%); 1H NMR (400 MHz, CDCl3): δ 7.33 (5H, m, ArH), 4.51 (2H, s, ArCH2O), 3.76 (2H, m, 
H-3), 3.65 (2H, t, J = 5.9 Hz, H-1), 2.56 (1H, brs, OH), 1.86 (2H, quin, J = 5.9 Hz, H-2); 13C 
NMR (75 MHz, CDCl3): δ 138.0 (C-1’), 128.3 (C-2’, C-6’), 127.6 (C-4’), 127.6 (C-3’, C-5’), 
73.1 (ArCH2O), 69.0 (C-3), 61.4 (C-1), 32.1 (C-2).  
 
2-(2-Benzyloxyethoxy)ethanol (72b)179 
 
                                                 
 
 
According to GP1: Diethylene glycol (4.46 mL, 47.12 mmol), NaH (60% in mineral oil, 1.88 g, 
47.12 mmol) in THF (50 mL) and benzyl bromide (5.60 mL, 47.12 mmol). A distillation (bp: 
98-103 oC/0.7 mm Hg); [lit. 90-95 oC/0.7 mm Hg] afforded 72b as a colourless oil (4.10 g, 
44%); 1H NMR (400 MHz, CDCl3): δ 7.34 (5H, m, ArH), 4.57 (2H, s, ArCH2O), 3.65 (8H, m, 4 
× CH2O), 2.91 (1H, brs, OH); 13C NMR (100 MHz, CDCl3): δ 137.9 (C-1”), 128.3 (C-2”, C-6”), 
127.7 (C-3”, C-5”), 127.6 (C-4”), 73.2 (ArCH2O), 72.5 (CH2O), 70.3 (CH2O), 69.3 (CH2O), 
61.6 (C-1).    
 
2-{2-[2-(2-Benzyloxy-ethoxy)-ethoxy]-ethoxy}-ethanol (72c) 
 
                                    
 
 
According to GP1: Tetraethylene glycol (4.44 mL, 25.74 mmol), NaH (60% in mineral oil, 1.03 
g, 25.74 mmol) in THF (50 mL) and benzyl bromide (3.06 mL, 25.74 mmol). Purification by 
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column chromatography using EtOAc / pet ether (9 / 1) afforded 72c as a colourless oil (2.88 
g, 39%); 1H NMR (400 MHz, CDCl3): δ 7.34 (5H, m, ArH), 4.56 (2H, s, ArCH2O), 3.66 (14H, 
m, 7 × CH2O), 3.58 (2H, t, J = 4.8 Hz, H-1), 2.80 (1H, brs, OH); 13C NMR (100 MHz, CDCl3): 
δ 138.2 (C-1””), 128.2 (C-2””, C-6””), 127.6 (C-3””, C-5””), 127.4 (C-4””), 73.1 (ArCH2O), 72.4 
(CH2O), 70.5 (2 × CH2O), 70.5 (2 × CH2O), 70.2 (CH2O), 69.3 (CH2O), 61.6 (C-1). 
 
2-[2-(2-{2-[2-(2-Benzyloxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethanol 
(72d) 
                       
 
 
 
According to GP1: Hexaethylene glycol (3.56 mL, 14.17 mmol), NaH (60% in mineral oil, 0.57 
g, 14.17 mmol) in THF (35 mL) and benzyl bromide (1.69 mL, 14.17 mmol). Purification by 
using column chromatography using EtOAc / MeOH (9 / 1) afforded 72d as a colourless oil 
(2.02 g, 38%); 1H NMR (300 MHz, CDCl3): δ 7.28 (5H, m, ArH), 4.52 (2H, s, ArCH2O), 4.18 
(2H, m, CH2O), 3.61 (22H, m, 12 × CH2O), 2.85 (1H, brs, OH); 13C NMR (75 MHz, CDCl3): δ 
138.2 (C-1”””), 128.2 (C-2”””, C-6”””), 127.6 (C-3”””, C-5”””), 127.4 (C-4”””), 73.0 (ArCH2O), 
72.4 (CH2O), 70.4 (3 × CH2O), 70.4 (3 × CH2O), 70.2 (CH2O), 69.3 (CH2O), 69.0 (CH2O), 
63.4 (CH2O), 61.5  
(C-1). 
 
General Procedure for the bromination of alcohol (GP2) 
 
To a solution of alcohol (1.00 mmol) in CH2Cl2 at 0 oC were added PPh3 (1.20 mmol) and 
CBr4 (1.20 mmol) at 0 oC, and the mixture stirred at rt for 30 min. The solvent was removed in 
vacuo. The crude product was purified directly by column chromatography using EtOAc / pet 
ether or CH2Cl2 / pet ether mixtures to give the product as a colourless oil. 
 
1-Benzyloxy-2-bromoethane (73)180  
                                              
 
 
 
According to GP2: Benzyloxyalcohol 72 (4.00 g, 26.28 mmol) in CH2Cl2 (30 mL), PPh3 (8.27 
g, 31.54 mmol) and CBr4 (10.46 g, 31.54 mmol). The crude product was purified by column 
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chromatography using pet ether / CH2Cl2 (95 / 5) to give 73 as a colourless oil (5.20 g, 92%); 
1H NMR (300 MHz, CDCl3):  7.38 (5H, m, ArH), 4.61 (2H, s, ArCH2O), 3.79 (2H, t, J = 6.2 
Hz, H-2), 3.51 (2H, t, J = 6.2 Hz, H-1); 13C NMR (100 MHz, CDCl3):  137.7 (C-1’), 128.4 (C-
2’, C-6’), 127.8 (C-4’), 127.7 (C-3’, C-5’), 73.1 (ArCH2O), 70.0 (C-2), 30.4 (C-1).  
 
1-Benzyloxy-3-bromopropane (73a) 
 
                                                    
 
 
 
According to GP2: Benzyloxyalcohol 72a (2.80 g, 16.85 mmol) in CH2Cl2 (20 mL), PPh3 (5.30 
g, 20.22 mmol) and CBr4 (6.71 g, 20.22 mmol). The crude product was purified by column 
chromatography using EtOAc / pet ether (10 / 90) to give 73a as a colourless oil (3.51 g, 
91%); 1H NMR (300 MHz, CDCl3):  7.36 (5H, m, ArH), 4.54 (2H, s, ArCH2O), 3.63 (2H, t, J = 
6.0 Hz, H-3), 3.55 (2H, t, J = 6.0 Hz, H-1), 2.16 (2H, quin, J = 6.0  Hz, H-2); 13C NMR (100 
MHz, CDCl3):  138.3 (C-1’), 128.4 (C-2’, C-6’), 127.6 (C-4’), 127.6 (C-3’, C-5’), 73.2 
(ArCH2O), 67.7 (C-3), 33.0 (C-1), 30.6 (C-2).  
2-(2-Benzyloxy)ethoxy-1-bromoethane (73b)  
 
 
 
 
 
According to GP2: Benzyloxyalcohol 72b (4.00 g, 20.38 mmol) in CH2Cl2 (40 mL), PPh3 (6.42 
g, 24.46 mmol) and CBr4 (8.11 g, 24.46 mmol). The crude product was purified by column 
chromatography using EtOAc / pet ether (2 / 8) to give 73b as a colourless oil (4.81 g, 91%); 
1H NMR (400 MHz, CDCl3):  7.33 (4H, m, ArH), 7.28 (1H, m, ArH), 4.56 (2H, s, ArCH2O), 
3.79 (2H, t, J = 6.3 Hz, CH2O), 3.67 (2H, m, CH2O), 3.62 (2H, m, CH2O), 3.45 (2H, t, J = 6.3 
Hz, H-1); 13C NMR (100 MHz, CDCl3):  138.2 (C-1”), 128.4 (C-2”, C-6”), 127.8 (C-3”, C-5”), 
127.7 (C-4”), 73.3 (ArCH2O), 71.3 (CH2O), 70.7 (CH2O), 69.5 (CH2O), 30.4 (C-1). 
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2-{2-[2-(2-Benzyloxy-ethoxy)-ethoxy]-ethoxy}-1-bromoethane (73c) 
                     
 
 
 
According to GP2: Benzyloxyalcohol 72c (2.50 g, 8.79 mmol) in CH2Cl2 (20 mL), PPh3 (2.77 
g, 10.55 mmol) and CBr4 (3.50 g, 10.55 mmol). The crude product was purified by column 
chromatography using EtOAc / pet ether (6 / 4) to give 73c as a colourless oil (2.69 g, 88%); 
1H NMR (400 MHz, CDCl3):  7.35 (4H, m, ArH), 7.28 (1H, m, ArH), 4.57 (2H, s, ArCH2O), 
3.80 (2H, t, J = 6.3 Hz, CH2O), 3.67 (12H, m, 6 × CH2O), 3.45 (2H, t, J = 6.3 Hz, H-1); 13C 
NMR (100 MHz, CDCl3):  138.2 (C-1””), 128.2 (C-2””, C-6””), 127.6 (C-3””, C-5””), 127.5 (C-
4””), 73.1 (ArCH2O), 71.1 (CH2O), 70.6 (2 × CH2O), 70.5 (2 × CH2O), 70.4 (CH2O), 69.4 
(CH2O), 30.2 (C-1). 
 
2-[2-(2-{2-[2-(2-Benzyloxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-1-
bromoethane (73d) 
 
 
         
 
According to GP2: Benzyloxyalcohol 72d (1.5 g, 4.03 mmol) in CH2Cl2 (15 mL), PPh3 (1.27 g, 
4.84 mmol) and CBr4 (1.61 g, 4.84 mmol). The crude product was purified by column 
chromatography using EtOAc to give a colourless oil 73d (2.94 g, 77%); 1H NMR (400 MHz, 
CDCl3):  7.36 (5H, m, ArH), 4.59 (2H, s, ArCH2O), 3.81 (2H, m, CH2O), 3.68 (20H, m, 10 × 
CH2O), 3.44 (2H, m, H-1).  
 
 
General Procedure for the N-Boc O-alkylated derivates (GP3) 
 
The alkylating agent as a tosylate or bromide (2.00 mmol) in dry acetonitrile (5 mL) was 
added dropwise over 1h to a refluxing and stirring mixture of the phenol 69 (1.00 mmol) and 
anhydrous potassium carbonate (4.00 mmol) in dry acetonitrile (15 mL). The reaction was 
refluxed for 20 h. The mixture was filtered, the acetonitrile evaporated and the residue 
subjected to silica-gel column chromatography (10% EtOAc / pet ether) to afford the product 
generally as a colourless solid. 
 
1"2" 2' 1'1"'
2"'1""2"" 121""'2""'1"""
2"""
3"""
4"""
O
O
O
O
O
O
Br
O
O
O
O
Br
1"
2"
122' 1'1"'2"'1""
2""
3""
4""
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
CHAPTER 5_________________________                                 EXPERIMENTAL SECTION  
 147 
N-(tert-Butoxycarbonyl)-2-(5-methoxy-2-propoxyphenyl)ethylamine (70a) 
                                                 
                                                      
               
 
 
 
 
According to GP3: The tosylate 138 (0.32 g, 1.50 mmol), phenol 69 (0.20 g, 0.75 mmol) and 
anhydrous potassium carbonate (0.42 g, 3.00 mmol) afforded a colourless solid 70a (0.22 g, 
95%): mp 52-54 °C; IR (CHCl3): max 3684, 3452 (NH), 3002, 2977 (C-H), 1706 (C=O), 1502 
(C=C) cm-1; 1H NMR (400 MHz, CDCl3):  6.76 (1H, d, J = 9.2 Hz, H-3’), 6.70 (2H, m, H-4’, H-
6’), 4.78 (1H, brs, NH), 3.88 (2H, t, J = 6.4 Hz, H-1”), 3.75 (3H, s, OCH3), 3.35 (2H, q, J = 6.6 
Hz, H-1), 2.78 (2H, t, J = 6.6 Hz, H-2), 1.80 (2H, m, H-2”), 1.42 (9H, s, OC(CH3)3), 1.04 (3H, 
t, J = 7.4 Hz, H-3”) ; 13C NMR (100 MHz, CDCl3):  155.9 (C=O), 153.5 (C-5’), 151.3 (C-2’), 
129.5 (C-1’), 116.8 (C-6’), 112.3 (C-3’), 112.0 (C-4’), 79.8 (OC(CH3)3), 70.2 (C-1”), 55.7 
(OCH3), 40.9 (C-1), 30.9 (C-2), 28.4 (OC(CH3)3), 22.8 (C-2”), 10.7 (C-3”); HRMS (EI): m/z 
found 309.19401 (M+). C17H27NO4 (M+) requires 309.19400; Anal. Found: C, 66.13; H, 8.80; 
N, 3.91. C17H27NO4 requires; C, 65.99; H, 8.80; N, 4.53. 
 
N-(tert-Butoxycarbonyl)-2-(5-methoxy-2-propargyloxy-phenyl)ethylamine (70b) 
 
 
 
 
 
 
According to GP3: Propargyl bromide (0.40 mL, 6.74 mmol), phenol 69 (0.90 g, 3.37 mmol) 
and anhydrous potassium carbonate (1.87 g, 13.50 mmol) to give 70b as colourless needles 
(0.77 g, 75%); m.p: 49-50 oC; IR (CHCl3): max 3691, 3454 (NH), 3308 (≡CH), 2124 (C≡C), 
1707 (C=O), 1501 (C=C) cm-1; 1H NMR (300 MHz, CDCl3):  6.90 (1H, d, J = 9.3 Hz, H-3’), 
6.72 (2H, m, H-4’, H-6’), 4.65 (3H, d, J = 2.4 Hz, H-1”, NH), 3.75 (3H, s, OCH3), 3.35 (2H, q, J 
= 6.8 Hz, H-1), 2.79 (2H, t, J = 6.8 Hz, H-2), 2.47 (1H, t, J = 2.4 Hz, H-3”), 1.42 (9H, s, 
OC(CH3)3); 13C NMR (75 MHz, CDCl3):  155.9 (C=O), 154.3 (C-5’), 149.8 (C-2’), 129.6 (C-
1’), 116.7 (C-6’), 113.6 (C-3’), 112.0 (C-4’), 79.0 (C-2”), 79.0 (OC(CH3)3), 75.2 (C-3”), 56.7 
(C-1”), 55.6 (OCH3), 40.6 (C-1), 30.9 (C-2), 28.4 (OC(CH3)3); HRMS (EI): m/z found 
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305.16244 (M+). C17H23NO4 (M+) requires 305.16271; Anal. Found: C, 66.90; H, 7.54; N, 
4.54. C17H23NO4 requires C, 66.86; H, 7.59; N, 4.59. 
 
N-(tert-Butoxycarbonyl)-2-[2-(3-butynyl-1-oxy)-5-methoxyphenyl]ethylamine 
(70c) 
 
 
 
 
 
 
According to GP3: The tosylate 139 (1.34 g, 6.00 mmol), phenol 69 (0.80 g, 3.00 mmol) and 
anhydrous potassium carbonate (1.70 g, 12.0 mmol) to give 70c as colourless needles (0.57 
g, 61%); mp: 76-77 °C; IR (CHCl3): max 3455 (NH), 3309 (≡CH), 2413 (C≡C), 1707 (C=O), 
1602 (C=C) cm-1; 1H NMR (300 MHz, CDCl3):  6.75 (3H, m, H-3’, H-4’, H-6’), 4.70 (1H, brs, 
NH), 4.05 (2H, t, J = 6.8 Hz, H-1”), 3.75 (3H, s, OCH3), 3.36 (2H, q, J = 6.6 Hz, H-1), 2.79 
(2H, t, J = 6.6 Hz, H-2), 2.66 (2H, dt, J = 2.7, 6.8 Hz, H-2”), 2.03 (1H, t, J = 2.7 Hz, H-4”), 
1.42 (9H, s, OC(CH3)3); 13C NMR (75 MHz, CDCl3):  155.9 (C=O), 153.9 (C-5’), 150.6 (C-2’), 
129.3 (C-1’), 116.8 (C-6’), 112.8 (C-3’), 112.0 (C-4’), 80.7 (C-3”), 78.9 (OC(CH3)3), 69.8 (C-
4”), 66.8 (C-1”), 55.6 (OCH3), 40.7 (C-1), 30.9 (C-2), 28.4 (OC(CH3)3), 19.7 (C-2”); HRMS 
(EI): m/z found 319.17756 (M+). C18H25NO4 (M+) requires 319.17836. Found: C, 67.10; H, 
7.66; N, 3.67. C18H25NO4 requires C, 67.89; H, 7.89; N, 4.39. 
 
N-(tert-Butoxycarbonyl)-2-[5-methoxy-2-(4-pentynyl-1-oxy)phenyl]ethylamine 
(70d)       
                        
 
 
 
 
 
According to GP3: The tosylate 140 (1.43 g, 6.00 mmol), phenol 69 (0.80 g, 3.00 mmol) and 
anhydrous potassium carbonate (1.70 g, 12.0 mmol) to give 70d as colourless needles (0.93 
g, 93%); m.p: 69-71 oC; IR (CHCl3): max 3696, 3452 (NH), 3307 (≡CH), 2980, 2344 (C≡C), 
1707 (C=O), 1502 (C=C), 1218, 1164 (C-N) cm-1; 1H NMR (300 MHz, CDCl3):  6.79 (1H, d, J 
= 9.6 Hz, H-3’), 6.70 (2H, m, H-4’, H-6’), 4.72 (1H, brs, NH), 4.02 (2H, t, J = 6.5 Hz, H-1”), 
3.75 (3H, s, OCH3), 3.34 (2H, q, J = 6.5 Hz, H-1), 2.78 (2H, t, J = 6.5 Hz, H-2), 2.41 (2H, td, J 
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= 2.7 Hz, 6.5 Hz, H-3”), 1.99 (2H, m, H-2”), 1.96 (1H, t, J = 2.7 Hz, H-5”), 1.43 (9H, s, 
OC(CH3)3); 13C NMR (75 MHz, CDCl3):  155.9 (C=O), 153.7 (C-5’), 151.0 (C-2’), 129.0 (C-
1’), 116.7 (C-6’), 112.5 (C-3’), 112.0 (C-4’), 83.4 (C-4”), 79.3 (OC(CH3)3), 68.9 (C-5”), 66.9 
(C-1”), 55.7 (OCH3), 40.8 (C-1), 30.9 (C-2), 28.4 (OC(CH3)3), 28.4 (C-3”), 15.4 (C-2”); Anal. 
Found: C, 68.44; H, 8.16; N, 4.20 C19H27NO4 requires; C, 68.53; H, 8.28; N, 3.87.   
  
N-(tert-Butoxycarbonyl)-2-[2-(2-butynyl-oxy)-5-methoxyphenyl]ethylamine (70e) 
 
                                                 
 
 
 
 
 
According to GP3: 1-Bromo-2-butyne (0.19 g, 1.50 mmol), phenol 69 (0.20 g, 0.75 mmol) and 
anhydrous potassium carbonate (0.42 g, 3.00 mmol) to give colourless crystals 70e (0.22 g, 
92%); m.p: 53–55 oC; IR (CHCl3): max 3681, 3449 (NH), 3014, 2246 (C≡C), 1703 (C=O), 
1501 (C=C), 1205 (C-N) cm-1; 1H NMR (300 MHz, CDCl3):  6.90 (1H, d, J = 9.6 Hz, H-3’), 
6.71 (2H, m, H-4’, H-6’), 4.65 (1H, brs, NH), 4.60 (2H, q, J = 2.3 Hz, H-1”), 3.76 (3H, s, 
OCH3), 3.35 (2H, q, J = 6.0 Hz, H-1), 2.79 (2H, t, J = 6.0 Hz, H-2), 1.83 (3H, t, J = 2.3 Hz, H-
4”), 1.43 (9H, s, OC(CH3)3); 13C NMR (75 MHz, CDCl3):  155.9 (C=O),  154.0 (C-5’), 150.1 
(C-2’), 129.4 (C-1’), 116.5 (C-6’), 113.6 (C-3’), 111.9 (C-4’), 83.3 (C-2”), 78.6 (OC(CH3)3), 
74.5 (C-3”), 57.3 (C-1”), 55.6 (OCH3), 40.6 (C-1), 30.6 (C-2), 28.4 (OC(CH3)3), 3.6 (C-4”); 
Anal. Found: C, 67.39; H, 7.97; N, 4.12 C18H25NO4 requires C, 67.69; H, 7.89; N, 4.23. 
 
N-(tert-Butoxycarbonyl)-2-(2-allyloxy-5-methoxyphenyl)ethylamine (70f)  
 
                                           
 
 
 
 
According to GP3: Allyl bromide (0.24 mL, 2.24 mmol), phenol 69 (0.30 g, 1.12 mmol), 
anhydrous potassium carbonate (0.62 g, 4.50 mmol) to afford 70f as a fine white powder 
(0.34 g, 99%); m.p: 54-56 oC; IR (CHCl3): max 3682, 3449 (NH), 3201 C-H), 1502 (C=C), 
1703 (C=O), 1210 (C-N) cm-1; 1H NMR (300 MHz, CDCl3): δ 6.68 (1H, d, J = 9.0 Hz, H-3’), 
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6.71 (3H, m, H-4’, H-6’), 6.05 (1H, ddt, J = 5.1 Hz, 10.5 Hz, 17.3 Hz, H-2”), 5.39 (1H, dq, J = 
1.6 Hz, 17.3 Hz, H-3b”), 5.26 (1H, dq, J = 1.6 Hz, 10.5 Hz, H-3a”), 4.71 (1H, brs, NH), 4.50 
(2H, dt, J = 1.6 Hz, 5.1 Hz, H-1”), 3.76 (3H, s, OCH3), 3.40 (2H, q, J = 6.5 Hz, H-1), 2.80 (2H, 
t, J = 6.5 Hz, H-2), 1.43 (9H, s, OCH3) ;13C NMR (75 MHz, CDCl3):  156.0 (C=O), 153.7 (C-
5’), 150.8 (C-2'), 133.6 (C-2”), 129.2 (C-1’), 117.1 (C-3”), 116.7 (C-6’), 112.9 (C-3’), 112.0 (C-
4’), 79.0 (OC(CH3)3), 69.5 (C-1”), 55.7 (OCH3), 40.8 (C-1), 30.9 (C-2), 28.4 (OC(CH3)3); Anal. 
Found C, 66.41; H, 8.21; N, 4.40 C17H25NO4 requires C, 66.43; H, 8.20; N, 4.56. 
 
N-(tert-Butoxycarbonyl)-2-(2-methoxycarbonylmethyloxy-5-
methoxyphenyl)ethylamine (70g)    
 
                                                        
 
 
 
 
According to GP3: Methyl chloracetate (0.25 mL, 2.24 mmol), phenol 69 (0.30 g, 1.12 mmol), 
and anhydrous potassium carbonate (0.62 g, 4.50 mmol) to afford 70g as a fine white 
powder (0.37 g, 98%); m.p 66-68 oC; IR (CHCl3): max 3681, 3449 (NH), 1758 , 1704 (C=O), 
1501 (C=C), 1227 (C-N) cm-1; 1H NMR (300 MHz, CDCl3): δ 6.67 (3H, m, H-3’, H-4’, H-6’), 
4.84 (1H, brs, NH), 4.61 (2H, s, ArOCH2), 3.78 (3H, s, CO2CH3), 3.74 (3H, s, ArOCH3), 3.40 
(2H, q, J = 6.5 Hz, H-1), 2.90 (2H, t, J = 6.5 Hz, H-2), 1.41 (9H, s, OC(CH3)3); 13C NMR (75 
MHz, CDCl3):  169.6 (OC=O), 156.0 (HNC=O), 154.3 (C-5’), 150.1 (C-2’), 129.5 (C-1’), 
116.9 (C-6’), 112.4 (C-3’), 112.0 (C-4’), 78.8 (OC(CH3)3), 66.0 (ArOCH2), 55.6 (OCH3), 52.1 
(CO2CH3), 40.7 (C-1), 30.9 (C-2), 28.4 (OC(CH3)3) ; Anal. Found C, 60.37; H, 7.36; N, 3.91 
C17H25NO6 requires C, 60.16; H, 7.42; N; 4.13. 
 
N-(tert-Butoxycarbonyl)-2-(2-cyanomethoxy-5-methoxyphenyl)ethylamine (70h)                       
                           
                                                   
 
 
 
According to GP3: Bromoacetonitrile (0.17 g, 1.50 mmol), phenol 69 (0.20 g, 0.75 mmol) and 
anhydrous potassium carbonate (0.42 g, 3.00 mmol)) to give colourless crystals 70h (0.22 g, 
96%); m.p: 98–102 oC; IR (CHCl3): max 3681, 3449 (NH), 2240 (C≡N), 1703 (C=O), 1501 
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(C=C), 1226 (C-N) cm-1; 1H NMR (300 MHz, CDCl3):  6.89 (1H, d, J = 9.6 Hz, H-3’), 6.74 
(2H, m, H-4’, H-6’), 4.73 (2H, s, H-1”), 4.61 (1H, brs, NH), 3.76 (3H, s, OCH3), 3.35 (2H, q, J 
= 6.8 Hz, H-1), 2.80 (2H, t, J = 6.8 Hz, H-2), 1.43 (9H, s, OC(CH3)3); 13C NMR (75 MHz, 
CDCl3):  155.9 (C=O), 155.4 (C-5’), 148.9 (C-2’), 130.1 (C-1’), 117.1 (C-6’), 115.4 (C-2”), 
112.8 (C-3’), 112.2 (C-4’), 79.2 (OC(CH3)3), 55.6 (OCH3), 54.9 (C-1”), 40.5 (C-1), 31.4 (C-2), 
28.4 (OC(CH3)3; Anal. Found: C, 62.87; H, 7.09; N, 8.30; C16H22N2O4 requires C, 62.73; H, 
7.24; N, 9.14. 
 
N-(tert-Butoxycarbonyl)-2-[2-(3-cyanoprop-1-yloxy)-5-
methoxyphenyl]ethylamine (70i) 
 
 
                                              
     
 
 
 
According to GP3: 4-Bromobutyronitrile (0.15 g, 0.74 mmol), phenol 69 (0.10 g, 0.37 mmol) 
and anhydrous potassium carbonate (0.20 g, 1.48 mmol) to give the title compound 70i as a 
colourless solid (0.12 g, 96%); m.p: 69–71 oC; IR (CHCl3): max 3681, 3449 (NH), 3014 (C-H), 
2246 (C≡N), 1703 (C=O) cm-1; 1H NMR (300 MHz, CDCl3): δ 6.74 (3H, m, H-3’, H-4’, H-6’), 
4.73 (1H, brs, NH), 4.03 (2H, t, J = 5.8 Hz, H-1”), 3.75 (3H, s, OCH3), 3.32 (2H, q, J = 6.8 Hz, 
H-1), 2.77 (2H, t, J = 6.8 Hz, H-2), 2.60 (2H, t, J = 7.0 Hz, H-3”), 2.14 (2H, m, H-2”), 1.42 (9H, 
s, OC(CH3)3); 13C NMR (75 MHz, CDCl3):  155.9 (C=O), 154.0 (C-5’), 150.6 (C-2’), 128.9 (C-
1’), 119.3 (C-4”), 116.8 (C-6’), 112.5 (C-3’), 112.0 (C-4’), 79.5 (OC(CH3)3), 66.3 (C-1”), 55.7 
(OCH3), 40.8 (C-1), 31.2 (C-2), 28.4 (OC(CH3)3), 25.7 (C-3”), 14.4 (C-2”); HRMS (EI): m/z 
found 334.1924 (M+). C18H26N2O4 (M+) requires 334.1893; Anal. Found: C, 63.62; H, 7.82; N, 
8.06 C18H26N2O4 requires C, 64.65; H, 7.84; N, 8.38. 
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N-(tert-Butoxycarbonyl)-2-[2-(2-benzyloxyeth-1-yloxy)-5-
methoxyphenyl]ethylamine (70j)           
                                         
 
 
 
 
 
 
 
According to GP3: 2-Benzyloxy-1-bromoethane 73 (0.69 g, 3.00 mmol), phenol 69 (0.40 g, 
1.50 mmol) and anhydrous potassium carbonate (0.83 g, 6.00 mmol) to afford 70j as a 
colourless solid (0.53 g, 85%); m.p: 56-58 oC; IR (CHCl3): max 3673, 3449 (NH), 3000, 2398 
(C-H), 1701 (C=O), 1501 (C=C) cm-1; 1H NMR (300 MHz, CDCl3) :  7.40 (5H, m, ArH), 6.79 
(1H, d, J = 8.8 Hz, H-3’), 6.70 (2H, m, H-4’, H-6’), 4.78 (1H, brs, NH), 4.63 (2H, s, ArCH2O), 
4.10 (2H, t, J = 4.8 Hz, H-1”), 3.82 (2H, t, J = 4.8 Hz, H-2”), 3.75 (3H, s, OCH3), 3.37 (2H, q, J 
= 6.5 Hz, H-1), 2.80 (2H, t, J = 6.5 Hz, H-2), 1.42 (9H, s, OC(CH3)3); 13C NMR (75 MHz, 
CDCl3):  155.9 (C=O), 153.7 (C-5’), 151.0 (C-2’), 138.1 (C-1”’), 129.2 (C-1’), 128.4 (C-2”’, C-
6”’), 127.7 (C-4”’), 127.6 (C-3”’, C-5”’), 116.6 (C-6’), 112.9 (C-3’), 111.9 (C-4’), 78.7 
(OC(CH3)3), 73.2 (ArCH2O), 68.7 (C-1”), 68.4 (C-2”), 55.5 (OCH3), 40.7 (C-1), 30.9 (C-2), 
28.4 (OC(CH3)3); HRMS (EI): m/z found 401.22044 (M+). C23H31NO5 (M+) requires 401.22022; 
Anal. Found C, 68.90; H, 7.80; N, 3.37. C23H31NO5 requires C, 68.80; H, 7.78; N, 3.49. 
 
N-(tert-Butoxycarbonyl)-2-[2-(3-benzyloxypropan-1-yloxy)-5-
methoxyphenyl]ethylamine (75)   
 
 
                                        
 
 
 
 
According to GP3: Bromide 73 (0.72 g, 3.14 mmol), phenol 69 (0.42 g, 1.57 mmol) and 
anhydrous potassium carbonate (0.87 g, 6.28 mmol) to give 75 as a white solid (0.65 g, 
100%); mp: 44-46 °C; IR (CHCl3): max 3681 (NH), 3015 (C-H), 1704 (C=O), 1516 (C=C) cm-
1; 1H NMR (300 MHz, CDCl3): δ 7.29 (5H, m, ArH), 6.78 (1H, d, J = 9.7 Hz, H-3’), 6.71(2H, m, 
H-4’, H-6’), 4.69 (1H, brs, NH), 4.53 (2H, s, ArCH2O), 4.04 (2H, t, J = 6.2 Hz, H-1”), 3.76 (3H, 
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s, OCH3), 3.67 (2H, t, J = 6.2 Hz, H-3”), 3.32 (2H, q, J = 6.4 Hz, H-1), 2.73 (2H, t, J = 6.4 Hz, 
H-2), 2.10 (2H, quin, J = 6.2, H-2”), 1.43 (9H, s, OC(CH3)3); 13C NMR (100 MHz, CDCl3): δ 
155.9 (C=O), 153.6 (C-5’), 151.1 (C-2’), 138.4 (C-1”’), 128.9 (C-1’), 128.4, (C-2”’, C-6”’) 
127.6, (C-4”’), 127.5 (C-3”’, C-5”’), 116.8 (C-6’), 112.4 (C-3’), 112.0 (C-4’), 73.0 (ArCH2O), 
79.0 (OC(CH3)3, 66.9 (CH2O), 65.6 (CH2O), 55.7 (OCH3), 40.7 (C-1), 31.0 (C-2), 29.9 (C-2”), 
28.4 (OC(CH3)3); Anal. Found C, 70.35; H, 7.01; N, 3.30; C24H33N3O5 requires C, 69.37; H, 
8.00; N, 3.37. 
 
N-(tert-Butoxycarbonyl)-2-[2-(5-benzyloxy-3-oxapent-1-yloxy)-5-
methoxyphenyl]ethylamine (75a)     
 
        
                                 
 
 
 
 
According to GP3: Bromide 73b (0.87 g, 3.36 mmol), phenol 69 (0.45 g, 1.68 mmol) and 
anhydrous potassium carbonate (0.93 g, 6.70 mmol) to give 75a as a colourless oil (0.61 g, 
81%.); IR (CHCl3): max 3442, 3377 (NH, OH), 3007, 2928 (C-H), 1697 (C=O), 1501 (C=O), 
1227 (C-N) cm1; 1H NMR (400 MHz, CDCl3): δ 7.31 (4H, m, ArH), 7.21 (1H, m, ArH), 6.76 
(1H, d, J = 8.7 Hz, H-3’), 6.70 (1H, d, J = 2.8 Hz, H-6’), 6.68 (1H, dd, J = 2.8, 8.7 Hz, H-4’),  
4.83 (1H, brs, NH), 4.55 (2H, s, ArCH2O), 4.06 (2H, t, J = 4.8 Hz, H-1”), 3.82 (2H, t, J = 4.8 
Hz, CH2O), 3.72 (3H, s, OCH3), 3.70 (2H, m, CH2O), 3.62 (2H, m, CH2O), 3.31 (2H, q, J = 6.5 
Hz, H-1), 2.76 (2H, t, J = 6.5 Hz, H-2), 1.38 (9H, s, OC(CH3)3); 13C NMR (100 MHz, CDCl3): δ 
156.0 (C=O), 153.8 (C-5’), 151.0 (C-2’), 138.2 (C-1”’), 129.4 (C-1’), 128.4 (C-2”’, C-6”’), 127.7 
(C-4”’), 127.6 (C-3”’, C-5”’), 116.6 (C-6’), 113.1 (C-3’), 112.0 (C-4’), 78.8 (OC(CH3)3), 73.3 
(ArCH2), 70.8 (CH2O), 69.9 (CH2O), 69.5 (CH2O), 68.5 (CH2O), 55.6 (OCH3), 40.7 (C-1), 31.0 
(C-2), 28.4 (OC(CH3)3); HRMS (EI): m/z found 445.24814 (M+). C25H35NO6 (M+) requires 
445.24644. 
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N-(tert-Butoxycarbonyl)-2-{2-[2-(2-(2-(2-benzyloxyethoxy)-ethoxy)-
ethoxy)ethoxy]-5-methoxyphenyl}ethylamine (75b)         
    
 
 
 
 
 
According to GP3: Bromide 73c (0.91 g, 2.62 mmol), phenol 69 (0.35 g, 1.31 mmol) and 
anhydrous potassium carbonate (0.72 g, 5.20 mmol) to give 75b as a colourless oil (0.56 g, 
80%.); IR (CHCl3): max 3681, 3449 (N-H), 3021, 2913 (C-H), 1700 (C=O), 1501 (C=C) cm-1; 
1H NMR (400 MHz, CDCl3): δ 7.34 (4H, m, ArH), 7.21 (1H, m, ArH), 6.78 (1H, d, J = 8.8 Hz, 
H-3’), 6.72 (1H, d, J = 3.0 Hz, H-6’),  6.70 (1H, dd, J = 3.0 Hz, 8.8 Hz, H-4’), 4.90 (1H, brs, 
NH), 4.57 (2H, s, ArCH2O), 4.08 (2H, t, J = 4.9 Hz, H-1”), 3.83 (2H, t, J = 4.9 Hz, CH2O), 3.76 
(3H, s, OCH3), 3.72–3.68 (10H, m, 5 × CH2O), 3.64 (2H, m, CH2O), 3.35 (2H, q, J = 6.7 Hz, 
H-1), 2.80 (2H, t, J = 6.7 Hz, H-2), 1.43 (9H, s, OC(CH3)3); 13C NMR (100 MHz, CDCl3): δ 
155.9 (C=O), 153.7 (C-5’), 151.0 (C-2’), 138.3 (C-1”’), 129.3 (C-1’), 128.3 (C-2”’, C-6”’), 127.6 
(C-4”’), 127.5 (C-3”’, C-5”’), 116.6 (C-6’), 113.0 (C-3’), 111.9 (C-4’), 78.7 (OC(CH3)3), 73.1 
(ArCH2), 78.7 (2 × CH2O), 70.6 (2 × CH2O), 70.6 (CH2O), 69.8 (CH2O), 69.4 (CH2O), 68.4 
(CH2O), 55.6 (OCH3), 40.6 (C-1), 31.0 (C-2), 28.4 (OC(CH3)3); HRMS (ES): m/z found 
534.3036 (M+ + H), C29H44NO8 requires (M+ + H) 534.3067. 
 
N-(tert-Butoxycarbonyl)-2-{2-[2-(2-(2-(2-(2-(2-benzyloxyethoxy)-ethoxy)-
ethoxy)ethoxy)ethoxy)ethoxy]-5-methoxyphenyl}ethylamine (75c)     
 
 
According to GP3: Bromide 73d (0.82 g, 1.88 mmol), phenol 69 (0.25 g, 0.94 mmol) and 
anhydrous potassium carbonate (0.52 g, 3.76 mmol) to give 75c as a colourless oil (0.46 g, 
79%.); IR (CHCl3): max  3449 (NH), 3007, 2913 (C-H), 1703 (C=O), 1501 (C=C), 1230 (C-N) 
cm-1; 1H NMR (400 MHz, CDCl3): δ 7.35-7.28 (5H, m, ArH), 6.78 (1H, d, J = 8.8 Hz, H-3’), 
6.70 (2H, m, H-4’, H-6’), 4.89 (1H, brs, NH), 4.57 (2H, s, ArCH2O), 4.08 (2H, t, J = 4.8 Hz, H-
1”), 3.83 (2H, t, J = 4.8 Hz, CH2O), 3.76 (3H, s, OCH3), 3.71 (2H, m, CH2O), 3.65 (18H, m, 9 
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× CH2O), 3.36 (2H, m, H-1), 2.80 (2H, t, J = 7.0 Hz, H-2), 1.43 (9H, s, OC(CH3)3); 13C NMR 
(100 MHz, CDCl3): δ 156.0 (C=O), 153.8 (C-5’), 151.0 (C-2’), 138.3 (C-1”’), 129.3 (C-1’), 
128.3 (C-2”’, C-6”’), 127.7 (C-3”’, C-5”’), 127.5 (C-4”’), 116.6 (C-6’), 113.0 (C-3’), 112.0 (C-4’), 
78.7 (OC(CH3)3), 73.2 (ArCH2), 70.7 (CH2O), 70.6 (4 × CH2O), 70.5 (4 × CH2O), 69.8 (CH2O), 
69.4 (CH2O), 68.4 (CH2O), 55.6 (OCH3), 40.6 (C-1), 31.0 (C-2), 28.4 (OC(CH3)3); HRMS 
(ES): m/z found (M+ + H), 622.3610, C33H52NO10 requires (M+ + H) 622.3591. 
 
. 
 
General Procedure for hydrogenolysis of the benzyl group (GP4) 
 
Hydrogen gas was introduced at atmospheric pressure to the carbamate 70j, 75 and 75a-c 
(1.00 mmol) and a suspension of 10% palladium-on-carbon (10 mol%) in ethanol (20 mL). 
The mixture was stirred at room temperature for 18 h. The catalyst was filtered through a pad 
of Celite, washed with EtOAc (3 × 15 mL) and the filtrate evaporated in vacuo. The crude 
product was purified by column chromatography using EtOAc / pet ether (8 / 2) to give the 
product. 
 
 
 
N-(tert-Butoxycarbonyl)-2-[2-(2-hydroxyethoxy)-5-methoxyphenyl]ethylamine 
(70m) 
 
                                                  
 
 
 
Compound 70m, colourless crystals (0.33 g, 93%); m.p: 90–91 oC; IR (CHCl3): max 3681, 
3615, 3449 (NH, OH), 3021, 2405 (C-H), 1700 (C=O), 1501 (C=C), 1165 (C-N) cm-1; 1H NMR 
(400 MHz, CDCl3)  : 6.74 (3H, m, H-3’, H-5’, H-6’), 4.87 (1H, brs, NH), 4.00 (4H, m, H-1”, H-
2”), 3.75 (3H, s, OCH3), 3.31 (2H, q, J = 6.7 Hz, H-1), 2.78 (2H, t, J = 6.7 Hz, H-2), 1.42 (9H, 
s, OC(CH3)3), 1.25 (1H, brs, OH); 13C NMR (100 MHz, CDCl3):  156.5 (C=O), 153.9 (C-5’), 
151.4 (C-2’), 128.9 (C-1’), 117.1 (C-6’), 112.6 (C-3’), 112.0 (C-4’), 79.7 (OC(CH3)3), 70.6 (C-
1”), 61.6 (C-2”), 55.9 (OCH3), 41.0 (C-2), 32.6 (C-1), 28.6 (OC(CH3)3); HRMS (EI): m/z found 
311.17278 (M+). C16H25NO5 (M+) requires 311.17327; Anal. Found: C, 61.70; H, 8.03; N, 
4.14. C16H25NO5 requires C, 61.72; H, 8.09; N, 4.50. 
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N-(tert-Butoxycarbonyl)-2-[2-(3-hydroxyprop-1-yloxy)-5-
methoxyphenyl]ethylamine (70n)   
 
  
 
                                              
 
 
Compound 70n, colourless crystals (0.45 g, 95%); mp: 44-46 oC; IR (CHCl3): max 3681, 
3623, 3449 (NH, OH), 2399 (C-H), 1700 (C=O), 1505 (C=C), 1205 (C-N) cm-1; 1H NMR (300 
MHz, CDCl3): δ 6.80 (1H, d, J = 9.6 Hz, H-3’), 6.70 (2H, m, H-4’, H-6’), 4.78 (1H, brs, NH), 
4.06 (2H, t, J = 5.9 Hz, H-1”), 3.87 (2H, t, J = 5.9 Hz, H-3”), 3.75 (3H, s, OCH3), 3.34 (2H, q, J 
= 6.6 Hz, H-1), 2.76 (2H, t, J = 6.6 Hz, H-2), 2.37 (1H, brs, OH), 2.03 (2H, quin, J = 5.9 Hz, 
H-2”), 1.41 (9H, s, OC(CH3)3); 13C NMR (100 MHz, CDCl3):  155.9 (C=O), 153.6 (C-5’), 
151.1 (C-2’), 128.9 (C-1’), 116.8 (C-6’), 112.4 (C-3’), 112.0 (C-4’), 79.0 (OC(CH3)3), 66.9 (C-
1”), 65.9 (C-3”), 55.7 (OCH3), 40.7 (C-1), 31.0 (C-2), 29.9 (C-2”), 28.4 (OC(CH3)3); Anal. 
Found C, 62.97; H, 8.35; N, 4.13 C17H27NO4 requires C, 62.75; H, 8.36; N, 4.30. 
 
N-(tert-Butoxycarbonyl)-2-{2-[2-(2-hydroxyethoxy)ethoxy]-5-
methoxyphenyl}ethylamine (70o)  
 
                                                 
 
 
 
 
 
Compound 70o, as a colourless oil (0.41 g, 93%); IR (CHCl3): max 3667, 3457, 3384 (NH, 
OH), 3007, 2928 (C-H), 1700 (C=O), 1501 (C=C), 1223 (C-N) cm-1; 1H NMR (400 MHz, 
CDCl3): δ 6.74 (1H, d, J = 8.4 Hz, H-3’), 6.68 (1H, d, J = 2.8 Hz, H-6’), 6.65 (1H, dd, J = 2.8, 
8.4 Hz, H-4’), 4.88 (1H, brs, NH), 4.07 (2H, t, J = 4.6 Hz, CH2O), 3.82 (2H, t, J = 4.6 Hz, 
CH2O), 3.71 (5H, m, OCH3, CH2O), 3.62 (2H, t, J = 4.6 Hz, CH2O), 3.32 (2H, m, H-1), 2.76 
(2H, t, J = 6.8 Hz, H-2), 2.51 (1H, brs, OH), 1.36 (9H, s, OC(CH3)3); 13C NMR (100 MHz, 
CDCl3): δ 156.0 (C=O), 153.9 (C-5’), 151.0 (C-2’), 129.3 (C-1’), 116.7 (C-6’), 113.0 (C-3’), 
112.0 (C-4’), 79.0 (OC(CH3)3), 72.6 (C-1”), 69.8 (CH2O), 68.4 (CH2O), 61.7 (C-5”), 55.6 
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(OCH3), 40.7 (C-1), 30.8 (C-2), 28.4 (OC(CH3)3); HRMS (EI): m/z found 355.19828 (M+). 
C18H29O6N (M+) requires 355.19949    
 
N-(tert-Butoxycarbonyl)-2-{2-[2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)-ethoxy]-
5-methoxyphenyl}ethylamine (70p)   
 
 
 
 
 
 
 
Compound 70p, as a colourless oil (0.38 g, 90%); IR (CHCl3) max 3667, 3449 (NH, OH), 
3007, 2928 (C-H), 1700 (C=O), 1501 (C=C), 1220 (C-N) cm-1; 1H NMR (400 MHz, CDCl3): δ 
6.78 (1H, d, J = 8.8 Hz, H-3’), 6.72 (1H, d, J = 3.0 Hz, H-6’), 6.69 (1H, dd, J = 3.0 Hz, 8.8 Hz, 
H-4’), 5.01 (1H, brs, NH), 4.08 (2H, t, J = 4.8 Hz, H-1”), 3.83 (2H, t, J = 4.8 Hz, CH2O), 3.75 
(3H, s, OCH3), 3.72–3.66 (10H, m, 5 × CH2O), 3.60 (2H, m, CH2O), 3.34 (2H, m, H-1), 2.80 
(2H, t, J = 7.0 Hz, H-2), 1.42 (9H, s, OC(CH3)3); 13C NMR (100 MHz, CDCl3):  156.0 (C=O), 
153.8 (C-5’), 150.9 (C-2’), 129.3 (C-1’), 116.6 (C-6’), 113.0 (C-3’), 112.0 (C-4’), 78.7 
(OC(CH3)3), 72.5 (C-1”), 70.7 (CH2O), 70.6 (2 × CH2O), 70.4 (CH2O), 69.8 (CH2O), 68.4 
(CH2O), 61.6 (CH2O), 55.6 (OCH3), 40.6 (C-1), 31.0 (C-2), 28.4 (OC(CH3)3); HRMS (ES): m/z 
found 444.2610 (M+ + H), C22H38NO8 requires (M+ + H) 444.2597.  
 
N-(tert-Butoxycarbonyl)-2-{2-[2-(2-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)-
ethoxy)ethoxy)ethoxy]-5-methoxyphenyl}ethylamine (70q) 
 
  
            
 
 
 
 
Compound 70q, as a colourless oil (0.31 g, 91%); IR (CHCl3): max 3652, 3449 (NH, OH), 
3007, 2884 (C-H), 1700 (C=O), 1501 (C=C), 1227, 1100 (C-N) cm-1; 1H NMR (400 MHz, 
CDCl3): δ 6.78 (1H, d, J = 8.8 Hz, H-3’), 6.71 (1H, d, J = 2.8 Hz, H-6’), 6.69 (1H, dd, J = 2.8, 
8.8 Hz, H-4’), 4.96 (1H, brs, NH), 4.08 (2H, t, J = 4.6 Hz, H-1”), 3.83 (2H, t, J = 4.6 Hz, 
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CH2O), 3.75 (3H, s, OCH3), 3.70 (2H, t, J = 4.6 Hz, CH2O), 3.64 (16H, m, 8 × CH2O), 3.59 
(2H, t, J = 4.6 Hz, CH2O), 3.34 (2H, q, J = 6.5 Hz, H-1), 2.79 (2H, t, J = 6.5 Hz, H-2), 1.41 
(9H, s, OC(CH3)3; 13C NMR (100 MHz, CDCl3):  156.0 (C=O), 153.8 (C-5’), 151.0 (C-2’), 
129.3 (C-1’), 116.6 (C-6’), 113.0 (C-3’), 112.0 (C-4’), 78.8 (OC(CH3)3), 72.6 (C-1”), 70.7 
(CH2O), 70.6 (CH2O), 70.5 (4 × CH2O), 70.4 (CH2O), 70.2 (CH2O), 69.8 (CH2O), 68.4 
(CH2O), 61.6 (C-17”), 55.6 (OCH3), 40.6 (C-1), 31.0 (C-2), 28.4 (OC(CH3)3; ); HRMS (ES): 
m/z found 532.3112 (M+ + H), C26H46NO10 requires (M+ + H) 532.3122.  
 
N-(tert-Butoxycarbonyl)-2-[5-methoxy-2- 
(2-p-toluenesulphonyloxyethoxy)phenyl]ethylamine (74) 
 
 
 
 
                      
 
 
Triethylamine (0.31 mL, 2.39 mmol) and p-toluenesulfonyl chloride (0.46 g, 2.39 mmol) were 
added to a solution of alcohol 70m (0.62 g, 1.99 mmol) in dry CH2Cl2 (15 mL) at 0 oC, 
followed by a catalytic amount of DMAP (20 mg). The reaction mixture was stirred at rt for 16 
h. The crude was diluted with CH2Cl2 (60 mL), washed with aq NH4Cl (20 mL), water (30 mL), 
and the organic extracts dried over MgSO4 and the solvent removed under reduced pressure. 
The crude product was purified by silica-gel column chromatography using EtOAc in light 
petroleum (2 / 8) to give 74 as a colourless oil (0.72 g, 77%); IR (CHCl3): max 3659, 3442 
(NH), 3007, 2934 (C-H), 1703 (C=O), 1501 (C=C), 1176 (-SO2-O) cm-1; 1H NMR (300 MHz, 
CDCl3): δ 7.80 (2H, d, J = 8.2  Hz, H-2”’, H-6”’), 7.34 (2H, d, J = 8.2 Hz, H-3”’, H-5”’), 6.68 
(3H, m, H-3’, H-4’, H-6’), 4.69 (1H, brs, NH), 4.35 (2H, t, J = 4.7 Hz, H-2”), 4.10 (2H, t, J = 4.7 
Hz, H-1”), 3.73 (3H, s, OCH3 ), 3.25 (2H, q, J = 6.8 Hz, H-1), 2.69 (2H, t, J = 6.8 Hz, H-2), 
2.43 (3H, s, ArCH3 ), 1.39 (9H, s, OC(CH3)3 ); 13C NMR (75 MHz, CDCl3): δ 155.9 (C=O), 
154.1 (C-5’), 150.2 (C-2’), 145.0 (C-1”’), 133.0 (C-4”’), 129.9 (C-3”’, C-5”’), 129.3 (C-1’), 127.9 
(C-2”’, C-6”’),116.7 (C-6’), 112.9 (C-3’), 112.0 (C-4’), 78.9 (OC(CH3)3), 68.3 (C-1”), 66.4 (C-
2”), 55.6 (OCH3), 40.5 (C-2), 30.9 (C-1), 28.4 (OC(CH3)3), 21.6 (ArCH3); HRMS (EI): m/z 
found 465.18130 (M+). C23H31NO7S (M+) requires 465.18212.  
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N-(tert-Butoxycarbonyl)-2-{5-methoxy-2-[2- 
(2-p-toluenesulphonyloxyethoxy)ethoxy]phenyl}ethylamine (74a) 
 
   
 
 
 
 
To a solution of alcohol 70o (0.56 g, 1.58 mmol) in dry CH2Cl2 (15 mL), triethylamine (0.25 
mL, 1.90 mmol) and p-toluenesulfonyl chloride (0.36 g, 1.90 mmol) were added at 0 oC, 
followed by a catalytic amount of DMAP (20 mg). The reaction mixture was stirred at rt for 16 
h.  The mixture was diluted with CH2Cl2 (70 mL), washed with aq NH4Cl (30 mL), water (30 
mL), dried over MgSO4 and solvent was removed under reduced pressure. Purification by 
column chromatography EtOAc in light petroleum (4 / 6 ) gave 74a as a colorless oil (0.64 g, 
80%); IR (CHCl3): max 3406 (NH), 3007, 2928 (C-H), 1704 (C=O), 1501 (C=C), 1223 (C-N), 
1176 (O-SO2-) cm-1; 1H NMR (300 MHz, CDCl3): δ 7.78 (2H, d, J = 8.4 Hz, H2”’, H-6”’), 7.30 
(2H, d, J = 8.4 Hz, H-3”’, H-5”’), 6.73 (3H m, H-3’, H-4’, H-6’), 4.79 (1H, brs, NH), 4.18 (2H, t, 
J = 4.7 Hz, H-5”), 4.01 (2H, t, J = 4.7 Hz, CH2O), 3.77 (4H, m, 2 × CH2O), 3.75 (3H, s, OCH3), 
3.30 (2H, q, J = 6.6 Hz, H-1), 2.75 (2H, t, J = 6.6 Hz, H-2), 2.41 (3H, s, ArCH3), 1.40 (9H, s, 
OC(CH3)3); 13C NMR (75 MHz, CDCl3): δ 150.9 (C=O), 153.8 (C-5’), 150.9 (C-2’), 144.8 (C-
1”’), 133.0 (C-4”’), 129.8 (C-3”’, C-5”’), 129.3 (C-1’), 127.9 (C-2”’, C-6”’), 116.6 (C-6’), 12.9 (C-
3’), 111.9 (C-4’), 78.8 (OC(CH3)3), 70.0 (CH2O), 69.2 (CH2O), 68.8 (CH2O), 68.3 (CH2O), 
55.6 (OCH3), 40.6 (C-1), 31.0 (C-2), 28.4 (OC(CH3)3, 21.5 (ArCH3); HRMS (EI): m/z found 
509.20675 (M+). C25H35NO8S (M+) requires 509.20834. 
 
N-(tert-Butoxycarbonyl)-2-{5-methoxy-2-[2-(2-(2-(2-p-
toluenesulphonyloxyethoxy)ethoxy)ethoxy)ethoxy]-phenyl}ethylamine (74b) 
 
                
 
 
 
 
 
p-Toluenesulfonyl chloride (0.26 g, 1.36 mmol) was added to a stirring solution of the alcohol 
70p (0.50 g, 1.13 mmol) containing triethylamine (0.18 mL, 1.36 mmol), and a catalytic 
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amount of DMAP (20 mg) in dry CH2Cl2 (15 mL) at 0 oC. The reaction mixture was stirred at rt 
for 16 h. The mixture was diluted with CH2Cl2 (80 mL), the organic extracts washed with aq 
NH4Cl (25 mL), water (30 mL), dried over MgSO4 and the solvent removed under reduced 
pressure. Purification by column chromatography EtOAc in petroleum ether (8 / 2) gave 74b 
as a colorless oil (0.58 g, 84%); IR (CHCl3): max 3377 (NH), 2928 (C-H), 1707 (C=O), 1501 
(C=C), 1223 (C-N), 1176 (O-SO2-) cm-1; 1H NMR (300 MHz, CDCl3): δ 7.77 (2H, d, J = 8.4 
Hz, H-2”’, H-6”’), 7.31 (2H, d, J = 8.4 Hz, H-3”’, H-5”’), 6.76 (1H, d, J = 9.2 Hz, H-3’), 6.68 
(2H, m, H-4’, H-6’), 4.85 (1H, brs, NH), 4.14 (2H, t, J = 4.8 Hz, H-11”), 4.06 (2H, t, J = 4.8 Hz, 
CH2O), 3.81 (2H, t, J = 4.8 Hz, CH2O), 3.73 (3H, s, OCH3), 3.69–3.57 (10H, m, 5 × CH2O), 
3.32 (2H, q, J = 6.5 Hz, H-1), 2.77 (2H, t, J = 6.5 Hz, H-2), 2.42 (3H, s, ArCH3), 1.40 (9H, s, 
OC(CH3)3); 13C NMR (75 MHz, CDCl3): δ 155.9 (C=O), 153.8 (C-5’), 151.0 (C-2’), 144.7 (C-
1”’), 133.0 (C-4”’), 129.7 ( C-3”’, C-5”’), 129.3 (C-1’), 127.9 (C-2”’, C-6”’), 116.6 (C-6’), 113.0 
(C-3’), 111.9 (C-4’), 78.8 (OC(CH3)3), 70.7 (3 × CH2O), 70.5 (CH2O), 69.8 (CH2O), 69.2 
(CH2O), 68.6 (CH2O), 68.4 (CH2O), 55.6 (OCH3), 40.6 (C-1), 31.0 (C-2), 28.4 (OC(CH3)3, 
21.5 (ArCH3); HRMS (ES): m/z found 598.2673 (M+ + H), C29H44NO10S requires (M+ + H) 
598.2686. 
 
N-(tert-Butoxycarbonyl)-2-{5-methoxy-2-[2-(2-(2-(2-(2-(2-p-
toluenesulphonyloxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy]-
phenyl}ethylamine (74c) 
 
                                                                                                                                      
To a solution of alcohol 70q (0.35 g, 0.66 mmol) in dry CH2Cl2 (10 mL), triethylamine (0.11 
mL, 0.79 mmol) and p-toluenesulfonyl chloride (0.15 g, 0.79 mmol) were added at 0 oC, 
followed by a catalytic a mount of DMAP (20 mg). The reaction mixture was stirred at rt for 16 
h.  The mixture was diluted with CH2Cl2 (50 mL), washed with aq NH4Cl (20 mL), water (20 
mL), dried over MgSO4 and the solvent removed under reduced pressure. Purification by 
column chromatography EtOAc in light petroleum (8 / 2) gave 74c as a colorless oil (0.42 g, 
93%); IR (CHCl3): max 3449 (NH), 3007, 2913 (C-H), 1704 (C=O), 1501 (C=C), 1176 (O-SO2-
) cm-1;1H NMR (300 MHz, CDCl3): δ 7.78 (2H, d, J = 8.2 Hz, H-2”, H-6”), 7.32 (2H, d, J = 8.2 
Hz, H-3”, H-5”), 6.77 (1H, d, J = 9.2 Hz, H-3’), 6.68 (2H, m, H-4’, H-6’), 4.87 (1H, brs, NH), 
4.14 (2H, t, J = 4.9 Hz, CH2O), 4.07 (2H, t, J = 4.9 Hz, CH2O), 3.82 (2H, t, J = 4.9 Hz, CH2O), 
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2.41 (3H, s, ArCH3), 3.74 (3H, s, OCH3), 3.70-3.56 (18H, m, 9 × CH2O), 3.34 (2H, q, J = 6.6 
Hz, H-1), 2.78 (2H, t, J = 6.6 Hz, H-2), 2.41 (3H, s, ArCH3), 1.41 (9H, s, OCH3); 13C NMR 
(100 MHz, CDCl3): δ 156.0 (C=O), 153.8 (C-5’), 151.0 (C-2’), 144.7 (C-1”’), 133.1 (C-4”’), 
129.8 ( C-3”’, C-5”’), 129.3 (C-1’), 127.9 (C-2”’, C-6”’), 116.6 (C-6’), 113.0 (C-3’), 112.0 (C-4’), 
78.8 (OC(CH3)3), 70.7 (CH2O), 70.7 (CH2O), 70.6 (CH2O), 70.5 (2 × CH2O), 70.5 (2 × CH2O), 
70.5 (CH2O), 69.8 (CH2O), 69.2 (CH2O), 68.7 (CH2O), 68.4 (CH2O), 55.6 (OCH3), 40.6 (C-1), 
31.0 (C-2), 28.4 (OC(CH3)3, 21.6 (ArCH3); ); HRMS (ES): m/z found 686.3192 (M+ + H), 
C33H52NO12S requires (M+ + H) 686.3210.  
 
 
General Procedure for O-alkylation of propargyl alcohol (GP5) 
 
To a stirred suspension of NaH (60% in mineral oil, 4.00 mmol) in THF at 0 oC was added 
propargyl alcohol dropwise (6.00 mmol). The mixture was refluxed for 30 min and the 
solution of tosylate N-Boc carbamate 74, 74a-c (1.00 mmol) in THF (10 mL) then added 
dropwise. After refluxing for 20 h, the crude product was diluted with EtOAc (70 mL), washed 
with a solution of NH4Cl (20 mL) and water (2 x 20 mL). The organic extracts were dried over 
MgSO4, filtered and the solvent evaporated under reduced pressure to afford a residue, 
which was purified by column chromatography (15% EtOAc in petroleum ether) to afford the 
following products as colourless oils. 
 
N-(tert-Butoxycarbonyl)-2-[5-methoxy-2-(2-
propargyloxyethoxy)phenyl]ethylamine (70k) 
 
 
 
 
 
 
Compound 70k (0.27 g, 73%); IR (CHCl3): max 3667, 3449 (NH), 3304 (≡C-H), 3007, 2935 
(C-H), 2123 (C≡C), 1703 (C=O), 1227 (C-N) cm-1; 1H NMR (300 MHz, CDCl3): δ 6.77 (1H, d,  
J = 7.8 Hz, H-3’), 6.70 (2H, m, H-4’, H-6’), 4.80 (1H, brs, NH), 4.25 (2H, d, J = 2.5 Hz, H-4”), 
4.10 (2H, m, H-1”), 3.88 (2H, m, H-2”) 3.74 (3H, s, OCH3 ), 3.35 (2H, q, J = 6.7 Hz, H-1), 2.80 
(2H, t, J = 6.7 Hz, H-2), 2.45 (1H, t, J = 2.5 Hz, H-6”), 1.41 (9H, s, OC(CH3)3 ); 13C NMR (75 
MHz, CDCl3): δ 156.0 (C=O), 153.9 (C-5’), 150.9 (C-2’), 129.4 (C-1’), 116.6 (C-6’), 113.0 (C-
3’), 112.0 (C-4’), 79.5 (C-5”), 78.9 (OC(CH3)3, 74.7 (C-6”), 68.3 (CH2O), 68.2 (CH2O), 58.4 
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(C-4”), 55.6 (OCH3), 40.7 (C-1), 30.9 (C-2), 28.4 (OC(CH3)3; HRMS (EI): m/z found 
349.18937 (M+). C19H27NO5 (M+) requires 349.18892. 
 
N-(tert-Butoxycarbonyl)-2-{5-methoxy-2-[2-(2-
propargyloxyethoxy)ethoxy]phenyl}ethylamine (70l) 
                               
 
 
 
 
 
 
Compound 70l (0.39 g, 90%); IR (CHCl3): max 3449 (NH), 3304 (≡CH), 3000, 2906 (C-H), 
2116 (C≡C), 1733, 1704 (C=O), 1501 (C=C) cm-1; 1H NMR (400 MHz, CDCl3): δ 6.75 (1H, d, 
J = 9.2 Hz, H-3’), 6.67 (2H, m, H-4’, H-6’), 4.83 (1H, brs, NH), 4.18 (2H, d, J = 2.4 Hz, H-7’’), 
4.06 (2H, t, J = 4.9 Hz, CH2O), 3.80 (2H, t, J = 4.9 Hz, CH2O), 3.72 (3H, s, OCH3), 3.69 (4H, 
m, 2 × CH2O), 3.32 (2H, q, J = 6.6 Hz, H-1), 2.76 (2H, t, J = 6.6 Hz, H-2), 2.40 (1H, t, J = 2.4 
Hz, H-9”), 1.39 (9H, s, OC(CH3)3; 13C NMR (100 MHz, CDCl3): δ 156.0 (C=O), 153.9 (C-5’), 
151.0 (C-2’), 129.4 (C-1’), 116.6 (C-6’), 113.1 (C-3’), 112.0 (C-4’), 79.6 (C-8”), 78.8 
(OC(CH3)3), 74.6 (C-9”), 70.6 (CH2O), 69.9 (CH2O), 69.2 (CH2O), 68.5 (CH2O), 58.4 (C-7”), 
55.7 (OCH3), 40.7 (C-2), 31.1 (C-1), 28.4 (OC(CH3)3); HRMS (EI): m/z found 393.21448 (M+), 
C21H31NO6 (M+) requires 393.21514. 
 
N-(tert-Butoxycarbonyl)-2-{5-methoxy-2-[2-(2-(2-(2-
propargyloxyethoxy)ethoxy)ethoxy)ethoxy]phenyl}ethylamine (70r)  
 
 
 
 
 
 
Compound 70r (0.29 g, 83%); IR (CHCl3): max 3449 (NH), 3304 (≡CH), 3007, 2920 (C-H), 
2116 (C≡C), 1703 (C=O), 1501 (C=C), 1227 (C-N) cm-1; 1H NMR (300 MHz, CDCl3): δ 6.77 
(1H, d, J = 8.8 Hz, H-3’), 6.68 (2H, m, H-4’, H-6’), 4.88 (1H, brs, NH), 4.18 (2H, d, J = 2.1 Hz, 
H-13”), 4.07 (2H, t, J = 4.8 Hz, H-1”), 3.82 (2H, t, J = 4.8 Hz, CH2O), 3.74 (3H, s, OCH3), 
3.72–3.64 (12H, m,  
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6 × CH2O), 3.34 (2H, q, J = 6.5 Hz, H-1), 2.78 (2H, t, J = 6.5 Hz, H-2), 2.40 (1H, t, J = 2.1 Hz, 
H-15”), 1.41 (9H, s, OC(CH3)3); 13C NMR (100 MHz, CDCl3): δ 156.0 (C=O), 153.8 (C-5’), 
151.0 (C-2’), 129.3 (C-1’), 116.6 (C-6’), 113.0 (C-3’), 112.0 (C-4’), 79.7 (C-14”), 78.8 
(OC(CH3)3), 74.4 (C-15”), 70.8 (CH2O), 70.7 (CH2O), 70.6 (2 × CH2O), 70.4 (CH2O), 69.9 
(CH2O), 69.1 (CH2O), 68.5 (CH2O), 58.3 (C-13”), 55.6 (OCH3), 40.6 (C-2), 31.0 (C-1), 28.4 
(OC(CH3)3); HRMS (ES): m/z found 482.2732 (M+ + H), C25H40NO8 requires (M+ + H) 
482.2754. 
 
N-(tert-Butoxycarbonyl)-2-{5-methoxy-2-[2-(2-(2-(2-(2-(2-
propargyloxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy]phenyl}ethylamine 
(70s)   
 
 
 
 
 
 
Compound 70s (0.21 g, 80%); IR (CHCl3): max 3362 (NH), 3246 (≡CH), 2870 (C-H), 2116 
(C≡C), 1707 (C=O), 1501 (C=C), 1223 (C-N) cm-1; 1H NMR (300 MHz, CDCl3): δ 6.77 (1H, J 
= 9.2 Hz, H-3’), 6.68 (2H, m, H-4’, H-6’), 4.87 (1H, brs, NH), 4.18 (2H, d, J = 2.4 Hz, H-19”), 
4.07 (2H, t, J = 4.9 Hz, H-1”), 3.82 (2H, t, J = 4.9 Hz, CH2O), 3.74 (3H, s, OCH3), 3.71-3.62 
(20H, m, 10 × CH2O), 3.34 (2H, q, J = 6.6 Hz, H-1), 2.78 (2H, t, J = 6.6 Hz, H-2), 2.41 (2H, t, 
J = 2.4 Hz, H-21”), 1.41 (9H, s, OC(CH3)3); 13C NMR (75 MHz, CDCl3): δ 156.0 (C=O), 153.8 
(C-5’), 151.0 (C-2’), 129.3 (C-1’), 116.6 (C-6’), 113.0 (C-3’), 112.0 (C-4’), 79.7 (C-20”), 78.8 
(OC(CH3)3), 74.5 (C-21”), 70.8 (2 × CH2O), 70.6 (2 × CH2O), 70.6 (3 × CH2O), 70.4 (CH2O), 
69.8 (CH2O), 69.1 (CH2O), 68.4 (2 × CH2O), 58.4 (C-19”), 55.6 (OCH3), 40.6 (C-2), 31.0 (C-
1), 28.4 (OC(CH3)3; HRMS (ES): m/z found 570.3289 (M+ + H), C29H48NO10 requires (M+ + H) 
570.3278.  
 
N-(5-Bromo-2-pyridinyl)-1H-imidazole-1-carbothioamide (49)
101 
 
 
 
 
 
1, 1’-Thiocarbonyldiimidazole (1.26 g, 7.07 mmol) was added to 2-amino-5-bromopyridine 
(1.22 g, 7.07 mmol) in dry CH3CN (20 mL) and the solution was stirred for 20 h at rt. The 
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precipitate was filtered and washed with cold CH3CN (10 mL) to yield 49 as a white solid 
(1.83 g, 92%); 1H NMR (300 MHz, CDCl3): δ 10.19 (1H, brs, NH), 8.49 (1H, d, J = 2.4 Hz, H-
6’), 8.16 (2H, m, H-2’, H-3’), 7.79 (1H, s, H-2), 7.09 (2H, m, H-4, H-5); 13C NMR (75 MHz, 
CDCl3): δ 176.8 (C=S), 151.2 (C-2’), 147.3 (C-6’), 140.7 (C-4’), 134.9 (C-2), 121.3 (C-4, C-5), 
116.2 (C-3’), 113.8 (C-5’). 
 
General Procedure for the Synthesis of Thioureas (GP6)  
 
Trifluoroacetic acid (0.20 mL) was added to a solution of the N-Boc carbamate 70a-q (1.00 
mmol) in CH2Cl2 (2 mL) at 0 °C, and the solution stirred for 2 h. Diisopropylethylamine (0.40 
mL) was added, the solvent evaporated in vacuo and the crude amine dried under vacuum 
for 1 h. Thiocarbonyl reagent 49 (1.30 mmol) was added to the crude amine in DMF (5 mL) 
and the mixture stirred at 100 oC for 16 h. The mixture was then poured into ice-cold water (5 
mL) and stirred for 30 min. The precipitate formed was filtered and washed with cold water (2 
× 5 mL) or alternatively extracted into ethyl acetate/ light petroleum mixtures as eluent. 
Alternatively, the condensation reaction with 49 could be carried out in THF (5 mL) at room 
temperature for 20 h. Following evaporation of the solvent, the residue was subjected directly 
to column chromatography to afford the desired thioureas. 
 
 
N-(5-Bromo-2-pyridinyl)-N’-[2-(5-methoxy-2-prop-1-yloxyphenyl)ethyl]-thiourea 
(77a) 
 
                                                               
 
 
Using THF/ rt, gave compound 77a (0.13 g, 65%); mp: 162-163 °C; IR (CHCl3): max 3696, 
3413 (NH), 3167, 2963 (C-H), 1512 (C=C), 1472 (C=S), 1212 (C-N) cm-1; 1H NMR (400 MHz, 
CDCl3):  11.18 (1H, brs, NH), 8.95 (1H, brs, NH), 8.08 (1H, d, J = 2.4 Hz, H-6”’), 7.67 (1H, 
dd, J = 2.4 Hz, 8.8 Hz, H-4”’), 6.81 (1H, d, J = 3.2 Hz, H-6’), 6.78 (1H, d, J = 8.8 Hz, H-3’), 
6.74 (1H, dd, J = 3.2, 8.8 Hz, H-4’), 6.72 (1H, d, J = 8.8 Hz, H-3”’), 4.02 (2H, m, H-1”), 3.87 
(2H, t, J = 6.4 Hz, H-1), 3.75 (3H, s, OCH3), 2.99 (2H, t, J = 6.4 Hz, H-2), 1.80 (2H, m, H-2’’), 
1.04 (3H, t, J = 7.4 Hz, H-3”); 13C NMR (100 MHz, CDCl3):  179.0 (C=S), 153.3 (C-5’), 151.7 
(C-2”’), 151.5 (C-2’), 146.8 (C-6”’), 141.1(C-4”’), 128.5 (C-1’), 117.7 (C-6’), 113.2 (C-3’), 
112.6 (C-3”’), 112.2 (C-5”’), 111.5 (C-4’), 70.2 (C-1”), 55.6 (OCH3), 45.8 (C-1), 30.0 (C-2), 
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22.8 (C-2”), 10.7 (C-3”); Anal. Found: C, 50.77; H, 5.21; N, 9.50; S, 7.14. C18H22BrN3O2S 
requires C, 50.95; H, 5.23; N, 9.90; S, 7.55. 
 
N-(5-Bromo-2-pyridinyl)-N'-[2-(5-methoxy-2-propargyloxyphenyl)ethyl]-thiourea 
(77b) 
 
 
   
 
 
 
Using DMF/ 100 oC, gave compound 77b (80 mg, 17%); mp: 121-122 °C; IR (CHCl3): max 
3691 (NH), 3307, 3174 (≡CH), 1602 (C=C), 1137 (C-N) cm-1; 1H NMR (400 MHz, CDCl3):  
11.13 (1H, brs, NH), 8.29 (1H, brs, NH), 8.12 (1H, d, J = 2.4 Hz, H-6”’), 7.69 (1H, dd, J = 2.4 
Hz, 8.8 Hz, H-4”’), 6.95 (1H, d, J = 8.8 Hz, H-3’”), 6.82 (1H, d, J = 3.1 Hz, H-6’), 6.76 (1H, dd, 
J = 3.2 Hz, 8.8 Hz, H-4’), 6.59 (1H, d, J = 8.8 Hz, H-3’), 4.67 (2H, d, J = 2.2 Hz, H-1”), 4.01 
(2H, q, J = 6.8 Hz, H-1), 3.76 (3H, s, OCH3), 3.01 (2H, t, J = 6.7 Hz, H-2), 2.47 (1H, t, J = 2.2 
Hz, H-3”); 13C NMR (75 MHz, CDCl3):  179.1 (C=S), 154.2 (C-5’), 151.7 (C-2”’), 150.0 (C-2’), 
146.7 (C-6”’), 141.1 (C-4”’), 129.2 (C-1’), 117.6 (C-6’), 113.5 (C-3’),113.3 (C-3”’), 112.6  (C-
5”’), 111.5 (C-4’), 79.0 (C-2”), 75.3 (C-3”), 56.8 (C-1”), 55.5 (OCH3), 45.7 (C-1), 29.8 (C-2); 
Anal. Found: C, 51.23; H, 4.50; N, 8.62 C18H18BrN3O2S requires C, 51.44; H, 4.32; N, 10.00. 
 
N-(5-Bromo-2-pyridinyl)-N'-{2-[2-(3-butynyl-1-oxy)-5-methoxyphenyl]ethyl}-
thiourea (77c) 
                          
 
 
 
 
 
Using DMF/ 100 oC, gave compound 77c (33 mg, 25%); mp: 155-156 °C; IR (CHCl3): max 
3691, 3415 (NH), 3308 (≡CH), 3152, 3018, 2956 (C-H), 2245 (C≡C), 1591 (C=C), 1511 
(C=S), 1138 (C-N) cm-1; 1H NMR (300 MHz, CDCl3):  11.13 (1H, brs, NH), 8.44 (1H, brs, 
NH), 8.10 (1H, d, J = 2.4 Hz, H-6”’), 7.68 (1H, dd, J = 2.4, 8.7 Hz, H-4”’), 6.76 (3H, m, H-3”’, 
H-4’,H-6’), 6.61 (1H, d, J = 8.7 Hz, H-3”’), 4.03 (4H, m, H-1, H-1”), 3.75 (3H, s, OCH3), 3.00 
(2H, t, J = 6.6 Hz, H-2), 2.68 (2H, td, J = 2.6, 6.9 Hz, H-2”), 2.04 (1H, t, J = 2.6 Hz, H-4”); 13C 
NMR (75 MHz, CDCl3):  179.2 (C=S), 153.8 (C-5’), 151.6 (C-2’), 150.9 (C-2”’), 146.9 (C-6”’), 
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141.2 (C-4”’), 128.9 (C-1’), 117.8 (C-6’), 113.1 (C-3”’), 112.8 (C-3’), 112.7 (C-5”’), 111.6 (C-
4’), 80.8 (C-4”) 69.9 (C-3”), 66.9 (C-1”), 55.6 (OCH3), 45.8 (C-1), 30.0 (C-2), 19.8 (C-2”’); 
Found: C, 52.01; H, 4.46; N, 9.00. C19H20BrN3O2S requires C, 52.54; H, 4.64; N, 9.67. 
 
N-(5-Bromo-2-pyridinyl)-N'-{2-[5-methoxy-2-(4-pentynyl-1-yloxy)phenyl]ethyl}-
thiourea (77d)   
                                            
 
 
 
 
Using THF/ rt, gave compound 77d (0.18 g, 69%); mp: 140-141 °C; IR (CHCl3): max 3684, 
3415 (NH), 3308 (C CH), 3152, 3018, 2956 (C-H), 2245 (C C), 1512 (C=C), 1468 (C=S), 
1226 (C-N) cm-1; 1H NMR (400 MHz, CDCl3):  11.18 (1H, brs, NH), 8.83 (1H, brs, NH), 8.10 
(1H, d, J = 2.4 Hz, H-6”’), 7.68 (1H, dd, J = 2.4 Hz, 8.8 Hz, H-4”’), 6.81 (1H, d, J = 9.0 Hz, H-
3’), 6.81 (1H, d, J = 3.0 Hz, H-6’), 6.75 (1H, dd, J = 3.0, 9.0 Hz, H-4’), 6.70 (1H, d, J = 8.8 Hz, 
H-3”’), 4.01 (4H, m, H-1, H-1”), 3.75 (3H, s, OCH3), 2.98 (2H, t, J = 6.8 Hz, H-2), 2.41 (2H, td, 
J = 2.4, 6.8 Hz, H-3”), 2.02 (2H, m, H-2”), 1.96 (1H, t, J = 2.4 Hz, H-5”); 13C NMR (100 MHz, 
CDCl3):  179.1 (C=S), 153.5 (C-5’), 151.7 (C-2”’), 151.2 (C-2’), 146.7 (C-6”’), 141.1 (C-4”’), 
128.5 (C-1’), 117.7 (C-6’), 113.2 (C-3’), 112.6 (C-3”’), 112.3 (C-5”’), 111.5 (C-4’), 83.5 (C-4”), 
68.9 (C-5”), 66.9 (C-1”), 55.6 (OCH3), 45.7 (C-1), 30.0 (C-2), 28.4 (C-3”), 15.4 (C2”); Anal. 
Found: C, 53.54; H, 4.78; N, 7.81; S, 5.62%. C20H22BrN3O2S requires C, 53.58; H, 4.95; N, 
9.37; S, 7.15. 
 
N-(5-Bromo-2-pyridinyl)-N'-{2-[2-(2-butynyloxy)-5-methoxyphenyl]ethyl}-
thiourea (77e) 
 
 
 
 
 
Using THF/ rt, gave compound 77e (0.12 g, 60%); mp: 149-150 °C; IR (CHCl3): max 3690, 
3410 (NH), 3018 (C-H), 2239 (≡CH), 1510 (C=C), 1469 (C=S), 1207 (C-N) cm-1; 1H NMR 
(400 MHz, CDCl3):  11.12 (1H, brs, NH), 8.58 (1H, brs, NH), 8.11 (1H, d, J = 2.4 Hz, H-6”’), 
7.68 (1H, dd, J = 2.4 Hz, 8.8 Hz, H-4”’), 6.93 (1H, d, J = 8.8 Hz, H-3’), 6.81 (1H, d, J = 3.2 Hz, 
H-6’), 6.75 (1H, dd, J = 3.2 Hz, 8.8 Hz, H-4’), 6.65 (1H, d, J = 8.8 Hz, H-3”’), 4.61 (2H, q, J = 
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2.4 Hz, H-1”), 4.01 (2H, q, J = 6.8 Hz, H-1), 3.75 (3H, s, OCH3), 3.00 (2H, t, J = 6.8 Hz, H-2), 
1.83 (3H, t, J = 2.4 Hz, CH3); 13C NMR (100 MHz, CDCl3):  179.1 (C=S), 153.9 (C-5’), 151.6 
(C-2”’),150.4 (C-2’), 146.8 (C-6”’), 141.1 (C-4”’), 129.1 (C-1’), 117.5 (C-6’), 113.6 (C-3’),113.1 
(C-3”’), 112.6  (C-5”’), 111.6 (C-4’), 83.4 (C-2”), 74.5 (C-3”), 57.5 (C-1”), 55.6 (OCH3), 45.8 
(C-1), 29.8 (C-2), 3.7 (CH3); Anal. Found: C, 52.51; H, 4.53; N, 8.95; S, 6.31. C19H20BrN3O2S 
requires C, 52.54; H, 4.64; N, 9.67; S, 7.38.  
 
N-(5-Bromo-2-pyridinyl)-N'-[2-(2-allyloxy-5-methoxy-phenyl)ethyl]-thiourea (77f) 
 
 
 
 
 
 
Using THF/ rt, gave compound 77f (65 mg, 67%); mp: 153-154 °C; IR (CHCl3): max 3681, 
3413 (N-H), 3041(C-H), 1509 (C=C), 1422 (C=S), 1212 (C-N) cm-1; 1H NMR (400 MHz, 
CDCl3):  11.11 (1H, brs, NH), 8.13 (1H, brs, NH), 8.10 (1H, d, J = 2.4 Hz, H-6”’), 7.69 (1H, 
dd, J = 2.4, 8.7 Hz, H-4”’), 6.82 (1H, d, J = 2.9 Hz, H-6’), 6.80 (1H, d, J = 9.0 Hz, H-3’), 6.74 
(1H, dd, J = 2.9, 9.0 Hz, H-4’), 6.55 (1H, d, J = 8.7 Hz, H-3”’), 6.05 (1H, ddt, J = 5.1, 10.5, 
17.3 Hz, H-2”), 5.39 (1H, dq, J = 1.6, 17.3 Hz, H-3”a), 5.26 (1H, dq, J = 1.6, 10.5 Hz, H-3”b), 
4.49 (2H, dt, J = 1.6, 5.1 Hz, H-1”), 4.01 (2H, m, H-1), 3.76 (3H, s, OCH3), 3.01 (2H, t, J = 6.6 
Hz, H-2); 13C NMR (100 MHz, CDCl3):  179.1 (C=S), 153.5 (C-5’), 151.5 (C-2”’), 151.0 (C-
2’), 146.9 (C-6”’), 141.1 (C-4”’), 133.6 (C-2”), 128.7 (C-1’), 117.7 (C-6’), 117.0 (C-3”), 113.0 
(C-3’), 112.8 (C-3”’), 112.6 (C-5”’), 111.5 (C-4’), 69.5 (C-1”), 55.6 (OCH3), 45.8 (C-1), 30.0 
(C-2); Anal. Found: C, 51.32; H, 4.62; N, 9.56. C18H20BrN3O2S requires C, 51.18; H, 4.78; N, 
9.95. 
 
N-(5-Bromo-2-pyridinyl)-N'-[2-(2-methoxycarbonylmethyloxy-5-
methoxyphenyl)ethyl]-thiourea (77g) 
 
 
 
 
 
Using THF/ rt, gave compound 77g (23 mg, 50%); mp: 161-164 °C; IR (CHCl3): max 3681 (N-
H), 3015 (C-H), 1519 (C=C), 1469 (C=S), 1212 (C-N) cm-1; 1H NMR (400 MHz, CDCl3):  
1'
2'
3'
4'
5'
6`
1
2 2'''
4'''
5'''
6'''
3'''
1''
2''
OMe
O
N
H
N
H
N
Br
S 
H
H
3''a
3''b
1'
2'
3'
4'
5'
6`
1
2 2'''
4'''
5'''
6'''
3'''
OMe
O
N
H
N
H
N
Br
O
O
S
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
CHAPTER 5_________________________                                 EXPERIMENTAL SECTION  
 168 
11.12 (1H, br s, NH), 8.32 (1H, br s, NH), 8.11 (1H, d, J = 2.4 Hz, H-6”’), 7.69 (1H, dd, J = 
2.4, 9.1 Hz, H-4”’), 6.83 (1H, d, J = 2.4 Hz, H-6’), 6.71 (2H, m, H-4’, H-3’), 6.61 (1H, d, J = 9.1 
Hz, H-3”’), 4.62 (2H, s, ArOCH2), 4.05 (2H, m, H-1), 3.78 (3H, s, ArOCH3), 3.74 (3H, s, 
COCH3), 3.06 (2H, t, J = 6.8 Hz, H-2); 13C NMR (100 MHz, CDCl3):  179.2 (C=S), 169.6 
(OC=O), 154.2 (C-5’), 151.5 (C-2”’), 150.3 (C-2’), 146.9 (C-6”’), 141.2 (C-4”’), 129.2 (C-1’), 
117.8 (C-6’), 113.0 (C-3’), 112.7 (C-3”’), 112.6 (C-5”’), 111.6 (C-4’), 66.3 (ArOCH2), 55.5 
(ArOCH3), 52.2 (CO2CH3), 45.7 (C-1), 29.9 (C-2); HRMS (EI): m/z found (M+ + H), 454.0437 
C18H21BrN3O4S requires (M+ + H) 454.0436. 
 
N-(5-Bromo-2-pyridinyl)-N'-[2-(2-cyanomethyloxy-5-methoxyphenyl)ethyl]-
thiourea (77h) 
                 
                               
 
 
 
 
Using THF/ rt, gave compound 77h (0.13 g, 68%); mp: 155-156 °C; IR (CHCl3): max 3681, 
3413, 3022 (NH), 2239 (C≡N), 1505 (C=C), 1469 (C=S), 1216 (C-N) cm-1; 1H NMR (400 
MHz, CDCl3) : 11.20 (1H, brs, NH), 8.72 (1H, brs, NH), 8.10 (1H, d, J = 2.4 Hz, H-6”’), 7.70 
(1H, dd, J = 2.4 Hz, 8.8 Hz, H-4”’), 6.92 (1H, d, J = 8.8 Hz, H-3’), 6.85 (1H, d, J = 3.2 Hz, H-
6’), 6.78 (1H, dd, J = 3.2 Hz, 8.8 Hz, H-4’), 6.69 (1H, d, J = 8.8 Hz, H-3”’), 4.75 (2H, s, H-1”), 
3.99 (2H, q, J = 6.8 Hz, H-1), 3.76 (3H, s, OCH3), 3.01 (2H, t, J = 6.8 Hz, H-2); 13C NMR (100 
MHz, CDCl3) : 179.4 (C=S), 155.4 (C-5’), 151.6 (C-2”’), 149.0 (C-2’), 146.7 (C-6”’), 141.3 (C-
4”’), 129.8 (C-1’), 117.9 (C-6’), 115.4 (C-2”), 114.0 (C-3’), 113.3 (C-3”’), 112.8 (C-5”’), 111.9 
(C-4’), 55.6 (OCH3), 54.9 (C-1”), 45.6 (C-1), 29.6 (C-2); Anal. Found: C, 48.38; H, 4.04; N, 
12.38; S; 6.76%. C17H17BrN4O2S requires C, 48.46; H, 4.07; N, 13.30; S, 7.61. 
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N-(5-Bromo-2-pyridinyl)]-N'-{2-[2-(3-cyanopropyl-1-oxy)-5-      
methoxyphenyl]ethyl}-thiourea (77i) 
 
 
 
 
 
 
Using THF/ rt, gave compound 77i (70 mg, 53%); mp: 165-166 °C; IR (CHCl3): max 3413 
(NH), 3167, 2964 (C-H), 2246 (C≡N), 1505 (C=C), 1465 (C=S), 1239 (C-N) cm-1; 1H NMR 
(400 MHz, CDCl3):  11.26 (1H, brs, NH), 9.34 (1H, brs, NH), 8.08 (1H, d, J = 2.4 Hz, H-6”’), 
7.67 (1H, dd, J = 2.4 Hz, 8.8 Hz, H-4”’), 6.82 (1H, d, J = 3.2 Hz, H-6’), 6.81 (1H, d, J = 8.8 Hz, 
H-3’), 6.77 (1H, d, J = 8.8 Hz, H-3”’), 6.74 (1H, dd, J = 3.2 Hz,  8.8 Hz, H-4’), 3.99 (4H, m, H-
1”, H-1), 3.74 (3H, s, OCH3), 2.98 (2H, t, J = 6.8 Hz, H-3”), 2.62 (2H, t, J = 7.0 Hz, H-2), 2.14 
(2H, m, H-2’’); 13C NMR (75 MHz, CDCl3):  179.0 (C=S), 153.7 (C-5’), 151.7 (C-2”’), 150.6 
(C-2’), 146.5 (C-6”’), 141.1(C-4”’), 128.4 (C-1’), 119.2 (C-4”), 117.7 (C-6’), 113.4 (C-3’), 112.7 
(C-3”’), 112.2 (C-5”’), 111.5 (C-4’), 66.0 (C-1”), 55.5 (OCH3), 45.6 (C-1), 29.9 (C-2), 25.6 (C-
3”), 14.4 (C-2”); Anal. Found: C, 50.61; H, 4.78; N, 12.37; S, 6.92; C19H21BrN4O2S requires C, 
50.78; H, 4.71; N, 12.47; S, 7.13. 
 
N-(5-Bromo-2-pyridinyl)]-N'-{2-[2-(2-Benzyloxyethoxy)-5-methoxyphenyl]ethyl}-
thiourea (77j) 
 
 
 
 
 
 
Using THF/ rt, gave compound 77j (70 mg, 58% yield); mp 110-111 °C; IR (CHCl3): max 
3692, 3416 (NH), 3175, 3016, (C-H), 1506 (C=C), 1475 (C=S) cm-1; 1H NMR (400 MHz, 
CDCl3):  11.09 (1H, brs, NH), 8.38 (1H, brs, NH), 8.04 (1H, d, J = 2.4 Hz, H-6”’), 7.66 (1H, 
dd, J = 2.4 Hz, 8.8 Hz, H-4”’), 7.31 (5H, m, ArH), 6.81 (1H, d, J = 8.8 Hz, H-3’), 6.80 (1H, d, J 
= 3.2 Hz, H-6’), 6.74 (1H, dd, J = 3.2 Hz, 8.8 Hz, H-4’), 6.58 (1H, d, J = 8.8 Hz, H-3”’), 4.63 
(2H, s, OCH2), 4.11 (2H, t, J = 4.8 Hz, H-1”), 4.03 (2H, m, H-1), 3.84 (2H, t, J = 4.8 Hz, H-2”), 
3.75 (3H, s, OCH3), 3.01 (2H, t, J = 6.6 Hz, H-2); 13C NMR (100 MHz, CDCl3):  179.0 (C=S), 
153.6 (C-5’), 151.8 (C-2”’), 151.3 (C-2’), 146.6 (C-6”’) , 141.0 (C-4”’), 138.1 (C-1””), 128.8 (C-
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1’), 128.5 (C-2””, C-6””), 127.7 (C-4””), 127.7 (C-3””, C-5””), 117.7 (C-6’), 113.4 (C-3’), 112.8 
(C-3”’), 112.9 (C-5”’), 111.6 (C-4’), 73.4 (ArOCH2), 68.9 (OCH2), 68.5 (OCH2), 55.6 (OCH3), 
45.7 (C-1), 30.0 (C-2); Anal. Found: C, 56.07; H, 4.86; N, 7.37; S, 5.80; C24H26BrN3O3S 
requires C, 55.82; H, 5.07; N, 8.14; S, 6.21. 
 
N-(5-Bromo-2-pyridinyl)-N'-{2-[5-methoxy-2-(2-
propargyloxyethoxy)phenyl]ethyl}-thiourea (77k) 
 
 
 
 
 
 
Using DMF/ 100 oC, gave compound 77k (42 mg, 62%); mp: 128-130 °C; IR (CHCl3): max 
3693, 3416 (NH), 3307 (≡CH), 3165, 2961 (C-H), 1506 (C=C), 1475 (C=S), 1223 (C-N) cm-1; 
1H NMR (300 MHz, CDCl3):  11.19 (1H, brs, NH), 9.24 (1H, brs, NH), 8.07 (1H, d, J = 2.6 
Hz, H-6”’), 7.66 (1H, dd, J = 2.6, 8.7 Hz, H-4”’), 6.81-6.77 (3H, m, H-3”’, H-3’, H-6’), 6.72 (1H, 
dd, J = 2.9, 9.2 Hz, H-4’), 4.25 (2H, d, J = 2.4 Hz, H-4”), 4.09 (2H, t, J = 4.8 Hz, H-1”), 4.01 
(2H, q, J = 6.6 Hz, H-1), 3.88 (2H, t, J = 4.8 Hz, H-2”), 3.74 (3H, s, OCH3), 2.99 (2H, t, J = 6.6 
Hz, H-2), 2.45 (1H, t, J = 2.4 Hz, H-6”); 13C NMR (75 MHz, CDCl3): δ 178.9 (C=S), 153.6 (C-
5’), 151.7 (C-2”’), 151.1 (C-2’), 146.6 (C-6”’), 141.0 (C-4”’), 128.8 (C-1’), 117.6 (C-6’), 113.4 
(C-3’), 112.9 (C-3”’), 112.6 (C-5”’), 111.5 (C-4’), 79.5 (C-5”), 74.7 (C-6”), 68.4 (CH2O), 68.2 
(CH2O), 58.5 (C-4”), 55.5 (OCH3), 45.6 (C-1), 29.9 (C-2); HRMS (EI): m/z found (M+), 
463.0578 C20H22BrN3O3S requires (M+) 463.0565; Anal. Found: C, 51.76; H, 4.72; N, 8.66; S, 
6.86; C20H22BrN3O3S requires C, 51.73; H, 4.78; N, 9.05; S, 6.91. 
 
N-(5-Bromo-2-pyridinyl)-N'-{2-[5-methoxy-2-(2-(2-
propargyloxyethoxy)ethoxy)phenyl]ethyl}-thiourea (77l) 
 
 
 
 
 
  
 
Using DMF/ 100 oC, gave compound 77l (53 mg, 60%); mp: 91-92 °C; IR (CHCl3): max 3691, 
3416 (NH), 3307 (≡CH), 3166, 2935 (C-H), 1506 (C=C), 1475 (C=S), 1266 (C-N) cm-1; 1H 
1'
2'
3'
4'
5'
6`
1
2 2'''
4'''
5'''
6'''
3'''
1''3''5''6"
OMe
O
N
H
N
H
N
S
Br
O
OH
7"8"9"
OMe
O
N
H
N
O
S
N
Br
H
H
1'
2'
3'
4'
5'
6`
1
2 2'''
4'''
5'''
6'''
3'''
1''
2''
3''
4''
5''6"
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
CHAPTER 5_________________________                                 EXPERIMENTAL SECTION  
 171 
NMR (300 MHz, CDCl3):  11.11 (1H, brs, NH), 8.67 (1H, brs, NH), 8.07 (1H, d, J = 2.4 Hz, 
H-6”’), 7.67 (1H, dd, J = 2.4, 8.7 Hz, H-4”’), 6.81-6.78 (2H, m, H-3’, H-6’), 6.73 (1H, dd, J = 
3.0, 8.7 Hz, H-4’), 6.67 (1H, d, J = 8.7 Hz, H-3”’),  4.21 (2H, d, J = 2.1 Hz, H-6”), 4.07 (2H, t, J 
= 4.9 Hz, H-1”), 4.01 (2H, q, J = 6.6 Hz, H-1), 3.85 (2H, t, J = 4.9 Hz, H-2”), 3.73 (7H, m, 
OCH3, H-4”, H-5”), 2.99 (2H, t, J = 6.6 Hz, H-2), 2.42 (1H, t, J = 2.1 Hz, H-9”); 13C NMR (75 
MHz, CDCl3): δ 179.1 (C=S), 153.6 (C-5’), 151.6 (C-2”’), 151.2 (C-2’), 146.8 (C-6”’), 141.1 (C-
4”’), 128.8 (C-1’), 117.7 (C-6’), 113.2 (C-3’), 112.8 (C-3”’), 112.6 (C-5”’), 111.5 (C-4’), 79.6 
(C-8”), 74.6 (C-9”), 70.6 (CH2O), 70.0 (CH2O), 69.2 (CH2O), 68.4 (CH2O), 58.5 (C-7”), 55.6 
(OCH3), 45.7 (C-1), 30.0 (C-2); HRMS (EI): m/z found (M+), 507.0821 C22H26BrN3O4S 
requires (M+) 507.0827; Anal. Found: C, 52.02; H, 4.10; N, 7.87; S, 6.24; C22H26BrN3O4S 
requires C, 51.97; H, 5.15; N, 8.26; S, 6.31. 
 
N-(5-Bromo-2-pyridinyl)]-N'-{2-[2-(2-hydroxyethoxy)-5-methoxyphenyl]ethyl}-
thiourea (77m) 
 
 
 
 
 
 
Using THF/ rt, gave compound 77m (120 mg, 65%); mp 162-163 °C; IR (CHCl3): max 3623, 
3413, 3181 (NH, OH), 2928, 1505 (C=C), 1472 (C=S) 1227 (C-N) cm-1; 1H NMR (400 MHz, 
CDCl3): δ 11.16 (1H, brs, NH), 8.47 (1H, brs, NH), 8.12 (1H, d, J = 2.4 Hz, H-6”’), 7.70 (1H, 
dd, J = 2.4 Hz, 8.8 Hz, H-4”’), 6.81 (1H, d, J = 2.8 Hz, H-6’), 6.77 (1H, d, J = 8.8 Hz, H-3’), 
6.73 (1H, dd, J = 2.8 Hz, 8.8 Hz, H-4’), 6.66 (1H, d, J = 8.8 Hz, H-3”’), 3.99 (6H, m, H-1”, H-
2”. H-1), 3.77 (3H, s, OCH3), 3.03 (2H, t, J = 7.2 Hz, H-2), 2.66 (1H, brs, OH); 13C NMR (75 
MHz, CDCl3): δ 179.4 (C=S), 153.7 (C-5’), 151.6 (C-2”’), 151.3 (C-2’), 146.7 (C-6”’), 141.3 (C-
4”’), 128.3 (C-1’), 117.4 (C-6’), 113.4 (C-3’), 112.8 (C-3”’), 112.5 (C-5”’), 111.7 (C-4’), 70.3 
(C-1”), 61.5 (C-2”), 55.6 (OCH3), 45.7 (C-1), 30.3 (C-2); Anal. Found: C, 47.96; H, 4.61; N, 
9.77; S, 7.01; C17H20BrN3O3S requires C, 47.89; H, 4.75; N, 9.86; S, 7.52. 
 
 
 
 
 
 
1'
2'
3'
4'
5'
6`
1
2 2'''
4'''
5'''
6'''
3'''
1''
2''
OMe
O
N
H
N
H
N
Br
S 
HO
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
CHAPTER 5_________________________                                 EXPERIMENTAL SECTION  
 172 
N-(5-Bromo-2-pyridinyl)]-N'-{2-[2-(3-hydroxypropoxy)-5-methoxyphenyl]ethyl}-
thiourea (77n)                            
 
 
 
 
 
Using THF/ rt, gave compound 77n (48 mg, 51%); mp 163-165 °C; IR (CHCl3): max 3681(N-
H), 3406 (O-H) 3014 (C-H), 1509, 1472 (C=S), 1216 (C-N) cm-1; 1H NMR (400 MHz, CDCl3): 
 11.15 (1H, brs, NH), 8.46 (1H, brs, NH), 8.10 (1H, d, J = 2.4 Hz, H-6”’), 7.68 (1H, dd, J = 
2.4, 8.8 Hz, H-4”’), 6.81 (1H, d, J = 8.8 Hz, H-3’), 6.81 (1H, d, J = 2.9 Hz, H-6’), 6.74 (1H, dd, 
J = 2.9, 8.8 Hz, H-4’), 6.62 (1H, d, J = 8.8 Hz, H-3”’), 4.05 (2H, t, J = 5.9 Hz, H-1”), 4.00 (2H, 
m, H-1), 3.87 (2H, q, J = 5.9 Hz, H-3”), 3.76 (3H, s, OCH3), 2.98 (2H, t, J = 6.6 Hz, H-2), 2.05 
(2H, quin, J = 5.9 Hz, H-2”), 2.04 (1H, brs, OH); 13C NMR (100 MHz, CDCl3):  179.1 (C=S), 
153.5 (C-5’), 151.6 (C-2”’), 151.3 (C-2’), 146.8 (C-6”’), 141.2 (C-4”’), 128.4 (C-1’), 117.7 (C-
6’), 113.2 (C-3’), 112.7 (C-3”’), 112.4 (C-5”’), 111.6 (C-4’), 65.9 (C-1”), 60.1 (C-3”), 55.6 
(OCH3), 45.8 (C-1), 32.3 (C-2”), 30.0 (C-2); Anal. Found: C, 49.37; H, 4.88; N, 9.08; S, 6.60. 
C18H22BrN3O4S requires C, 49.09; H, 5.04; N, 9.54; S, 7.28.  
 
N-(5-Bromo-2-pyridinyl)]-N'-{2-[2-(2-(2-hydroxyethoxy)ethoxy)-5-
methoxyphenyl]ethyl}-thiourea (77o) 
 
 
 
 
 
 
Using THF/ rt, gave compound 77o (150 mg, 62%); mp: 97-98 oC; IR (CHCl3): max 3652, 
3413 (NH), 3007, 2942 (C-H), 1591, 1501 (C=C), 1469 (C=S), 1230 (C-N) cm-1; 1H NMR (300 
MHz, CDCl3): δ 11.34 (1H, t, J = 4.6 Hz, NH), 9.09 (1H, brs, NH), 8.06 (1H, d, J = 2.4 Hz, H-
6”’), 7.66 (1H, dd, J = 2.4, 8.8 Hz, H-4”’), 6.80 (1H, d, J = 2.7 Hz, H-6’), 6.76 (1H, d, J = 8.8 
Hz, H-3’), 6.74 (1H, d, J = 8.8 Hz, H-3”’), 6.72 (1H, dd, J = 2.7, 8.8 Hz, H-4’), 4.02 (4H, m, H-
1”, H-1), 3.84 (2H, t, J = 4.6 Hz, CH2O), 3.76 (5H, m, OCH3, CH2O), 3.66 (2H, t, J = 4.6 Hz, 
CH2O), 2.98 (2H, t, J = 6.5 Hz, H-2), 2.54 (1H, brs, OH); 13C NMR (75 MHz, CDCl3): δ 179.0 
(C=O), 153.6 (C-5’), 151.7 (C-2”’), 151.2 (C-2’), 146.6 (C-6”’), 141.0 (C-4”’), 128.7 (C-1’), 
117.7 (C-6’), 113.4 (C-3’), 112.7 (C-3”’), 112.6 (C-5”’), 111.5 (C-4’), 72.6 (C-1”), 69.8 (CH2O), 
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68.3 (CH2O), 61.8 (C-5”), 55.5 (OCH3), 45.7 (C-1), 29.9 (C-2); HRMS (ES): m/z found (M+ + 
H), 470.0749 C19H25BrN3O4S requires (M+ + H) 470.0741. 
 
N-(5-Bromo-2-pyridinyl)]-N'-{2-[2-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)-
ethoxy)-5-methoxyphenyl]ethyl}-thiourea (77p) 
 
 
        
 
 
 
 
Using THF/ rt, gave compound 77p (110 mg, 63 %); mp: 44-45 oC; IR (CHCl3): max 3616, 
3413 (NH, OH), 3007, 2935 (C-H), 1501 (C=C), 1469 (C=S), 1227 (C-N) cm-1; 1H NMR (400 
MHz, CDCl3): δ 10.51 (1H, brs, NH), 8.89 (1H, brs, NH), 8.06 (1H, d, J = 2.4 Hz, H-6”’), 7.67 
(1H, dd, J = 2.4, 8.8 Hz, H-4”’), 6.80 (1H, d, J = 2.8 Hz, H-6’), 6.78 (1H, d, J = 8.8 Hz, H-3’), 
6.74 (1H, dd, J = 2.8, 8.8 Hz, H-4’), 6.72 (1H, d, J = 8.8 Hz, H-3”’), 4.04 (4H, m, H-1”, H-1), 
3.84 (2H, t, J = 4.8 Hz, CH2O), 3.76 (3H, s, OCH3), 3.74-3.69 (10H, m, 5 × CH2O), 3.62 (2H, 
m, CH2O), 2.99 (2H, t, J = 6.6 Hz, H-2), 2.98 (1H, brs, OH); 13C NMR (100 MHz, CDCl3): δ 
179.1 (C=S), 153.6 (C-5’), 151.7 (C-2”’), 151.2 (C-2’), 146.6 (C-6”’), 141.0 (C-4”’), 128.8 (C-
1), 117.6 (C-6’), 113.4 (C-3’), 112.8 (C-3”’), 112.5 (C-5”’), 111.5 (C-4’), 72.5 (C-1”), 70.8 
(CH2O), 70.6 (2 × CH2O), 70.3 (CH2O), 69.9 (CH2O), 68.4 (CH2O), 61.7 (C-11”), 55.5 (OCH3), 
45.8 (C-1), 29.9 (C-2); HRMS (ES): m/z found (M+ + H), 558.1273 C23H33BrN3O6S requires 
(M+ + H) 558.1296. 
 
N-(5-Bromo-2-pyridinyl)]-N'-{2-[2-(2-(2-(2-(2-(2-(2-hydroxyethoxy)ethoxy)-
ethoxy)ethoxy)ethoxy)-5-methoxyphenyl]ethyl}-thiourea (77q) 
 
 
 
 
 
 
 
Using THF/ rt, gave compound 77q as a colourless oil (33 mg, 52%); IR (CHCl3): max 3652, 
3413 (NH, OH), 3007, 2913 (C-H), 1501 (C=C), 1469 (C=S), 1227 (C-N) cm-1; 1H NMR (300 
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MHz, CDCl3): δ 11.07 (1H, t, J = 4.7 Hz, NH), 8.56 (1H, brs, NH), 8.04 (1H, d, J = 2.4 Hz, H-
6”’), 7.67 (1H, dd, J = 2.4, 8.8 Hz, H-4”’), 6.80 (1H, d, J = 2.9 Hz, H-6’), 6.78 (1H, d, J = 8.8 
Hz, H-3’), 6.73 (1H, dd, J = 2.9, 8.8 Hz, H-4’), 6.67 (1H, d, J = 8.8 Hz, H-3”’), 4.02 (4H, m, H-
1”, H-1), 3.82 (2H, t, J = 4.9 Hz, CH2O), 3.75 (3H, s, OCH3), 3.71-3.58 (20H, m, 10 × CH2O), 
2.98 (2H, t, J = 6.5 Hz, H-2), 2.90 (1H, brs, OH); 13C NMR (75 MHz, CDCl3): δ 179.3 (C=S), 
153.6 (C-5’), 151.6 (C-2”’), 151.3 (C-2’), 146.7 (C-6”’), 141.0 (C-4”’), 128.8 (C-1’), 117.5 (C-
6’), 113.3 (C-3’), 112.7 (C-3”’), 112.6 (C-5”’), 111.5 (C-4’), 72.6 (C-1”), 70.8 (CH2O), 70.7 (2 × 
CH2O), 70.6 (CH2O), 70.5 (CH2O), 70.3 (CH2O), 69.9 (CH2O), 69.7 (CH2O), 68.6 (CH2O), 
68.4 (CH2O), 61.7 (C-17”), 55.6 (OCH3), 45.9 (C-1), 29.8 (C-2); HRMS (ES): m/z found (M+ + 
H), 646.1799 C27H41BrN3O8S requires (M+ + H) 646.1798. 
 
Uridine-2',3',5'-trimesylate (109)181 
 
 
 
 
 
 
 
 
Methanesulfonyl chloride (28.54 mL, 368.58 mmol) was slowly added to a stirred solution of 
uridine (20.00 g, 81.90 mmol) in pyridine (120 mL) at 0 oC. The reaction was stirred for 5h at 
0 oC. The reaction mixture was poured into an ice-water mixture (500 mL) with rapid stirring 
and the product precipitated. The precipitate was collected by filtration, washed with water (3 
× 200 mL) and dried over P2O5 to give the product 109 as a white solid (39.11 g, 80%); mp: 
180-183 oC; (lit. 184-186 oC); 1H NMR (400 MHz, DMSO-d6): δ 11.51 (1H, brs, NH), 7.70 (1H, 
d, J = 8.4 Hz, H-6), 5.98 (1H, d, J = 5.6 Hz, H-1’), 5.69 (1H, d, J = 8.4 Hz, H-5), 5.61 (1H, t, J 
= 5.6 Hz, H-2’), 5.35 (1H, t, J = 5.6 Hz, H-3’), 4.56 (1H, m, H-4’), 4.46 (2H, m, H-5’), 3.35 (3H, 
s, O3SCH3), 3.33  (3H, s, O3SCH3), 3.22 (3H, s, O3SCH3); 13C NMR (100 MHz, DMSO-d6): δ 
163.0 (C-4), 150.3 (C-2), 141.5 (C-6), 102.4 (C-5), 88.6 (C-1’), 78.5 (C-4’), 76.0 (C-2’), 74.0 
(C-3’), 67.3 (C-5’), 38.0 (O3SCH3), 37.9 (O3SCH3), 36.9 (O3SCH3). 
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5'-O-Benzoyl-3'-O-methanesulfonyl-2,2'-anhydrouridine (110)181 
 
 
 
 
 
 
 
Trimesylate 109 (38.80 g, 81.10 mmol) was added to a stirred slurry of sodium benzoate 
(40.88 g, 283.86 mmol) in acetamide (180 g). The reaction was stirred at 132 oC for 2 h. The 
reaction mixture was poured into ice-water (500 mL) with rapid stirring and the product 
precipitated. The precipitate was collected by filtration, washed with water (3 × 200 mL) and 
dried over P2O5 to give the product 110 as a white solid (25.64 g, 77%); mp: 218-219 oC, (lit. 
226-227 oC); 1H NMR (400 MHz,  DMSO-d6): δ 7.89 (3H, m, H-2”, H-6”, H-6), 7.64 (1H, m, H-
4”), 7.50 (2H, t, J = 7.6 Hz, H-3”, H-5”), 6.45 (1H, d, J = 5.6 Hz,  H-1’), 5.86 (1H, d, J = 7.6 
Hz, H-5),  5.69 (1H, d, J = 5.6 Hz, H-2’), 5.63 (1H, d, J = 2.8 Hz, H-3’), 4.78 (1H, m, H-4’), 
4.32 (1H, dd, J = 5.0, 12.3 Hz , H-5’), 4.22 (1H, dd, J = 7.2, 12.3 Hz, H-5’), 3.43 (3H, s, 
O3SCH3); 13C NMR (100 MHz, DMSO-d6): δ 170.5 (C=O), 165.1 (C-4), 159.1 (C-2), 136.5 (C-
6), 133.5 (C-4”), 129.2 (C-2”, C-6”), 128.9 (C-1”), 128.7 (C-3”, C-5”), 109.0 (C-5), 89.6 (C-1’), 
86.0 (C-2’), 82.1 (C-4’), 80.9 (C-3’), 62.5 (C-5’), 37.5 (O3SCH3). 
 
5'-O-Benzoyl-2'-bromo-3'-O-methanesulfonyl-2'-deoxyuridine (111)182   
               
 
 
 
 
 
 
 
Acetyl bromide (18.46 mL, 249.72 mmol) was added to a stirring solution of 5’-benzoyl-3’-O-
methanesulfonyl-2,2’-anhydrouridine 110 (25.49 g, 62.43 mmol) in EtOAc (90 mL) and MeOH 
(10 mL). The reaction mixture was refluxed at 80 oC for 1 h and then the solvent was reduced 
under vacuum. The crude residue was diluted with aq. NaHCO3 (200 mL) and extracted with 
EtOAc (3 × 250 mL). The organic layer was dried over MgSO4 and the solvent reduced under 
vacuum. Purification by chromatography using a silica-gel column employing EtOAc / pet 
ether (7 / 3) afforded compound 111 as a white solid (26.22 g, 86%); mp. 52-58 oC, (lit. 90-
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140 oC); 1H NMR (400 MHz, CDCl3): δ 9.78 (1H, brs, NH), 8.02 (2H, d, J = 7.5 Hz,  H-2”, H-
6”), 7.61 (1H, d, J = 7.5 Hz, H-4”), 7.47 (2H, t, J = 7.5 Hz, H-3”, H-5”), 7.34 (1H, d, J = 8.2 Hz, 
H-6), 6.13 (1H, d, J = 5.6 Hz, H-1’), 5.62 (1H,d, J = 8.2 Hz, H-5), 5.29 (1H, t, J = 5.3 Hz, H-
3’), 4.77 (1H, d, J = 5.3 Hz, H-2’), 4.74-4.61 (3H, m, H-4’, H-5’), 3.19 (3H, s, O3SCH3); 13C 
NMR (100 MHz, CDCl3): δ 165.9 (C=O), 163.0 (C-4), 150.0 (C-2), 139.7 (C-6), 133.7 (C-4”), 
129.6 (C-2”, C-6”), 129.0 (C-1”), 128.7 (C-3”, C-5”), 103.4 (C-5), 91.8 (C-1’), 80.6 (C-4’), 75.7 
(C-3’), 62.2 (C-5’), 47.5 (C-2’), 38.7 (O3SCH3).  
 
5'-Benzoyl-2',3'-didehydro-2',3'-dideoxyuridine (112)158c 
 
 
                                                
 
 
 
 
To a solution of 5’-O-benzoyl-2’-bromo-3’-O-methanesulfonyl-2’-deoxyuridine 111 (20.17 g, 
41.22 mmol) in MeOH (120 mL), was added zinc dust (8.09 g, 123.66 mmol) followed by 
addition of conc HCl (2 mL). The reaction mixture was stirred at room temperature for 15 min. 
The excess zinc was then removed by filtration through celite and the solvent reduced under 
vacuum. The crude residue was diluted with NaHCO3 (200 mL) and the product extracted 
with EtOAc (3 x 250 mL). The organic layer was dried over MgSO4, filtered and the solvent 
was removed under reduced pressure to afford pure compound 112 as a white solid (11.82 
g, 91%): mp: 135-138 oC; (lit. 138.5-139 oC); 1H NMR (300 MHz, CDCl3): δ 9.61 (1H, brs, 
NH), 7.97 (2H, d, J = 7.4 Hz, H-2”, H-6”), 7.58 (1H, m, H-4”), 7.45 (2H, t, J = 7.4 Hz, H-3”, H-
5”), 7.33 (1H, d, J = 8.2 Hz, H-6), 7.00 (1H, m, H-1’), 6.37 (1H, dt, J = 1.7, 6.2 Hz, H-3’), 5.88 
(1H, dq, J = 1.5, 6.2 Hz, H-2’), 5.32 (1H, d, J = 8.2 Hz, H-5), 5.14 (1H, m, H-4’), 4.68 (1H, dd, 
J = 3.5, 12.5 Hz, H-5’), 4.52 (1H, dd, J = 2.9, 12.5 Hz, H-5’); 13C NMR (75 MHz, CDCl3): δ 
166.0 (C=O), 163.3 (C-4), 150.7 (C-2), 139.8 (C-6), 133.5 (C-4”), 133.5 (C-3’), 129.5 (C-2”, 
C-6”), 129.2 (C-1”), 128.6 (C-3”, C-5”), 127.1 (C-2’), 102.6 (C-5), 89.7 (C-1’), 84.8 (C-4’) 64.6 
(C-5’). 
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5'-Benzoyl-2',3'-didehydro-2',3'-dideoxy-5-iodouridine (47)142   
       
                                               
 
 
 
 
To a solution of 5’-O-benzoyl-2’-bromo-3’-O-methanesulfonyl-2’-deoxyuridine 112 (2.00 g, 
6.36 mmol) in CH3CN (30 mL), were added cerium ammonium (IV) nitrate (1.74 g, 3.18 
mmol) and iodine (0.49 g, 1.93 mmol). The mixture was stirred at 35 oC for 4 h. The crude 
residue was diluted with a solution of sodium thiocyanate (100 mL) and extracted with EtOAc 
(3 x 200 mL). The organic layer was dried over MgSO4 and the solvent reduced under 
vacuum. Purification by chromatography using a silica-gel column using EtOAc / pet ether (6 
/ 4) gave compound 47 as a white solid (2.30 g, 82%); mp: 168-170 oC; 1H NMR (300 MHz, 
CDCl3): δ 11.78 (1H, brs, NH), 7.96 (2H, d, J = 7.9 Hz, H-2”, H-6”), 7.73 (1H, s, H-6), 7.67 
(1H, m, H-4”), 7.55 (2H, t, J = 7.9 Hz, H-3”, H-5”), 6.76 (1H, m, H-1’), 6.54 (1H, dt, J = 1.7, 
6.0 Hz, H-3’), 6.12 (1H, dq, J = 1.5, 6.0 Hz, H-2’), 5.18 (1H, m, H-4’), 4.52 (2H, m, H-5’); 13C 
NMR (75 MHz, CDCl3): δ 165.5 (C=O), 160.2 (C-4), 150.1 (C-2), 144.0 (C-6), 133.5 (C-4”), 
133.3 (C-3’), 129.2 (C-2”, C-6”), 129.0 (C-1”), 128.7 (C-3”, C-5”), 126.5 (C-2’), 90.0 (C-1’), 
84.0 (C-4’), 69.6 (C-5), 65.3 (C-5’). 
 
 5-{4-[2-(2-tert-Butoxycarbonylaminoethyl)-4-methoxyphenoxy]but-1-ynyl}-5'-O-
benzoyl-2',3'-didehydro-2',3'-dideoxyuridine (48) 
 
 
 
 
 
 
 
 
A solution of 5’-benzoyl-5-iodouridine 47 (70 mg, 0.20 mmol) in dry DMF (2.5 mL) was added 
to a stirred solution of triethylamine (0.05 mL, 0.30 mmol) and alkyne 70c (0.10 g, 0.30 
mmol) in THF (4 mL). The mixture was thoroughly degassed with nitrogen for 1h. CuI (20 mg, 
0.10 mmol) and Pd(PPh3)4 (20 mg, 0.02 mmol) were added to the degassed solution under a 
nitrogen atmosphere. The mixture was left stirring at rt for 4h. The crude mixture was 
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dissolved in CHCl3 (20 mL) which was washed with portions (2 x 15 mL) of 5% aq disodium 
EDTA, water (15 mL) and dried over MgSO4. Following filtration and solvent evaporation 
under reduced pressure, the crude product was purified by column chromatography 
employing 50% EtOAc in pet ether to give 48 as a yellow oil (95 mg, 94%): [ ]D  -14.4 o (c 
1.60, CHCl3); IR (CHCl3): max  3692, 3606, 3451 (NH), 3011, 2934 (C-H), 2243 (C≡C), 1707 
(C=O), 1502 (C=C) cm-1; 1H NMR (300 MHz, CDCl3):  8.79 (1H, brs, NH), 8.00 (2H, d, J = 
7.7 Hz, H-2””, H-6””), 7.61 (1H, s, H-6), 7.53 (1H, t, J = 7.7 Hz, H-4””), 7.42 (2H, t, J = 7.7 Hz, 
H-3””, H-5””), 6.91 (1H, m, H-1’), 6.70 (3H, m, H-3”, H-5”, H-6”), 6.39 (1H, dt, J = 1.7, 5.8 Hz, 
H-3’), 5.99 (1H, dq, J = 1.4, 5.8 Hz, H-2’), 5.20 (1H, m, H-4’), 4.83 (1H, brs, NH), 4.64 (1H, 
dd, J = 4.3, 12.5 Hz, H-5’), 4.50 (1H, dd, J = 3.0, 12.5 Hz, H-5’), 3.94 (2H, t, J = 6.8 Hz, H-
4”’), 3.74 (3H, s, OCH3), 3.32 (2H, m, H-2””’), 2.77 (2H, t, J = 6.9 Hz, H-1””’), 2.68 (2H, t, J = 
6.8 Hz, H-3”’), 1.40 (9H, s, OC(CH3)3); 13C NMR (75 MHz, CDCl3):  166.2 (PhCO2), 161.4 
(C-4), 153.9 (NHCO), 153.9 (C-4”), 150.5 (C-1”), 149.4 (C-2), 141.6 (C-6), 133.5 (C-4””), 
133.3 (C-3’), 132.0 (C-1”), 129.7 (C-2”, C-6”), 129.2 (C-2”), 128.6 (C-3”, C-5”), 127.0 (C-2’), 
116.7 (C-3”), 112.9 (C-6”), 112.0 (C-5”), 100.7 (C-2”’), 91.3 (C-1”’), 90.7 (C-1’), 85.0 (C-4’), 
78.8 (O2C(CH3)3), 72.4 (C-5), 66.7 (C-4”’), 65.1 (C-5’), 55.6 (OCH3), 40.6 (C-2””’), 31.0 (C-
1””’), 28.4 (OC(CH3)3), 20.8 (C-3”’); FABHRMS: m/z found 654.24300 [M+Na]+. C34H37N3O9 
[M+Na]+ requires 654.24274. 
 
5-{6-[2-(2-tert-Butoxycarbonylaminoethyl)-4-methoxyphenoxy]hexa-4-oxa-1-
ynyl}-5’-O-benzoyl-2’, 3’-didehydro-2’, 3’-dideoxyuridine (113)                                                                                                                                                                                                                              
                       
 
 
 
 
 
 
 
 
A solution of 5’-O-Benzoyl-2’,3’-didehydro-2’,3’-dideoxy-5-iodouridine 47 (0.30 g, 0.68 mmol) 
in dry DMF (3 mL) was added to a stirred solution of triethylamine (0.19 mL, 1.36 mmol) and 
alkyne 70k (0.26 g, 0.75 mmol) in THF (4 mL). The mixture was thoroughly degassed with 
nitrogen for 1h. CuI (65 mg, 0.34 mmol) and Pd(PPh3)4 (79 mg, 0.07 mmol) were added to 
the degassed solution under a nitrogen atmosphere. The mixture was left stirring at rt for 4h. 
The crude was dissolved in CHCl3 (30 mL) which was washed with portions (2 x 15 mL) of 
5% aq disodium EDTA, water (20 mL) and dried over MgSO4. Following filtration and solvent 
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evaporation under reduced pressure, the crude product was purified by column 
chromatography employing 60% EtOAc in pet ether to give 113 as a yellow oil (0.34 g, 76%): 
[ ]D  +16.2 o (c 1.0, CHCl3); IR (CHCl3): max 3449, 3384 (NH), 3007, 2928 (C-H), 2246 (C≡C), 
1711 (C=O), 1501 (C=C), 1169 (C-N) cm-1;  1H NMR (300 MHz, CDCl3): δ 8.42 (1H, brs, NH), 
8.01 (2H, d, J = 7.5 Hz, H-2””, H-6””), 7.68 (1H, s, H-6), 7.56 (1H, m, H-4””), 7.45 (2H, t, J = 
7.5 Hz, H-3””, H-5””), 6.92 (1H, m, H-1’), 6.76 (1H, d, J = 8.7 Hz, H-6”), 6.68 (2H, m, H-3”, H-
5”), 6.40 (1H, dt, J = 1.7, 6.0 Hz, H-3’), 6.00 (1H, dq, J = 1.3, 6.0 Hz, H-2’), 5.21 (1H, m, H-
4’), 4.94 (1H, brs, NH), 4.69 (1H, dd, J = 4.2, 12.5 Hz, H-5’), 4.50 (1H, dd, J = 3.0, 12.5 Hz, 
H-5’), 4.27 (2H, s, H-3”’), 4.07 (2H, t, J = 4.5 Hz, H-6”’), 3.85 (2H, m, H-5”’), 3.74 (3H, s, 
OCH3), 3.33 (2H, m, H-2””’), 2.78 (2H, t, J = 6.9 Hz, H-1””’), 1.42 (9H, s, OC(CH3)3; 13C NMR 
(75 MHz, CDCl3): δ 166.2 (C6H5OCO), 161.3 (C-4), 156.0 (NHCO), 153.8 (C-4”), 151.0 (C-
1”), 149.4 (C-2), 142.2 (C-6), 133.6 (C-4””), 133.5 (C-3’), 129.7 (C-2””, C-6””), 129.3 (C-1””), 
129.2 (C-2”), 128.6 (C-3””, C-5””), 127.0 (C-2’), 116.5 (C-3”), 113.0 (C-6”), 111.9 (C-5”), 99.9 
(C-2”’), 90.8 (C-1’), 90.0 (C-1”’), 85.1 (C-4’), 78.8 (OC(CH3)3, 77.2 (C-5), 68.4 (OCH2), 68.2 
(OCH2), 65.0 (C-5’), 59.0 (C-3”’), 55.6 (OCH3), 40.6 (C-2””’), 30.8 (C-1””’), 28.4 (OC(CH3)3; 
HRMS (ES): m/z found 662.2698 (M+ + 2H), C35H40N3O10 requires (M+ + 2H) 662.2714. 
 
5-{9-[2-(2-tert-Butoxycarbonylaminoethyl)-4-methoxyphenoxy]nona-4, 7-dioxa-
1-ynyl}-5’-O-benzoyl-2’, 3’-didehydro-2’, 3’-dideoxyuridine (115) 
        
 
 
 
 
 
 
 
 
A solution of 5’-O-Benzoyl-2’,3’-didehydro-2’,3’-dideoxy-5-iodouridine 47 (0.20 g, 0.46 mmol) 
in dry DMF (2 mL) was added to stirred solution of triethylamine (0.13 mL, 0.92 mmol) alkyne 
70l (0.20 g, 0.51 mmol) in THF (3 mL). The mixture was thoroughly degassed with nitrogen 
for 1h. CuI (44 mg, 0.23 mmol) and Pd(PPh3)4 (53 mg, 0.05 mmol) were added to the 
degassed solution under a nitrogen atmosphere. The mixture was left stirring at rt for 4h. The 
crude was dissolved in CHCl3 (20 mL) which was washed with portions of (2 x 10 mL) 5% aq 
disodium EDTA, water (15 mL) and dried over MgSO4. Filtration and solvent removal under 
reduced pressure gave a crude product, which was purified by column chromatography 
employing EtOAc in pet ether (7 / 3) to give compound 115 as a yellow oil (0.23 g, 72%): [ ]D  
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+32.1 o (c 1.0, CHCl3); IR (CHCl3): max  3674, 3377 (NH), 3014 (C-H), 2225 (C≡C), 1711 
(C=O), 1501 (C=C), 1212 (C-N) cm-1; 1H NMR (400 MHz, CDCl3): δ 8.82 (1H, brs, NH), 8.02 
(2H, d, J = 7.6 Hz, H-2””, H-6””), 7.68 (1H, s, H-6), 7.56 (1H, m, H-4””), 7.46 (2H, t, J = 7.6 
Hz, H-3””, H-5””), 6.92 (1H, m, H-1’), 6.77 (1H, d, J = 8.8 Hz, H-6”), 6.69 (2H, m, H-3”, H-5”), 
6.39 (1H, dt, J = 1.5, 6.0 Hz, H-3’), 5.99 (1H, dq, J = 1.3, 6.0 Hz, H-2’), 5.21 (1H, m, H-4’), 
4.97 (1H, brs, NH), 4.70 (1H, dd, J = 4.2, 12.4 Hz, H-5’), 4.51 (1H, dd, J = 2.9, 12.4 Hz, H-5’), 
4.25 (2H, s, H-3”’), 4.08 (2H, t, J = 4.9 Hz, H-9”’), 3.84 (2H, t, J = 4.9 Hz, H-8”’), 3.75 (3H, m, 
OCH3), 3.73 (4H, m,  2 × OCH2), 3.35 (2H, m, H-2””’), 2.80 (2H, t, J = 6.9 Hz, H-1””’), 1.43 
(9H, s, OC(CH3)3); 13C NMR (75 MHz, CDCl3): δ 166.2 (PhOCO), 161.1 (C-4), 156.0 (NHCO), 
153.7 (C-4”), 151.0 (C-1”), 149.4 (C-2), 142.2 (C-6), 133.5 (C-4””), 133.4 (C-3’), 129.7 (C-2””, 
C-6””), 129.3 (C-1””), 129.2 (C-2”), 128.6 (C-3””, C-5””), 127.0 (C-2’), 116.5 (C-3”), 113.0 (C-
6”), 112.0 (C-5”), 99.9 (C-2”’), 90.7 (C-1’), 90.1 (C-1”’), 85.1 (C-4’), 78.9 (OC(CH3)3), 77.2 (C-
5), 70.5 (OCH2), 69.8 (OCH2), 69.1 (OCH2), 68.4 (OCH2), 65.0 (C-5’), 58.9 (C-3”’), 55.6 
(OCH3), 40.6 (C-2””’), 31.0 (C-1””’), 28.4 (OC(CH3)3); HRMS (ES): m/z found 706.2958 (M+ + 
H), C37H44N3O11 requires (M+ + H) 706.2976. 
 
5-{4-[2-(2-(5-Bromo-2-pyridinyl)amino thiocarbonylamino)ethyl)-4-
methoxyphenoxy]but-1-ynyl}-5’-O-benzoyl-2’,3’-didehydro-2’,3’-dideoxyuridine 
(50) 
 
 
 
 
 
 
 
 
Trifluoroacetic acid (0.20 mL) was added to a solution of compound 48 (0.10 g, 0.16 mmol) in 
CH2Cl2 (3 mL) at 0 °C, and the solution stirred for 2 h. Diisopropylethylamine (0.30 mL) was 
added, the solvent evaporated in vacuo and the crude amine dried under vacuum for 1 h. 
Thiourea 49 (0.54 mg, 0.19 mmol) was added to the crude amine in THF (5 mL) and the 
reaction mixture was stirred at room temperature for 20 h. Following evaporation of the 
solvent, the residue was subjected directly to column chromatography using (70% EtOAc in 
pet ether) to give 50 as a yellow solid (72 mg, 60%): mp: 95-97 °C; [ ]D - 9.9 o (c 0.8, CHCl3); 
IR (CHCl3): max  3934, 3681 (NH), 2297 (C≡C), 1714 (C=O), 1602 (C=C), 1418 (C=S), 1212 
(C-N) cm-1;  1H NMR (400 MHz, CDCl3):  10.92 (1H, t, J = 2.7 Hz, NH), 9.75 (1H, brs, NH), 
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9.13 (1H, s, NH), 8.03 (2H, m, H-2””, H-6””), 7.91 (1H, d, J = 2.3 Hz, H-6”””), 7.61 (1H, s, H-
6), 7.56 (1H, m, H-4”), 7.45 (2H, m, H-3””, H-5””), 7.28 (1H, dd, J = 2.3, 8.8 Hz, H-4”””), 6.96 
(1H, m, H-1’), 6.80 (1H, m, H-3”), 6.76 (2H, m, H-5”, H-6”), 6.62 (1H, d, J = 8.8 Hz, H-3”””), 
6.37 (1H, dt, J = 1.6, 6.0 Hz, H-3’), 6.09 (1H, m, H-2’), 5.19 (1H, m, H-4’), 4.65 (1H, dd, J = 
4.2, 12.3 Hz, H-5’), 4.53 (1H, dd, J = 3.8, 12.3 Hz, H-5’), 3.97 (4H, m, H-4”’, H-2””’), 3.79 (3H, 
s, OCH3), 3.03 (1H, m, H-3”’), 2.88 (1H, m, H-3”’), 2.71 (2H, t, J = 6.3 Hz, H-1””’); 13C NMR 
(100 MHz, CDCl3):  179.1 (C=S), 162.2 (C-4), 153.6 (C-2”””), 151.6 (C-1”), 150.9 (C-4”), 
149.3 (C-2), 141.8 (C-6”””), 141.2 (C-6), 140.6 (C-4”””), 133.3 (C-4””), 133.3 (C-3’), 129.7 (C-
2””, C-6””), 129.3 (C-1””), 128.9 (C-2”), 128.6 (C-3””, C-5””), 127.7 (C-2’), 118.3 (C-3”), 113.3 
(C-3”””), 112.0 (C-6”), 111.1 (C-5”””), 100.6 (C-2”’), 91.3 (C-1”’), 90.7 (C-1’), 84.9 (C-4’), 72.6 
(C-5), 66.5 (C-4”’), 65.3 (C-5’), 55.5 (OCH3), 45.4 (C-2””’), 30.3 (C-3”’), 20.9 (C-1””’); HRMS 
(ES): m/z found 746.1262 (M+ + H), C35H33N5O7BrS requires (M+ + H) 746.1284. 
    
5-{6-[2-(2-(5-Bromo-2-pyridinylaminothiocarbonylamino)ethyl)-4-
methoxyphenoxy]hexa-4-oxa-1-ynyl}-5’-O-benzoyl-2’,3’-didehydro-2’,3’-
dideoxyuridine (114) 
 
 
 
 
 
 
 
Trifluoroacetic acid (0.20 mL) was added to a solution of compound 113 (0.20 g, 0.30 mmol) 
in CH2Cl2 (3 mL) at 0 °C, and the solution stirred for 2 h. Diisopropylethylamine (0.30 mL) 
was added, the solvent evaporated in vacuo and the crude amine dried under vacuum for 1 
h. Thiourea 49 (0.11 g, 0.39 mmol) was added to the crude amine in THF (5 mL) and the 
reaction mixture was stirred at room temperature for 20 h. Following evaporation of the 
solvent, the residue was subjected directly to column chromatography using (70% EtOAc in 
pet ether) to give 114 as a yellow solid (0.13 g, 60%): mp: 73-76 oC; [ ]D   – 20.2 o  (c 1.0, 
CHCl3); IR (CHCl3): max  3601, 3391 (NH), 2957 (C-H), 2254 (-C≡C-), 1718 (C=O), 1501 
(C=C), 1462 (C=S) cm-1; 1H NMR (300 MHz, CDCl3): δ 10.82 (1H, m, NH), 9.00 (1H, brs, 
NH), 8.84 (1H, brs, NH), 8.03 (1H, d, J = 2.4 Hz, H-6”””), 8.00 (2H, m, H-2””, H-6””), 7.70 (1H, 
s, H-6), 7.65 (1H, dd, J = 2.4, 8.8 Hz, H-4”””), 7.56 (1H, , m, H-4””), 7.45 (2H, m, H-3””, H-5””), 
6.93 (1H, m, H-1’), 6.87 (1H, d, J = 8.8 Hz, H-3”””), 6.79 (1H, d, J = 2.8 Hz, H-3”), 6.77 (1H, d, 
J = 8.8 Hz, H-6”), 6.73 (1H, dd, J = 2.8, 8.8 Hz, H-5”), 6.40 (1H, dt, J = 1.7, 6.0 Hz, H-3’), 
6.02 (1H, dq, J = 1.4, 6.0 Hz, H-2’), 5.21 (1H, m, H-4’), 4.68 (1H, dd, J = 4.3, 12.5 Hz, H-5’), 
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4.54 (1H, dd, J = 2.9, 12.5 Hz, H-5’), 4.25 (2H, s, H-3”’), 4.00 (4H, m, H-2””’, H-6”’), 3.83 (2H, 
m, H-5”’), 3.75 (3H, s, OCH3), 2.98 (2H, m, H-1””’); 13C NMR (100 MHz, CDCl3): δ 179.2 
(C=S), 166.3 (PhCO2), 161.6 (C-4), 153.7 (C-4”), 151.8 (C-2”””), 151.2 (C-1”), 149.4 (C-2), 
146.6 (C-6”””), 142.6 (C-6), 141.0 (C-4”””), 133.6 (C-4””), 133.4 (C-3’), 129.7 (C-2””, C-6””), 
129.2 (C-1””), 128.9 (C-2”), 128.7 (C-3””, C-5””), 127.0 (C-2’), 117.5 (C-3”), 113.6 (C-3”””), 
112.8 (C-6”), 112.5 (C-5”””), 111.6 (C-5”), 100.0 (C-2”’), 90.9 (C-1’), 90.0 (C-1”’), 85.2 (C-4’), 
77.2 (C-5), 68.5 (OCH2), 68.3 (OCH2), 65.1 (C-5’), 59.2 (C-3”’), 55.6 (OCH3), 45.7 (C-2””’), 
29.9 (C-1””’); HRMS (ES): m/z found 776.1379 (M+ + H), C36H35N5O8SBr requires (M+ + H) 
776.1390. 
 
5-{9-[2-(2-(5-Bromo-2-pyridinylaminothiocarbonylamino)ethyl)-4-
methoxyphenoxy]nona-4,7-dioxa-1-ynyl}-5’-O-benzoyl-2’,3’-didehydro-2’,3’-
dideoxyuridine (116) 
        
       
 
 
 
 
 
 
 
To a solution of compound 115 (0.15 g, 0.21 mmol) in CH2Cl2 (3 mL), trifluoroacetic acid 
(0.20 mL) was added at 0 °C, and the solution stirred for 2 h. Diisopropylethylamine (0.40 
mL) was added, the solvent evaporated in vacuo and the crude amine dried under vacuum 
for 1 h. Thiourea 49 (76 mg, 0.27 mmol) was added to the crude amine in THF (5 mL) and 
the reaction mixture was stirred at room temperature for 20 h. Following evaporation of the 
solvent, the residue was subjected directly to column chromatography using EtOAc/ pet ether 
(8 / 2) to give 116 as a  yellow solid (0.10 g, 63%): m.p: 88-91 oC; [ ]D  -18.5 o (c 1.0, CHCl3); 
IR (CHCl3): max 3406 (NH), 3029, 2949 (C-H), 2152 (-C≡C-), 1718, 1671 (C=O), 1501 (C=C), 
1469 (C=S), 1126 (C-N) cm-1; 1H NMR (300 MHz, CDCl3): δ 11.01 (1H, t, J = 4.8 Hz, NH), 
9.29 (1H, brs, NH), 8.94 (1H, brs, NH), 8.04 (1H, d, J = 2.4 Hz, H-6”””), 8.00 (2H, d, J = 7.4 
Hz, H-2””, H-6””), 7.67 (1H, s, H-6), 7.65 (1H, dd, J = 2.4, 8.8 Hz, H-4”””), 7.56 (1H, m, H-4””), 
7.43 (2H, t, J = 7.4 Hz, H-3””, H-5””), 6.91 (1H, m, H-1’), 6.80 (1H, d, J = 9.2 Hz, H-6”), 6.79 
(1H, d, J = 2.9 Hz, H-3”), 6.77 (1H, d, J = 8.8 Hz, H-3”””), 6.73 (1H, dd, J = 2.9, 9.2 Hz, H-5”), 
6.38 (1H, dt, J = 1.6, 6.0 Hz, H-3’), 5.98 (1H, m, H-2’), 5.19 (1H, m, H-4’), 4.67 (1H, dd, J = 
4.3, 12.5 Hz, H-5’), 4.50 (1H, dd, J = 3.0, 12.5 Hz, H-5’), 4.21 (2H, s, H-3”’), 4.03 (2H, t, J = 
4.7 Hz, H-9”’), 3.98 (2H, q, J = 6.6 Hz, H-2””’), 3.82 (2H, t, J = 4.7 Hz, H-8”’), 3.74 (3H, s, 
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OCH3), 3.71-3.64 (4H, m, 2 × OCH2), 2.97 (2H, t, J = 6.6 Hz, H-1”’”); 13C (75 MHz, CDCl3): δ 
179.2 (C=S), 166.2 (PhCO2), 161.4 (C-4), 153.6 (C-4”), 151.7 (C-2”””), 151.2 (C-1”), 149.5 
(C-2), 146.6 (C-6”””), 142.5 (C-6), 141.0 (C-4”””), 133.5 (C-4””), 133.4 (C-3’), 129.7 (C-2””, C-
6””), 129.2 (C-1””), 128.8 (C-2”), 128.6 (C-3””, C-5””), 127.0 (C-2’), 117.5 (C-3”), 113.5 (C-
3”””), 112.7 (C-6”), 112.5 (C-5”””), 111.5 (C-5”), 100.0 (C-2”’), 90.8 (C-1’), 90.1 (C-1”’), 85.1 
(C-4’), 77.0 (C-5), 70.6 (OCH2), 69.8 (OCH2), 69.2 (OCH2), 68.4 (OCH2), 65.1 (C-5’), 59.0 (C-
3”’), 55.5 (OCH3), 45.6 (C-2””’), 29.8 (C-1””’); HRMS (ES): m/z found 820.1638 (M+ + H), 
C38H39N5O9SBr requires (M+ + H) 820.1652. 
 
5-{15-[2-(2-(5-Bromo-2-pyridinylaminothiocarbonylamino)ethyl)-4-
methoxyphenoxy]pentadeca-4,7,10,13-tetraoxa-1-ynyl}-5’-O-benzoyl-2’,3’-
didehydro-2’,3’-dideoxyuridine (119) 
 
 
 
 
 
 
 
 
Trifluoroacetic acid (0.20 mL) was added to a solution of alkyne 70r (0.12 g, 0.25 mmol) in 
CH2Cl2 (3 mL) at 0 °C, and the solution stirred for 2 h. Anhydrous K2CO3 (0.10 g, 0.75 
mmol)was added, the mixture stirred for a further 15 min then filtered through Celite, the 
solvent evaporated in vacuo and the crude amine dried under vacuum for 1 h. The crude 
amine was dissolved in dry THF (4 mL), DMF (2 mL), and 5’-O-Benzoyl-2’,3’-didehydro-2’,3’-
dideoxy-5-iodouridine 47 (0.10 g, 0.23 mmol) and triethylamine (0.06 mL, 0.46 mmol) were 
added. The mixture was thoroughly degassed with nitrogen for 1h. CuI (23 mg, 0.12 mmol) 
and Pd(PPh3)4 (27 mg, 0.02 mmol) were added to the degassed solution under a nitrogen 
atmosphere. The mixture was left stirring at rt for 4h. The reaction mixture was then 
dissolved in MeOH: CHCl3 (1: 4) (30 mL), which was washed with portions (15 mL)  of 5% aq 
disodium EDTA, water (10 mL) and dried over MgSO4. Filtration and solvent removal under 
reduced pressure gave a crude product, which was subjected to column chromatography 
employing EtOAc / MeOH / Et3N (5 / 4 / 1). The amine product was dissolved in dry THF (5 
mL), thiourea 49 (85 mg, 0.30 mmol) was added and the mixture was stirred at room 
temperature for 20 h. Following evaporation of solvent, the residue was subjected directly to 
column chromatography using EtOAc / pet ether (9 / 1) to afford the title compound 119 as a 
solid (76 mg, 40% over the 3 steps): 
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m.p: 112-115 oC; [ ]D  - 24.1 o (c 1.0, CHCl3); IR (CHCl3): max  3377, 3217 (NH), 3007, 2920 
(C-H), 2239 (-C≡C-), 1722, 1675 (C=O), 1501 (C=C), 1465 (C=S), 1227 (C-N) cm-1; 1H NMR 
(400 MHz, CDCl3): δ 11.09 (1H, t, J = 5.1 Hz, NH), 8.88 (1H, brs, NH), 8.76 (1H, brs, NH), 
8.05 (1H, d, J = 2.4 Hz, H-6”””), 8.02 (2H, d, J = 7.6 Hz, H-2””, H-6””),  7.68 (1H, s, H-6), 7.68 
(1H, dd, J = 2.4, 8.8 Hz, H-4”””), 7.58 (1H, m, H-4””), 7.46 (2H, t, J = 7.6 Hz, H-3””, H-5””), 
6.93 (1H, m, H-1’) 6.81 (1H, d, J = 2.8 Hz, H-3”), 6.78 (1H, d, J = 8.8 Hz, H-6”), 6.75 (1H, dd, 
J = 2.8, 8.8 Hz, H-5”), 6.74 (1H, d, J = 8.8 Hz, H-3”””), 6.41 (1H, dt, J = 1.7, 6.0 Hz, H-3’), 
6.00 (1H, dq, J = 1.2, 6.0 Hz, H-2’), 5.22 (1H, m, H-4’), 4.70 (1H, dd, J = 4.2, 12.5 Hz, H-5’), 
4.52 (1H, dd, J = 3.0, 12.5 Hz, H-5’), 4.21 (2H, s, H-3”’), 4.02 (4H, m, H-2””’, H-15”’), 3.83 
(2H, t, J = 5.8 Hz, OCH2), 3.77 (3H, s, OCH3), 3.71-3.64 (12H, m, 6 × OCH2), 2.99 (2H, t, J = 
6.6 Hz, H-1”’’); 13C NMR (75 MHz, CDCl3): δ 179.1 (C=S), 166.2 (PhOCO), 161.3 (C-4), 
153.5 (C-4”), 151.8 (C-2”””), 151.2 (C-1”), 149.5 (C-2), 146.4 (C-6”””), 142.3 (C-6),141.0 (C-
4”””), 133.5 (C-4””), 133.4 (C-3’), 129.6 (C-2””, C-6””), 129.1 (C-1””), 128.8 (C-2”), 128.6 (C-
3””, C-5””), 126.9 (C-2’), 117.5 (C-3”), 113.6 (C-3”””), 112.7 (C-6”), 112.4 (C-5”””), 111.5 (C-
5”), 100.0 (C-2”’), 90.7 (C-1’), 90.1 (C-1”’), 85.1 (C-4’), 76.9 (C-5), 70.8 (OCH2), 70.6 (OCH2), 
70.5 (2 × OCH2), 70.3 (OCH2), 69.8 (OCH2), 69.1 (OCH2), 68.4 (OCH2), 65.0 (C-5’), 58.9 (C-
3”’), 55.5 (OCH3), 45.7 (C-2””’), 29.8 (C-1””’); HRMS (ES): m/z found 908.2178 (M+ + H), 
C42H47N5O11SBr requires (M+ + H) 908.2176. 
                  
5-{4-[2-(2-(5-Bromo-2-pyridinylaminothiocarbonylamino)ethyl)-4-
methoxyphenoxy]but-1-ynyl}-2’,3’-didehydro-2’,3’-dideoxyuridine (51)142 
 
                                                        
 
 
 
 
 
 
 
A solution of NaOMe in methanol (0.01 mL, 2M, 0.01 mmol), was added to                                                           
a solution of the nucleoside 50 (83 mg, 0.11 mmol) in MeOH (2 mL) at 0 oC. The mixture was 
stirred for 30 min, then acetic acid (0.05 mL) was added, and the crude mixture was diluted 
with CH2Cl2 (1 mL) and subjected to column chromatography employing MeOH/ CH2Cl2 (2 / 
8) to give the title product 51 as a pale yellow solid  (43 mg, 60%): mp: 121-122 oC; [ ]D   
+22.4 o  (c 1.10, CHCl3); IR (CHCl3): max  3934, 3688 (NH), 2304 (-C≡C-), 1696 (C=O), 1606 
(C=C), 1425 (C=S) cm-1; 1H NMR (400 MHz, CDCl3):  11.05 (1H, t, J = 4.2 Hz, NH), 8.70 
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(1H, brs, NH), 9.13 7.99 (1H, d, J = 2.6 Hz, H-6”””), 7.97 (1H, s, H-6), 7.56 (1H, dd, J = 2.6, 
8.8 Hz, H-4”””), 6.97 (1H, m, H-1’), 6.80 (1H, m, H-3”), 6.77 (2H, m, H-5”, H-6”), 6.66 (1H, d, J 
= 8.8 Hz, H-3”””), 6.37 (1H, dt, J = 1.5, 5.8 Hz, H-3’), 5.86 (1H, m, H-2’), 4.93 (1H, m, H-4’), 
4.05 (2H, t, J = 5.9 Hz, H-4”’), 3.95 (2H, m, H-2””’), 3.80 (2H, m, H-5’), 3.78 (3H, s, OCH3), 
2.98 (2H, m, H-3”’), 2.84 (2H, t, J = 5.8 Hz, H-1””’); 13C NMR (100 MHz, CDCl3):  178.9 
(C=S), 162.2 (C-4), 153.4 (C-4”), 151.5 (C-2”””), 150.9 (C-1”), 149.1 (C-2), 146.6 (C-6”””), 
143.6 (C-6), 140.8 (C-4”””), 135.6 (C-3’), 129.3 (C-2”), 128.9 (C-2’), 118.0 (C-3”), 113.4 (C-
3”””), 112.8 (C-6”), 111.4 (C-5”), 110.8 (C-5”””), 100.3 (C-2”), 91.3 (C-1”’), 90.4 (C-1’), 87.7 
(C-4’), 72.5 (C-5), 66.8 (C-4”’), 62.9 (C-5’), 55.6 (OCH3) 45.7 (C-2””’), 30.2 (C-1””’), 21.0 (C-
3”’); HRMS (ES): m/z found 642.1008 (M+ + H), C28H29N5O6BrS requires (M+ + H) 642.1022. 
 
5-{6-[2-(2-(5-Bromo-2-pyridinylaminothiocarbonylamino)ethyl)-4-
methoxyphenoxy]hexa-4-oxa-1-ynyl}-2’,3’-didehydro-2’,3’-dideoxyuridine (78)        
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A solution of NaOMe in methanol (0.03 mL, 2M, 0.06 mmol), was added to                                                                         
a solution of the nucleoside 114 (100 mg, 0.14 mmol) in MeOH (2 mL) at 0 oC. The mixture 
was stirred for 30 min, then acetic acid (0.05 mL) was added, and the crude mixture was 
diluted with CH2Cl2 (1 mL) and subjected to column chromatography employing EtOAc / pet 
ether (8 / 2) to give the title product 78 as a pale yellow solid  (59 mg, 69%): m.p: 76-79 0C; 
[ ]D +49.1 o (c 1.0, CHCl3); IR (CHCl3): max 3681, 3594, 3391 (NH, OH), 3022, 2928 (C-H), 
2239 (-C≡C-), 1715, 1697 (C=O), 1501 (C=C), 1465 (C=S), 1216 (C-N) cm-1; 1H NMR (300 
MHz, CDCl3): δ 11.09 (1H, t, J = 5.1 Hz, NH), 9.44 (1H, brs, NH), 9.09 (1H, brs, NH), 8.14 
(1H, s, H-6), 8.00 (1H, d, J = 2.4 Hz, H-6”””), 7.65 (1H, dd, J = 2.4, 8.7 Hz, H-4”””), 6.97 (1H, 
m, H-1’), 6.83 (1H, d, J = 8.7 Hz, H-3”””), 6.75 (3H, m, H-3”, H-5”, H-6”), 6.35 (1H, dt, J = 1.7, 
6.0 Hz, H-3’), 5.85 (1H, m, H-2’), 4.93 (1H, m, H-4’), 4.38 (2H, s, H-3”’), 4.06–3.78 (8H, m, H-
2””’, H-5’, H-5”’, H-6”’), 3.75 (3H, s, OCH3), 3.36 (1H, brs, OH), 2.97 (2H, t, J = 6.6 Hz, H-1””’); 
13C NMR (100 MHz, CDCl3): δ 178.8 (C=S), 161.8 (C-4), 153.7 (C-4”), 151.8 (C-2”””), 151.1 
(C-1”), 149.9 (C-2), 146.4 (C-6”””), 144.7 (C-6), 141.0 (C-4”””), 135.1 (C-3’), 128.9 (C-2”), 
126.0 (C-2’), 117.5 (C-3”), 113.8 (C-3”””), 112.9 (C-6”), 112.6 (C-5”””), 111.6 (C-5”), 99.3 (C-
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2”’), 90.3 (C-1”’), 89.4 (C-1’), 87.7 (C-4’), 77.5 (C-5), 68.4 (2 × OCH2), 62.8 (C-5’), 59.3 (C-
3”’), 55.6 (OCH3), 45.8 (C-2””’), 30.0 (C-1””’); HRMS (ES): m/z found 672.1139 (M+ + H), 
C29H31N5O7SBr requires (M+ + H) 672.1128. 
5-{9-[2-(2-(5-Bromo-2-pyridinylaminothiocarbonylamino)ethyl)-4-
methoxyphenoxy]nona-4,7-dioxa-1-ynyl}-2’,3’-didehydro-2’,3’-dideoxyuridine 
(79) 
 
 
              
 
 
 
 
 
 
A solution of NaOMe in methanol (0.03 mL, 2M, 0.06 mmol), was added to                                                                         
a solution of the nucleoside 116 (80 mg, 0.11 mmol) in MeOH (2 mL) at 0 oC. The mixture 
was stirred for 30 min, then acetic acid (0.05 mL) was added, and the crude product was 
subjected to column chromatography employing EtOAc to give the product 79 as a white 
solid (37 mg, 54%): m.p: 130-134 0C; [ ]D + 41.1 o (c 1.0, DMSO); IR (DMSO): max 3442, 
3260 (NH, OH), 2928 (C-H), 2246, 2123 (-C≡C-), 1700 (C=O), 1462 (C=S), 1223 (C-N) cm-1; 
1H NMR (300 MHz, DMSO-d6): δ 11.50 (1H, brs, NH), 11.05 (1H, t, J = 5.0 Hz, NH), 10.52 
(1H, brs, NH), 8.11 (1H, d, J = 2.6 Hz, H-6”””), 8.10 (1H, s, H-6), 7.93 (1H, dd, J = 2.6, 8.7 
Hz, H-4”””), 7.12 (1H, d, J = 8.7 Hz, H-3”””), 6.92 (1H, d, J = 8.7 Hz, H-6”), 6.82 (1H, d, J = 
3.0 Hz, H-3”), 6.80 (1H, m, H-1’), 6.77 (1H, dd, J = 3.0, 8.7 Hz, H-5”), 6.40 (1H, dt, J = 1.7, 
6.0 Hz, H-3’), 5.93 (1H, dq, J = 1.4 Hz, 6.0 Hz, H-2’), 4.94 (1H, t, J = 5.0 Hz, OH), 4.81 (1H, 
m, H-4’), 4.31 (2H, s, H-3”’), 4.03 (2H, t, J = 4.9 Hz, H-9”’), 3.84 (2H, q, J = 6.6 Hz, H-2””’), 
3.74 (2H, t, J = 4.9 Hz, H-8”), 3.68 (3H, s, OCH3), 3.66-3.58 (6H, m, H-5’, 2 × OCH2), 2.90 
(2H, t, J = 6.6 Hz, H-1”’”); 13C NMR (75 MHz, DMSO-d6): δ 179.1 (C=S), 161.3 (C-4), 153.1 
(C-4”), 152.1 (C-2”””), 150.6 (C-1”), 149.5 (C-2), 145.6 (C-6”””), 144.5 (C-6), 141.0 (C-4”””), 
135.2 (C-3’), 128.4 (C-2”), 127.4 (C-2’), 116.8 (C-3”), 114.3 (C-3”””), 113.4 (C-6”), 111.6 (C-
5”), 111.4 (C-5”””), 97.5 (C-2”’), 89.4 (C-1’), 88.5 (C-1”’), 87.5 (C-4’), 78.1 (C-5), 69.5 (OCH2), 
68.9 (OCH2), 68.5 (OCH2), 68.2 (OCH2), 61.7 (C-5’), 58.0 (C-3’”), 55.1 (OCH3), 44.5 (C-2””’), 
28.9 (C-1””’); HRMS (ES): m/z found 716.1389 (M+ + H), C31H35N5O8SBr requires (M+ + H) 
716.1390. 
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5-{15-[2-(2-(5-Bromo-2-pyridinylamino thiocarbonylamino)ethyl)-4-
methoxyphenoxy]pentadeca-4,7,10,13-tetraoxa-1-ynyl}-2’,3’-didehydro-2’,3’-
dideoxyuridine (80) 
 
 
 
 
 
 
 
 
 
 
A solution of NaOMe in methanol (0.02 mL, 2M, 0.04 mmol), was added to                                                                         
a solution of the nucleoside 119 (70 mg, 0.08 mmol) in MeOH (1 mL) and THF (1 mL) at 0 
oC. The mixture was stirred for 30 min, then acetic acid (0.05 mL) was added and the crude 
product was subjected to column chromatography employing EtOAc/ MeOH (8 / 2) to give 
the title product 80 as a white solid (32 mg, 52%): m.p: 63-65 oC; [ ]D  + 53.2 o (c 1.0, 
DMSO); IR (DMSO): max 3442, 3283 (NH, OH), 2246, 2123 (C≡C), 1660 (C=O), 1469 (C=S), 
1226 (C-N) cm-1; 1H NMR (400 MHz, DMSO-d6): δ 11.60 (1H, brs, NH), 11.09 (1H, t, J = 4.8 
Hz, NH), 10.62 (1H, brs, NH), 8.12 (1H, s, H-6), 8.09 (1H, d, J = 2.4 Hz, H-6”””), 7.93 (1H, dd, 
J = 2.4, 8.8 Hz, H-4”””), 7.09 (1H, d, J = 8.8 Hz, H-3”””), 6.89 (1H, d, J = 8.8 Hz, H-6”), 6.81 
(1H, d, J = 3.2 Hz, H-3”), 6.78 (1H, m, H-1’), 6.75 (1H, dd, J = 3.2, 8.8 Hz, H-5”), 6.38 (1H, dt, 
J = 1.7, 6.0 Hz, H-3’), 5.91 (1H, dq, J = 1.4, 6.0 Hz, H-2’), 5.02 (1H, t, J = 5.2 Hz, OH), 4.79 
(1H, m, H-4’), 4.28 (2H, s, H-3”’), 4.00 (2H, t, J = 4.9 Hz, H-15”’), 3.81 (2H, q, J = 6.6 Hz, H-
2””’), 3.71 (2H, t, J = 4.9 Hz, H-14”’), 3.66 (3H, s, OCH3), 3.60-3.47 (14H, m, H-5’, 6 × OCH2), 
2.87 (2H, t, J = 6.6 Hz, H-1””’); 13C NMR (75 MHz, DMSO-d6): δ 179.1 (C=S), 161.4 (C-4), 
153.0 (C-4”), 152.2 (C-2”””), 150.6 (C-1”), 149.6 (C-2), 145.6 (C-6”””), 144.6 (C-6), 141.1 (C-
4”””), 135.2 (C-3’), 128.4 (C-2”), 125.5 (C-2’), 116.8 (C-3”), 114.3 (C-3”””), 113.3 (C-6”), 111.6 
(C-5”), 111.5 (C-5”””), 97.5 (C-2”’), 89.4 (C-1’), 88.5 (C-4’), 87.5 (C-1”’), 78.2 (C-5), 69.8 
(OCH2), 69.7 (OCH2), 69.6 (2 × OCH2), 69.4 (OCH2), 68.9 (OCH2), 68.4 (OCH2), 68.2 
(OCH2), 61.7 (C-5’), 58.0 (C-3”’), 55.1 (OCH3), 44.5 (C-2””’), 29.0 (C-1””’); HRMS (ES): m/z 
found 804.1932 (M+ + H), C35H43N5O10SBr requires (M+ + H) 804.1914. 
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2',3’-Didehydro-2',3'-dideoxy-5-iodouridine (122)183 
 
 
 
 
 
 
 
 
To a solution of 5’-benzoyl-5-iodouridine 47 (0.80 g, 1.82 mmol) in dry MeOH (15 mL), was 
added a solution of NaOMe in methanol (0.90 mL, 2M, 1.82 mmol) at 0 oC. The mixture was 
stirred at rt for 2 h. The crude residue was diluted with aq NH4Cl (25 mL) and then was 
extracted using CHCl3: MeOH (4:1) (40 mL), the organic extract dried over MgSO4 and the 
solvent removed in vacuum to give a crude product, which was purified on silica-gel using 
EtOAc to give compound 122 as a colourless solid (0.45 g, 74%): m.p:176-177 oC; 1H NMR 
(300 MHz, DMSO-d6): δ 11.58 (1H, brs, NH), 8.23 (1H, s, H-6), 6.78 (1H, m, H-1’), 6.40 (1H, 
dt, J = 1.7, 6.0 Hz, H-3’), 5.94 (1H, dq, J = 1.4, 6.0 Hz, H-2’), 5.01 (1H, t, J = 4.9 Hz, OH), 
4.83 (1H, m, H-4’), 3.62 (2H, m, H-5’); 13C NMR (75 MHz, DMSO-d6): δ 160.3 (C-4), 150.3 
(C-2), 145.7 (C-6), 135.2 (C-3’), 125.7 (C-2’), 89.1 (C-1’), 87.4 (C-4’), 68.6 (C-5), 61.5 (C-5’).  
 
L-Alanine methyl ester hydrochloride (141)172          
 
     
 
 
To a solution of L-alanine (1.00 g, 11.22 mmol) in MeOH (20 mL) was added thionyl chloride 
(0.82 mL, 11.22 mmol) at 0 oC after which the mixture was warmed to rt and stirred for 20 h. 
The solvent was evaporated and diethyl ether (5 mL) was added to precipitate the product. 
The resultant product was filtered and washed with diethyl ether (10 mL) to give 141 a 
colourless solid (1.8 g, 100%): 1H NMR (400 MHz, DMSO-d6): δ 8.74 (3H, brs, NH3Cl), 4.00 
(1H, q, J = 7.0 Hz, CH), 3.70 (3H, s, CO2CH3), 1.42 (3H, d, J = 7.0 Hz, CH3). 
 
p-Methylphenyl phosphorodichloridate (120)172  
 
 
 
 
A solution of p-methylphenol (10.0 g, 92.50 mmol) and triethylamine (12.90 mL, 92.50 mmol) 
in anhydrous diethyl ether (200 mL) was added dropwise to a vigorously stirred solution of 
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phosphoryl chloride (10.30 mL, 111.0 mmol) in diethyl ether (100 mL) at 0 0C over 2 h. The 
mixture was allowed to warm to rt with stirring for 15 h, and then refluxed for 2 h. The mixture 
was filtered, and the precipitate was washed with diethyl ether. The combined filtrate and 
washings were evaporated under reduced pressure to give a coloured oil. This was 
subjected to a vacuum distillation to give the product 120 as a colourless oil (16.80 g, 81%): 
(bp 85-90 0C, 0.1 mmHg), (lit. bp 80-85 0C, 0.1 mmHg); 1H NMR (400 MHz, CDCl3): δ 7.19 
(4H, m, ArH), 2.38 (3H, d, JHP = 2.4 Hz, ArCH3); 31P NMR (CDCl3): δ 3.9.   
 
p-Methylphenyl methoxyalaninyl phosphorochloridate (121)172 
 
 
 
 
 
A solution of triethylamine (2.80 mL, 20.00 mmol) in dry CH2Cl2 (60 mL) was added drop wise 
with vigorous stirring to a solution of L-alanine methyl ester hydrochloride 141 (1.40 g, 10.04 
mmol) and p-methylphenyl phosphorodichloridate 120 (2.26 g, 10.04 mmol) in CH2Cl2 (80 
mL) at -78 0C over 2 h. The reaction mixture was slowly warmed to rt with stirring for 12 h, 
and the solvent was then removed in vacuum. The residue was treated with diethyl ether (30 
mL), and the solid formed filtered and washed with diethyl ether (20 mL). The solvent was 
evaporated in vacuum to give the product 121 as a colourless oil (2.90, 100%), which was 
used in the next step without further purification. 
 
2’,3’-Didehydro-2’,3’-dideoxy-5-iodouridine-5’-[p-methylphenyl methoxyalaninyl 
phosphate] (123) 
 
 
 
 
 
 
 
p-Methylphenyl methoxylalaninyl phosphorodichloridate 121 (1.77 g, 6.42 mmol) and 5-
iodouridine 122 (0.72 g, 2.14 mmol) were dissolved in THF (25 mL) and N-methylimidazole 
(1.02 mL, 12.84 mmol), was added with vigorous stirring. After 24 h at rt the solvent was 
removed under vacuum. The residue was dissolved in CHCl3 (50 mL) and washed with 
hydrochloric acid solution (1M, 2 × 60 mL), aq NaHCO3 (2 × 40 mL), and then water (3 × 40 
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mL). The organic layer was dried over MgSO4, and evaporated under vacuum, and the 
residue was purified by chromatography on silica-gel by elution with 3% MeOH in CHCl3 to 
give the product 123 as a (1:1) mixture of diastereoisomers and as a colourless solid (0.45 g, 
54%): m.p: 40-44 oC; IR (CHCl3): max  3384 (NH), 3007 (C-H), 1743, 1704 (C=O), 1505 
(C=C), 1245 (P=O) cm-1 ; 1H NMR (400 MHz, CDCl3): δ (peaks are split due to 
diastereoisomers at P) 8.91 (1H, brs, NH), 7.92, 7.90 (1H, s, H-6), 7.11 (4H, m, ArH), 6.94, 
6.92 (1H, m, H-1’), 6.38, 6.32 (1H, dt, J = 1.7, 6.0 Hz, H-3’), 5.94, 5.86 (1H, dq, J = 1.3, 6.0 
Hz, H-2’), 5.05 (1H, m, H-4’), 4.46-3.82 (4H, m, H-5’, Ala-CH, Ala-NH), 3.72, 3.71 (3H, s, 
OCH3), 2.31 (3H, s, ArCH3), 1.41, 1.36 (3H, d, J = 7.6 Hz, Ala-CH3); 13C NMR (75 MHz, 
CDCl3): δ (starred peaks are split due to diastereoisomers: δ values given as an average) 
173.9* (CO2Me), 159.9* (C-4), 150.3 (C-2), 148.2* (C-1”), 144.6* (C-6), 134.6 (C-4”), 133.7* 
(C-3’), 133.0* (C-3”, C-5”), 126.9* (C-2’), 120.0* (C-2”, C-6”), 90.2* (C-1’), 85.3* (C-4’), 69.0* 
(C-5), 66.6* (C-5’), 52.4* (Ala-OCH3), 50.0* (Ala-CH), 21.0* (Ala-CH3), 20.8* (ArCH3); 31P 
NMR (CDCl3): δ 3.7, 3.5 (1:1); HRMS (ES): m/z found 592.0356 (M+ + H), C20H24N3O8PI 
requires (M+ + H) 592.0346. 
 
5-{15-[2-(2-(5-Bromo-2-pyridinylaminothiocarbonylamino)ethyl)-4-
methoxyphenoxy]pentadeca-4,7,10,13-tetraoxa-1-ynyl}-2’,3-didehydro-2’,3’-
dideoxy-5-iodouridine-5’-5’-(p-methylphenyl methoxyalaninyl phosphate)-2’,3’-
didehydro-2’,3’-dideoxyuridine (81) 
 
Trifluoroacetic acid (0.20 mL) was added to a solution of alkyne 70r (92 mg, 0.19 mmol) in 
CH2Cl2 (2 mL) at 0 °C, and the solution stirred for 2 h. Anhydrous K2CO3 (80 mg, 0.57 mmol) 
was added, the mixture was stirred for a further 15 min and then filtered through Celite, The 
solvent was then evaporated in vacuo, the crude amine dried under vacuum for 1 h and then 
used in the next step without further purification. The crude amine was dissolved in dry THF 
(3 mL), DMF (2 mL), and 5-iodouridine-5’-[p-methylphenyl methoxyalaninyl phosphate] 123 
(0.10 g, 0.17 mmol), triethylamine (0.05 mL, 0.34 mmol) were added, The mixture was 
thoroughly degassed with nitrogen for 1h. CuI (17 mg, 0.09 mmol) and Pd(PPh3)4 (20 mg, 
0.02 mmol) were added to the degassed solution under a nitrogen atmosphere. The mixture 
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was left stirring at rt for 2h. The crude was dissolved in MeOH: CHCl3 (1: 4) (20 mL), which 
was washed with portions (10 mL) of 5% aq disodium EDTA, water (10 mL) and finally dried 
over MgSO4. Filtration and solvent evaporation under reduced pressure gave a crude 
product, which was flashed through a silica-gel column employing EtOAc/ MeOH/ Et3N (5/ 4/ 
1) as eluent. The amine product was dissolved in dry THF (3 mL), thiourea 49 (65 mg, 0.23 
mmol) was added and the mixture was stirred at room temperature for 20h. Following 
evaporation of solvent, the residue was subjected directly to column chromatography using 
EtOAc/ MeOH (9/ 1) to give a yellow solid 81 (36 mg, 20% over the 3 steps): m.p: 51-54 oC; 
[ ]D +4.4 o (c 1.0, CHCl3); IR (CHCl3): max  3391 (NH), 3007, 2928 (C-H) 1707 (C=O), 1505 
(C=C), 1462 (C=S), 1259 (P=O), 1223 (C-N) cm-1;  1H NMR (300 MHz, CDCl3): δ (peaks are 
split due to diastereoisomers) 11.11 (1H, t, J = 4.9 Hz, NH), 9.11 (1H, brs, NH), 9.05, 9.00 
(1H, s, NH), 8.03 (1H, d, J = 2.4 Hz, H-6”””), 7.79, 7.78 (1H, s, H-6), 7.66, 7.63 (1H, dd, J = 
2.4, 8.8 Hz, H-4”””), 7.08 (4H, s, ArH), 6.96, 6.94 (1H, m, H-1’), 6.80 (1H, d, J = 3.0 Hz, H-3”), 
6.78 (1H, d, J = 8.8 Hz, H-6”), 6.74 (1H, d, J = 8.8 Hz, H-3”””), 6.72 (1H, dd, J = 3.0, 8.8 Hz, 
H-5”), 6.37, 6.27 (1H, dt, J = 1.7, 6.0 Hz, H-3’), 5.91, 5.81 (1H, dq, J = 1.4, 6.0 Hz, H-2’), 5.02 
(1H, m, H-4’), 4.41-3.97 (10H, m, Ala-CH, Ala-NH, H-5’, H-15”’, H-2””’, H-3”’), 3.81 (2H, t, J = 
4.9 Hz, H-14”’), 3.75 (3H, s, OCH3), 3.68, 3.67 (3H, s, CO2CH3), 3.70-3.57 (12H, m, 6 × 
CH2O), 2.97 (2H, t, J = 6.6 Hz, H-1””’), 2.28 (3H, s, ArCH3), 1.37, 1.33 (3H, d, J = 6.3 Hz, Ala-
CH3); 13C NMR (75 MHz, CDCl3): δ (starred peak are split due to diastereoisomers: δ values 
given as an average) 179.2 (C=S), 173.9* (CO2Me), 161.2 (C-4), 153.6 (C-4”), 151.9 (C-2”””), 
151.3 (C-1”), 149.6 (C-2), 148.3* (C-1””), 146.5 (C-6”””), 143.1* (C-6), 141.0 (C-4”””), 134.7 
(C-4””), 133.8 (C-3’), 130.1* (C-3””, C-5””), 128.8 (C-2”), 126.7* (C-2’), 120.0* (C-2””, C-6””), 
117.5 (C-3”), 113.6 (C-3”””), 112.7 (C-6”), 112.4 (C-5”””), 111.5 (C-5”), 99.9 (C-2”’), 91.3* (C-
1’), 90.2 (C-1”’), 85.4* (C-4’), 77.2 (C-5), 70.8 (OCH2), 70.6 (OCH2), 70.5 (2 × OCH2), 70.2* 
(OCH2), 69.9 (OCH2), 69.2* (OCH2), 68.4 (OCH2), 66.7 (d, Jcp = 4.5 Hz, C-5’), 58.9 (C-3”’), 
55.6 (OCH3), 52.5 (CO2CH3), 50.3* (Ala-CH), 45.8 (C-2””’), 29.8 (C-1””’), 20.9* (Ala-CH3), 
20.7 (Ph-CH3); 31P NMR (CDCl3): δ 3.63, 3.56 (1:1); HRMS (ES): m/z found 1059.2548 (M+ + 
H), C46H57N6O14SBrP requires (M+ + H) 1059.2574. 
     
Diisopropyl hydrogen phosphonate (124)177 
 
 
 
 
Isopropanol (5.24 g, 68.82 mmol) was added dropwise to a suspension of NaH (60% in 
mineral oil, 1.84 g, 45.88 mmol) in THF (60 mL) and the mixture was stirred for 15 min at 0 
oC. Phosphorus trichloride (2.00 mL, 22.94 mmol) was added dropwise and then the mixture 
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was warmed to rt with stirring for 1h. The reaction was quenched using aqueous NH4Cl (10 
mL). The mixture was diluted with EtOAc (80 mL), washed with aq NH4Cl (50 mL), water (2 × 
40 mL), dried over MgSO4 and the solvent was evaporated under reduced pressure to give 
the product 124 without purification as a colourless oil (11.20 g, 98%): 1H NMR (300 MHz, 
CDCl3): δ 6.77 (1H, d, JHP = 687.0 Hz, H-P=O), 4.67 (2H, m, CH(CH3)2), 1.30 and 1.28 (2 × 
6H, 2 × d, CH(CH3)2 ; 31P NMR (CDCl3): δ 4.6. 
 
Diisopropyl hydroxymethylphosphonate (125)177 
 
 
 
 
  
To a solution of diisopropyl hydrogen phosphonate 124 (5.00 g, 30.10 mmol), 
paraformaldehyde (1.05 g, 36.12 mmol) in isopropanol (20 mL) was added anhydrous 
potassium carbonate (0.21 g, 1.51 mmol). The mixture was stirred vigorously for 1h at 60 oC, 
filtered through Celite and the solvent was evaporated in vacuum to give the product 125 as 
a colourless oil (5.81 g, 98%) pure enough for the next step: 1H NMR (300 MHz, CDCl3): δ 
4.73 (2H, m, CH(CH3)2), 3.82 (2H, d, JHP  = 6.6 Hz, CH2P), 2.15 (1H, brs, OH), 1.32 (12H, d, J 
= 6.3 Hz, CH(CH3)2); 31P NMR (CDCl3): δ  22.9. 
 
Diisopropyl p-toluenesulphonyloxymethylphosphonate (126) 
 
 
 
 
     
To a solution of diisopropyl hydroxymethyl phosphonate 125 (5.00 g, 25.49 mmol) in dry 
CH2Cl2 (30 mL), were added triethylamine (4.26 mL, 30.59 mmol) and p-toluenesulfonyl 
chloride (5.81 g, 30.59 mmol) followed by DMAP (0.02 g). The reaction mixture was stirred at 
rt for 16h. The mixture was diluted with CH2Cl2 (120 mL), washed with aq. NH4Cl (60 mL), 
water (70 mL), dried over MgSO4 and solvent was removed under reduced pressure. 
Purification by column chromatography using EtOAc / pet ether (6 / 4) gave a colourless oil 
126 (8.20 g, 92%): IR (CHCl3): max  2986 (C-H), 1252 (P=O), 1176 (O-SO2-), 1003 (P-O) cm-
1; 1H NMR (400 MHz, CDCl3): δ 7.80 (2H, d, J = 8.0 Hz, H-2, H-6), 7.36 (2H, d, J = 8.0 Hz, H-
3, H-5), 4.73 (2H, m, CH(CH3)2), 4.12 (2H, d, JHP  = 10.0 Hz, CH2P), 2.46 (3H, s, ArCH3), 1.33 
and 1.29 (2 × 6H, 2 × d, J = 6.2 Hz, CH(CH3)2); 13C NMR (100 MHz, CDCl3): δ 145.3 (C-1), 
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131.8 (C-4), 129.9 (C-3, C-5), 128.1 (C-2, C-6), 72.3 (d, JCP = 6.1 Hz, CH(CH3)2), 61.9 (d, JCP 
= 169.1 Hz, CH2P), 23.9 (d, JCP = 3.8 Hz, CH(CH3)2) 23.7 (d, JCP = 4.6 Hz, CH(CH3)2), 21.5 
(Ph-CH3); 31P NMR (CDCl3): δ 13.3; HRMS (ES): m/z found 351.1044 (M+ + H), C14H24O6SP 
requires (M+ + H) 351.1031. 
 
Diisopropyl (2-benzyloxyethoxy)methylphosphonate (127) 
 
 
 
 
 
2-Benzyloxyethanol 72 (2.09 g, 13.70 mmol) was added dropwise to a suspension of NaH 
(60% mineral oil, 0.69 g, 17.13 mmol) in THF (60 mL) at 0 oC. The mixture was stirred for 30 
min and the tosylate 126 (4.00 g, 11.42 mmol) was added. The mixture was heated at reflux 
for 3 h. The crude mixture was added to EtOAc (80 mL), which was washed with aqueous 
NH4Cl (50 mL), water (2 × 40 mL), dried over MgSO4 and the solvent evaporated under 
reduced pressure. The crude product was purified by column chromatography employing 
EtOAc / pet ether (7 / 3) to give  compound 127 as a colourless oil (2.70 g, 72%): IR (CHCl3): 
max  2986, 2935 (C-H), 1241 (P=O), 999 (P-O) cm-1; 1H NMR (400 MHz, CDCl3): δ 7.31 (4H, 
m, ArH), 7.29 (1H, m, H-4’), 4.76 (2H, m, CH(CH3)2), 4.54 (2H, s, ArCH2O), 3.82 (2H, d, JHP = 
8.4 Hz, CH2P), 3.79 (2H, t, J = 4.7 Hz, H-2), 3.66 (2H, t, J = 4.7 Hz, H-1), 1.33 and 1.31 (2 × 
6H, 2 × d, J = 6.3 Hz, CH(CH3)2); 13C NMR (100 MHz, CDCl3): δ 138.2 (C-1’), 128.3 (C-2’, C-
6’), 127.6 (C-3’, C-5’), 127.5 (C-4’), 73.2 (ArCH2O), 72.5 (d, JCP = 10.5 Hz, C-2), 71.0 (d, JCP 
= 6.6 Hz, CH(CH3)2), 69.4 (C-1), 66.1 (d, JCP = 165.9 Hz, CH2P), 24.0 (m, CH(CH3)2); 31P 
NMR (CDCl3): δ 19.7; HRMS (ES): m/z found 331.1668 (M+ + H), C16H28O5P requires (M+ + 
H) 331.1674. 
 
Diisopropyl (2-hydroxyethoxy)methylphosphonate (128) 
 
 
 
 
 
Hydrogen gas was introduced at atmospheric pressure to compound 127 (2.00 g, 6.05 mmol) 
and a suspension of 10% palladium-on-carbon (0.65 g, 0.61 mmol) in MeOH: THF (1: 1) (15 
mL). The mixture was stirred at room temperature for 6 h. The catalyst was filtered through a 
pad of Celite, washed with MeOH (2 × 15 mL) and the filtrate evaporated in vacuo to give the 
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product 128 as a colourless oil pure enough for the next step (1.12 g, 77%): IR (CHCl3): max 
3200(OH), 2986 (C-H), 1234 (P=O), 996 (P-O) cm-1: 1H NMR (300 MHz, CDCl3): δ 4.75 (2H, 
m, CH(CH3)2), 3.79 (2H, d,  JHP = 7.8 Hz, CH2P), 3.72 (4H, m, H-1, H-2), 2.52 (1H, brs, OH), 
1.33 (12H, d, J = 6.2 Hz, CH(CH3)2); 13C NMR (75 MHz, CDCl3): δ 75.0 (d, JCP = 9.5 Hz, C-2), 
71.2 (d, JCP = 6.6 Hz, CH(CH3)2), 66.0 (d, JHP = 167.3 Hz, CH2P), 61.5 (C-1), 23.9 (m, 
CH(CH3)2); 31P NMR (CDCl3): δ 20.2.   
 
 Diisopropyl (2-p-toluenesulphonyloxyethoxy)methylphosphonate (129) 
 
 
 
 
   
 
p-Toluenesulfonyl chloride (1.05 g, 5.50 mmol) was added to a stirring solution of the alcohol 
128 (1.10 g, 4.58 mmol) containing triethylamine (0.77 mL, 5.50 mmol), and a catalytic a 
mount of DMAP in dry CH2Cl2 (20 mL) at 0 oC. The reaction mixture was stirred at rt for 16 h. 
The mixture was diluted with CH2Cl2 (80 mL), washed with aq NH4Cl (25 mL), water (30 mL), 
dried over MgSO4 and the solvent removed under reduced pressure. Purification by column 
chromatography using EtOAc / pet ether (9 / 1) gave a colourless oil 129 (1.63 g, 90%): IR 
(CHCl3): max 2986 (C-H), 1234 (P=O), 1176 (O-SO2), 999 (P-O) cm-1: 1H NMR (300 MHz, 
CDCl3): δ 7.78 (2H, d, J = 8.3 Hz, H-2’, H-6’), 7.33 (2H, d, J = 8.3 Hz, H-3’, H-5’), 4.71 (2H, 
m, CH(CH3)2), 4.14 (2H, t, J = 4.8 Hz, H-1), 3.77 (2H, t, J = 4.8 Hz, H-2), 3.69 (2H, JHP = 8.4 
Hz, CH2P), 1.31 and 1.28 (2 × 6H, 2 × d, J = 6.0 Hz, CH(CH3)2);  2.43 (3H, s, ArH); 13C NMR 
(75 MHz, CDCl3): δ 144.8 (C-1’), 132.9 (C-4’), 129.8 (C-3’, C-5’), 127.9 (C-2’, C-6’), 71.2 (d, 
JCP = 6.6 Hz, CH(CH3)2), 70.4 (d, JCP = 11.0 Hz, C-2), 68.7 (C-1), 66.1 (d, JCP = 166.5 Hz, 
CH2P), 24.0 (m, CH(CH3)2), 21.5 (d, JCP = 3.7 Hz, ArCH3); 31P NMR (CDCl3): δ 18.6; HRMS 
(ES): m/z found 395.1297 (M+ + H), C16H28O7PS requires (M+ + H) 395.1293. 
   
1-{2-[(diisopropoxyphosphoryl)methoxy]ethyl}uracil (131)176 
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A mixture of uracil (0.61 g, 5.47 mmol) and caesium carbonate (1.64 g, 5.02 mmol) in DMF 
(10 mL) was heated at 100 0C for 1 h. A solution of the tosylate 129 (1.80 g, 4.56 mmol) in 
DMF (2 mL) was added to the mixture and stirred for 20 h at 100 0C. The reaction mixture 
was diluted with CHCl3 / MeOH (4 / 1) (40 mL) and washed with aqueous NH4Cl (25 mL), 
water (3 × 30 mL), dried over MgSO4 and the solvent was removed under reduced pressure. 
The crude product was purified on silica-gel using EtOAc / MeOH (8 / 2) to give compound 
131 as a colourless oil (0.35 g, 35%): IR (CHCl3): max  3413 (NH), 2986 (C-H), 1707, 1660 
(C=O), 1241 (P=O), 999 (P-O) cm-1; 1H NMR (300 MHz, CDCl3): δ 8.90 (1H, brs, NH), 7.36 
(1H, d, J = 7.8 Hz, H-6), 5.64 (1H, d, J = 7.8 Hz, H-5), 4.72 (2H, m, CH(CH3)2), 3.94 (2H, t, J 
= 4.5 Hz, H-1’), 3.80 (2H, t, J = 4.5 Hz, H-2’), 3.72 (d, JHP = 8.1 Hz, CH2P), 1.34 and 1.32 (2 × 
6H, 2 × d, J = 6.2 Hz, CH(CH3)2); 13C NMR (100 MHz, CDCl3): δ 163.5 (C-4), 150.8 (C-2), 
145.8 (C-6), 101.5 (C-5), 71.2 (d, JCP = 6.8 Hz, CH(CH3)2), 71.0 (d, JCP = 10.6 Hz, C-2’), 66.2 
(d, JCP = 166.9 Hz, CH2P), 48.3 (C-1’), 24.0 (m, CH(CH3)4); 31P NMR (CDCl3): δ 18.8; HRMS 
(ES): m/z found (M+ + H), 335.1376, C13H24N2O6P requires (M+ + H) 335.1376. 
 
5-Iodo-1-{2-[(diisopropoxyphosphoryl)methoxy]ethyl}uracil (132) 
 
 
 
 
 
 
 
 
Cerium ammonium (IV) nitrate (0.18 g, 0.32 mmol) and iodine (96 mg, 0.38 mmol) were 
added to the uracil phosphonate 131 (0.21 g, 0.63 mmol) in CH3CN (8 mL). The mixture was 
stirred at 40 oC for 4 h. The solvent was then reduced under vacuum after which the crude 
residue was diluted with a solution of sodium thiocyanate (20 mL) and extracted with EtOAc / 
MeOH (4 / 1) (2 x 30 mL). The organic fractions were dried over MgSO4 and the solvent 
reduced under vacuum. Purification by chromatography using a silica-gel column with EtOAc 
gave compound 132 as a yellow solid (0.18 g, 62%): m.p: 89-91 oC; IR (CHCl3): max  3377 
(NH), 2986 (C-H), 1711, 1689 (C=O), 1241 (P=O), 999 (P-O) cm-1: 1H NMR (300 MHz, 
CDCl3): δ 9.00 (1H, brs, NH), 7.78 (1H, s, H-6), 4.76 (2H, m, CH(CH3)2), 3.94 (2H, t, J = 4.7 
Hz, H-1’), 3.79 (2H, t, J = 4.7 Hz, H-2’), 3.73 (2H, JHP = 8.4 Hz, CH2P), 1.34, 1.30 (2 × 6H, 2 × 
d, J = 6.0 Hz, CH(CH3)2); 13C NMR (100 MHz, CDCl3): δ 160.7 (C-4), 150.6 (C-2), 150.0 (C-
6), 71.2 (d, JCP = 6.1 Hz, CH(CH3)2), 70.6 (d, JCP = 10.7 Hz, C-2’), 67.2 (C-5), 66.0 (d, JCP = 
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166.9 Hz, CH2P), 48.5 (C-1’), 23.9 (d, JCP = 3.1 Hz, CH(CH3)2); 31P NMR (CDCl3): δ 18.7; 
HRMS (ES): m/z found (M+ + H), 461.0341 C13H23N5O6PI requires (M+ + H) 461.0339. 
5-{15-[2-(2-(5-Bromo-2-pyridinylaminothiocarbonylamino)ethyl)-4-
methoxyphenoxy]pentadeca-4,7,10,13-tetraoxa-1-ynyl}-1-{2-
[(diisopropoxyphosphoryl)methoxy]ethyl}uracil (134) 
 
 
 
 
 
 
 
 
Trifluoroacetic acid (0.20 mL) was added to a solution of the alkyne 70r (0.12 g, 0.25 mmol) 
in CH2Cl2 (3 mL) at 0 °C, and the solution stirred for 2 h. Anhydrous K2CO3 (0.10 g, 0.75 
mmol) was added, the mixture was stirred for a further 15 min, then filtered through Celite 
and the solvent evaporated in vacuo. The crude amine was dried under vacuum for 1 h and 
used in the next step without further purification. The crude amine was dissolved in dry THF 
(3 mL)/ DMF (2 mL), and iodide 132 (0.10 g, 0.22 mmol) and triethylamine (0.06 mL, 0.44 
mmol) were added, The mixture was thoroughly degassed with nitrogen for 1 h. CuI (21 mg, 
0.11 mmol) and Pd(PPh3)4 (23 mg, 0.02 mmol) were added to the degassed solution under a 
nitrogen atmosphere. The mixture was left stirring at rt for 2 h. The crude was dissolved in 
MeOH: CHCl3 (1: 4) (25mL) which was washed with portions of 5% aq disodium EDTA (15 
mL), water (15 mL) and dried over MgSO4.  Filtration and a solvent removal under reduced 
pressure gave the crude product, which was flushed through a column of silica-gel employing 
EtOAc / MeOH / Et3N (5 / 4 / 1) to afford the coupled amine product, which was dissolved in 
dry THF (4 mL). Thiourea 49 (85 mg, 0.30 mmol) was then added and the mixture was stirred 
at room temperature for 20 h. Following evaporation of solvent, the residue was subjected 
directly to column chromatography to give 134 as a colourless oil (40 mg, 20% over the 3 
steps): IR (CHCl3): max  3406, 3167 (NH), 3000 (C-H), 2232 (C≡C), 1693 (C=O), 1501 (C=C), 
1465 (C=S), 1230 (P=O), 1097 (C-N), 999 (P-OCH) cm-1; 1H NMR (400 MHz, CDCl3): δ  
11.20 (1H, t, J = 5.0 Hz, NH), 9.12 (1H, brs, NH), 8.04 (1H, d, J = 2.4 Hz, H-6”””), 7.70 (1H, s, 
NH), 7.68 (1H, dd, J = 2.4, 8.8 Hz, H-4”””), 7.58 (1H, s, H-6), 6.82 (1H, d, J = 8.8 Hz, H-6”), 
6.80 (1H, d, J = 2.9 Hz, H-3”), 6.78 (1H, d, J = 8.8 Hz, H-3”””), 6.73 (1H, dd, J = 2.9, 8.8 Hz, 
H-5”), 4.74 (2H, m, CH(CH3)2), 4.33 (2H, s, H-3’”), 4.02 (4H, m, H-15”’, H-2””’), 3.95 (2H, t, J 
= 4.8 Hz, H-1’), 3.82 (4H, m, H-2’, H-14”’), 3.75 (3H, s, OCH3), 3.70-3.64 (14H, m, 6 × CH2O, 
H-4’), 2.98 (2H, t, J = 6.4 Hz, H-1””’), 1.32 (12H, m, CH(CH3)2); 13C NMR (75 MHz, CDCl3): δ 
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179.2 (C=S), 162.2 (C-4), 153.5 (C-4”), 151.9 (C-2””””), 151.1 (C-1”), 149.8 (C-2), 148.7 (C-
6), 146.4 (C-6”””), 140.9 (C-4””””), 128.8 (C-2”), 117.5 (C-3”), 113.6 (C-3”””), 112.7 (C-6”), 
112.4 (C-5”””), 111.5 (C-5”), 98.7 (C-2”’), 89.7 (C-1”’), 77.3 (C-5), 71.3 (d, JCP = 6.2 Hz, 
CH(CH3)2), 70.7 (CH2O), 70.6 (CH2O), 70.5 (2 × CH2O), 70.3 (CH2O), 69.8 (CH2O), 69.1 
(CH2O), 68.3 (CH2O), 66.1 (d, JCP = 166.7 Hz, C-4’), 59.0 (C-3”’), 55.5 (OCH3), 48.8 (C-1’), 
45.6 (C-2””’), 29.8 (C-1””’), 23.9 (m, CH(CH3)2); 31P NMR (CDCl3): δ 18.7; HRMS (ES): m/z 
found (M+ + H), 928.2603, C39H56N5O12PSBr requires (M+ + H) 928.2567. 
 
5-{21-[2-(2-(5-Bromo-2-pyridinyl)amino thiocarbonylamino)ethyl)-4-
methoxyphenoxy]heneicosa-4,7,10,13, 16,19-heptoxa-1-ynyl}-1-{2-
[(diisopropoxyphosphoryl)methoxy]ethyl}uracil (135) 
 
Trifluoroacetic acid (0.12 mL) was added to a solution of the alkyne 70s (80 mg, 0.14 mmol) 
in CH2Cl2 (2 mL) at 0 °C, and the solution stirred for 2 h. Anhydrous K2CO3 (58 mg, 0.42 
mmol) was added, the mixture was stirred for a further 15 min before being filtered through 
Celite and the solvent evaporated in vacuo. The crude amine was dried under vacuum for 1 h 
and used in the next step without further purification. It was dissolved in dry THF (3 mL)/ 
DMF (1 mL) and the iodide 132 (60 mg, 0.13 mmol), and triethylamine (0.04 mL, 0.26 mmol) 
were then added. The mixture was thoroughly degassed with nitrogen for 1h. CuI (13 mg, 
0.07 mmol) and Pd(PPh3)4 (15 mg, 0.013 mmol) were added to the degassed solution under 
a nitrogen atmosphere and the mixture was left stirring at rt for 2h. The crude was dissolved 
in MeOH: CHCl3 (1: 4) (20 mL), which was washed with portions (10 mL) of 5% aq disodium 
EDTA, water (10 mL) and dried over MgSO4. Filtration and solvent removal under reduced 
pressure gave a crude product, which was flushed through a column of silica-gel employing 
EtOAc / MeOH / Et3N (5 / 4 / 1). The amine product was dissolved in dry THF (2 mL), 
thiourea 49 (48 mg, 0.17 mmol) was then added and the mixture stirred at room temperature 
for 20h. Following evaporation of solvent, the residue was subjected directly to column 
chromatography to afford 135 as a colourless oil (20 mg, 15% over the 3 steps): IR (CHCl3): 
max 3413, 3167 (NH), 3007 (C-H), 2239 (C≡C), 1693 (C=O), 1501 (C=C), 1469 (C=S), 1259, 
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1230 (P=O), 1097 (C-N), 1006 (P-O) cm-1; 1H NMR (400 MHz, CDCl3): δ 11.17 (1H, t, J = 4.7 
Hz, NH), 9.00 (1H, brs, NH), 8.06 (1H, d, t, J = 2.4 Hz, H-6”””), 7.74 (1H, brs, NH), 7.69 (1H, 
dd, J = 2.4, 8.8 Hz, H-4”””), 7.61 (1H, s, H-6), 6.81 (1H, d, J = 3.2 Hz, H-3”), 6.79 (1H, d, J = 
8.8 Hz, H-3”””), 6.79 (1H, d, J = 8.8 Hz, H-6”), 6.74 (1H, dd, J = 3.2, 8.8 Hz, H-5”), 4.75 (2H, 
m, CH(CH3)2), 4.37 (2H, s, H-3”’), 4.02 (4H, m, H-21”’, H-2””’), 3.96 (2H, t, J = 4.7  Hz, H-1’), 
3.83 (4H, m, H-2’, H-20”’), 3.76 (3H, s, OCH3), 3.75-3.63 (22H, m, 10 × CH2O, H-4’), 2.99 
(2H, t, J = 6.6 Hz, H-1””’), 1.33 (12H, m, CH(CH3)2); 13C NMR (75 MHz, CDCl3): δ 179.3 
(C=S), 161.8 (C-4), 153.6 (C-4”), 151.8 (C-2”””), 151.2 (C-1”), 149.6 (C-2), 148.7 (C-6), 146.5 
(C-6”””), 141.0 (C-4”””), 128.8 (C-2”), 117.5 (C-3”), 113.6 (C-3”””), 112.8 (C-6”), 112.4 (C-5”””), 
111.5 (C-5”), 98.8 (C-2”’), 89.9 (C-1”’), 77.1 (C-5), 71.3 (d, JCP = 6.2 Hz, CH(CH3)2), 70.8 
(CH2O), 70.7 (2 × CH2O), 70.5 (5 × CH2O), 70.4 (CH2O), 69.9 (CH2O), 69.1 (CH2O), 68.4 
(CH2O), 66.2 (d, JCP = 166.7 Hz, C-4’), 59.0 (C-3”’), 55.6 (OCH3), 48.9 (C-1’), 45.7 (C-2””’), 
29.8 (C-1””’), 24.0 (m, CH(CH3)2); 31P NMR (CDCl3): δ 18.7; HRMS (ES): m/z found (M+ + H), 
1016.3100, C43H64N5O14PSBr requires (M+ + H) 1016.3091.  
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APPENDIX 
 
AN MTT-ASSAY 
An MTT-assay was carried out at Yale University to determine the target compounds have 
been synthesized in this project. The tetrazolium-based colorimetric (MTT) assay using MT-4 
cells for detection of anti-HIV compounds has been widely used, since 20 years ago. This 
method, which remains popular, provides more information than more recently developed 
methods and very efficiently. 
  
An MTT-assay procedure 
1 x 105 MT-2 cells per millitre were infected with HIV-1 IIIB at a 0.1 multiplicity of infection 
(MOI). 100 μL of of this solution was mixed with each serial dilution of inhibitor in triplicate on 
a 96-well plate. Mock infected cells were also mixed with inhibitor in a similar manner. After 
five days of incubation, a cell-permeable tetrazolium dye (MTT) was added. The MTT 
reaction was stopped after 5 h adding acidified isopropanol. The plates were gently shaken 
overnight, quantitated on a plate reader and the absorbance measured at 595 nm. The 
absorbance values were then plotted versus inhibitor concentration (EC50) and 50% 
cytotoxic concentration (CC50) of the test compounds were defined as the compound 
concentrations required to inhibit cell viability (MT-2) by 50% or to reduce by 50% the 
number of viable cells in mock-infected cell cultures, respectively.    
                                                                                                                                                                                                                                                                                              
                           Cell-Culture Assay                                              
   
                                                       
 
CC50 = cytotoxicity 
 
 
EC50 = antiviral potency 
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